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ABSTRACT 
 
 T cells recognize cognate peptide antigen in complex with major histocompatibility 
complex (MHC) proteins; however, the molecular events which trigger T cells upon binding of 
MHC-peptide to the T cell receptor (TCR) are unclear.  To gain a better understanding of this 
mechanism, CD4+ T cells were treated with soluble class II MHC-peptide monomers and 
oligomers instead of antigen-presenting cells, and the activation response was monitored.  These 
experiments showed a requirement for multivalent TCR engagement to induce activation.  
Mathematical modeling of oligomeric equilibrium binding states indicates that the level of the T 
cell response correlates with the predicted number of receptor cross-links formed by soluble 
MHC oligomers.  Treatment of CD8+ T cells with class I MHC monomers and oligomers 
revealed a confusing process whereby peptide derived from soluble MHC reagents was loaded 
on to endogenous MHC complexes on the T cell surface and re-presented to other cells.  When 
this method of stimulation was circumvented, multivalent TCR engagement was found to be 
required for CD8+ T cell activation, similar to CD4+ T cells.  In both types of cells, monomeric 
MHC-peptide binding can compete off activation responses induced by MHC-peptide oligomers 
in the same mixture, further emphasizing the non-productive nature of monovalent TCR 
engagement.  However, exquisite antigen sensitivity might be achieved on the surface of an APC 
due to the contribution of non-activating MHC-peptide complexes.  Even though solubme 
monomeric MHC does not cause activation, soluble heterodimeric MHC-peptide ligands with 
only one activating peptide induce T cell activation responses. 
 Identification and characterization of T cell epitopes derived from infectious agents or 
vaccines can greatly enhance the ability to study and eventually direct the immune response.  
This work contains a description of a novel technique for identifying and characterizing specific 
T cell responses in parallel.  The system involves incubating heterogeneous T cell mixtures with 
artificial antigen-presenting microarrays, which include immobilized cytokine capture 
antibodies, co-stimulatory molecules, and MHC complexes presenting many different potential T 
cell epitope peptides.  These microarrays can rapidly, conveniently, and sensitively detect 
antigen-specific T cells and characterize the functional responses to many different epitopes in 
parallel in a location-dependent manner. 
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I. Introduction 
 The immune system consists of a conglomeration of defenses that serves to protect an 
organism from invasion by foreign material.  In this chapter, I will give an overview of the 
different aspects of the immune system in mammals.  I will touch upon the strategy of the 
adaptive immune system and specifically focus on the role of T cells in responding to infection 
or disease.  I will discuss the mechanism of antigen recognition by T cells in the context of 
antigen-presenting cells (APCs) and major histocompatibility proteins (MHCs).  Finally, I will 
discuss the importance of T cell epitope identification in the study of diseases and the methods 
employed to address this issue.  For more information on these and other general topics in 
immunology, I would direct the reader to consult a textbook on the subject (Janeway, 2004). 
 
I.A. The Immune System 
 The immune system consists of many layers, each designed to protect an organism from 
foreign invasion.  These layers span from very crude to extremely specific and specialized, and 
the system includes organs, cells, and proteins.  All of these components are designed to 
segregate “self” from “non-self.”  A would-be pathogen must be able to avoid all of these 
defenses in order to cause stable infection and disease.  I have outlined some of the layers of 
defense here. 
I.A.1 Anatomical and Physiological Barriers 
 The first line of defense protecting any organism includes elements that serve to disallow 
entry and survival of anything foreign to the organism.  For example, skin and mucous 
membranes form physical barriers against entry, while enzymes present in tears and saliva act to 
terminate potential infections.  Additional factors such as low pH in the stomach and partial 
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pressure of oxygen in the blood (oxygen tension) create a hostile environment for invaders that 
do enter the organism.  These primary defenses do an excellent job of excluding most 
environmental threats. 
I.A.2 Innate Immunity 
 Should a pathogen surpass the physical barriers, the body possesses fast-response cellular 
and protein-based defenses that target general molecular patterns not present in vertebrates.  
These molecules include particular lipids, carbohydrates, peptidoglycans present in bacterial or 
yeast cell walls, or polynucleotides.  Cells called phagocytes, including macrophages and 
dendritic cells, recognize these molecular patterns and ingest and break down the pathogens that 
carry them, and also secrete cytokines to recruit other immune cells to the site of infection.  In 
addition, a series of soluble proteins referred to collectively as complement have the ability to 
augment the destruction of pathogens either directly or with the aid of antibody binding or by 
enhancing phagocytic cell recognition. 
 While these responses are rapid, they are often not effective enough to eliminate an 
infection, and can only contain the infection until the slower adaptive immune response can 
begin. 
I.A.3. Adaptive Immunity 
 The strategy of the adaptive immune response is to create cells that can recognize 
tremendously diverse molecular patterns, taking care to eliminate any immune cells that target 
“self” patterns.  These cells are slow to be activated upon their first encounter with their cognate 
molecule or antigen because of the need for selection of the appropriate specificities, but 
eventually the recognition results in proliferation of cells that specifically recognize the 
problematic pathogen and induction of a variety of effector functions that hopefully lead to 
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clearance of the infection.  After the challenge, some of the cells that specifically recognize that 
pathogen remain in the body as memory cells.  If the same pathogen should ever try to re-infect, 
the memory cells would respond much more quickly, fighting the infection before it can gain a 
foothold.  This memory response is extremely valuable, and memory-like responses to certain 
diseases can be induced by vaccination without ever allowing an actual infection to take place. 
 The method by which this extraordinary diversity, specificity, and memory is achieved is 
through genetic recombination.  Immune cells, specifically B cells and T cells, express surface 
receptors that recognize antigen called the B cell receptor (BCR) and T cell receptor (TCR), 
respectively.  A developing B cell or T cell rearranges a unique antigen receptor from a set of 
genes by splicing different sections together, often with hypervariation at the junctions between 
sections (see Figure I.1).  This process leads to ~1015 possible T cell receptors with different 
specificities (reviewed in (Marrack and Kappler, 1988)). The recombined receptor is then 
expressed at the surface, where it can recognize its unique antigen by binding to it. 
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FIGURE I.1 DNA rearrangement creates great diversity in antigen receptors. Developing B and T 
cells rearrange their chromosomal DNA to combine different variable (V), joining (J), diversity (D) genes, 
and a single constant (C) gene is spliced into a final polypeptide.  An example of this rearrangement is 
shown for the T cell receptor beta chain.  The germline DNA is shown at the top.  First, D-J 
rearrangement occurs, followed by V-DJ rearrangement, excising and discarding the intervening DNA 
sequences at each step.  Then, the sequence is transcribed into RNA, where further splicing results in a 
final mRNA sequence.  That sequence is then translated into a polypeptide, which is finally trimmed of its 
leader (L) sequence to give the final beta chain.  Similar rearrangements occur for the T cell receptor 
alpha chain and for the B cell receptor heavy and light chains.  In addition, further diversity arises from N-
nucleotides added at junctions increasing randomness.  For B cells, somatic hypermutation occurs after 
activation leading to affinity maturation of the progeny’s B cell receptor for the recognized antigen. 
 
 B cells are an important part of the adaptive immune response.  These cells originate in 
the bone marrow where they develop and individually rearrange their receptors.  The structure of 
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the B cell receptor contains two identical binding sites for antigen, each composed of the variable 
regions of one heavy chain and one light chain, respectively.  The receptor also contains 
associated subunits that do not bind antigen called Igα and Igβ which exist as disulfide-linked 
heterodimers, and have large intracellular immunoreceptor tyrosine activation motif (ITAM) 
domains, which can become phosphorylated and initiate signaling cascades upon receptor 
triggering.  A schematic representation of the B cell receptor can be seen in Figure I.2 A.  Once 
the B cell has rearranged and expressed its receptor, it is checked for autoreactivity.  B cell 
clones that respond to autoantigens are deleted.  The clones that are not self-reactive are released 
to monitor the body for their specific foreign antigens.  If a B cell encounters a soluble antigen 
that it recognizes by binding specifically to its receptor, it becomes activated and proliferates, 
during which a process called somatic hypermutation occurs, resulting in further changes to the 
BCR sequence.  The subsequent population contains clones with a higher affinity for the antigen, 
a phenomenon known as affinity maturation.  The B cells can further differentiate into plasma 
cells which secrete soluble versions of the B cell receptor, known as antibodies (Figure I.2 B). 
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A B FIGURE I.2  The B cell 
antigen receptor.  (A) The B 
cell receptor consists of two 
transmembrane heavy chains 
linked to each other by 
disulfide bonds (green), and 
two light chains, each linked to 
one heavy chain by a disulfide 
bond.  The two identical 
antigen binding sites are 
comprised of the variable 
regions (VH and VL) of both the 
heavy chain and the light 
chain.  The antigen binding  
portion of the receptor is associated with signaling subunit heterodimers containing 
disulfide-linked Igα and Igβ.  These subunits have intracellular ITAM domains which 
can interact with cytoplasmic signaling proteins.  The B cell becomes activated when 
the receptor binds to soluble antigen expressing multiple binding epitopes.  (B) Upon 
activation of the B cell, it can produce an alternatively spliced BCR without 
transmembrane domains.  This results in a soluble, secreted version known as an 
antibody.  These antibodies bind to their antigens, labeling them for immune clearance. 
 
 T cells also play an important role in adaptive immunity.  They originate in the bone 
marrow like B cells; however, they then migrate to the thymus for further development and 
differentiation.  Unlike B cells which recognize soluble antigens, T cells recognize small 
antigens presented in complex with cell-surface major histocompatibility complex (MHC) 
proteins on the surface of other cells.  During development, each T cell clone recombines its 
receptor similarly to B cells, creating a unique specificity, that must be within certain limits of 
affinity for self-antigen to avoid deletion.  High affinity for self antigen results in autoreactivity, 
while low affinity suggests that the T cell receptor can not recognize the antigen-presenting 
MHC protein itself.  T cells will be the focus of the following sections. 
 
I.B. Antigen Recognition by T cells 
I.B.1 The T cell receptor 
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The T cell receptor contains an alpha (α) and beta (β) chain that together form a single 
binding site for antigen.  The alpha and beta chains are associated with two membrane 
heterodimers (delta-epsilon, δε, and gamma-epsilon, γε) that contain one cytoplasmic ITAM on 
each chain, and a zeta-zeta (ζ2) homodimer which contains three intracellular ITAM domains on 
each chain and a very small extracellular portion. (Figure I.3).  The signaling subunits of the 
TCR complex are collectively known as CD3.  The exact stoichiometry of the different subunits 
of the T cell receptor has been in dispute for many years.  Convincing evidence has been shown 
that the complex assembles with the stoichiometry αβδεγεζ2 (Call et al., 2002); however, the 
possibility of altered arrangements based on activation or developmental state is not ruled out 
(Fahmy et al., 2001; Fernandez-Miguel et al., 1999; Garcia, 1999).     
FIGURE I.3  The T cell antigen 
receptor.  The T cell receptor 
consists of two transmembrane 
chains, α and β linked to each 
other by a membrane-proximal 
disulfide bond (green), which 
form the antigen-specific binding 
site.  The binding chains are 
associated with two 
heterodimers δε and γε and a 
disulfide-linked ζζ homodimer, 
collectively referred to as CD3.   
These subunits contain signaling ITAM domains.  The complex is held together by 
conserved transmembrane charge associations—positive charges on the αβ chains 
associate with negative charges on the CD3 chains.  T cells also express a co-receptor 
for the MHC, either CD4 or CD8, which can associate with the cytoplasmic kinase LCK. 
 
T cells recognize small peptides derived from antigen in complex with MHC molecules 
on the surface of APCs.  When T cells detect specific antigen-MHC complexes through binding, 
cytoplasmic signaling cascades are initiated, leading to T cell receptor subunit phosphorylation, 
increased calcium flux, proliferation and other effector functions specific to the type of T cell 
cytoplasm
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(Cantrell, 1996; Qian and Weiss, 1997; Wange and Samelson, 1996).  Some common indicators 
used to measure T cell activation are TCR downregulation (Valitutti et al., 1997), and 
upregulation of cell-surface proteins such as CD69 (Testi et al., 1994), CD25 (Waldmann, 1989), 
and CD71 (Ponka and Lok, 1999). 
 T cells also express a co-receptor, either CD8 or CD4, which binds to MHC proteins in 
an antigen non-specific manner.  There are two main classes of MHC molecules: class I MHCs 
which present primarily intracellular antigens to CD8+ T cells, and class II MHCs which present 
primarily extracellular antigens to CD4+ T cells.  The co-receptor, which associates with the 
intracellular kinase Lck, can bind to its class of MHC regardless of the peptide antigen is 
presented.  CD8+ T cells, usually cytotoxic T lymphocytes (CTLs), recognize 8-11 amino acid 
long peptides in complex with class I MHCs, which are present on the surface of all nucleated 
cells.  When a CD8+ T cell becomes activated by a specific class I MHC-peptide complex on the 
surface of an antigen-presenting cell (APC), it initiates processes to kill or lyse the cell with 
which it is interacting.  This activity is useful in eliminating virally infected cells or possibly 
mutated or cancerous cells.  CD4+ T cells, usually T helper cells (TH), recognize 9-25 amino acid 
long peptides presented in complex with class II MHCs, which are present on the surface of 
professional antigen presenting cells, including macrophages, dendritic cells, and B cells.  Upon 
recognition of its specific MHC-peptide complex, a CD4+ T cell initiates effector functions such 
as cytokine secretion and cell-surface protein upregulation that can recruit and activate other 
immune cells or induce B cells to produce antibodies. 
 In addition to these main two types of T cells, there are further delineations between 
members of these sets.  For example, T-helper cells can secrete different panels of cytokines if 
they are TH1 cells (IL-2, IFN-γ, and TNF-α) as opposed to TH2 cells (IL-4, IL-5, IL-6, and IL-
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10).  Also, an inhibitory subset called T-regulatory cells has been identified that downregulates 
an immune response in an antigen-specific manner (O'Garra and Vieira, 2004).  Some T cells 
have also been identified that express a γδ antigen-binding receptor instead of αβ, and exhibit 
specificity to non-classical MHC-bound antigens (Holtmeier, 2003; Kabelitz et al., 2000; 
Kabelitz and Wesch, 2003).  Finally, a novel lymphocyte subset related to innate immune cells, 
Natural Killer T cells, has been identified to play a role in cancer, autoimmunity, infection, and 
transplantation.  These cells use a semi-invariant T cell receptor to recognize non-typical 
antigens such as glycolipids in complex with the non-classical class I-like molecule CD1d (Seino 
and Taniguchi, 2004; Swann et al., 2004). 
I.B.2 Antigen Presentation by the Major Histocompatibility Complex (MHC) 
The Major Histocompatibility Complex (MHC) is a polymorphic cell-surface 
glycoprotein expressed on antigen-presenting cells.  These proteins form complexes with short 
peptides derived from self or antigenic proteins which can be recognized by T cells through TCR 
binding.  There are two main classes of MHC proteins: class I and class II (see Figure I.4 A-B).  
The molecules are structurally related to one another, consisting of immunoglobulin-like lower 
domains and an upper domain that binds peptides between two alpha helices atop a beta-sheet 
floor, orienting residues for TCR recognition (reviewed in (Stern and Wiley, 1994)).  Class I 
MHCs have a single heavy chain that crosses the cell membrane and associates with the β2-
microglobulin (β2M) light chain.  Short peptides are anchored in conserved N-terminal and C-
terminal pockets in the peptide binding groove, disallowing very long peptides from binding 
(Figure I.4 C).  Class II MHCs have two roughly equal sized chains, both with transmembrane 
spans, that form the complex.  Longer peptides (9-25 amino acids long (Chicz et al., 1992; 
Rudensky et al., 1991)) can be bound, and the termini may extend out from both ends of the 
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peptide binding groove (Figure I.4 D).  The peptides in class II MHCs are held in a polyproline 
type II conformation by conserved hydrogen bond interactions with the peptide backbone, and 
the binding specificity is defined by pockets in the protein at positions P1, P4, P6, and P9.  Each 
type of MHC can bind a wide variety of peptides, leading to many potential T cell epitopes being 
presented by a single molecule.  Different MHC alleles have slightly different anchor residue 
specificities, leading to a different spectrum of epitopes being presented.  Peptide binding 
prediction algorithms have been developed in an attempt to determine which pieces of an 
antigenic sequence may be presented by a given MHC allele with varying success (Hammer et 
al., 1994; Rammensee et al., 1995; Southwood et al., 1998; Sturniolo et al., 1999).  
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A  HLA-A2 with peptide derived from 
influenza matrix protein M1 
 
B HLA-DR1 with peptide derived from 
influenza haemagglutinin protein 
 
C D 
FIGURE I.4.  Structural comparison between class I and class II MHCs. (A) Cartoon 
representation of the structure of human class I MHC HLA-A2 in complex with a peptide 
derived from the influenza matrix protein, M1.  Heavy chain is shown in magenta, light 
chain is shown in blue, and peptide is shown in yellow as spheres.  (B) Cartoon 
depiction of the structure of human class II MHC HLA-DR1 in complex with a peptide 
derived from the influenza haemagglutinin protein.  Alpha chain is shown in blue, beta 
chain is shown in magenta, and peptide is shown in yellow as spheres.  (C-D) Side view 
surface topology of the peptide-binding domain is shown with space-filled 
representations of bound peptide.  (C) The class I MHC HLA-A2 bound to a peptide 
derived from the reverse transcriptase protein of HIV.  Note that the peptide termini are 
buried in the MHC.  (D) HLA-DR1 is shown bound to hemagglutinin-derived peptide 
from above.  In contrast to class I, the class II MHC peptide binding groove is open-
ended, and peptide binding specificity is determined by residues in several distinct 
pockets along the groove, labeled P1, P4, P6 and P9.  (C-D) are reproduced from Stern 
& Wiley, Structure, 1994. 
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Class I MHC proteins are synthesized in the endoplasmic reticulum (ER) of all nucleated 
cells, where they are loaded with short peptides, 8-11 amino acids long.  These peptides are 
brought into the ER from the cytoplasm by the ATP-dependent transporter associated with 
antigen processing (TAP).  Often these peptides are derived from proteosomally degraded 
proteins, and can come from intracellular antigens such as viral components.  Once the complex 
has loaded peptide, it is translocated through the golgi apparatus to the surface of the cell for 
recognition by CD8+ T cells (Figure I.5 A).  The process is reviewed in (Pamer and Cresswell, 
1998). 
Class II MHC proteins are also synthesized in the ER and immediately associate with the 
invariant chain (Ii), which places a loop in the peptide binding groove of the MHC.  The two 
proteins are trafficked together to the endosome, where the invariant chain is trimmed to leave a 
small, loosely bound peptide called CLIP in the MHC binding groove.  Peptides derived from 
extracellular antigens that have been endocytosed and degraded in lysosomes are also present in 
the endosome.  With the help of the MHC homologue protein HLA-DM, the class II MHC 
exchanges CLIP for other peptides in the endosome.  The resulting complex is then sent to the 
cell surface for recognition by CD4+ T cells (Figure I.5 B).  This process is reviewed in (Watts, 
1997). 
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FIGURE I.5 The antigen processing, loading, and presentation pathways for class 
I and class II MHCs. 
Class II MHC processing pathway: 
1. Extracellular antigen is internalized via 
receptor-mediated endocytosis, 
phagocytosis, or pinocytosis. 
2. Antigenic particles are broken down in low 
pH compartments by proteases. 
3. Class II is synthesized in the ER with the 
Invariant Chain (Ii), which places a loop in 
the peptide binding groove of the MHC. 
4. The MHC-Ii complex is trafficked through 
the golgi into endosomes. 
5. The Ii protein is cleaved, leaving a small 
peptide fragment called CLIP in the MHC 
binding site. 
6. The MHC-CLIP complex and antigen 
fragments meet in the endosome.  HLA-
DM, an MHC homologue, aids in peptide 
exchange. CLIP is released and antigenic 
peptide is bound. 
7. The MHC-peptide complex is trafficked to 
the surface of the cell for presentation to 
CD4+ T cells 
Class I MHC processing pathway: 
i. Intracellular antigen in the cytoplasm is 
tagged for degradation.  These may 
include viral components or self proteins. 
ii. Antigenic proteins are broken down into 
peptides by the proteasome. 
iii. Peptides are pumped from the cytosol into 
the ER by TAP. 
iv. Peptide is loaded onto newly synthesized 
class I MHC. 
v. The class I MHC-peptide complex is 
trafficked to the golgi. 
vi. The MHC-peptide buds off of the golgi in a 
vesicle. 
vii. The MHC-peptide is sent to the cell surface 
for presentation to CD8+ T cells 
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I.B.3 Other interactions between T cells and APCs (antigen non-specific) 
While antigen-specific recognition is controlled by TCR binding to MHC-peptide 
complexes on the surface of APCs, it is not the only protein-protein interaction involved in the 
interface between the two cells.  Other interactions contribute to both binding and signaling 
regardless of the antigenicity of the MHC-peptide. 
Adhesion molecule interactions are some of the first interactions to form between the T 
cell and the APC.  Molecules on the T cell including LFA-1 (CD11a) and LFA-2 (CD2) bind to 
ICAMs and LFA-3 (CD58) on the surface of APCs (Pribila et al., 2004).  These interactions aid 
in T cell stimulation in response to antigenic stimuli, but do not cause T cell triggering without 
the presence of stimulatory MHC-peptide complexes. 
Second, the MHCs on the surface of the APC which are in complex with non-antigenic 
peptide still seem to have some effect on the activation of the T cell.  The precise contribution of 
these non-stimulatory complexes is not clear, but the presence of excess null MHC-peptide 
complexes seems to aid in the recognition of stimulatory MHC-peptide complexes (Irvine et al., 
2002; Wulfing et al., 2002).  
Third, the co-receptor expressed by the T cells is able to bind to the MHC in a distal site 
to the peptide binding groove.  The co-receptor, CD4 or CD8, can associate intracellularly with 
the kinase Lck, which is thought to be involved in signaling cascades.  It is unknown precisely 
what the contribution of the co-receptor is to the overall signaling mechanism.  However, 
binding of co-receptor to the MHC can increase the overall affinity of the T cell for the complex, 
and may lower the threshold for antigenic MHC-peptide complexes required for T cell responses, 
or it may play a more direct role by bringing the co-receptor cytoplasmic domain associated with 
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Lck into the proximity of the TCR complex. (Delon et al., 1998; Garcia et al., 1996; Irvine et al., 
2002; Luescher et al., 1995; Purbhoo et al., 2001; Renard et al., 1996; Zamoyska, 1998). 
Finally, the T cell receives a number of co-stimulatory signals through cell-surface 
molecules such as CD28 and CTLA-4.  These molecules bind to a class of co-stimulatory 
molecules called B7 on the surface of APCs, and the resultant signals are important for 
amplifying and then later downregulating the T cell response (Chambers, 2001; McAdam et al., 
1998; Schwartz, 1992; Wulfing et al., 2002). 
These interactions together make it difficult to dissect out the specific molecular events 
leading to T cell triggering by antigenic MHC-peptide complexes. 
I.B.4 The Molecular Mechanism of T cell antigen recognition 
The molecular trigger that causes T cell activation by foreign antigen presented by an 
APC has been problematical to determine.  In the case of B cells which recognize soluble 
antigens, it has been possible to study the mechanism of activation by supplying antigen with 
defined epitope valencies; in those systems, multivalent antigen engagement has been shown to 
be crucial (Metzger, 1992; Siraganian et al., 1975).  However, in the case of T cell stimulation by 
an antigen-presenting cell, antigen receptor binding to MHC-peptide complex alone does not 
define the interaction.  The T cell can also interact with other non-stimulatory MHC-peptide 
complexes (either with the TCR or co-receptors CD4 or CD8) as well as co-stimulatory and 
adhesion molecules.  Thus, it is difficult to determine specifically what features of the antigenic 
MHC-peptide binding cause the T cell to become activated. 
In an attempt to uncover the mechanism of TCR signaling, many different techniques 
have been applied.  It had been shown that a specific T cell clone can be activated by adding 
APCs pulsed with the appropriate chemically synthesized peptide (Lamb et al., 1982), but it was 
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initially difficult to produce soluble MHC-peptide reagents.  Experiments done using peptide on 
APCs to stimulate T cells gave some insight into sensitivity (Brower et al., 1994; Reay et al., 
2000; Sykulev et al., 1995; Sykulev et al., 1996), but were ultimately complicated by both the 
myriad of antigen non-specific interactions present between the cells and also the uncertainty of 
how (and how many) MHC-peptide complexes were being presented.  Many studies were 
conducted treating T cells with antibodies against the T cell receptor (Kappler et al., 1983; Kaye 
et al., 1983; Yoon et al., 1994), or by creating chimeric receptors expressing TCR signaling 
subunit intracellular domains with unrelated extracellular domains that could be crosslinked with 
other ligands (Irving and Weiss, 1991; Letourneur and Klausner, 1991).  Together, these studies 
suggested that crosslinking of T cell receptor complexes or subunits via multivalent ligand 
binding was sufficient to initiate signaling processes. 
As soluble MHC-peptide reagents became more easily available, studies were conducted 
using soluble monovalent and multivalent arrangements of MHC-peptide complexes to study T 
cell clones or TCR transgenic mouse T cells (reviewed in (Cochran et al., 2001a)).  Soluble 
MHC-peptide monomers were found to bind weakly to T cell receptors (Kd ~ 10-6-10-4M), and 
exhibited short half-lives (1-100 sec.) (Crawford et al., 1998; Davis et al., 1998).  Oligomeric 
MHC-peptide reagents of defined sizes were used to show that for both CD4+ and CD8+ T cells, 
dimers or higher order oligomers were able to stimulate responses (Abastado et al., 1995; 
Boniface et al., 1998; Casares et al., 1999; Cochran et al., 2000; Daniels and Jameson, 2000; 
Doucey et al., 2001), although monomeric class I MHC reagents were shown in some studies to 
activate CD8 T cells in a co-receptor dependent manner (Delon et al., 1998).   
Another technique applied to this issue has been confocal microscopy of the real-time 
immune response using fluorescently-labeled proteins.  Dramatic images of a large 
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supramolecular activation complex (SMAC), termed the immunological synapse, were observed 
between T cells and APCs or supported bilayers containing molecules found on the APC cell 
surface (Dintzis et al., 1976; Grakoui et al., 1999; Monks et al., 1998).  These supramolecular 
clusters consisting of a central region (C-SMAC) of TCR and MHC and a peripheral region (P-
SMAC) containing adhesion molecules were thought to be related to T cell activation.  However, 
signaling events have been seen without formation of the immunological synapse (Zaru et al., 
2002), and CTL activity in CD8+ cells doesn’t require formation of these supramolecular 
structures (Purbhoo et al., 2004).   
The high sensitivity of CD8+ T cells suggested by target lysis without formation of an 
immunological synapse and at extremely low peptide antigen levels approaching one per cell 
(Sykulev et al., 1996), creates an apparent sensitivity difference between them and CD4+ T cells, 
which can recognize a single antigenic peptide on an APC, but require higher antigen levels for 
functional activity (Irvine et al., 2002).  It is unknown whether some these differences are due to 
differential co-receptor involvement or potentially even a different signaling mechanism. 
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FIGURE I.6. Possible mechanisms for antigen-specific activation through the T 
cell receptor. The T cell antigen-binding receptor is shown in gold. Activating MHC-
peptide complex is shown as a light blue oval, while non-activating MHC-peptide 
complex is shown in yellow.  Co-receptor is shown in green as a tall stalk with a binding 
site near the top.  TCR complex subunits are shown where relevant to the mechanism 
as dark blue stalks. 
 
Many possible models for T cell triggering through the TCR have been proposed.  These 
are outlined in Figure I.6.  First, a mechanism common to seven transmembrane helix proteins 
which activate G proteins (Wess et al., 1997) describes a conformational change upon 
extracellular ligand binding that is transmitted through the membrane (Figure I.6 A).  This 
mechanism has seemed unlikely for T cell triggering, as it is difficult to imagine a single 
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conserved conformational change resulting from diverse MHC-peptide stimuli binding to 
genetically dissimilar receptor binding domains.  Additionally, the intracellular domains of the 
antigen binding chains (α and β) are very small, and signaling through the receptor is carried out 
through non-covalently associated CD3 chains (ε, δ, γ, and ζ) rather than the binding chains.  In 
fact, multiple crystal structures of MHC-peptides bound to T cell receptors have failed to show 
structural differences between complexes with agonist versus antagonist peptides (Ding et al., 
1999).  However, it has been suggested that tight-binding immunodominant MHC-peptide 
complexes may induce a conformational change in the AB loop of the Cα chain of the TCR, 
which forms part of the putative interaction site with the CD3ε subunit (Kjer-Nielsen et al., 
2003). 
An alternative model suggests that T cell signaling is initiated when the T cell receptor is 
clustered with the MHC co-receptor by both binding to a single MHC-peptide complex, holding 
the intracellular kinase (Lck) associated with the co-receptor close to the TCR signaling subunit 
ITAM domains (Figure I.6 B).  A variation on this model has also been proposed (Irvine et al., 
2002; Krogsgaard et al., 2003) where an activating MHC-peptide bound TCR is associated with 
a co-receptor molecule that can bind to a non-activating MHC-peptide bound to an adjacent 
TCR, causing activation of the first TCR via a co-receptor linked pseudodimer (Figure I.6 C).  
This model was proposed in part due to structural studies showing that soluble CD4 bound to an 
MHC forms a sharp angle with the MHC-TCR axis, making it difficult to imagine a CD4 
molecule and a TCR bound to the same MHC complex bringing their cytoplasmic domains into 
close proximity (Wang et al., 2001).  Co-receptor models might explain how activation could 
occur from a single activating peptide on an APC.  However, studies showing that signaling does 
not depend on co-receptor involvement (Cho et al., 2001; Kerry et al., 2003 and Chapter III of 
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this thesis) seem to suggest that this is not the main trigger for T cells, and may simply alter 
sensitivity levels or contribute to binding energy.  
Another mechanism involves multivalent ligand binding which promotes receptor 
dimerization or oligomerization (Figure I.6 D).  This type of mechanism is found in receptor 
tyrosine kinases which can transphosphorylate one another when brought together by ligand 
(Hubbard and Till, 2000).  The T cell receptor subunits do not contain any enzymatic activity 
that might act in a trans manner upon receptor dimerization; however, there is much evidence 
that crosslinking of TCR or TCR complex subunits by soluble MHC-peptide reagents is 
sufficient for triggering activation responses (Abastado et al., 1995; Cochran et al., 2000; Daniels 
and Jameson, 2000; Doucey et al., 2001; Maile et al., 2001).  Signaling occurs even for antibody-
induced crosslinking or clustering of chimeric receptors which would not involve the MHC co-
receptor (Irving and Weiss, 1991; Kappler et al., 1983; Kaye et al., 1983; Letourneur and 
Klausner, 1991).  However, an oligomerization model does not explain how responses to single 
activating peptide-MHC complexes could occur.  
Other researchers have suggested disruption of an inhibitory pre-defined oligomeric 
receptor structure (Figure I.6 E)(Cameron et al., 2001b; Reth, 2001).  This mechanism can be 
seen with the bacterial aspartate receptor (Falke et al., 1997; Ottemann et al., 1999).  However, 
the T cell receptor has been shown to assemble with a single antigen binding receptor per 
complex (Call et al., 2002).  There is also evidence showing a lack of orientation dependence for 
T cell stimulation by multivalent MHC-peptide ligands (Cochran et al., 2001b).  A different but 
related model proposes a rearrangement of the TCR subunits, possibly exposing novel epitopes 
for adaptor and signaling proteins (Gil et al., 2002; Sigalov, 2004).  Evidence has been shown 
that T cell receptor signaling subunits homooligomerize through their unstructured cytoplasmic 
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domains (Sigalov et al., 2004), and are present on the cell surface unassociated with the larger 
TCR complex after activation (La Gruta et al., 2004).  It is unsure whether this kind of 
mechanism would be initiated by a binding-induced conformational change (Figure I.6 F) or a 
clustering of receptors into close proximity (Figure I.6 G). 
Further discussion of the antigen-specific trigger for CD4 and CD8 T cells can be found 
in Chapters II-IV of this thesis. 
 
I.C. Detection and characterization of antigen-specific T cells 
I.C.1 Importance for study of infection and vaccination 
 The population of T cells in the body is diverse.  Different types of T cells exhibit 
different effector functions that may be more or less effective at controlling particular pathogens.  
For example, while some diseases are effectively controlled by antibody responses, other 
infections such as hepatitis C are not cleared despite the presence of neutralizing antibodies 
(Logvinoff et al., 2004).  Likewise, the balance between TH1 and TH2 responses or particular 
protein epitope recognition in HIV-1 infection has been related to disease control or progression 
(Becker, 2004; Rosenberg et al., 1997), where the virus has developed mechanisms for evading 
CTL responses (Collins, 2003).  Improper immune responses to certain infections can even lead 
to immunopathology or autoimmunity (Brehm et al., 2004; Christen and von Herrath, 2004; 
Mongkolsapaya et al., 2003; Terajima et al., 2004).  One goal of health care is to create safer 
vaccines and immunotherapies that elicit appropriate adaptive immune responses for disease 
control and clearance. 
 An important step in studying the T cell response to a given infection is to identify T cell 
epitopes, or the portions of pathogenic proteins that are presented in complex with MHCs on the 
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surface of APCs that are then recognized by clonotypic T cells present in the overall repertoire.  
The low frequency of T cells that can recognize a given epitope, combined with the large number 
of peptides that may be derived from a single pathogen for presentation on MHC molecules, 
create challenges to routine identification of T cell epitopes from novel or emergent diseases. 
I.C.2 Methods for identifying and quantifying antigen-specific T cells 
 Screening epitopes in cellular assays is usually accomplished by synthesizing 20-22 
amino acid long peptides which cover the sequence of a pathogenic protein, keeping an overlap 
of 10-12 amino acids between adjacent peptides, and then testing each peptide for the ability to 
elicit a T cell response when added to a mixture of T cells and APCs.  It is costly to synthesize 
the peptides, and many valuable cells from limited ex vivo samples must be used for the tests.  
When using recombinant MHCs to screen epitopes, the problem is further complicated.  Class I 
MHC molecules can only bind short peptides of 8-10 amino acid lengths, requiring 
approximately 30 times as many peptides to be synthesized and screened as for class II.  
Attempts to reduce the pool of potential peptides by use of positional scanning prediction 
methods have thus far failed to be sensitive and predictive enough to reduce the number of 
peptides to a more reasonable number (Hammer et al., 1994; Rammensee et al., 1995; 
Southwood et al., 1998; Sturniolo et al., 1999). 
There are several techniques which have been applied to screening T cell populations for 
specific reactivities.  Many functional assays involve cellular presentation elements (APCs) that 
process and present overlapping peptides derived from a given pathogenic sequence to a 
responding bulk T cell population.  The T cells can be monitored for functional activation 
responses such as proliferation in bulk (Strong et al., 1973) or by limiting dilution analysis 
(Merkenschlager et al., 1988), lysis of labeled target cells (Engers et al., 1975; Koenig et al., 
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1990; Kurokohchi et al., 2001), or cytokine secretion by bulk enzyme-linked immunosorbent 
assay (ELISA), intracellular cytokine staining (Kern et al., 1998; Maecker et al., 2001; Prussin 
and Metcalfe, 1995), or ELISPOT (Czerkinsky et al., 1988).  These techniques can utilize 
overlapping peptides for both class I and class II MHC presentation, since APCs process and 
load the peptides.  However, large sample sizes are needed to screen a reasonable number of 
peptides, and only a few functional aspects of the cells can be monitored simultaneously.  Also, 
it can be difficult to establish the frequency of the T cells of interest in the ex vivo sample, and 
determination of the MHC restriction of an observed response is non-trivial since most APCs 
express multiple MHC alleles. 
 Another group of techniques do not depend upon functional responses, but identify 
responding populations by their binding to recombinant oligomeric MHC in complex with 
cognate peptide.  One such technique is to stain mixed T cell populations with MHC-peptide 
complexes linked to fluorescently-labeled streptavidin molecules via biotin incorporated into the 
MHC molecule either chemically or enzymatically—so-called “tetramer staining” (Altman et al., 
1996; Cameron et al., 2002; Dunbar and Ogg, 2002; Kwok et al., 2002).  The cells are then 
analyzed using flow cytometry, and the cells which are bound to the specific MHC-peptide 
complexes are fluorescently stained.  This technique, popularized first for class I MHCs and then 
extended to class II MHC reagents, has not only provided much information about the 
frequencies of antigen-specific T cells over the course of infections and vaccinations, but has 
also become somewhat ubiquitous in recent years, with MHC oligomers becoming available 
from various core facilities (National Institutes of Health) or companies (Becton Dickinson 
“DimerX”, Beckman Coulter “iTag Tetramers”, or ProImmune “Pro5” MHC pentamers).  
Several disadvantages exist, however.  Recombinant peptide-MHC complexes are not available 
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for every possible allele, and a relatively large number of cells is required to find a low-
frequency response in a diverse population.  In addition, no functional information is attained 
from this technique, and staining must be combined with other techniques to obtain that 
information.  A related screening technique involves adhesion of cells to elements of a 
microarray containing recombinant MHC-peptides (Soen et al., 2003).  This technique allows 
multiple peptide-MHC complexes to be tested with a smaller sample size, and can also be used 
to detect transient calcium flux in adhering cells.   
 Chapter V of this thesis reports progress made on a technique which can be used to 
screen small T cell samples for specific MHC-peptide binding and for induced functional 
responses using microarrays of artificial antigen-presenting cells containing recombinant MHC-
peptide complexes and co-stimulatory molecules.  These arrays can detect responses such as 
binding, cell-surface molecule expression, and cytokine secretion in a location-dependent 
manner. 
 
I.D. Overview of this thesis 
 This thesis contains work directed at increasing our understanding of the molecular 
mechanism of CD4+ and CD8+ T cell activation as well as work on a method for screening 
potential T cell epitopes and characterizing the antigen-specific responses induced.  Background 
related to these topics has been summarized in this chapter. 
 Chapter II describes the application of a mathematical model of equilibrium multivalent 
binding to CD4+ T cell responses induced by MHC-peptide monomers and oligomers.  CD4+ T 
cells had previously been shown to respond to soluble dimers, trimers, and tetramers of MHC-
peptide complexes, but not soluble monomers (Cochran et al., 2000).  The concentration 
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dependence of these responses showed characteristic curves with responses rising at lower 
concentrations for higher valency oligomers, and the responses decreasing at high concentrations 
for all oligomers.  This work shows that the level and concentration dependence of activation 
responses can be explained by the number of multivalently-bound T cell receptors.  The number 
of crosslinked receptors can be predicted by two parameters: a monovalent binding constant, KD, 
and a crosslinking constant, KX, which can be fit from activation parameter curves.  Data 
generated using these same parameters can be fit to multiple different activation read-outs as 
well as direct binding data.  The association found between the predicted number of 
multivalently-engaged TCR and the level of T cell activation by multivalent MHC ligands argues 
that activation corresponds to TCR clustering or multivalent ligation.  Jennifer R. Cochran, a 
former member of the Stern lab, contributed to these efforts by developing the experimental 
system and gathering much of the data modeled.  This work was published in November, 2001 in 
Biophysical Journal (Stone et al., 2001). 
 Chapter III presents a confounding phenomenon uncovered in attempts to study CD8+ T 
cell activation using soluble MHC-peptide monomers and oligomers.  CD8+ T cells, unlike CD4+ 
T cells, were found to be activated when soluble syngeneic MHC-peptide monomers were added 
to the cells, and were even able to respond to free cognate peptide.  Further investigation 
revealed that peptides derived from soluble complexes were able to be loaded onto endogenous 
MHC complexes on the surface of T cells and re-presented to other T cells in the assay.  
However, MHC monomers did not cause stimulation under conditions where peptide re-
presentation was not possible; for example, allospecific MHC-peptide monomers yielded 
peptides that did not form stimulatory complexes with cell surface MHCs, and T cells engineered 
not to express class I MHCs on their surface did not respond to soluble syngeneic MHC 
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monomers.  However, in both cases, immobilizing the stimulatory MHC complex on assay well 
surfaces resulted in T cell recognition.  This work showed that observed monomer activation in 
CD8+ T cells could be explained by multivalent peptide re-presentation on the surface of other T 
cells.  Qing Ge in Jianzhu Chen’s lab at the Massachusetts Institute of Technology Cancer Center 
contributed equally to myself in these endeavors, and other contributors include M. Todd 
Thompson, Jennifer R. Cochran, and Mia Rushe in the Stern lab, and Herman Eisen helped with 
extensive discussions.  This work was published in October, 2002 in the Proceedings of the 
National Academy of Sciences, USA (Ge et al., 2002). 
 Chapter IV includes further investigations into the requirements for T cell activation by 
soluble MHC-peptide monomers and oligomers.  CD8+ T cells were presented with allogeneic 
MHC monomers and oligomers, which do not cause activation through peptide re-presentation at 
the T cell surface.  Under these conditions, CD8+ T cells were shown to have similar responses 
to the soluble complexes as CD4+ T cells.  For both CD4+ and CD8+ T cells, addition of soluble 
MHC-peptide monomers can antagonize activation induced by MHC-peptide oligomers.  
However, T cell responses could be induced by a single activating MHC-peptide complex when 
linked to a non-activating MHC-peptide complex in a heterodimer, consistent with studies 
showing that a single activating peptide can cause T cell signaling (Irvine et al., 2002; Sykulev et 
al., 1996), and that non-activating MHC-peptide complexes can contribute to activation 
responses (Wulfing et al., 2002).  Jennifer R. Cochran contributed to this work by performing the 
monomer antagonism experiment for CD4+ T cells.  This work has been submitted for 
publication. 
 Chapter V illustrates a technique for mapping pathogen-derived T cell epitopes and 
characterizing functional antigen-specific T cell responses using microarrays of synthetic 
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antigen-presenting cells.  Each element of the microarray presents a distinct potential peptide 
epitope derived from an infectious agent in complex with recombinant MHC co-immobilized 
with costimulatory molecules that allow full activation responses in the T cells.  Effector 
responses to the arrayed proteins, including cytokine secretion, can be detected in a location-
specific manner by including cytokine capture antibodies into the array elements where the 
cytokines are captured locally and are detected by fluorescently-labeled detection antibodies.  
Other facets of T cell activation such as adhesion or surface molecule modulation can be 
analyzed using this type of microarray as well.  Responses from CD8+ and CD4+ T cells are 
detected specifically and at a sensitivity level similar to ELISPOT, but for many more antigens in 
parallel.  Multiple responses can be measured simultaneously; for example, IFN-γ and IL-4 can 
both be detected at once.  This technique shows potential for multidimensional specificity and 
functional information to be collected conveniently and rapidly, increasing our understanding of 
the immune response to novel infectious agents.  Walter Demkowicz in the Stern lab contributed 
to this study by growing several T cell lines and clones.  This work has been submitted for 
publication, and there is a patent pending on this technique (Pending patent application 
10/823,866  “Major Histocompatability Complex (MHC)-Peptide Arrays”). 
 Chapter VI contains overall conclusions and a discussion of the significance of this work.  
The Appendices contain detailed protocols from this work as well as information about 
constructs, peptides, and materials. 
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II. T cell activation by soluble MHC oligomers can be described by a two-
parameter binding model1 
 
SUMMARY 
 
 T cell activation is essential for initiation and control of immune system function.  T cells 
are activated by interaction of cell-surface antigen receptors with major histocompatibility 
complex (MHC) proteins on the surface of other cells.  Studies using soluble oligomers of MHC-
peptide complexes and other types of receptor cross-linking agents have supported an activation 
mechanism that involves T cell receptor clustering.  Receptor clustering induced by incubation of 
T cells with MHC-peptide oligomers leads to the induction of T cell activation processes, 
including downregulation of engaged receptors and upregulation of the cell-surface proteins 
CD69 and CD25.  Dose-response curves for these T cell activation markers are bell-shaped, with 
different maxima and midpoints depending on the valency of the soluble oligomer used.  In this 
study, we have analyzed the activation behavior using a mathematical model that describes the 
binding of multivalent ligands to cell-surface receptors.  We show that a simple equilibrium 
binding model accurately describes the activation data for T cells treated with MHC-peptide 
oligomers of varying valency.  The model can be used to predict activation and binding behavior 
for T cells and MHC oligomers with different properties.
                                                 
1 The research presented in this chapter has been published:  
 J.Stone, J.R. Cochran, and L.J.Stern. Biophys J. 2001 Nov;81(5):2547-57. 
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A. Introduction 
 CD4+ T cells have an important role in the immune system in recognition and response to 
foreign antigens.  CD4+ T cell activation is triggered upon specific interaction of T cell surface 
receptors (TCR) with foreign antigens bound to class II major histocompatibility complex 
(MHC) proteins found on the surface of B cells, macrophages, and other antigen-presenting cells 
(Davis et al., 1998; Germain, 1994).  MHC-TCR engagement triggers a cascade of signaling 
events, including phosphorylation of receptor subunits, docking of receptor-associated signaling 
and adapter proteins, activation of cytoplasmic signaling cascades, and up-regulation of several 
gene products (Cantrell, 1996; Qian and Weiss, 1997).  The complete activation program also 
requires participation of antigen-independent adhesion and costimulatory molecules from both 
the T cell and antigen-presenting cell (Chambers, 2001), which can lead to formation of cell-
surface supramolecular activating clusters or “immune synapses” (van der Merwe et al., 2000), 
and eventually cytokine secretion, clonal proliferation, and induction of other T cell effector 
functions required to help clear the foreign antigen from the host.   
 The precise molecular events that induce T cell triggering upon TCR ligation are not well 
understood, but substantial evidence points to receptor clustering as an important component of 
the signaling in this system (Germain, 1997).  Early studies showed that antibody-mediated 
clustering of TCR (Janeway, 1995), or clustering of chimeric TCR cytoplasmic domains (Irvine 
et al., 2002; Letourneur and Klausner, 1991) could trigger T cell activation processes.  More 
recently, soluble MHC-peptide oligomers have been used as reagents to investigate T cell 
activation processes (reviewed in (Cochran et al., 2001a)).  These reagents include antibody-
linked MHC dimers (Abastado et al., 1995), dimers created through chimeric fusions of MHC-
peptide complexes to antibody Fc domains (Appel et al., 2000; Casares et al., 1999; Hamad et 
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al., 1998), streptavidin-linked oligomers of biotinylated MHC-peptide complexes (Boniface et 
al., 1998; Crawford et al., 1998), and a series of chemically-defined MHC dimers, trimers, and 
tetramers prepared using a flexible peptide-based cross-linkers (Cochran and Stern, 2000).  
These studies demonstrated that multivalent TCR engagement is necessary for T cell triggering, 
with an MHC dimer as the minimal activating unit (Boniface et al., 1998; Cochran et al., 2000).  
T cell activation induced by such soluble oligomeric reagents exhibits non-saturating, bell-
shaped dose-response curves (Cochran et al., 2000), but these activation relationships have not 
been related to binding constants or other molecular properties of the system.   Moreover, 
fluorescent MHC oligomers increasingly are used to track antigen-specific T cell populations in 
clinical samples (Ferlin et al., 2000; McMichael and O'Callaghan, 1998), and understanding the 
correlation between binding levels and molecular properties such as MHC-TCR affinity or TCR 
clustering is urgently needed. 
 To gain insight into the binding behavior of MHC oligomers, and the relationship 
between MHC-TCR binding and the resultant activation response, we have applied a simple 
receptor cross-linking model developed originally for characterization of equilibrium binding of 
multivalent ligands to receptors on mast cells (Perelson, 1981).  Here, we show that the model 
accurately describes the behavior of soluble MHC oligomers in inducing activation processes in 
T cells for a variety of oligomer valencies, MHC-TCR affinities, and cross-linking strategies.  
The striking correlation of the model with the experimental data in this system show that several 
T cell responses are directly related to the number of multivalently engaged receptors.  The 
behavior of the model under different experimental conditions suggests possible mechanisms for 
the cellular regulation of antigen sensitivity in T cells. 
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B. Materials and Methods 
1. Preparation of class II MHC-peptide oligomers 
HLA-DR1 α and β extracellular domains (Cochran and Stern, 2000) were expressed in E. 
coli cells as inclusion bodies, solubilized in 8M urea, purified by ion exchange, and refolded by 
dilution of the denaturant under redox-controlled conditions in the presence of peptide, as 
previously described (Frayser et al., 1999 and Protein Expression and Purification protocols in 
Appendix).  Cysteine residues introduced into the α or β subunit C-termini (αcys, βcys, αLcys, and 
βLcys) were used for cross-linking.  In some experiments, the cysteine was introduced 
immediately after the membrane proximal immunoglobulin domain (αcys, βcys); in others, the 5-
10 residue connecting peptide region was included before the cysteine (αLcys, βLcys).  Antigenic 
peptide Ha[306-318] (PKYVKQNTLKLAT) derived from influenza hemagglutinin (Lamb et al., 
1982), control peptide A2[103-117] (VGSDWRFLRGYKQYA) (Chicz et al., 1992), and cross-
linkers X3X (fβΕΚ′SGSΚ′G) and X14X (fβΕΚ′SGSGESGSEGSSEGΚ′G) (Cochran et al., 
2001b) and related trivalent and tetravalent peptide-based cross-linkers (Cochran and Stern, 
2000), where fβ is fluoresceinyl−β-alanine and  Κ′  is N(ε)aminocaproylbenzylmaleimide lysine, 
were synthesized using FMOC chemistry, purified by reverse phase high performance liquid 
chromatography, and verified using mass spectrometry.  The refolded HLA-DR1-peptide 
complexes carrying a cysteine on either the α or β subunit were oligomerized by reaction of the 
introduced thiols with maleimidyl groups on the peptide-based cross-linkers. Cross-linker was 
added in small aliquots to freshly-reduced MHC protein at room temperature over a period of 
five hours to a final molar ratio of MHC:cross-linker of 2:1 for dimers, 3:1 for trimers, and 4:1 
for tetramers (Cochran and Stern, 2000 and Cross-linking Proteins Using Pep2x, Pep3x, and 
Pep4x (and relatives) protocol in Appendix).  Purified MHC-peptide oligomers were isolated 
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using two Superdex 200 HR 10/30 columns (Pharmacia, Peapack, New Jersey) in series, and 
further characterized by SDS-PAGE (Cochran and Stern, 2000).  For binding assays, FITC-
labeled MHC-peptide monomers were prepared by reaction of the HLA-DR1 introduced cysteine 
residue with fluorescein-malemide (Pierce, Rockford, Illinois) followed by purification by gel 
filtration chromatography (Cochran and Stern, 2000).   
 
2. T cell activation and binding assays 
The T cell clone HA1.7 (Lamb et al., 1982) used in many of the experiments presented 
herein is specific for the Ha peptide bound to HLA-DR1, and was maintained by biweekly 
stimulation with peptide-pulsed irradiated antigen presenting cells and rested seven days before 
activation assays (Cochran et al., 2000 and T Cell Maintenance—CD4+ Clones and Lines 
protocol in Appendix).  Two HLA-DR1-restricted, Ha-peptide specific, T cell clones, Cl-1 (Sette 
et al., 1994) and HaCOH8 (gift of Corrine Moulon, Warner-Lambert, Paris), and a short-term 
polyclonal T cell line, HA03 (Cameron et al., 2001a), were maintained similarly.  T cell 
activation assays were performed as previously described (Cochran et al., 2000). Briefly, MHC-
peptide oligomers were added to 7.5 x 104 T cells in round bottom 96 well plates and incubated 
at 37°C, 5% CO2.  After the desired incubation time, cells were placed on ice and stained 
concurrently with fluorescent monoclonal antibodies against T cell surface markers: R-
phycoerythrin (PE) labeled anti-CD3 (UCHT-1) and allophycocyanin (APC) labeled anti-CD69 
(FN50) or APC-anti-CD25 (M-A251) (all from Pharmingen, San Diego, California).  Cells were 
washed with phosphate-buffered saline (0.01 M KH2PO4, 0.1 M Na2HPO4, 1.37 M NaCl, 0.027 
M KCl, pH 7.4) containing 1% fetal bovine serum and 0.1% sodium azide and analyzed by flow 
cytometry.  Fluorescence data were obtained with a Becton-Dickinson FACS Calibur flow 
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cytometer and analyzed using Cell Quest software.   The number of MHC-peptide complexes 
bound during the course of the T cell activation assay was simultaneously measured with 
multicolor flow cytometry, using the fluorescein molecules incorporated into the cross-linkers 
(Cochran et al., 2000).  The number of CD3 molecules downregulated upon oligomer treatment, 
and the number of MHC-peptide complexes bound per cell, were converted from mean 
fluorescence using SPHERO Rainbow calibration particles (Spherotech, Libertyville, Illinois) 
containing known amounts of PE and fluorescein equivalents (See Quantitation of Cell Surface 
Receptors by Flow Cytometry protocol in Appendix).   
 
3. Generation of calculated cross-linking and binding curves 
For a given KX, KD, and Rtot, the implicit equation for Req (Perelson, 1981) was solved 
numerically for each valency of oligomer and each concentration using the secant method 
(Kreyszig, 1993).  That value was then used to calculate the number of oligomers bound per cell 
with each possible valency.  The calculations were performed using programs created in 
FORTRAN 77 and MAPLE V.  Φxlink, Rmulti, Rdimer, and Lbound were calculated from binding 
distributions as described in the model section of this paper. 
 
4. Fitting experimental activation and binding data             
Fits of the model to the experimental sets were solved by a three-parameter minimization 
of KX, KD, and scale factor, using known Rtot.  Minimization reduced the total χ2 by iterative 
testing of combinations of parameter values one interval above and below the current values of 
KD, KX, and scale factor, and adopting the combination with the lowest χ2 as the new values.  
The interval was reduced until convergence.  A wide range of initial guesses was tried for each 
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data set to ensure uniqueness of the fit parameters.  The uncertainty for each parameter, δaj2, was 
determined by the following equation: 
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where N is the number of measurements used for the fit, n is the number of parameters being fit 
by the program, and the χ2  values correspond to the values calculated with the parameter p 
varying about the best fit value by the interval σ (Bevington, 1969). 
 
C. Model  
1. Distribution of bound states for a multivalent ligand of a cell-surface receptor 
 A simple equilibrium model that describes the interaction of multivalent ligands with cell 
surface receptors was used to simulate activation dose-response curves.  Binding and cross-
linking parameters were obtained by least-squares fitting of curves to experimental binding and 
activation data.  This model was originally developed to describe general receptor binding by 
multivalent ligands, and has been applied to the release of histamine from basophils (Perelson, 
1981), a response which requires receptor cross-linking (DeLisi and Siraganian, 1979).  Similar 
models have been used to fit data for IgE-Fcε receptor clustering (Hlavacek et al., 1999), 
dissociation of insulin and nerve growth factor from their cross-linked receptors (DeLisi and 
Chabay, 1979), viral attachment to cell-surface receptors (Wickham et al., 1990), and dimeric 
MHC-peptide complexes binding to CD8+ T cells (Fahmy et al., 2001).   
 The model describes the distribution of different bound states of a multivalent ligand 
interacting with a monovalent receptor (Figure II.1).  For example, a ligand dimer may be bound 
monovalently (21) or divalently (22), assuming both ligand units can bind simultaneously, or it 
may not be bound at all (20, Figure II.1, top).   Similar states can be described for a ligand 
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tetramer (Figure II.1, bottom).  The model can be used to describe the relative amounts of these 
states under different conditions.  The monovalent binding of a ligand to its receptor is 
characterized by the equilibrium dissociation constant KD (units of molarity).  The tendency for 
multivalent binding is assigned to the cross-linking constant KX (units of (#/cell)-1), with the 
assumption that binding of each additional monomer within the oligomer is described by the 
same constant.  The actual independent modeling parameter is κ, the unitless product of the 
receptor density (Rtot/A, units of (area)-1, where A is the surface area of the cell) and a 2-
dimensional equilibrium binding constant (KX*A, units of area).  Since the receptor density is 
less convenient to measure experimentally than the number of receptors per cell, we report the 
cross-linking constant KX = κ / Rtot.  The model also assumes that rapid binding equilibrium is 
attained, and that the free ligand concentration is not significantly depleted by binding to cell 
surface receptors.  At the cell densities conventionally used in these experiments (1-5 x 106 
cells/mL), ligand is not significantly depleted for ligand concentrations greater than 10-10 M, even 
at 100% receptor occupancy.   
 
FIGURE II.1   Schematic description of 
oligomer binding for a dimer (top) and a 
tetramer (bottom).  The top row shows a 
dimer binding sequentially to monomeric 
cell surface receptors.  The terminology for 
the binding state is shown above each 
oligomer.  The bottom panels show the 
same scheme for a tetramer binding 
sequentially to monomeric cell surface 
receptors. 
 
Calculation over a range of concentrations yields the distinctive distribution of the 
various bound states, which is sensitive to changes in KD, KX, and the total receptor number 
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(Rtot).  At equilibrium, the amount of oligomer with valency (v) that is bound using i ligands can 
be found by the following equation (Perelson, 1981): 
  ieq
D
01i
Xeqi, )(RK
L
)(K
i)!(vi!
v!ν −−=                                                   (II.1) 
where νi,eq is the number of oligomers of valency v bound i times per cell at equilibrium, L0 is 
the bulk concentration of oligomer, and Req is the number of unbound receptors per cell at 
equilibrium.  The value of Req must be found from the numerical solution of the implicit 
equation: 
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and Rbound is found by: 
                  Rbound = Rtot – Req                                                             (II.3) 
  
 Several related parameters describing the system can be extracted from this type of 
calculation.  For example, the number of cross-links (Φxlink) formed by oligomers bound 
multivalently can be calculated as follows: 
∑
=
−=
v
2i
eqi,xlink 1)ν(iΦ                                                         (II.4) 
This is the original measure that was employed in previous studies (Hlavacek et al., 1999; 
Perelson, 1981).  A tetramer bound divalently is considered to have one cross-link, whereas one 
bound trivalently has two cross-links.  In addition, the number of cross-linked receptors, i.e., 
those associated with oligomers bound multivalently (Rmulti), can be found by: 
∑
=
=
v
2i
eqi,multi iνR                                                               (II.5) 
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The number of discrete receptor dimers per cell (Rdimer) per cell can be found using the following 
equation: 
∑
=
=
v
2,4,6,...i
eqi,dimer ν2
iR                                                          (II.6) 
A tetramer bound tetravalently forms two discrete receptor dimers, while one bound trivalently 
forms only one.  Finally, the total number of oligomers bound per cell (Lbound) can be calculated 
using the following equation: 
∑
=
=
v
1i
eqi,bound νL                                                                (II.7) 
 
2. Theoretical distribution curves  
The predicted distribution of bound states as a function of concentration for fixed KX, KD, 
and Rtot values is shown for a dimeric ligand in the upper panels of Figure II.2 (panels A, B, and 
C) and for a tetrameric ligand in the lower panels (Figure II.2 D, E, and F).  The plots in Figure 
II.2 were calculated using the same Rtot (24,000 per cell) and KD (1.4 µM) values, but with three 
different values for KX.  When the cross-linking tendency (KX) is low (2.0 x 10-5 per cell-1), as in 
Figure II.2A and D, the fraction of oligomers bound multivalently (using two, three, or four 
ligands) is low.  The number of ligands bound monovalently rises rapidly to saturation with 
increasing ligand concentration.  In the tetramer plot (Figure II.2D), the dashed line representing 
the sum of ligands bound multivalently (Rmulti) is similar to the symmetric plot of divalently 
bound tetramers (42), as little or no trivalently (43) or tetravalently (44) bound oligomers are 
present.  When the tendency to cross-link (KX) is ten-fold higher, as in Figure II.2B and E, 
significant amounts of di-, tri-, and tetramerically bound ligands accumulate at intermediate 
concentrations, and decrease at higher concentrations.  The decrease at high concentrations can 
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be understood by considering that mass action drives formation of monovalently bound 
oligomers at high concentrations of ligand.  In the tetramer plot (Figure II.2E, dashed line), the 
curve describing the total number ligands bound multivalently (Rmulti) begins to show some 
discernible asymmetry with a shallower slope at low ligand concentration and a sharper slope at 
high concentration.   In Figure II.2C and F, the cross-linking tendency (KX) is again raised by 10-
fold, and the asymmetry of the multivalently bound curve in Figure II.2F is even more 
pronounced.  The curves representing oligomers bound with their maximum valency rise rapidly 
with concentration.  These oligomers remain maximally bound with increasing concentration, 
and are only slowly replaced by oligomers bound with lower valency, and then by monovelently 
bound oligomers.  The curve describing monovalently bound oligomer rises at an even higher 
concentration than for lower KX, as it is even more difficult for a monovalent interaction to 
compete with multivalent interactions of bound oligomers.   
The effect of varying parameters other than KX also can be determined.  If the KD is 
reduced by a factor of ten, the result is a linear shift of the curves to lower concentrations.  
Increasing KD shifts the curves in the opposite direction.  Alternatively, if Rtot is changed ten-
fold, an identical effect on the shape of the curves is observed as for the corresponding change in 
KX; however, the height of the curve will be scaled to correspond to the increased number of 
receptors per cell. 
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FIGURE II.2  Binding distribution plots.  The distribution of variously bound oligomers 
as a function of oligomer concentration is shown in terms of the number of MHC 
molecules bound.  (A-C) show the behavior of a dimeric ligand binding to monovalent 
cell surface receptors as the cross-linking capacity KX increases in each panel as shown 
above the plots.  (D-F) show the behavior of a tetrameric ligand binding to monovalent 
cell surface receptors.  Oligomers bound monomerically (z), dimerically (), 
trimerically (▲), and tetramerically (■), are shown.  The dashed line on the tetramer 
plots (D)-(F) represents the sum of the multivalently bound oligomers, Rmulti. 
 
D. Results  
1. Analysis of experimental dose-response curves for activation of a T cell clone by a series of 
MHC oligomers 
 To investigate the molecular triggering mechanism of T cell activation, we have 
previously developed a series of chemically-defined MHC-peptide oligomers of the human class 
II protein HLA-DR1 (Cochran and Stern, 2000) and used these to trigger activation processes in 
the well characterized, influenza-specific human T cell clone HA 1.7 (Lamb et al., 1982).  This 
series of MHC dimers, trimers, and tetramers was prepared using synthetic peptide-based cross-
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linking reagents that were designed to be flexible and to allow simultaneous binding of multiple 
MHC molecules to the T cell surface.   Activation processes induced by these oligomers were 
measured as changes in cell surface expression of activation markers detected by multicolor flow 
cytometry.   The dose-response of T cell activation induced by MHC dimers, trimers, and 
tetramers was measured for three activation markers: downregulation of T cell receptor subunits 
(CD3) (Valitutti et al., 1997), upregulation of a T-cell associated lectin-like protein 
conventionally used as an early T-cell activation marker (CD69) (Testi et al., 1994), and 
upregulation of the interleukin-2 receptor α subunit involved in the autocrine proliferative 
response (CD25) (Waldmann, 1989).   The dose-response for T cell activation triggered by each 
of the oligomers displayed a bell-shaped curve (Cochran et al., 2000) similar to those predicted 
by the simple equilibrium binding model.  Increasing oligomer size caused a shift in the 
activation maximum to lower concentration and an increase in the maximum amplitude, behavior 
characteristic of the model applied here (Perelson, 1981).   
   The dose-response curves were fit using the model described above, using an 
experimentally determined value (24,000) for Rtot, the number receptors per untreated T cell.  
Figure II.3 shows the fits of the predicted Rmulti values to experimental data for CD3 
downregulation in the HA1.7 T cell clone (Cochran et al., 2000) measured at 12 and 27 hours, 
respectively, after addition of MHC oligomers to the T cell culture.  Filled symbols indicate the 
experimental data (dimers, diamonds; trimers, triangles; tetramers, squares), and smooth curves 
represent the predicted number of TCR multivalently bound (Rmulti) using best-fit values for KD, 
KX, and a scale factor relating Rmulti to the experimental measure of internalized TCR.  The 
curves obtained from a single experiment with different oligomers were fit simultaneously.  The 
predicted curves fit well to the experimental data to within the expected uncertainty of the 
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measurements.  Best-fit parameters for data collected at different times after oligomer addition 
are similar: KD = 1.4 ± 0.1 µM  (12 hr) or KD = 1.7 ± 0.4 µM (27hr), and KX = 1.92 ± 0.05 x 10-4 
per cell-1  (12 hr) or KX = 3.15 ± 0.01 x 10-4 per cell-1 (27hr) (Table II.1).  The scale factor 
relating the predicted number of multivalently-engaged receptors to the experimental number of 
downregulated receptors was 0.776 ± 0.001 at 12 hr and 0.996 ± 0.001 at 27 hr.  The value of the 
scale factor approaches one at long incubations, indicating that all engaged receptors eventually 
become downregulated as part of the T cell activation program, as suggested by cellular studies 
(Germain, 1997; Valitutti et al., 1997).  The extracted values for KD are within the range of 
affinities reported for other class II MHC-TCR systems determined by direct binding 
measurements using soluble receptors and ligands (Davis et al., 1998).  The extracted values for 
KX, and for the dimensionless value κ = KX*Rtot, are comparable to those observed in other 
systems (Fahmy et al., 2001; Hlavacek et al., 1999; Wickham et al., 1990).  For example, the KX 
determined for IgE-Fcε receptor cross-linking by multivalent antigen was 1.35 x 10-5 per cell-1 
(Hlavacek et al., 1999), and for the attachment of adenovirus to HeLa cells, a KX of 5 x 10-3 per 
cell-1 was calculated (Wickham et al., 1990).  These values correspond to κ values of 13 and 30, 
respectively.  The κ values determined for binding of class I MHC-IgG fusion proteins to CD8+ 
T cells range from 1-73 for cells in different activation states (Fahmy et al., 2001).  Our values of 
κ = 4-8 are within the range observed in these systems. 
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FIGURE II.3  Comparison of 
experimental CD3 downregulation 
data and model predictions.  The 
predicted sum of multivalently bound 
oligomers at each concentration was fit 
to experimental CD3 downregulation 
data for treatment with a dimer (), 
trimer (▲), and tetramer (■) (Cochran 
et al., 2000).  (A) shows the response 
of HA1.7 T cells at 12 hours of  
incubation with the oligomers, and (B) shows the response at 27 hours of incubation 
with the oligomers.  Best fit parameters shown in Table II.1. 
 
TABLE II.1 Binding and cross-linking parameters for several experimental 
markers of T cell activation for the clone HA1.7*  
 
Experiment     KD       KX 
    (µM)   (x10-4cell) 
CD3 (12 hrs)    1.40 (0.12)   1.92 (0.05) 
CD3 (27 hrs)    1.70 (0.40)   3.15 (0.01) 
CD69 (12 hrs)    1.40 (0.60)   2.30 (0.60) 
CD25 (27 hrs)#    1.80 (0.30)   3.00 (0.01) 
Direct Binding    1.60 (0.30)   0.95 (0.01)  
 
*Rtot was measured at 24,000 in these experiments, MHCs were linked through β 
subunit cysteines (βLcys) using peptide-based cross-linkers (Cochran et al., 2000).  
Values in parentheses represent parameter uncertainties from the least squares fit (see 
Methods). 
#CD25 upregulation was fit with this scale:  CD25 = 4 x 10-6 x (Rmulti)2 - 0.0073 x Rmulti 
 
 Activation of HA1.7 T cells measured using other markers could also be described by the 
model.  Upregulation of the early activation marker CD69 also was described by the model, 
although the data are noisier (Figure II.4A).  This fit yielded a KD of 1.4 ± 0.6 µM, and a KX of 
2.3 ± 0.6 x 10-4 per cell-1 (Table II.1), values similar to those obtained for CD3.   If the CD3 
downregulation and CD69 upregulation data are correlated, a linear relationship is seen with a 
slope of roughly 0.035 between the two (Figure II.4B).  This corresponds well with the ratio of 
the fit scale factors (0.027).   Upregulation of CD25, the low-affinity IL-2 receptor, was not 
0
10000
20000
C
D
3 
(c
el
l-1
)
[O ligomer]  M [Oligomer]  M
A B
12 hr 27 hr
10-10         10-8          10-6 10
-10         10-8          10-6
 51
described well by the model using a linear scale factor (not shown).  However, the plot of CD25 
(IL-2R) upregulation versus CD3 downregulation did not exhibit a linear relationship as 
observed for CD69 with CD3, but rather a distinct curve (Figure II.4C).  A best-fit quadratic 
function was found for the relationship of CD3 and CD25, and that function was applied to the 
model predictions to better represent the behavior of the data.  After this application, the CD25 
upregulation data were fit well by the model (Figure II.4D), giving best-fit values for KD (1.8 ± 
0.3 µM) and KX (3.00 ± 0.01 per cell-1) (Table II.1).  Again, these values were similar to those 
observed for the other markers.    
FIGURE II.4  CD69 (A,B) and CD25 
(C,D) upregulation data and model 
predictions for a T cell clone.  (A) 
The predicted sum of multivalently 
bound oligomers at each concentration 
was fit to experimental HA1.7 CD69 
upregulation data for treatment with a 
dimer (), trimer (▲), and tetramer (■) 
(Cochran et al., 2000).  (B) shows the 
relationship between CD69 and CD3 
responses with a best fit line.  The 
linear relationship suggests that a 
single scale factor could be used to 
relate CD69 response to Rmulti.  (C) 
shows the relationship between CD3 
and CD25 responses with a best fit 
quadratic curve.  The curved 
relationship suggests that CD25 
response is not directly related to Rmulti, 
and a quadratic filter was used to  
relate the model predictions to the data.  (D) shows the experimental HA1.7 CD25 
response to the dimer (), trimer (▲), and tetramer (■) treatments fit using a quadratic 
filter based on the relationship in (C).  Parameters for the fits are shown in Table II.1. 
 
Thus, a good correlation was observed between the predicted number of cross-linked 
receptors (Rmulti) and the scaled experimental data (R2 = 0.99) as shown in Figures II.3 and II.4.  
We also fit each of the data sets using the number of cross-links (Φxlink), or the number of distinct 
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dimers formed (Rdimer), instead of the number of cross-linked receptors.  While these fits were 
slightly less good (not shown), the experimental data are not sufficiently precise to be able to 
distinguish definitively between the different measures.  
 
2. Analysis of other T cell clones and MHC cross-linking strategies 
Additional tests of this model were performed using two other influenza-specific T cell 
clones, Cl-1 and HACoH8, and also a short-term polyclonal influenza-specific T cell line raised 
from the peripheral blood of a DR1+ homozygous individual, HA03 (Figure II.5).   The dose-
response of CD3 downregulation for the MHC oligomer series was measured for Cl-1 and 
HACoH8 after 24 hr (Figure II.5A and B) and for HA03 after 12 hr (Figure II.5C).  For Cl-1, the 
CD3 downregulation dose-response curves were best-fit using KD = 5.00 ± 0.01 x 10-5 M and KX 
= 3.10 ± 0.01 x 10-4 per cell-1 (Table II.2).  These values are significantly different from those 
observed for HA1.7, particularly for KD.  The other T cell clone, HACoH8, exhibited KD =1.80 ± 
0.07 x 10-6 M, and KX = 42.2 ± 1.4 x 10-4 per cell-1 (Table II.2).  In this case, the KX value is 
substantially different from those observed for the other clones.  Finally, the polyclonal line 
HA03 exhibited best-fit values of KD = 1.60 ± 0.04 x 10-5 M and KX = 0.96 ± 0.04 x 10-4 per cell-
1 (Table II.2).  These data show that KD and KX values can vary among different T cell lines, and 
that the model can describe these differences.  
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FIGURE II.5  CD3 response in other T cells.  These plots show the CD3 
downregulation response to dimer (), trimer (▲), and tetramer (■) for the T cell clones 
Cl-1 (A) and HACoH8 (B) and for the polyclonal cell line HA03 (C).  The smooth curves 
show the model fits for these data sets.  Model parameters for these fits are shown in 
Table II.2. 
 
TABLE II.2  Comparison of binding parameters between different T cell clones* 
 
T cell    Rtot      KD          KX 
 (per cell)    (µM)     (x10-4cell) 
HA1.7 24,000    1.70 (0.40)    3.15 (0.01) 
Cl-1 16,700  50.00 (0.02)    3.10 (0.01) 
HACoH8 19,300    1.80 (0.07)  42.2   (1.4) 
HA03# 27,000  16.00 (0.42)    0.96 (0.04)    
 
*Parameters obtained by fitting CD3 downregulation data for HA1.7 (27 hrs), Cl-1 (24 
hrs), HACoH8 (24 hrs), and HA03 (12 hrs).  MHCs were linked through β subunit 
cysteines using peptide-based cross-linkers (Cochran et al., 2000).  Rtot was measured 
directly by flow cytometry.  Values in parentheses represent parameter uncertainties 
from the least squares fit (see Methods). 
#Polyclonal T cell line 
 
Another set of class II MHC oligomers has been used to investigate the effect of receptor 
proximity and orientation on T cell activation (Cochran et al., 2001b).  In this series, MHC 
dimers were linked using a direct disulfide bond between cysteines introduced at the end of the α 
or β subunit, or using peptide-based synthetic cross-linkers of varying length.  Dimers linked 
through either the α or β subunits, using either a disulfide bond (S-S) or a long cross-linker 
(X14X), were tested for their ability to induce CD3 downregulation in the HA1.7 T cell clone 
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(Figure II.6).  Dose-response curves for these dimers exhibited characteristic bell-shaped curves, 
with the S-S dimers (closed symbols) activating more potently than the X14X dimers (open 
symbols) with more activation induced at lower concentrations and a higher maximum response.  
The activation data were described well by the binding model (lines).  Since the cross-linking 
site is remote from the peptide-binding region, the cross-links are not expected to interfere with 
the TCR interaction, and a single KD value was globally fit to the curves.  The KX was allowed to 
vary between the curves.  The KD extracted from these curves (1.61 ± 0.31 µM) was consistent 
with other KD values obtained for the HA1.7 T cell clone.  However, the best-fit KX varied 
significantly within the series, with values (per cell)-1 of 18.6 ± 0.8 x 10-4 (αS-S), 10.2 ± 0.2 x 
10-4 (βS-S), 3.15 ± 0.02 x 10-4 (αX14X), and 3.79 ± 0.03 x 10-4 (βX14X) (Table II.3).   The KX 
was greater for the S-S dimers, in which the MHC monomer units are positioned close together, 
and lower for the X14X dimers, which are more loosely tethered by the long, flexible linker.  
Thus, the KX parameter appears to reflect more facile receptor cross-linking for the more 
compact dimers, as expected by their geometrical constraints.   
 
FIGURE II.6  CD3 response to MHC dimers with 
different length cross-links.  This plot shows the 
CD3 downregulation in response to directly disulfide-
bonded S-S dimers linked through the αcys () or the 
βcys (▼) cysteine, and X14X dimers connected by a 
long flexible linker between the αcys () or βcys (V) 
cysteine.  The smooth lines show the model fit to the 
data.  Best-fit parameters are shown in Table II.3. 
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TABLE II.3  Comparison of KX parameters obtained with differently linked MHC 
dimers* 
 
MHC linkage# Cross-linker Length§     KX 
              (Å) (x 10-4cell) 
S-S  (α)                2  18.7 (0.8) 
S-S  (β)                2  10.2 (0.2) 
X14X (α)              90   3.15 (0.02) 
X14X (β)              90   3.78 (0.03) 
 
*CD3 downregulation for HA1.7 at 20 hours.  A single KD value was globally fit to the 
data set as 1.6 µM.  Rtot was measured at 21,300 per cell. 
#MHC’s were linked by disulfide bonds (S-S) or long peptide-based cross-linkers 
(X14X) through cysteine residues on either the α or β subunit. 
§The length represents the predicted spacing of the linked Cα atoms when the cross-
linker is in an extended conformation. 
 
3. Analysis of binding and competition data 
In addition to the number of multivalently-bound receptors Rmulti, the model can be used 
to predict the number of bound ligands, Lbound.  This parameter is a sum over all of the variously 
bound states, and would be expected to correspond to the experimental ligand binding behavior.  
Figure II.7 (A-C) shows the predicted binding behavior for a series of oligomers of total valency 
1 to 8, using values for KD (1.4 µM) and KX (0.2 –20 x 10-4 cell-1) similar to those observed 
experimentally (and identical to those of Figure II.2).  For the lowest KX value (2 x 10-5 cell-1), 
the curves are closely spaced and similarly shaped, with slightly more shallow slope and closer 
spacing for the oligomers with increased valency (Figure II.7A).  At saturating concentration, 
distribution plots indicate that each oligomer is bound predominately monovalently (not shown). 
With a ten-fold increase in KX, striking differences in shape are observed, with a strong 
asymmetry and greater spacing at lower oligomer concentrations as compared to the behavior at 
lower KX (Figure II.7B).  At high concentration, the multivalent curves cross below the curve for 
monomeric binding.  A high-valency oligomer will compete very effectively for binding sites 
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relative to a monomeric ligand, and will occupy a given number of receptors using a smaller total 
number of bound oligomers (Lbound) as compared to a monomer.  With another ten-fold increase 
in KX (Figure II.7C), this behavior is even more pronounced.  Higher valency leads to a rapid 
rise in the number of oligomers bound at lower concentration, as seen by the wide spacing of the 
curves at low concentration.  At higher concentration, the strength of the multivalent binding is a 
significant impediment to binding of additional oligomers, and increasing oligomer size results 
in fewer total oligomers bound as compared to smaller oligomers.  Thus, the predicted binding 
behavior is very sensitive to the parameter KX.  Changes in the parameter KD do not affect the 
shape of the curves, but simply shift them to different concentrations, with lower KD resulting in 
a linear shift to lower concentrations (not shown).  This is the same behavior as observed for the 
binding distribution plots (Figure II.2).  As before, changes in Rtot resulted in changes identical to 
the corresponding change in KX, but with changes in the saturation value. 
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FIGURE II.7  Simulation of binding and competition.  (A-C): Direct binding of 
multivalent ligands to a cell surface in terms of number of oligomers bound, Lbound.  Each 
curve shows the behavior of a given valency of oligomer binding to the cell.  KX 
increases as shown from panel (A) to (C).  (D-F): Competition of a labeled tetramer 
(35nM) by different valency unlabeled oligomers of the same ligand.  KX increases as 
shown from (D) to (F).  Rtot = 24,000 per cell in all panels. 
 
Experimental oligomer binding data were described well by the model.  Binding of the 
MHC oligomers can be measured concurrently with T cell activation markers using fluorescent 
labels incorporated into the oligomer cross-linking reagents and multicolor flow cytometry 
(Cochran and Stern, 2000), although internalization of bound oligomer occurs during the 
extended incubations used for the activation assays (Cameron et al., 2001a).  The MHC oligomer 
series used earlier in the activation experiments was tested for direct binding to the HA 1.7 clone 
(Figure II.8).  The experimental binding curves exhibit some of the characteristics of the 
predicted binding curves, including variable spacing depending on ligand concentration and 
convergence at high concentration (Figure II.8).  These data were fit to the modeled total number 
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of oligomers predicted to bind per cell at equilibrium (Lbound).  The best fit to this data (Figure 
II.8) gives a KD of 1.6 ± 0.3 µM and a KX of 0.950 ± 0.001 x 10-4 per cell-1 (Table II.1).  These 
values are similar to the KD and KX values obtained independently from the T cell activation data 
(Table II.1).   The scale factor from the direct binding fit was 0.806 ± 0.002, which is somewhat 
below unity perhaps because of partial quenching of the fluorescein labels in acidic 
compartments after endocytosis (Cameron et al., 2001a).  
 
 
FIGURE II.8  Direct binding data and fit.  These 
curves show the experimental results for direct 
binding of labeled monomer (z), dimer (), trimer 
(▲), and tetramer (■) (Cochran et al., 2000), and 
the model fit to these data (lines).  Parameters 
shown in Table II.1. 
 
 
The model can be used also to simulate competition experiments, in which a constant 
labeled “probe” oligomer is incubated in the presence of a variable concentration of unlabeled 
“competitor” oligomer or monomer.  Figure II.7 (D-F) shows a series of predicted competition 
curve for oligomers of various valency, in each case using a constant concentration of probe 
tetramer (35nM).  These conditions are similar to those that have been used to evaluate relative 
oligomer binding (Cochran et al., 2000; Reichstetter et al., 2000).  As before, three different 
values of KX in the range of the experimental values are shown in panels (D-F), with each panel 
varying by a factor of ten from the adjacent panel.  In contrast to the predicted binding curves, 
the shape of the competition curves are quite similar for oligomers of different valency, with 
only a small decrease in curve spacing with increasing valency.  Moreover, changes in KX result 
only in small shifts on the concentration axis rather than substantial changes in curve shape or 
spacing.  A similar effect can be seen for changes of KD.  Thus, although the predicted curves fit 
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well to experimental data (not shown), much less information about binding and cross-linking 
parameters can be extracted from this type of competition binding experiment. 
 
E. Discussion 
 We have applied a simple two-parameter binding model to the activation of antigen-
specific T cells by oligomeric class II MHC proteins.  We find that the model accurately 
describes important features of the T cell responses to soluble MHC oligomers, including the 
bell-shaped, non-saturating concentration dependence and the variation of response maxima with 
oligomer size.  Similar dissociation constants (KD) and cross-linking constants (KX) were 
extracted from different assays, including direct oligomer binding data and measurement of the T 
cell activation markers CD3 downregulation, CD69 upregulation, and CD25 upregulation, 
indicating that these parameters reflect intrinsic properties of the system.  The strong correlation 
observed throughout the dose response between the levels of cellular activation and the predicted 
number of multivalently-bound receptors suggests that these activation markers simply report the 
number of suitably engaged receptors.   Elaborate multi-step cytoplasmic signaling pathways 
have been elucidated for T cell signaling pathways that lead to upregulation of gene expression, 
including receptor phosphorylation, assembly of multi-component signaling complexes on 
receptor cytoplasmic domains, activation of various tyrosine and serine/threonine kinase 
cascades, changes in intracellular Ca++ concentration, and activation and nuclear translocation of 
transcription factors (Cantrell, 1996).  The CD3 downregulation (receptor internalization) 
pathway is less completely understood, but appears to involve many of the same early processes 
(Itoh and Germain, 1997).  Despite the apparent complexity of these signaling cascades, they do 
not appear to substantially modify the original binding signal and the final cellular readout 
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essentially reports the number of multivalently engaged receptors.  For one marker (CD25), the 
relationship between binding and response was best described by a quadratic rather than linear 
relationship.  Other activation responses may show other dependences and may incorporate 
information from other signaling pathways.  Nonetheless, the simple correspondence between 
the number of engaged receptors and the degree of cellular activation observed many hours after 
stimulation is striking.  
Implicit in the model is the notion that multivalent engagement of receptors leads to 
signaling, but that monovalent engagement does not.  Although this is supported by recent 
experimental work, particularly in CD4+ T cells (Boniface et al., 1998; Cochran et al., 2000), the 
biochemical basis of signal initiation is not yet clear.  Receptor clustering is known to lead to 
phosphorylation of receptor cytoplasmic domains, but currently it is not clear how clustering 
results in kinase activation or in exposure of cytoplasmic domains, although several models have 
been proposed (Aivazian and Stern, 2000; Chan et al., 1994; Shaw and Dustin, 1997).  The 
modeling performed here cannot definitively distinguish between a generic clustering 
mechanism where Rmulti is the parameter that scales with T cell activation, or a specific 
dimerization mechanism where Rdimer describes the triggering.   
An individual’s T cell repertoire includes many different T cell clones of varying MHC-
TCR affinity and signaling capacity (Janeway and Travers, 1994).  Moreover, a T cell in 
different developmental and activation states has different sensitivities to antigenic stimulation.  
Parameters derived from least-squares fitting of the model to experimental activation data can be 
used to understand and predict these functional differences between T cells.  We applied the 
model to several different T cell clones and to a polyclonal cell line representative of a 
subpopulation present in blood.  The KD and KX parameters extracted from activation data 
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differed for the different T cells, with the differences consistent with behavior observed in 
cellular assays.  For example, the HACoH8 clone has a KX value 13-fold higher than for than 
HA1.7, indicating an increased tendency to form receptor cross-links.  This clone can be stained 
by class II MHC oligomers even at 4°C, while most clones, including HA1.7 and Cl-1, require 
incubation at increased temperature to stain with those reagents (Cameron et al., 2001a).  The 
temperature dependence has been attributed to membrane and/or cytoskeletal rearrangements 
that are necessary for monomeric TCR to co-localize sufficiently to allow multivalent binding of 
MHC oligomers, and which are inhibited at low temperature (Cameron et al., 2001a).  The 
increased cross-linking tendency of HACoH8 would increase its ability to multivalently engage 
MHC oligomers, allowing oligomer staining under conditions where other clones are not stained.   
With the increasing use of MHC tetramers in detection and analysis of specific T cells in 
clinical samples (McMichael and O'Callaghan, 1998), it is important to understand the 
parameters that govern the multivalent MHC-TCR interaction.  Our analysis suggests that this 
relationship can be complex, with substantial non-linear contributions from the receptor number 
(Rtot) and cross-linking propensity (KX).  In an early description of the use class II MHC 
oligomers, a linear correlation was observed between oligomer staining intensity and binding 
affinity KD, for several T cell hybridomas after correction for the total receptor number 
(Crawford et al., 1998).  Our analysis suggests that this relationship will only hold for a restricted 
range of Rtot, and only for cells with similar KX values.  Finally, it is important to note that IC50 
values determined from competition analysis cannot be related to MHC-TCR KD values unless 
the relevant KX values are known.   
The sensitivity of the model to changes in KX suggests a novel mechanism by which T 
cell could regulate their activation state.   A naïve T cell, which has never previously seen 
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antigen, is much more difficult to activate than the corresponding memory T cell, which is the 
long-lived product of a prior encounter to antigen (Janeway and Travers, 1994).  Certain 
treatments with high antigen dose or with partial antigenic stimuli are known to “anergize” T 
cells, i.e. to drive them to non-antigen responsive state (Schwartz, 1997).  In both cases, the 
responsive and non-responsive T cells express the same receptor, and so have the same MHC-
TCR affinity.  It has generally been thought that these changes in activation sensitivity are due to 
changes in the intracellular signaling pathways.  However, it is possible that T cells could 
regulate their activity by changing their ability to cluster TCR in the plane of the membrane, 
without any change in cytoplasmic signaling processes.  In our model, this would correspond to a 
change in KX.    Such changes could be effected by alteration of receptor-cytoskeletal 
interactions (Viola et al., 1999), by receptor localization to membrane raft microdomains (Xavier 
and Seed, 1999), or by alteration of the receptor oligomeric state (Fernandez-Miguel et al., 
1999).  Recently, differences in the binding avidity of naïve as compared to activated T cells 
have been observed, and attributed to differences in TCR oligomeric state (Fahmy et al., 2001); 
these could as well be due to differences in the dynamic cross-linking propensity rather than the 
static oligomeric state.  The pronounced effects on ligand sensitivity that we have observed for 
relatively small changes in KX (Figures II.2, II.5) suggest that substantial changes in activation 
potential can be realized without any change in the intracellular signaling pathways.  In principle, 
this possible mechanism is similar to one hypothesized to regulate cellular sensitivity to soluble 
monomeric antigen through changes in receptor organization (Bray et al., 1998).   
There are some shortcomings of this approach in modeling the activation of T cells.  We 
assume that all cross-linking events are equivalent, but it is possible that sequential cross-linking 
interactions are governed by different KX values.  The model assumes a constant receptor 
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number Rtot, although activated receptors become downregulated as part of the activation 
response (Liu et al., 2000), thus altering Rtot during the course of the experiment.  We used the 
initial Rtot in calculating KX values, since the T cell response to soluble MHC oligomers is rapid 
((Boniface et al., 1998), and JRC and LJS, unpublished results).  Using a constant Rtot, similar 
KX values were obtained at different times in the response with only a change in scale factor.  
However, for derivation of an actual thermodynamic association constant, a more sophisticated 
analysis might be warranted.  Finally, since this is an equilibrium model, it does not account for 
kinetic features of the interaction which may play a role in triggering; for example, the off-rate of 
the MHC-TCR complex has been proposed to be more important in regulating activation 
behavior than the affinity (Matsui et al., 1994).   
Despite the simplifications made by the model, it correctly predicts T cell binding and 
activation behavior within observed experimental error.  This model should prove useful in 
guiding experimental detection of T cells using MHC oligomers, and it provides a quantifiable 
measure of cellular parameters that appear to regulate antigen sensitivity in T cells. 
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III. Soluble peptide-MHC monomers cause activation of CD8+ T cells  
through re-presentation of the peptide on T cell MHC molecules2 
 
SUMMARY 
 
 T cell receptor (TCR)-mediated activation of CD4+ T cells is known to require 
multivalent engagement of the TCR by, for example, oligomeric peptide-MHC complexes.  In 
contrast, for CD8+ T cells, there is evidence for TCR-mediated activation by univalent 
engagement of the TCR.  We have here compared oligomeric and monomeric Ld and Kb peptide-
MHC complexes, and free peptide, as stimulators of CD8+ T cells expressing the 2C TCR.  We 
found that the monomers are indeed effective in activating naïve and effector CD8+ T cells, but 
through a novel mechanism that involves transfer of peptide from soluble monomers to the T 
cells’ endogenous MHC (Kb) molecules.  The result is that T cells, acting as antigen-presenting 
cells, are able to activate other naïve T cells.
                                                 
2 This research presented in this chapter has been published: 
 Ge Q, Stone JD, Thompson MT, Cochran JR, Rushe M, Eisen HN, Chen J, and Stern LJ.  
Proc Natl Acad Sci USA. 2002 Oct 15; 99(21):13729-34. 
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A. Introduction 
 Antigen-driven activation of cells of the immune system generally involves multivalent 
antigen engagement that leads to clustering or "cross-linking" of cell-surface receptors.  This 
concept arose largely from observations of antigen-induced capping of surface immunoglobulins 
on B cells (Dintzis et al., 1976; Roelants et al., 1973), and multivalent antigen triggering of 
histamine release from mast cells (Metzger, 1992).  Whether multivalent engagement of T cell 
antigen receptors (TCR) is required to initiate T cell activation has been difficult to determine, 
primarily because the antigens are peptide-MHC complexes normally found as integral 
membrane proteins on the surfaces of other cells.  However, experiments using soluble 
recombinant MHC molecules lacking transmembrane domains and carrying defined synthetic 
peptides have shown clearly that peptide-MHC oligomers, but not monomers, can activate CD4+ 
T cells (Abastado et al., 1995; Boniface et al., 1998; Casares et al., 1999; Cochran et al., 2000).  
Thus, for CD4+ T cells, multivalent engagement of TCR is sufficient to initiate cellular 
activation, whereas monovalent engagement is apparently non-productive. 
 For CD8+ T cells, however, the issue remains unclear.  Several studies have found that 
multivalent engagement is required to activate these cells (Abastado et al., 1995; Daniels and 
Jameson, 2000; Doucey et al., 2001; Maile et al., 2001), but some evidence suggests the 
sufficiency of monovalent TCR engagement to trigger a cytolytic response, such as the 
requirement for such a small number of peptide-MHC complexes per target cell in cytolytic 
assays as to imply that a single complex can trigger the cytolytic response in CD8 T cells 
(Sykulev et al., 1996).  Activation of CD8+ T cells by peptide-MHC monomers has been clearly 
observed in the presence of CD8 molecules (Delon et al., 1998; Goldstein et al., 1997).  It was 
suggested from that result that monovalent engagement of TCR can serve as the initiating event 
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when it results in TCR association with CD8 (Delon et al., 1998).  However, in another study, 
TCR-CD8 hetero-dimerization induced by peptide-MHC monomers was observed, but found not 
to activate the cells (Doucey et al., 2001).   
   In this study, we investigated the requirements for initiating signaling processes in naïve 
and activated CD8+ T cells carrying the 2C TCR.  The 2C TCR recognizes various peptide-MHC 
complexes, including i) the potent allogenic activator QLSPFPFDL-Ld  (QL9-Ld), which binds 
with the highest affinity so far measured for any TCR/peptide-MHC interaction (Kd ~ 0.07-0.1 
µM, (Sykulev et al., 1994)), and ii) an agonist isolated from a random peptide library (Udaka et 
al., 1996) SIYRYYGL-Kb (SIY-Kb), which binds almost as strongly if cell-surface CD8+  is 
present (Kd ~ 0.3 µM), but more weakly if cells do not express CD8 (Kd > 3 µM, (Cho et al., 
2001)).  Using soluble monomeric and oligomeric forms of these class I MHC-peptide 
complexes, we find that monomers can induce a variety of characteristic T cell activation 
processes in naïve and activated CD8+ T cells, but only if the T cells express a class I MHC 
molecule able to form peptide-MHC complexes with peptide released from the offered peptide-
MHC complexes.  In addition to clarifying how MHC monomers activate CD8 T cells, these 
results show that CD8+ T cells can act as antigen-presenting cells able to stimulate naïve T cells 
to undergo a variety of activation and development processes.   
 
B. Materials and Methods 
1. Soluble peptide-Kb complexes 
Soluble murine class I MHC proteins H-2 Kb and Ld were produced by expression in E. 
coli and folded in vitro in the presence of peptide, as described for human class I MHC proteins 
(Garboczi et al., 1992 and Protein Expression and Purification Protocols in Appendix), except 
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that the heavy chains carried a C-terminal biotinylation signal peptide (bsp,(Altman et al., 1996; 
Chapman-Smith and Cronan, 1999)).  E. coli expression vectors coding for Kb-bsp, Ld-bsp, and 
human β2M, were a gift from J. Lippolis and J. Altman (NIH Tetramer Facility).  Peptides were 
synthesized using 9-fluorenylmethoxycarbonyl chemistry and verified using mass spectrometry: 
OVA (SIINFEKL), SIY (SIYRYYGL), and QL9 (QLSPFPFDL).  For preparation of oligomers, 
folded peptide-MHC complexes were biotinylated at the bsp sequence using birA enzyme 
(Avidity, Denver, CO, see Biotinylation of MHC Proteins Using the BirA Enzyme protocol in 
Appendix). Biotinylated complexes were isolated by gel filtration and oligomerized by stepwise 
addition of streptavidin to ¼ the molar ratio of the MHC (Crawford et al., 1998 and Staining 
CD4+ T Cells With DR Tetramers protocol in Appendix).  Oligomers were characterized by gel 
filtration and non-denaturing SDS-PAGE.  Protein concentration was estimated by UV 
absorbance (ε280nm=90,000 M-1cm-1 for Kb, 108,000 M-1cm-1 for Ld).   Immediately before use, 
peptide-MHC complexes were re-purified by gel filtration chromatography (Superdex 200) to 
remove aggregates and any free peptide released during storage. 
 
2. Fluorescent labeling of class I MHC complexes 
 In some experiments, the association of MHC complexes with cells was monitored by 
flow cytometry, using fluorescein labels incorporated into the Kb and Ld heavy chain sequences 
at the free cysteine present at position 122.   Cysteine 122 is not very reactive and generally was 
found in the reduced state after conventional isolation, so that treatment with reducing agent was 
not required to generate a free thiol prior to labeling.  For labeling, purified MHC (100 µM) in 
PBS, pH 7.4, was treated with a 20-fold molar excess of fluorescein maleimide (Molecular 
Probes, 20 mM in DMSO). The mixture was incubated for 1 hour at room temperature, with 
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peptide-MHC complexes re-isolated by gel filtration to remove unreacted fluorescein.  Labeling 
efficiency, determined by UV absorbance, was ~99%.  For details, see Modifying Free Cysteines 
in a Protein Using Maleimide Reactive Groups protocol in the Appendix.  
 
3. T cell clones  
 Murine CD8+ T cell clones 4G3 (specific for OVA-Kb) (Walden and Eisen, 1990) and 
L3.100 (expressing the 2C TCR, specific for SIY-Kb and QL9-Ld) (Sykulev et al., 1998) were 
cultured at 37ºC, 5% CO2, in RPMI medium with 10% fetal calf serum; cells were used 6-7 days 
after weekly stimulation using irradiated antigen presenting cells (EG7OVA and P815, 
respectively).  See T Cell Maintenance—Murine CD8+ T Cell Clone L3.100 for more details. 
 
4. Naïve T cell purification 
 Rag-/- 2C TCR transgenic mice (H-2b) (Manning et al., 1997) were used as a source of 
naïve T cells.  Lymph nodes were isolated, and naïve T cells were purified from antigen 
presenting cells by depletion of CD44+ cells using magnetic sorting (see Single Cell Suspensions 
from Mouse Organs protocol in Appendix).  At least 99% of the resultant cell population 
expressed the 2C TCR, with 60-70% of the 2C TCR positive population CD8+ and 30-40% CD8-
.  In some experiments, Rag-/- 2C TCR transgenic mice crossed onto a constitutive GFP 
transgenic background, were used as the source of naïve T cells (Cho et al., 1999; Okabe et al., 
1997).  Naïve H-2Kb-/-Db-/- 2C T cells were obtained by adoptive transfer of 107 bone marrow 
cells from mice carrying the 2C transgene on an H-2Kb-/-Db-/- background (Maurice et al., 2001) 
into sublethally irradiated RAG-/-, H-2b+ C57BL/6 recipients.  This procedure allows the H-2Kb-/-
Db-/- T cells to undergo positive selection in an H-2b+environment.  Eight weeks after transfer, T 
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cells isolated from the recipients were mostly 2C TCR+ H-2Kb-/-Db-/-, and were further purified to 
approximately 98% by depletion of (host) CD44+ cells using magnetic sorting.   
  
5. T cell activation assays 
 Activation assays were carried out in 96-well plates with 50,000-100,000 cells per well in 
50 µl.   Plates were pre-blocked by overnight incubation with 1% BSA in PBS solution at 4ºC.  
Cells were incubated with dilutions of peptide-MHC complexes or free peptide in culture 
medium for 2, 3, or 6 hours at 37ºC, then washed in cold FACS buffer (PBS with 1% BSA and 
0.1% sodium azide), and stained with fluorescent antibodies (Pharmingen) to cell surface 
markers such as TCR (α-pan-TCRβ), CD69, CD25, and CD8, prior to analysis using a Becton-
Dickinson FACS Calibur flow cytometer.  Data from flow cytometry experiments is shown in 
units of mean fluorescence intensity (MFI).  For experiments with soluble or plate-bound QL9-
Ld complexes, an excess of purified QL9 peptide was included to prevent degradation or peptide 
loss from the complex.  QL9 peptide alone does not activate 2C (H-2b) cells up to concentrations 
of at least 10 µM.  For antigen re-presentation assays, naïve 2C T cells (GFP-) were incubated 
with peptide-MHC complexes or free peptide for 3 hours at 37ºC, washed four times, and re-
suspended in media.  Naïve GFP+ 2C T cells were added, and the GFP+ and GFP- cells were 
incubated together for an additional 3 hours at 37ºC before staining as described above.  
Responses by GFP+ and GFP- cells were separated by gating on GFP fluorescence.  For 
proliferation assays, naïve 2C T cells were incubated in the presence of soluble or plate-bound 
stimuli in 96-well plates for 3 days at 37ºC, after which  3H-thymidine (1 µCi/well) was added, 
and the cells were incubated at 37ºC for an additional 12 hours, before harvest and assay for 3H 
incorporation. For IFN-γ assay, naïve 2C T cells were treated with immobilized anti-CD3, 
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soluble peptide-MHC complex, or peptide alone for 3 days at 37ºC, then re-stimulated with SIY 
peptide in the presence of brefeldin-A.  After 6 hours, the cells were stained for CD8 and TCR, 
fixed with paraformaldehyde, and stained with anti-IFN-γ antibodies in the presence of 0.1% 
saponin, before analysis by flow cytometry as described above. 
 
C. Results 
1. Activation of CD8+ T cell clones by class I MHC monomers 
 Soluble peptide-MHC complexes carrying a biotinylation signal sequence at the heavy 
chain C-terminus were produced by a standard in vitro folding method (Garboczi et al., 1992).  
Streptavidin-mediated oligomerization (Altman et al., 1996) yielded primarily tetramers (~70%), 
with small amounts of trimers (~20%), dimers (~3%), and monomers (7%) (as detected by high-
resolution gel filtration, see Figure III.1).  We prepared monomers and oligomers of the 2C 
agonist SIY-Kb and the non-activating control complex OVA-Kb, and tested their ability to 
stimulate the CD8+ T cell clone L3.100, which carries the 2C TCR (Sykulev et al., 1998).   
Several conventional activation markers were observed after incubation of L3.100 cells with 
SIY-Kb complexes, including downregulation of TCR (Figure III.2A) (Valitutti et al., 1997), 
upregulation of the early activation marker CD69 (Figure III.2B) (Testi et al., 1994), and 
upregulation of the high-affinity IL-2 receptor α subunit CD25 (Figure III.2C) (Waldmann, 
1989).   SIY-Kb oligomers (Figure III.2A-C, squares) were more potent than monomers (closed 
circles), and consistently induced equivalent activation responses at lower concentrations than 
the corresponding monomer. Activation was dependent on the specific peptide-MHC 
combination, as OVA-Kb complexes, which carry a different peptide, did not activate L3.100 
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cells (Figure III.2D), although they did activate 4G3 T cells, which are specific for OVA-Kb 
(Figure III.2E) (Walden and Eisen, 1990).  
FIGURE III.1  High resolution gel 
filtration of MHC monomers and 
oligomers.  High resolution gel 
filtration (Superdex 200) of OVA-Kb 
monomer, streptavidin (SA), and 
oligomer (OVA-Kb + SA).  SIY-Kb and 
QL9-Ld complexes behaved similarly.   
Oligomers were prepared using 
biotinylated peptide-MHC complexes 
mixed with streptavidin. The peptide-
MHC oligomers produced by this 
method are predominately tetramers, 
with some trimers, dimers, and 
monomers also present.  Gel filtration 
of standard molecular weight markers 
is shown at the bottom.   
 
FIGURE III.2 Activation of CD8+ T 
cell clones by class I MHC 
monomers and oligomers.  (A-C)  
Response of a T cell clone 
expressing the 2C TCR (L3.100) to 
MHC monomers, oligomers, and free 
peptide.  (A) TCR downregulation in 
response to 3 hour incubation with 
SIY-Kb oligomer (filled squares), SIY-
Kb monomer (filled circles), and SIY 
peptide alone (open circles).  Mean 
Fluorescence Intensity (MFI) shown  
on y-axis.  (B) CD69 upregulation  
(MFI) and (C) CD25 upregulation (MFI) in response to the same treatment as (A).  (D-E) 
Specificity of the response.  (D) TCR downregulation (MFI) is observed for L3.100 
incubated for 3 hours with SIY-Kb monomers (circles), but not for non-specific OVA-Kb 
(inverted triangles).  (E) Response of a T cell clone specific for OVA-Kb complex (4G3) 
shows TCR downregulation (MFI) after 3 hours of incubation with OVA-Kb monomers 
(inverted triangles), but not with SIY-Kb (circles). 
 
 We have previously used these same activation markers in studies of the response of 
CD4+ T cells, where we observed activation by class II MHC oligomers but not by monomers 
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(Cochran et al., 2000).  In contrast, the CD8+ T cells clearly were activated in the presence of 
class I MHC monomers.  Given this result, we performed several control experiments to verify 
that no multivalent protein was present in the experiments.  Since immobilized monomeric SIY-
Kb is a potent T cell stimulus, we verified that the activation was not due to adventitious 
immobilization of the soluble molecules on the BSA-blocked assay wells.  Removal of the 
medium containing SIY-Kb before addition of T cells completely abrogated activation (not 
shown).  Activation by the monomeric preparations was not likely to be the result of 
contaminating MHC oligomers or aggregates, as none were observable by gel filtration 
(detection limit ~0.5%, Figure III.1) or by native gel electrophoresis (not shown), and a 
miniscule amount of oligomer contamination would not be expected to account for the observed 
activation, because oligomers were only ~6-fold more potent activators than the monomers (1.5-
fold per peptide-MHC complex, Figure III.2A-C, filled symbols).   
 Since SIY peptide alone was able to induce activation processes in the T cells (Figures 
III.2A-C, open circles), we wanted to evaluate any contribution of released peptide to the 
observed monomer activation.  Peptide-MHC monomers and oligomers routinely were separated 
from free peptide by gel filtration immediately before the activation assay.  We incubated the 
peptide-MHC preparations under assay conditions, and separated free peptide by centrifugal 
ultrafiltration.  Bioassay of the filtrates using peptide-induced CTL-mediated lysis of target cells 
indicated that very little peptide was released during the 3-hour assay period (the approximate 
half-time for peptide release was 27 hrs, consistent with earlier studies (Gakamsky et al., 1999)).  
Moreover, in many experiments the response to peptide-MHC monomers was significantly 
greater than that induced by an equivalent amount of peptide alone (see below).  These details 
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suggest that the observed activation induced by MHC monomers predominately was not due to 
release of peptide into the solution.   
 
2. Activation of naïve T cells by peptide-MHC monomers 
 To investigate whether naïve T cells could be activated by incubation with monomeric 
peptide-MHC complexes, we used T cells obtained from 2C TCR+/+ RAG-/- (H-2b) transgenic 
mice. We observed that the purified naïve 2C T cells exhibited TCR downregulation (Figure 
III.3A), CD69 upregulation (Figure III.3B), and CD25 upregulation (not shown), in response to 
peptide-Kb monomers and oligomers.  Activation levels and half-maximal activation 
concentrations were similar to those observed with the T cell clones, with tetramers activating 
substantially more potently than monomers.  In addition to these activation markers, we also 
observed naïve 2C cells to proliferate in response to soluble SIY-Kb (Figure III.3C).  In this 
assay, the SIY-Kb monomers were substantially more active then free peptide (compare open and 
closed circles), giving further indication that the monomer activation was not due to simple 
peptide release into the media.  The T cell proliferation due to denatured (boiled) SIY-Kb 
activated T cell proliferation was similar to the corresponding concentration of purified peptide 
alone, suggesting that endotoxins or other bacterial products potentially present in the SIY-Kb 
preparations were not contributing significantly to the observed activation (Figure III.3C).  
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Figure III.3   Activation of naïve CD8+ 
T cells by class I MHC monomers 
and oligomers.  (A-B) Response of 
naïve T cells expressing the 2C TCR to 
MHC monomers, oligomers, and free 
peptide.  (A) TCR downregulation in 
response to 2 hr. treatment with SIY-Kb 
oligomer (filled squares), SIY-Kb 
monomer (filled circles), and SIY 
peptide alone (open circles).  Mean 
Fluorescence Intensity (MFI) shown on 
y-axis.  (B) CD69 upregulation (MFI) in 
response to the same treatment.  (C) 
Proliferation of naïve 2C T cells 
measured by 3H-thymidine 
incorporation 3 days after treatment in 
response to SIY-Kb monomer (filled 
circles), SIY peptide alone (open 
circles), denatured (boiled) SIY-Kb  
monomer (X), and non-specific OVA-Kb monomer (inverted triangles).  (D) TCR 
downregulation (MFI) of CD8+ (circles) or CD8- (diamonds) populations present in 
purified naïve 2C T cells in response to SIY-Kb monomers (filled symbols) or SIY 
peptide alone (open symbols).  (E) Maturation of naïve 2C T-cells in response to MHC 
monomers, oligomers, and free peptide.  Naïve 2C T cells were stimulated with 
immobilized anti-CD3 antibody (10 µg/ml), SIY-Kb oligomers, SIY-Kb monomers, or free 
SIY peptide for 3 days.  Intracellular IFN-γ production was measured after 6-hr 
restimulation by SIY peptide (bold line).  The shaded area corresponds to isotype 
control staining. 
  
To evaluate the importance of CD8 in the 2C-Kb system, we analyzed the substantial 
CD8- subpopulation present in naïve T cells isolated from 2C TCR transgenic mice, and 
compared it to the corresponding CD8+ population.  Both CD8+ and CD8- subpopulations 
exhibited activation responses after treatment with specific SIY-Kb but not control OVA-Kb 
monomers, although the CD8- population required ~103-fold greater concentration to induce 
comparable activation levels (Figure III.3D and Figure III.4).    
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FIGURE III.4   Activation of naïve T 
cells by MHC monomers does not 
require CD8.  (A-B) 2C T cells treated 
for 6 hours with 1 µM SIY-Kb monomers 
or non-specific OVA-Kb monomers were 
assayed by multicolor flow cytometry 
simultaneously for (A) TCR 
downregulation, (B) CD69 upregulation, 
and CD8 expression (horizontal scale).  
Both CD8+ (60-70%) and CD8- (30-40%) 
were obtained from Rag-/- 2C transgenic 
mice.  (C-D) shows the concentration 
dependence of the CD8+ and CD8- 2C T 
cell response to 6 hour treatment.  (C) 
TCR downregulation in the titration 
response to SIY-Kb monomers (filled 
symbols) or SIY peptide alone (open 
symbols), for CD8+ (circles) or CD8- 
(diamonds) cells.  (D) CD25 
upregulation in response to the same 
stimuli. 
 
 Finally, we evaluated the ability of Kb monomers and oligomers to drive conversion of 
the naïve cells to effector cells.  Effector but not naïve cells are able to produce IFN-γ in 
response to antigenic stimulation, and we used this as an assay of conversion from naïve to 
effector cells. After treatment with SIY-Kb monomers or oligomers, the 2C cells responded to 
antigenic stimulation with production of IFN-γ (Figure III.3E).  Although less effective than 
SIY-Kb, free SIY peptide alone also was able to elicit a small degree of conversion to effector 
cells (Figure III.3E and data not shown), a response that conventionally is believed to require the 
participation of co-stimulatory molecules. 
 
3. Activation mechanism: direct engagement or uptake/re-presentation? 
 The results presented above indicate that addition of peptide-MHC monomers to CD8+ T 
cells is sufficient to induce T cell activation.  Such activation could occur by direct monovalent 
0
200
400
600
D
CD8+
CD8-
C
D
69
Conc. (M)
10-15 10-12 10-9 10-6
CD8-
10-15 10-12 10-9 10-6
100
300
500
700
C
CD8+T
C
R
Conc. (M)
TC
R
TC
R
SIY-KbOVA-Kb
C
D
69
TC
R
CD8
A
B
CD8- CD8+ CD8- CD8+
 76
engagement of TCR by soluble MHC (Figure III.5A), and conventionally this is the 
interpretation given to such results (Delon et al., 1998).  However, another process could also 
lead to the observed activation.  Peptide-MHC complexes that bind to TCR on one cell could 
release peptides that are then transferred onto endogenous MHC proteins for presentation to 
other T cells (Figure III.5B).  While T cells generally are not thought to be antigen presenting 
cells, we observed potent activation of such cells after treatment with peptide alone (Figure 
III.3), and T cell fratricide has been described previously (Su et al., 1993).  Participation of T cell 
co-stimulatory and adhesion molecules in the activation process could help to explain the 
observed high sensitivity of the L3.100 and naïve 2C T cell response to soluble MHC monomers 
(ED50 ~ 1 nM), which contrasts with the relatively weak binding affinity measured for the 
corresponding MHC-TCR interaction (Kd ~300nM, (Cho et al., 2001)).  To distinguish between 
these two mechanisms, we performed additional activation studies, as described below. 
FIGURE III.5   Two potential 
mechanisms for activation of T cells 
by MHC monomers.  (A) Binding of 
monomeric peptide-MHC complexes to 
cell-surface T cell receptors directly 
leads to activation (direct engagement 
model).  (B) Transfer of peptide from the 
soluble MHC molecules to endogenous 
MHC molecules expressed by the T cell  
indirectly leads to activation of another T cell through interaction with peptide-MHC 
complexes on the surface of the first cell (re-presentation model).  Binding of soluble 
peptide-MHC to cell-surface TCR (or CD8) could facilitate peptide transfer, although 
other mechanisms are possible. 
 
4. Activation by soluble monomers requires the presence of endogenous MHC proteins 
 To evaluate the ability of a soluble monomer to activate 2C cells without contribution 
from the peptide re-presentation pathway, we made use of the allogeneic agonist (QL9-Ld) that 
has been described for the 2C TCR.   QL9 peptide pulsed onto cell-surface Ld of antigen-
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presenting cells (T2-Ld) was a potent stimulator for 2C cells (Figure III.6A), confirming previous 
work using other activation markers; and soluble QL9-Ld monomer bound tightly to 2C (Figure 
III.6B), consistent with previous measurements (Cho et al., 2001; Sykulev et al., 1994).  The 2C 
T cells express Kb but not Ld molecules on their surface.  By comparing the response to soluble 
SIY-Kb, which can access the re-presentation pathway, with that of QL9-Ld, which cannot, we 
were able to evaluate the role of re-presention by endogenous T cell MHC molecules to the 
observed activation processes.  In contrast to SIY-Kb monomers, QL9-Ld monomers were not 
able to stimulate 2C TCR downregulation and CD69 upregulation (Figure III.6C,D).  To 
demonstrate that the recombinant QL9-Ld complexes were functionally active, we used plate-
bound QL9-Ld to stimulate 2C T cells: both TCR downregulation (Figure III.6E) and CD69 
upregulation (not shown) were observed.  Taken together, these results show that the allogeneic 
QL9-Ld monomer bound to the 2C TCR but did not induce activation processes, whereas the 
syngeneic SIY-Kb monomer induced substantial activation despite being an intrinsically weaker-
binding ligand.  Thus, only minimal activation is induced by direct binding of peptide-MHC 
monomers to TCR, and activation of 2C T cells induced in the presence of peptide-Kb monomers 
requires the participation of endogenous (Kb) MHC molecules. 
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FIGURE III.6  CD8+ T cell 
activation by MHC monomers 
requires endogenous MHC 
proteins.  2C T cells expressing Kb, 
but not Ld, are activated by soluble 
monomers of the syngeneic SIY-Kb 
but by not the potent alloantigen 
QL9-Ld.  (A) Response of naïve 2C 
T cells to 3 hr of incubation with 
peptide-pulsed APCs.  T2 cells 
expressing Kb were pulsed with 
OVA (inverted triangles) and SIY 
(circles) peptides, and T2 cells 
expressing Ld were incubated with 
QL9 peptide (diamonds).  TCR 
Mean Fluorescence Intensity (MFI) 
shown on y-axis.  (B) Binding of 
fluorescein-labeled SIY-Kb (circles), 
OVA-Kb (inverted triangles), or QL9-
Ld (diamonds) to naïve 2C T cells.  
Cell-associated fluorescence was 
measured after incubation with 
MHC monomers for 30 min at 4°C,  
washing, and fixation with parafomaldehyde.  (C-D) Response of naïve 2C T cells to 3 
hr incubation with SIY-Kb (circles), OVA-Kb (inverted triangles), or QL9-Ld (diamonds) 
monomers.  (C) TCR downregulation (percentage of maximum TCR expression), and 
(D) CD69 upregulation (MFI).  (E) TCR downregulation of naïve 2C T cells in response 
to 6 hr incubation with plate-bound and soluble monomers or free peptide.  Open bars 
represent SIY or SIY-Kb; shaded bars represent QL9 or QL9-Ld. 
 
 To further evaluate the role of endogenous MHC in activation by soluble peptide-MHC 
monomers, we used 2C T cells that lacked the classical class I MHC molecules Kb and Db 
(Maurice et al., 2001) (see Methods).  We compared the activation of 2C TCR+ Kb-/-Db-/- cells and 
normal (Kb+) 2C T cells after incubation with soluble peptide-MHC monomers.  Binding curves 
for fluorescent SIY-Kb monomers were nearly identical for normal naïve and Kb-/-Db-/- 2C cells 
(Figure III.7A, open and closed circles), as were TCR expression levels.  Activation by SIY-
pulsed T2-Kb antigen-presenting cells was nearly indistinguishable between the two cell types, as 
measured by TCR downregulation (Figure III.7B). However, activation by soluble SIY-Kb 
10-1510-12 10-9 10-610-1510-12 10-9 10-6
10-1510-12 10-9 10-6
0
200
400
600
800
TC
R
A
APC response
QL9 
(T2-Ld)
OVA (T2-Kb)
SIY 
(T2-Kb)
0
40
80
E
TC
R
   
   
   
   
   
   
   
 
(%
 d
ow
nr
eg
ul
at
ed
)
Immob
pep-MHC
Peptide Pep-MHC 
monomer
Not 
Treated
SIY
QL9
[peptide] (M)
0
100
200
M
H
C
-F
IT
C
B
[MHC monomer] (M)
SIY-Kb
QL9-Ld
OVA-Kb
Pep-MHC binding
30
50
70
90
110
TC
R
 (%
 m
ax
)C
SIY-Kb
T cell activation
[MHC monomer] (M)
OVA-Kb
QL9-Ld
10-1510-12 10-9 10-6
0
100
200
300
C
D
69
D
SIY-Kb
OVA-Kb, 
QL9-Ld
T cell activation
[MHC monomer] (M)
 79
monomer was severely reduced for the Kb-/-Db-/- 2C cells (Figure III.7B).  The response was not 
completely eliminated, and the low level of monomer-induced TCR downregulation observed for 
the Kb-/-Db-/- cells (Figure III.7C), probably resulted from the small fraction of contaminating Kb+ 
cells in the T cell preparations.  Nonetheless, these results show clearly that T cell activation by 
soluble SIY-Kb relies largely or completely on the participation of endogenous Kb. 
 
FIGURE III.7  Lack of activation of H2-
Kb/Db-/- T cells by soluble MHC 
monomers.  T cells expressing the 2C 
TCR, but not H2-Kb/Db, are unable to be 
efficiently activated by soluble MHC 
monomers.  (A) Binding of fluorescein-
labeled MHC monomers to naïve 2C T 
cells (closed symbols) and 2C+, Kb-/-Db-/- T 
cells (open symbols).  Binding is shown for 
SIY-Kb (circles) and OVA-Kb (inverted 
triangles). Mean Fluorescence Intensity 
(MFI) shown on y-axis.  (B) Bar graph 
showing the % TCR downregulation for 
treatment of naïve 2C T cells (shaded 
bars) and 2C+, Kb-/-Db-/- T cells (open bars) 
with peptide-pulsed T2-Kb cells and 
soluble SIY-Kb monomer.  (C) Concentration dependence of TCR downregulation (MFI) 
response in Kb+/+Db+/+ (closed symbols) and Kb-/-Db-/- (open symbols) naïve 2C T cells 
after 3 hr incubation with soluble SIY-Kb (circles) and OVA-Kb (inverted triangles). 
 
5. Triggering by soluble MHC monomers does not require direct exposure 
In the proposed re-presentation mechanism, T cells that have not been directly exposed to 
antigen are activated by contact with other T cells that present peptide antigens on their surface.  
To determine whether or not this behavior was present in our system, we used naïve 2C T cells 
expressing green fluorescent protein (Cho et al., 1999; Okabe et al., 1997) to track antigen 
exposure in a mixed T cell population.  The presence of GFP does not interfere with T cell 
activation, and GFP+ 2C T cells exhibited Kb monomer and peptide activation profiles that were 
essentially indistinguishable from their GFP- counterparts (see Figure III.8).  In the experiments 
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shown in Figure III.9, GFP- 2C cells were incubated with specific Kb monomers for 3 hours at 
37ºC, then washed and cultured with untreated GFP+ 2C cells for an additional three hours 
before analysis of activation markers by flow cytometry.   Untreated GFP+ cells, as well as GFP- 
cells that had been directly exposed to antigen, both exhibited characteristic TCR 
downmodulation (Figure III.9A) and CD69 upregulation (Figure III.9B) responses.  Thus, 
activation of naïve 2C T cells did not require direct exposure to monomeric SIY-Kb complexes.  
To evaluate the efficiency of the uptake/re-presentation mechanism, we compared the titration 
profiles for GFP+ T cells that were directly exposed to monomer or peptide (Figure III.9C,D), 
with the profiles for GFP+ T cells that had been co-cultured with GFP- monomer- or peptide-
pulsed counterparts for 3 hours (Figure III.9E,F).  The profiles were similar, with only  ~10-fold 
decreased sensitivity for the indirectly exposed cells.  The difference is likely due to more 
effective activation in the continuous presence of stimulators for the directly exposed GFP+ cells 
(Figure III.9C,D), as compared to the indirectly exposed GFP+ cells (Figure III.9E,F).   These 
results indicate that uptake/re-presentation can provide an efficient antigenic stimulus able to 
activate untreated T cells, and that such a process is sufficient to account for all or nearly all of 
the T cell activation induced by soluble class I peptide-MHC monomers (and perhaps also for 
soluble oligomers, to some extent). 
FIGURE III.8  Activation 
profiles for GFP+ and 
GFP- naïve 2C T cells are 
similar.  Activation 
response of GFP+ 
(diamonds) and GFP- 
(circles) naïve 2C T cells 
in response to SIY-Kb 
monomer (closed 
symbols) or SIY peptide 
(open symbols) incubated  
at 37˚C for 3 hours.  (A) TCR downregulation, and (B) CD69 upregulation.
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FIGURE III.9  T cell activation by uptake 
and re-presentation of antigen.  Naïve 
GFP+ 2C T cells were activated by exposure 
to GFP- 2C T cells that previously had been 
treated with MHC monomers.  (A-B) GFP- 
cells were treated with control media or SIY-
Kb for three hours, washed, and then GFP+ 
cells were added to the GFP- cells in fresh 
media.  The cells were incubated together 
for an additional 3 hours at 37˚C.  (A) TCR 
downregulation and (B) CD69 upregulation.  
The horizontal scale is GFP fluorescence 
level.  (C-D) Response of directly treated 
GFP+ 2C T cells.  (C) TCR downregulation 
by GFP+ 2C T cells in response to 3 hr 
incubation with SIY-Kb (filled circles) or SIY 
peptide (open circles).  Mean Fluorescence 
Intensity (MFI) shown on y-axis.  (D) CD69 
upregulation (MFI) by GFP+ 2C T cells in  
response to the same treatment.  (E-F) Response of indirectly exposed GFP+ 2C T 
cells.  (E) TCR downregulation (MFI) by GFP+ 2C T cells incubated for 3 hours with 
GFP- 2C T cells that had been pre-treated with SIY-Kb (filled circles) or SIY peptide 
(open circles).  (F) CD69 upregulation (MFI) of GFP+ 2C T cells in response to the same 
stimuli.    
 
D. Discussion 
 The results presented here demonstrate that CD8+ cytolytic T cells and freshly isolated 
naïve CD8+ T cells can be activated effectively by cognate soluble peptide-MHC monomers.  
Rather than arising directly from monomeric engagement of the TCR, however, the activation 
apparently stems from a mechanism that involves transfer of peptide from monomer to T cell 
MHC molecules.  Support for this mechanism rests upon two independent lines of evidence.  
Firstly, T cells were stimulated effectively only when they expressed the same MHC as the 
activating monomer:  2C cells, which express Kb but not Ld, were activated by the SIY-Kb 
monomer but not by the more strongly binding QL9-Ld monomer; and 2C T cells that lacked Kb 
were not activated efficiently by the SIY-Kb monomer.  Thus, T cell expression of the 
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appropriate class I MHC molecule is required for activation by soluble peptide-MHC monomers.  
Secondly, 2C cells that were not themselves exposed to the SIY-Kb monomer were activated in 
trans by 2C cells that had been previously exposed to this monomer.  Thus, T cell class I MHC 
molecules can present peptides derived from soluble peptide-MHC monomers.  Both of these 
independent results are consistent with a peptide re-presentation mechanism in which cognate 
peptide derived from soluble MHC monomers are presented on the T cells’ own MHC 
molecules. 
 Although we found no evidence for an activation response triggered by monovalent 
engagement of the TCR, we cannot rule out the possibility that some intracellular signals result 
from monomeric engagement.  Any such response, however, would have to be very small 
relative to that induced by re-presentation of  peptide, and would not contribute significantly to 
the activation processes observed here. Since monomeric TCR engagement is ineffective in 
activating CD8+ T cells, it seems reasonable to conclude that CD8+ T cell triggering is due to 
TCR clustering, as seen for CD4+ T cells.  However, we do not know how many re-presented 
peptides are needed per cell for effective re-presentation, and there remain important differences 
between the activation of CD8+ and CD4+ T cells, particularly with regard to the minimal 
peptide-MHC density required on conventional presenting cells to induce T cell activation 
processes (Brower et al., 1994; Reay et al., 2000; Sykulev et al., 1995; Sykulev et al., 1996; 
Valitutti et al., 1995).    
 Precisely how peptide is transferred from soluble monomers to T-cell MHC molecules is 
unclear.  The possibility that transfer results from quantitative dissociation of complexes in 
culture medium to yield free peptide that binds to T cell MHC is incompatible with estimates of 
the SIY-Kb complex’s lifetime under conditions of the assay, and the observation that free 
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peptide usually induced less response than an equivalent concentration of peptide-MHC 
monomer.  MHC-bound peptide is protected from proteolytic degradation in culture medium, 
and, by being slowly released, could be more effective than free peptide in loading onto T cell 
MHC molecules.  The efficiency of peptide loading also might be enhanced by a high local 
concentration of monomers at the cell surface after binding to TCR and/or CD8 molecules.  Still 
another possibility is that TCR-bound monomers are internalized into T-cell endocytic 
compartments where dissociating peptide is reloaded onto endogenous class I MHC molecules 
for recycling to the cell surface.  Some evidence suggests that live cells are required for efficient 
re-presentation of monomer-derived peptides (Figure III.10).  Further studies are needed to 
evaluate these possibilities.   
FIGURE III.10  Fixation reduces indirect T cell 
activation induced by pep-MHC monomer but 
not by peptide alone.  Naïve GFP- 2C T cells 
treated with soluble peptide or peptide-MHC 
complexes are able to induce activation in GFP+ 
2C T cells that have not been exposed to soluble 
antigen.  GFP- cells were either fixed with 0.5% 
paraformaldehyde for 20 minutes at room 
temperature or kept in media at 4˚C. Both 
populations were then washed and incubated with 
SIY-Kb or SIY peptide at 37˚C.  After three hours, 
the cells were washed four times, and then GFP+  
cells were added to the GFP- cells in fresh media.  The GFP+ and GFP- cells were 
incubated together at 37˚C for an additional 3 hours.  CD69 upregulation by GFP+ 2C T 
cells is shown in response to GFP- 2C T cells that were either pre-fixed (triangles) or 
alive (circles) when treated with SIY-Kb monomers (closed symbols) or SIY peptide 
(open symbols). 
 
 T cell adhesion to antigen-presenting cells is known to sometimes result in the T cell’s 
acquisition of antigen from the presenting cell.  This phenomenon has been observed with CD4+ 
and CD8+ T cells and even with B cells (Hudrisier and Bongrand, 2002). The system described 
here is distinctive, however, in that antigen-presenting cells are absent: it consists only of 
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purified T cells and soluble peptide-MHC monomers.  It resembles most closely the situation in 
which addition of cognate peptide at relatively high concentration to cultured CTL clones can, in 
the absence of any other cells, result in specific T cell-T cell interactions and extensive cell lysis 
(“fratricide”) (Su et al., 1993; Walden and Eisen, 1990).  Here, however, the resulting specific T 
cell-T cell interaction leads not to fratricide of activated cells, but to activation of naïve cells. 
 Much evidence indicates that, in general, activation of naive T cells requires that they 
recognize peptide-MHC complexes on professional antigen-presenting cells, usually dendritic 
cells (Mellman and Steinman, 2001).  Our finding that naïve T cells can act as antigen-presenting 
cells able to induce maturation of naïve T cells is unexpected.  In connection with a possible 
physiologic role of soluble peptide-MHC monomers in this unusual T cell behavior, it should be 
noted that soluble MHC proteins are found in human serum and synovial fluid, most likely as 
soluble peptide-MHC complexes (Munoz-Fernandez et al., 2001).   
 In conclusion, CD8+ T cells are activated by soluble MHC monomers via a mechanism 
that involves T cell presentation of peptide derived from MHC-peptide complexes.  The ability 
of CD8+ T cells to acquire and present antigenic peptide derived from soluble molecules and/or 
presenting cells could be important in maturation of naïve T cells in vivo.  
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IV. On the valency requirements for T cell activation by soluble MHC-peptide 
complexes.3 
 
SUMMARY 
 
Soluble MHC-peptide complexes are useful tools for studying valency requirements for T 
cell activation.  In several studies, CD4 T cells have been shown to respond to soluble oligomers, 
but not monomers, of activating class II MHC-peptide complexes.  For CD8 T cells, however, 
some studies have reported that monomers can activate while others find a requirement for 
multivalent engagement.   The studies reported here use soluble, allogeneic class I MHC-peptide 
complexes, to avoid potential re-presentation of antigenic peptide by cellular MHCs.  In the 
absence of such representation, a dimer is necessary and sufficient to stimulate downstream 
activation in murine CD8 T cells. Soluble MHC-peptide monomers bind, but do not activate.  
For both murine CD8 and human CD4 T cells, monomeric MHC-peptide complexes antagonize 
activation induced by oligomers, providing further evidence that monomeric engagement is not 
productive.  However, MHC dimers can be active even if only one of the MHC-peptide 
complexes is stimulatory.   
                                                 
3 The research presented in this chapter has been submitted for publication. 
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A. Introduction 
 Determination of the molecular event(s) detected by a T cell upon interaction with a 
cognate APC has been problematic. For B cells and mast cells, which recognize soluble particles, 
activation requirements have been investigated using monomeric and oligomeric ligands, and 
multivalent receptor engagement has been observed to be crucial (Metzger, 1992).  T cells, by 
contrast, are triggered by antigenic peptides in complex with MHC molecules on the surface of 
APCs.  This signal is coupled with a multitude of non-antigen specific interactions including 
MHC co-receptor and adhesion molecule binding, co-stimulation, and possible contributions of 
non-stimulatory peptide-MHC complexes, which have made it difficult to deconvolute the 
antigen-specific signal recognized by the T cell.  
One method that has been employed to investigate the molecular trigger for T cell 
activation is to treat T cells with soluble, recombinant MHC-peptide monomers and oligomers.  
This type of study in CD4 T cells showed that dimers and larger oligomers of cognate class II 
MHC-peptides were able to stimulate many conventional T cell markers while monomers were 
unable to induce a response (Boniface et al., 1998; Casares et al., 1999; Cochran et al., 2000).  In 
the context of an APC, however, the contribution of non-activating MHC-peptide complexes 
may lower the threshold for specific MHC-peptide complexes (Irvine et al., 2002; Wulfing et al., 
2002).   
Conflicting results have been reported for similar studies of CD8 T cells (Abastado et al., 
1995; Daniels and Jameson, 2000; Delon et al., 1998; Doucey et al., 2001; Schott et al., 2002 and 
Chapter III of this thesis).  CD8 T cells generally are more sensitive to low antigen doses than 
are CD4 T cells.  Calcium flux has been observed for both CD8 and CD4 T cells at a single 
activating peptide per APC, but only CD8 T cells exhibit functional behavior at that level (Irvine 
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et al., 2002; Sykulev et al., 1996), and CTL responses can occur without the formation of a stable 
immunological synapse associated with full activation in CD4 cells (Purbhoo et al., 2004).   
Several studies with soluble MHC complexes have seen triggering for oligomeric but not 
monomeric class I MHCs (Abastado et al., 1995; Daniels and Jameson, 2000; Doucey et al., 
2001; Purbhoo et al., 2004), while another study reported CD8-dependent triggering by 
monomers (Delon et al., 1998).  One complication of this approach for CD8 cells is that peptide 
from soluble MHC monomers can be presented on endogenous T cell class I MHC, causing 
activation through cell-mediated presentation (Schott et al., 2002 and Chapter III).  Still, some 
evidence suggests that soluble class I MHC monomers are sufficient to induce signaling in T 
cells which have been “adhesion primed” by antigen non-specific interactions on an APC or a 
surface coated with antibodies to T cell surface molecules (Randriamampita et al., 2003).   
 In this study, we addressed these issues by taking advantage of the murine 2C TCR which 
reacts specifically to the allogeneic class I MHC-peptide complex LdQL9 (Sykulev et al., 1994).  
Soluble monomers and oligomers of LdQL9 were used to treat CD8 T cells to observe the 
response without the complication of peptide re-presentation (Schott et al., 2002 and Chapter 
III).  The results showed that like CD4 cells (Cochran et al., 2000), CD8 T cells are stimulated by 
dimers and higher-order oligomers of soluble peptide-MHC complexes, but are not activated by 
soluble monomers.  In fact, binding of soluble monomers blocks the activation induced by 
oligomers, further highlighting the non-productive nature of monomeric engagement.  However, 
T cells can be activated by an MHC heterodimer carrying a single activating MHC-peptide 
linked to an irrelevant MHC-peptide complex. 
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B. Materials and Methods 
1. Antibodies and peptides 
Fluorescent monoclonal antibodies to cell-surface molecules were obtained from BD 
Pharmingen (San Diego, CA), calibration beads for flow cytometry from Spherotech 
(Libertyville, IL), and unlabeled anti-CD11a monoclonal antibody from Leinco Technologies 
(St. Louis, MO).  Peptides: SIY (SIYRYYGL), OVA (SIINFEKL), QL9 (QLSPFPFDL,), Ha 
(PKYVKQNTLKLAT), and A2 (VGSDWRFLRGYHQYA), were synthesized using FMOC 
chemistry and verified using mass spectrometry. 
 
2. T cells 
The murine CD8+ T cell clone L3.100 (expressing the 2C TCR, specific for KbSIY and 
LdQL9 complexes) and the human CD4+ T cell clone HA1.7 (specific for the HLA-DR1 – Ha 
complex), were maintained in culture as previously described (Cochran et al., 2000; Ge et al., 
2002), and were used for assays after resting 7-10 days post-stimulation (see T Cell Maintenance 
protocols in Appenix).  Lymph nodes cells from 2C TCR transgenic mice (H-2b (Manning et al., 
1997)) were depleted of APCs and CD4+ T cells using magnetic beads (Dynal Biotech, Brown 
Deer, WI), and were at least 99% TCR+ after purification (75-80% of T cells were CD8+, 20-
25% were CD8- in 2C transgenic T cell preparations).  For details, see Single Cell Suspensions 
from Mouse Organs protocol in Appendix. 
 
3. Soluble MHC-peptide complex monomers and oligomers 
 Soluble murine class I MHC heavy chain H2-Kb and H2-Ld extracellular domains and 
β2M were expressed in E. coli and refolded in vitro as described previously for human class I 
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MHC complexes (Garboczi et al., 1992 and Protein Expression and Purification protocols in 
Appendix).  For tetramerization, Ld heavy chain included a C-terminal signal peptide for 
biotinylation using birA (Avidity, Denver, CO) and incorporation into streptavidin-linked 
tetramers as previously described (Crawford et al., 1998 and Staining CD4+ T Cells with DR 
Tetramers in Appendix for rough protocol).  Fluorescein maleimide was used to label Cys122 
(Molecular Probes, Eugene, OR, see Modifying Free Cysteines in a Protein Using Maleimide 
Reactive Groups protocol in Appendix).  For dimerization, heavy chains carried a C122R 
mutation and an introduced C-terminal cysteine.  Disulfide bonds were formed by oxidation as 
previously described (Cochran and Stern, 2000 and Dimerizing Proteins Through Free Cysteines 
by Creating a Disulfide Bond protocol in Appendix). 
 Soluble human class II MHC HLA-DR1 extracellular domains were produced as 
inclusion bodies and refolded in vitro as previously described (Frayser et al., 1999).  To make 
homodimers, a cysteine introduced at the C-terminus of either the alpha or beta subunit was 
oxidized as above (Cochran and Stern, 2000).  For heterodimer formation, cysteine-containing 
MHCs were separately labeled with either 3-bromopyruvate (Sigma) or N-(ß-
maleimidopropionic acid) hydrazide (BMPH, Pierce, Rockford, IL).  Excess reagent was 
removed, and labeled MHCs were combined 1:1 in 30 mM acetate, pH 4.5 for 1 hr., 4˚C to 
promote hydrazone formation.  The mixture was then rapidly transferred to 50 mM phosphate, 
pH 7.4, and incubated with 5 mM DTT for 30 min. at room temperature to cleave any disulfide-
linked dimers.  All monomeric and oligomeric MHC complexes were purified by size exclusion 
chromatography.  For details, see Heterogeneous Crosslinking protocol in Appendix. 
 
4. T cell activation and binding assays 
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T cell assays were carried out as previously described (Cochran et al., 2000 and Chapter 
III).  Briefly, T cells and soluble protein were incubated in BSA-blocked, 96-well plates at 37˚C 
for 3-6 hours for CD8 T cells or 24 hours for CD4 T cells.  After incubation, the samples were 
chilled on ice, stained for 30 minutes with fluorescent antibodies, then washed, fixed, and 
analyzed by flow cytometry.  For adhesion-priming assays, wells were first incubated with anti-
CD11a in PBS overnight at 4˚C, then blocked as above.  Fluorescent MHC binding assays were 
carried out for 30 min. at 4˚C.  Flow cytometry was performed on a FACSCalibur flow 
cytometer (BD Biosciences, Mountain View, CA). 
 
C. Results 
1. Allogeneic MHC-peptide complexes activate CD8 T cells as oligomers, but not monomers. 
The murine 2C TCR has well-characterized responses to the syngeneic complex KbSIY 
(Udaka et al., 1996), and the allogenic complex LdQL9 (Sykulev et al., 1994).  These complexes 
do not directly activate 2C T cells as a soluble monomers (Chapter III), although peptide from 
KbSIY can cause activation via peptide transfer to T cell Kb and cellular re-presentation.  We 
used the LdQL9 complex, which cannot be presented by H-2b cells, to investigate whether 
murine CD8+ T cells were activated by multivalent TCR engagement by soluble MHCs, as was 
seen in human CD4+ T cells (Cochran et al., 2000).  L3.100, a CD8+ T cell clone carrying the 2C 
TCR, was treated with soluble LdQL9 monomers, dimers, and tetramers (Figure IV.1A-B).  The 
soluble MHC-peptide complex LdQL9 was able to induce TCR downregulation (Figure IV.1A) 
and CD69 upregulation (Figure IV.1B) when present as a dimer or tetramer, but not as a soluble 
monomer.  Soluble KbSIY monomer was able to activate due to re-presentation of SIY on 
L3.100 Kb, as previously described (Schott et al., 2002 and Chapter III).  The lack of activation 
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seen for the LdQL9 monomer is not due to a lack of specific binding to the TCR, since the 
fluorescently-labeled monomer was able to bind to the T cells as well as KbSIY (Figure IV.1C-
D), consistent with previous studies (Chapter III).   Cross-correlation of CD69 upregulation and 
TCR downregulation shows that MHC dimers, tetramers, and immobilized monomers all 
activate qualitatively similar responses (Figure IV.1E).  To address the possible significance of 
the activation signals observed at the highest monomer concentrations (Figure IV.1A,B), in a 
separate experiment we examined the relationship between the amount of T-cell activation 
observed and the number of associated MHC.   LdQL9 monomers show no significant T cell 
activation response at levels of MHC bound that give maximal response for tetramers (Figure 
IV.1F).  Similar results are seen for ex-vivo CD8+ 2C transgenic T cells, although with a different 
dose-response (Figure IV.1G).  These results show that while monomers of class I MHC-peptide 
complexes bind, dimers or higher-order oligomers are required to activate CD8 T cells, similar to 
CD4 T cells (Cochran et al., 2000). 
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FIGURE IV.1  CD8+ T cells are activated by 
allogeneic MHC oligomers, but not 
monomers.  (A-B) L3.100, a murine CD8+ T 
cell clone, was stimulated with soluble 
allospecific LdQL9 monomers (closed circles), 
dimers (closed diamonds), or tetramers 
(closed squares), or soluble syngeneic KbSIY 
monomers (dashed line), or immobilized 
KbOVA (open circles).  (A) TCR 
downregulation and (B) CD69 upregulation 
responses are shown.  (C-D) Binding of 
fluorescently-labeled soluble KbOVA (open 
circles), KbSIY (dashed line), or LdQL9 (closed 
circles) monomers, or LdQL9 tetramers (closed 
squares).  (C) Scaled MFI values reflecting 
relative number of MHCs bound.  (D) MFI 
values with non-specific binding of KbOVA 
subtracted.  (E) Correlation between CD3 
downregulation and CD69 upregulation in 
L3.100 stimulated by soluble LdQL9 tetramers 
(closed squares), dimers (closed diamonds), or 
coated on a surface (black stars).  (F-G) 
Relationship between MHC binding and TCR 
downregulation when treated with soluble 
LdQL9 (closed circles), KbOVA (open circles), 
or KbSIY monomers (dashed line), or LdQL9 
tetramers (closed squares).  (F) L3.100 T cells.  
(G) Murine CD8+ 2C transgenic T cells. 
 
 
2. Adhesion priming does not lead to sustained T cell signaling from a MHC-peptide monomer. 
In the context of an adherent T cell, a soluble MHC-peptide monomer may be sufficient 
to trigger some activation directly.  CD8+ T cells allowed to adhere to a surface coated with 
antibodies against cell-surface molecules have showed rapid calcium flux responses to soluble 
syngeneic MHC-peptide monomer, possibly too quickly for peptide re-presentation 
(Randriamampita et al., 2003).  We tested the ability of allogeneic MHC-peptide monomers and 
oligomers to induce activation in the presence of a similar adhesion signal.  Assay wells were 
either blocked as normal or coated with antibody against the adhesion molecule CD11a (LFA-1), 
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which is expressed highly on the surface of 2C TCR transgenic T cells.  Soluble monomeric 
MHC-peptide complexes did not induce TCR downregulation (Figure IV.2A-B) or CD69 
upregulation (not shown), regardless of whether immobilized adhesion molecules were present.  
Responses induced by LdQL9 tetramers and dimers also were essentially identical with or 
without adhesion molecules.  We conclude that while some signaling from an MHC-peptide 
monomer cannot be ruled out, TCR engagement by a soluble monomer does not lead to sustained 
signaling and modulation of cell-surface molecules typical of an activation response. 
To evaluate a possible role for CD8 in activation by MHC oligomers, we analyzed the 
relatively large population of CD8- T cells naturally occurring in 2C transgenic mice.  Similar 
responses were observed for both CD8+ and CD8- populations, but with a shifted dose-response 
for activation of CD8- cells (Figure IV.2C-D).  These results show that MHC-peptide dimers are 
sufficient for activation without help from the CD8 co-receptor. 
 
FIGURE IV.2  Adhesion priming does 
not cause allogeneic MHC complexes 
to activate downstream processes.  
CD8+ and CD8- 2C transgenic T cells were 
stimulated with soluble LdQL9 monomer 
(circles), dimer (diamonds), or tetramer 
(squares), with coated anti-CD11a 
antibody (open symbols) or without (closed 
symbols).  (A-B) TCR downregulation for 
CD8+ cells (A) in suspension or (B) with 
coated anti-CD11a.  (C-D) TCR 
downregulation for CD8- cells (C) in 
suspension or (D) with coated anti-CD11a. 
 
  
3. Monomeric MHC-peptide binding antagonizes activation induced by MHC-peptide oligomers. 
To further evaluate the functional consequences of monovalent TCR engagement by 
soluble MHC-peptide complexes, we performed a competition experiment.   L3.100 cells were 
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incubated with a constant activating concentration of LdQL9 tetramer (10 nM) together with 
various concentrations of LdQL9 or control KbOVA monomer (Figure IV.3A).  TCR 
downregulation was reduced by LdQL9 monomer in a dose-dependent manner (top panel), with 
the inhibition occurring in the same concentration range as MHC-peptide binding (bottom 
panel).  The ability of MHC-peptide monomers to inhibit oligomer-induced activation was 
observed also for CD8+ and CD8- 2C cells from transgenic mice (Figure IV.3B), and for the 
human CD4+ T cell clone HA1.7, which is specific to HLA-DR1 bound to the Ha peptide (Figure 
IV.3C).   
FIGURE IV.3  Monovalent MHC binding 
antagonizes T cell responses to MHC 
oligomers.  (A) top panel, TCR 
downregulation in L3.100 stimulated with 
10 nM LdQL9 tetramer and increasing 
soluble LdQL9 (closed squares) or KbOVA 
(open squares) monomer.  (A) bottom 
panel, Binding for LdQL9 (closed circles) 
and KbOVA (open circles) monomers.  (B) 
top panel, TCR downregulation in CD8+ 
(squares) and CD8- (triangles) 2C 
transgenic T cells stimulated with 10 nM  
LdQL9 tetramer and increasing soluble LdQL9 monomer.  (B) bottom panel, Binding of 
LdQL9 monomer to CD8+ (circles) and CD8- (diamonds) 2C transgenic T cells.  (C) 
CD4+ HA1.7 T cells (specific to DR1-Ha) were incubated with 100 nM DR1-Ha dimer 
with increasing soluble monomeric DR1-Ha (closed squares) or non-specific complex 
DR1-A2 (open squares). 
 
4. T cell activation induced by soluble heterodimers containing one activating and one non-
activating MHC-peptide complex 
 Evidence that a single activating peptide on a cell can cause signaling (Irvine et al., 2002; 
Sykulev et al., 1996), combined with indications that non-activating MHC-peptide complexes 
play an important supporting role in T cell stimulation (Wulfing et al., 2002), caused us to 
investigate whether a single activating MHC-peptide complex could activate in the context of a 
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soluble MHC oligomer.  We devised a method for specifically linking an activating MHC-
peptide complex to a non-activating MHC-peptide complex using a unidirectional chemical 
crosslinking strategy (Figure IV.4A-B).  This approach disallows any spontaneous disulfide-
linked homodimers by reduction (see Heterogeneous Crosslinking protocol in Appendix).  We 
were then able to compare the responses of the human CD4+ T cell clone HA1.7 to a soluble 
homodimer of DR1-Ha vs. a heterodimer of DR1-Ha linked to DR1-A2 (Figure IV.4C).  TCR 
downregulation was evident for both soluble dimeric complexes, although the heterodimer was 
significantly less potent than was the homodimer of DR1-Ha.  We were not able to extend this 
approach to class I MHC proteins because of instability under the crosslinking conditions. 
 
FIGURE IV.4  Soluble dimers consisting 
of activating and non-activating MHC 
complexes can activate T cells.  (A) 
Mixing activating (closed) and non-
activating (open) MHC complexes, each 
with a reactive cysteine, results in a 
mixture of products.  Mixing a hydrazide-
tagged MHC with a ketone-tagged MHC 
results in a specific heterodimer.  (B) 
Chemistry used to create specific 
heterodimer.  Free cysteine on one MHC 
was modified with BMPH, and free 
cysteine on the other MHC was modified 
with 3-bromopyruvate.  Combining at low  
pH under reducing conditions results in only the specific heterodimer.  (C) The human 
CD4+ T cell clone HA1.7 (specific to DR1-Ha) was stimulated with DR1-Ha monomer 
(closed circles), DR1-A2 tetramer (open squares), DR1-Ha dimer (closed diamonds), or 
a heterodimer (half-open diamonds) of one complex DR1-Ha and one complex DR1-A2.  
 
D. Discussion 
 In this study, we have shown that CD8 T cell triggering by soluble MHC-peptide 
complexes follows the same pattern as CD4 T cell triggering (Cochran et al., 2000) when not 
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MHC-peptide complexes is necessary and sufficient to induce TCR downregulation and CD69 
upregulation, with or without expression of the MHC co-receptor CD8.  Adhesion priming by 
immobilized antibodies to T cell adhesion molecules does not allow allogeneic MHC monomers 
to activate these processes.  Activation by an oligomer of MHC-peptide complexes is 
antagonized by high concentrations of soluble MHC-peptide monomer.  These results taken 
together suggest that the molecular trigger for CD8 T cells and CD4 T cells is likely to be the 
same: multivalent TCR engagement. 
The nature of the antigen-specific signal transmitted through the TCR is still not 
completely understood.  The fact that a soluble MHC-peptide monomer binding to the TCR does 
not result in productive signaling argues for a model where TCR clustering is a critical event.  
However, a soluble heterodimer consisting of only one activating MHC-peptide was able to 
induce T cell activation.  This triggering may be due to the ability of some non-activating 
complexes to weakly bind the TCR when held in close proximity (extremely high local 
concentration) by a covalently-linked, bound, activating complex.  When a T cell is stimulated 
by an APC, a single activating peptide could bring about a signal if endogenous MHC-peptide 
complexes could contribute to binding and promote TCR clustering, with the activating peptide 
serving as an anchor around which weaker MHC-TCR interactions can play a larger role.  The 
threshold for these interactions could be lowered by the involvement of MHC co-receptors CD4 
and CD8, either by simply increasing the affinity of non-stimulatory MHC-peptide complexes, or 
by a complex bridging model where a co-receptor bound to one MHC is associated with the 
cytoplasmic domain of a separate MHC-bound TCR (Irvine et al., 2002).  However, we note that 
class I MHC dimers were stimulatory in the absence of CD8 (Figure IV.2D), indicating that any 
such co-receptor bridging process is not required for activation. 
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There has been discussion of a potential conformational change, or allosteric re-
arrangement of subunits, induced in the TCR upon MHC-peptide binding, which could initiate 
signaling (Alarcon et al., 2003).  Productive activation in T cells correlates with the very early 
exposure of an intracellular binding epitope for Nck (Gil et al., 2002).  Whether the exposure of 
this epitope is a result of interaction with a single stimulatory MHC-peptide complex propagated 
through some conformational change, or a result of appropriate TCR clustering, is not known.  It 
is known that the cytoplasmic domains of several components of the TCR complex tend to 
homo-oligomerize at high concentrations (Sigalov et al., 2004); perhaps ligand-induced 
clustering of the TCR drives the cytoplasmic domains of proximal receptors to rearrange, 
exposing the Nck binding epitope and propelling other signaling cascade processes.  These 
results are intriguing for further study.  
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V. HLA-restricted epitope identification and detection of functional T cell 
responses using MHC-peptide and co-stimulatory microarrays4 
 
SUMMARY 
 
Identification of T cell epitopes is a vital but often slow and difficult step in studying the 
immune response to infectious agents and autoantigens.  We report a spatially-addressable 
technique for screening large numbers of T cell epitopes both for specific antigen recognition 
and for functional activity induced.  This system uses microarrays of immobilized, recombinant 
MHC-peptide complexes, co-stimulatory molecules, and cytokine capture antibodies.  The array 
elements act as synthetic antigen-presenting cells, and specifically elicit T cell responses 
including adhesion, secretion of cytokines, and modulation of surface markers.  The method 
allows facile identification of pertinent T cell epitopes out of a large number of candidates and 
simultaneous determination of the functional outcome of the interaction.  Using this method, we 
have characterized the activation of human CD4+ and CD8+ T cells responding to vaccinia, 
influenza, HIV-1, and Epstein Barr Viruses. 
 
                                                 
4 This work has been submitted for publication. 
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A. Introduction 
 T cells recognize specific antigenic peptides bound to major histocompatibility complex 
(MHC) proteins on the surface of antigen-presenting cells (APCs), triggering intracellular 
signaling and T-cell effector functions.  The particular functions expressed determine how 
successfully the infection can be eliminated, and insufficient or inappropriate responses can 
result in lack of clearance (Collins, 2003; Levitsky and Masucci, 2002), immunopathology 
(Terajima et al., 2004), or autoimmunity (Christen and von Herrath, 2004).  An important step in 
studying T cell responses is to identify the relevant epitopes, usually short peptides derived from 
pathogenic molecules that are recognized by clonotypic T cells present in the overall repertoire.  
The typically low frequency of  specific T cells within the overall circulating T cell population 
and the large number of potential epitopes present in a pathogenic or autoimmune proteome, 
present challenges to facile and routine identification of T cell epitopes.   
 T cell epitopes currently are identified by testing overlapping peptides from pathogenic 
sequences in cellular assays such as T cell proliferation (Yamada et al., 1985), target lysis 
(Engers et al., 1975), bulk or intracellular cytokine secretion (Maecker et al., 2001), or ELISPOT 
(Czerkinsky et al., 1988) assays.  Screening synthetic peptides that span the entire length of a 
pathogenic sequence in cellular assays is time- and reagent-intensive, particularly consuming 
large numbers of T cells, which are often a limiting factor when testing clinical samples.  This 
normally tedious and expensive process can be simplified by using an array format that can both 
identify pathogen-derived epitopes out of many candidates, and give broad functional 
information about the nature of the T cell response induced.  
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B. Materials and Methods 
1. Recombinant production of human MHC proteins    
 Recombinant MHC proteins were prepared by adaption of standard methods for multiple 
parallel small-scale preparations. Soluble, extracellular portions of HLA-DR1 (HLA-
DRB1*0101 and HLA-DRA1*0101) including a uniquely reactive cysteine engineered at the C-
terminus of the alpha chain were produced in S2 Schneider cells, chemically-modified with 
PEO-maleimide–biotin (Pierce Chemical),  and loaded with peptide as previously described 
(Cameron et al., 2002).  HLA-A2 (A*0201) extracellular heavy chain carrying a biotinylation 
signal peptide (Altman et al., 1996), and β2 microglobulin light chain were produced in E. coli as 
inclusion bodies, refolded in the presence of peptide, biotinylated, and purified by size exclusion 
chromatography  as previously described (Garboczi et al., 1992).  For details, see Protein 
Expression and Purification and Protein Modification and Cross-linking sections of the 
Appendix. 
 
2. Peptides   
 Ha[306-318] (PKYVKQNTLKLAT) from influenza hemagglutinin, PP16 
(PEVIPMFSALSEGATP) and PG13 (PEVIPMFSALSEG) from the HIV-1 p24 gag protein, 
QHY (QHYREVAAAKSSE) from the EBV protein BZLF-1, TT (QYIKANSKFIGITE) from 
tetanus toxin, MVA-74A (CLTEYILWV) and MVA-165 (KVDDTFYYV) from vaccinia, and 
null peptides A2[103-117] (VGSDWRFLRGYKQYA) from HLA-A2, and Tfr 
(RVEYHFLSPYVSPKESP) from transferrin receptor, were chemically synthesized  and verified 
using mass spectrometry.   
 102
 
3. T cell clones and lines, growth and maintenance  
 The CD4+ HA1.7 human TH0 clone specific to the influenza Ha peptide bound to the class 
II MHC protein HLA-DR1 (Lamb et al., 1982), CD4+ CTL cell clone AC25 specific to the HIV-
1 gag peptide PP16 in complex with HLA-DR1 (Norris et al., 2004), the CD8+ T cell lines VA55 
3.13 and VA49 3.12 specific to the vaccinia peptides MVA-74A and MVA-165, respectively, in 
complex with HLA-A2 (Terajima et al., 2003), and a short term polyclonal CD4+ T cell line 
specific to the EBV-derived peptide QHY in complex with HLA-DR1 (Precopio et al., 2003) 
were maintained in RPMI 1640 medium (Invitrogen), 10% fetal bovine serum, with biweekly 
stimulation with irradiated allogeneic peripheral blood mononuclear cells (PBMC), 12F6 α-CD3 
antibody (from Johnson Wong, Massachusetts General Hospital) and IL2 (BD Biosciences).  A 
murine T cell hybridoma transfected with T cell receptor and CD4 binding domains derived from 
HA1.7 was maintained in S-MEM (Invitrogen) containing 10% fetal calf serum.  See Media 
Recipes and T Cell Maintenance protocols in the Appendix. 
 
4. Tetramer production and staining   
 Fluorescently-labeled streptavidin (SA) tetramers used for staining T cells were produced 
by stepwise addition of SA-phycoerythrin (SA-PE, Biosource) or SA-allophycocyanin (BD 
Pharmingen) to purified biotinylated MHC samples to a final molar ratio of 1:4, as previously 
described (Altman et al., 1996; Cameron et al., 2002). Cells were stained at 37°C, fixed with 1% 
paraformaldehyde, and measured using a BD FacsCalibur flow cytometer. 
 
5. Production of artificial antigen-presenting arrays   
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 Polystyrene, Permanox, and LabTek II CC2 slides were from Nalge Nunc Inc..  MHC-
peptide monomers (50 µg/mL) and unlabeled SA-linked tetramers (50 µg/mL bio-MHC with 
14µg/mL SA) were immobilized by spotting onto the surface in phosphate-buffered saline 
(PBS), pH 7.4.  We investigated several direct and indirect immobilization strategies and found 
simple adsorption to plastic or treated glass to be straightforward and reproducible.  Co-
stimulatory or adhesion antibodies (α-CD11a, α-CD2, and α-CD28, Leinco) were included at 
5 µg/mL in the same solution.  For cytokine capture chips, the capture antibody (α-IFN, α-TNF, 
α-IL4, or α-granzyme B, BD Pharmingen) was first spotted at 40 µg/mL and allowed to dry, and 
the MHC/adhesion antibody solution was spotted onto the dry spots.  The arraying was 
accomplished by either hand-spotting of 0.1-0.5 µL of solution, by a Cartesian Microsystems 
(Genomic Solutions) automatic non-contact array printer, or by using a Xenopore Manual 
Microarrayer (Xenopore Corp.).  After air-drying, the chips can be stored for more than 3 months 
at 4 degrees without loss of activity.  See Making MHC and Co-stimulatory Array Chips 
protocol in the Appendix. 
 
6. Cytokine capture detection using artificial antigen-presenting arrays   
 Spotted, dry chips were blocked by incubation with serum-containing T cell medium for 
30 minutes at room temperature.  Then cells were added to the chip and incubated 4-16 hours at 
37°C, contained within individual chamber slides (Nalge Nunc Inc.) or within a hydrophobic 
barrier (Ted Pella, Inc.).  Typically ~106 cells per slide were used, although this was varied as 
noted.  After removal of the supernatant, the chip was rinsed with fresh medium and examined 
for cell adhesion by eye or microscope.  T cells were removed by washing with distilled water 
twice and with tris-buffered saline solution containing 0.1% Tween 20, pH 7.6 (TBST) three 
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times.  Biotinylated detection antibody and fluorescently-labeled SA (Alexa 555 or Alexa 647, 
Molecular Probes) were pre-incubated at high concentration (>1mg/mL), and then diluted (1:250 
final antibody dilution, 2 µg/mL final concentration SA) into TBST containing 0.3% BSA and 
100 µM free biotin.  Labeled MHC-detection antibodies were used at a final concentration of 1 
µg/mL.  Chips were stained for 1.5 hours at room temperature; then the slide was washed 3 times 
with TBST, 2 times with ddH2O, and then dried.  The chips were scanned using an Affymetrix 
428 array scanner, and data were analyzed using Jaguar 2.0 software (Affymetrix Inc.).  A 
single-pixel wide median averaging was performed to remove speckle noise from the images 
(Adobe Photoshop 7.0.1), and surface plots were prepared using ImageJ 1.30v (National 
Institutes of Health, USA).  Spots exhibiting average fluorescence intensities significantly above 
no-MHC controls were considered positive. Typically, duplicate or triplicate spots were 
examined.  For precipitating substrate analysis, SA-HRP (Sigma-Aldrich) was used in place of 
fluorescently-labeled SA, and the spots were developed using an AEC precipitating substrate 
(BD Pharmingen), and were observed by eye and under a dissection microscope.  See the T-Cell 
Epitope Detection Experiment Using MHC and Co-stimulatory Arrays protocol in the Appendix. 
 
7. Fluorescence microscopy   
 After incubation as above, the chips were chilled to 4°C and fluorescent antibodies and 
Hoechst stain were added on ice for 40 minutes.  The chip was then fixed with 1% 
paraformaldehyde for 5 minutes at room temperature, rinsed twice with PBS, and dehydrated 
once with 70% ethanol.  A coverslip was applied with Vectashield, and the spots were observed 
using a Nikon Eclipse E800 fluorescence microscope.  Images were obtained using a Spot RT 
Slider camera with SpotBasic version 4.0.2 software (Diagnostic Instruments, Inc.). 
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C. Results 
1. Artificial Antigen-Presenting Element Arrays can be used to detect T cell activation.   
 We prepared microarrays of soluble, recombinant MHC-peptide complexes immobilized 
together with cytokine capture antibodies (see Methods).  When T cells are incubated with such 
arrays, antigen-specific activation occurs in the particular array elements carrying appropriate 
MHC-peptide complexes, and this interaction leads to secretion of cytokines and effector 
molecules.  These molecules are captured locally by capture antibodies immobilized along with 
the MHC-peptide complexes, and are detected in a position-specific manner using fluorescent 
anti-cytokine detection antibodies (Figure V.1A).  An example of such a microarray is shown, 
consisting of a polystyrene slide with a hydrophobic barrier surrounding the arrayed MHC-
peptide complexes (Figure V.1B).  Small volumes of cell suspension or staining antibody 
solutions (0.5-1.0 mL) are contained within the barrier.  Up to ~1000 individual elements can be 
arrayed on a slide with each element maintaining its ability to function as a complete antigen 
presenting entity.  Both class I and class II MHC complexes maintain their native conformation 
after immobilization as detected by conformationally specific antibodies (Figure V.1C, left and 
Figure V.2).  Incubation of these arrays with T cell samples leads to T cell activation and 
expression of measurable responses.  In this example, a T cell hybridoma specific for HLA-DR1 
in complex with an influenza peptide (Ha) was incubated with an array carrying various DR1-
peptide complexes.  While native DR1 conformation was detected in all the array spots, antigen-
induced secretion of IL-2 was detected only on the spots that contain the specific DR1-Ha 
complex (Figure V.1C, right).  Devices such as these allow parallel testing of many potential T 
cell epitopes, conservation of T cells and other reagents, mass-production, and convenient use. 
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Figure V.1  Artificial antigen-
presentation chips.  (A) Schematic 
representation of artificial antigen-
presenting microarray technology.  
Top: MHC-peptide complexes 
immobilized with different peptide 
antigens in distinct areas.  
Costimulatory and cytokine capture 
antibodies can be co-immobilized 
(not shown).  Center: T cells are 
incubated with the array.  Only 
specific MHC-peptide complexes 
induce T cell responses.  Cytokines 
are captured locally by immobilized 
anti-cytokine antibodies.  Bottom: 
Captured cytokines are detected by 
labeled antibodies in the locations 
where they were secreted, 
identifying the activating epitopes.  
(B) Photograph of a microarray with 
solution held in place by a 
hydrophobic barrier.  (C) Microarray 
carrying different DR1-peptide 
complexes on a polystyrene slide,  
incubated with 106 murine hybridoma cells specific to DR1-Ha for 16 hours, and stained 
for native MHC with LB3.1-CY5 (left), and for captured mouse IL2 using biotinylated α-
mouse-IL2 pre-incubated with SA-Alexa 555 (right).  The pattern was repeated in four 
areas. 
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Figure V.2   Native 
MHC is detected on 
the arrays.  The 
numbers below each 
fluorescent image 
indicate the 
concentration of MHC 
in the solution 
spotted onto the 
array in µg/mL.  (A) 
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antibody which recognizes properly folded A2 associated with light chain.  Antibody 
binding was detected using goat anti-mouse conjugated to Alexa-555.  (B) HLA-DR1 is 
detected using CY3-labeled LB3.1; an antibody which recognizes natively-folded empty 
and peptide-loaded DR1.  (C) Denatured HLA-DR1 is detected using MEM-267, an 
antibody which recognizes empty or denatured but not peptide-loaded HLA-DR1. 
Antibody binding was detected using goat anti-mouse conjugated to Alexa-555. 
 
2. The effect of co-immobilized co-stimulatory molecules on MHC-peptide arrays 
 Most non-transformed and primary T cells require non-specific co-stimulatory and/or 
adhesion signals in addition to specific MHC-peptide stimulus for induction of full activation 
responses.  Engagement of conventional costimulatory molecules on the T cell surface such as 
CD28, or integrins such as CD2 (LFA-3) and CD11a (LFA-1), serves to amplify and/or stabilize 
signals that lead to cytokine secretion (Davis et al., 2003).  In the absence of costimulatory 
signals, T cells adhere to the MHC-peptide coated surfaces in a peptide-specific manner, as has 
been previously described for murine T cells (Soen et al., 2003).  VA55 3.13, a CD8+ human T 
cell line isolated from a vaccinia-vaccinated individual, specifically recognizes HLA-A2 bound 
to MVA-74A, a peptide derived from the vaccinia 189R gene product (Terajima et al., 2003).  
VA55 T cells adhere to array elements containing the specific A2-74A complex, but not the non-
specific A2-165 complex (Figure V.3A, left panels).  When we included costimulatory signals in 
the form of antibodies to cell-surface molecules together with the MHC-peptide complexes, 
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VA55 adhesion was more robust, and T cell spreading indicative of productive interaction is 
induced in the area containing the specific complex (shown for α-CD11a in Figure V.3A, lower 
right panel).  Although adhesion to non-specific areas is observed in the presence of α-CD11a 
(Figure V.3A, upper right panel), cytokine secretion is induced only in the specific areas (see 
below).  
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Figure V.3  The effect of co-stimulation 
on T cell detection.  (A) HLA-A2+ MVA-
74A peptide specific T cells, incubated for 
5 hours on a MHC-peptide array at ~10 
cells/mm2 (3x105/chamber on a 4-
chamber slide), and stained with Hoechst 
nuclear stain.  Left: MHC complexes were 
arrayed alone at 50 µg/mL.  Right: α-
CD11a adhesion antibodies were co-
immobilized with MHCs.  The top panels 
each show a non-activating MHC-peptide 
array element, while the bottom panels 
each show an activating MHC-peptide 
spot.  The single spot images shown are 
characteristic of such spots on replicate 
arrays. (B-C) Average spot intensities (in 
arbitrary fluorescence units) for IFN-γ 
secretion by 106 cells in response to 6 
hours incubation with array elements 
incorporating different types of co-
stimulatory antibodies.  (B) Response of 
VA55 3.13, a CD8+ line specific to A2-
74A.  (C) Response of AC25, a CD4+ 
clone specific to DR1-PP16.   
 
 
Cytokine secretion is greatly enhanced by inclusion of co-immobilized costimulatory 
molecules in the microarray elements.  VA55 3.13 T cells were tested for IFN-γ secretion in 
response to activating and non-activating MHC-peptide array elements, with and without various 
co-immobilized adhesion and costimulatory antibodies.  IFN-γ secretion was observed in 
response to A2-74A immobilized on the array, but not to non-specific complexes or in the 
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absence of MHC’s (Figure V.3B).  The IFN-γ detected was significantly enhanced in the 
presence of each of the costimulatory antibodies α-CD11a, α-CD2, and α-CD28 without the 
large increase in background as for adhesion (Figure V.3A).  Similar results were obtained for 
AC25, a CD4+ T cell clone, raised from an individual infected with HIV-1, that recognizes HLA-
DR1 bound to PP16, a peptide from HIV-1 gag p24 (Norris et al., 2004).  AC25 also secretes 
IFN-γ specifically in spots containing the appropriate MHC-peptide complex, and again the 
signal is enhanced in the presence of the costimulatory molecules tested (Figure V.3C).  The 
combination of specific MHC-peptide complexes and costimulatory antibodies allow the array 
elements to act as artificial antigen presenting cells with a single epitope localized to each area, 
and enhances detection of relevant specific T cell responses. 
 
3. Specificity of the response   
 Identical MHC-peptide chips were created with specific and non-specific MHC-peptide 
complexes, and tested for IFN-γ induction.  Incubations of both CD4+ AC25 (Figure V.4A) and 
CD8+ VA55 3.13 (Figure V.4B) on these chips result in clear, specific reactions with the correct 
complex, with little or no detection on non-specific spots.  Tetramer staining experiments 
performed for these same cells indicate the same specificity as observed by the microarrays 
(Figure V.5).  
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Figure V.4  Arrayed Class I and Class II epitopes are specifically recognized by human CD8+ and 
CD4+ T cells.  (A-B) MHC-peptide complexes and α-CD11a antibody were immobilized with α-IFN-γ 
capture antibody.  The chips were incubated with 1x106 T cells and IFN-γ was detected.  Fluorescence 
intensity on the chip is shown as a 3-D surface plot of the array area; raw fluorescence image is shown as 
an inset.   (A) CD4+ clone AC25, specific to DR1-gag.  (B) CD8+ line VA55 3.13, specific to A2-74A.  (C) 
Response of a short-term polyclonal human T cell line against the EBV protein BZLF-1 (Precopio et al., 
2003) was analyzed using overlapping peptides covering the sequence of the protein, each in complex 
with HLA-DR1.  Additional spots contained the previously identified minimal epitope peptide QHY (BZLF-
1 [198-210]), a series of HIV p24 gag overlapping peptides, and other control complexes, for a total of 50 
spots in an area of 192 mm2.  A partial map of the array is shown on top.  The array was incubated with 
100,000 T cells, of which ~13% were specific to BZLF-1 by intracellular cytokine staining (about 13,000 
specific cells, or 60/mm2).  The secreted IFNγ detected after 6-hours incubation is shown below the map.  
Small spots, corresponding to cytokines secreted by single responding cells, can be seen within the 
overall spot areas for two specific array elements that contain BZLF-1 [196-220] (green) from the 
overlapping peptide series, and the previously identified minimal epitope BZLF-1 [198-210] (“QHY,” red).  
Surface plots for the boxed array elements BZLF-1 [221-245] (non-activating) and BZLF-1 [198-210] 
(QHY, activating) are shown below the array.  Intensity spikes from individual secretion sources can be 
seen.  (D) The average number of such spots observed for each element of the microarray in (C) is 
shown as a bar graph, with the same layout (n=4). 
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Figure V.5  
Tetramer staining 
of AC25 and VA55 
3.13 T cells.  Left 
panel: The CD4+ 
DR1-PP16 specific 
T cell clone AC25 
binds to DR1-PP16 
SA-PE tetramers 
(solid line) but not 
DR1-Ha SA-PE 
tetramers  
(dashed line).  Right panel: The CD8+ A2-74A specific T cell line VA55 3.13 binds to A2-
74A SA-allophycocyanin tetramers (solid line), but not A2-165 SA-allophycocyanin 
tetramers (dashed line). 
 
Often to determine T cell epitopes, one must test the T cells with overlapping peptides 
covering the entire sequence of a known protein immunogen.  We prepared microarrays carrying 
overlapping peptides covering the sequence of the lytic stage antigen BZLF-1 from Epstein-Barr 
virus, and used them to screen for reactivity in a short-term T cell line raised from the PBMCs of 
a HLA-DR1+ patient presenting with acute infectious mononucleosis (Precopio et al., 2003).  In 
addition to the BZLF-1 overlapping 25-mer peptide series, the arrays also included the known 
minimal peptide epitope QHY (BZLF-1 [196-210]), and a second overlapping peptide series 
covering the sequence of HIV-1 gag p24.5  Each peptide epitope was allowed to bind to peptide-
receptive DR1, and the resulting complexes were spotted onto the array, resulting in 50 possible 
spots with which the cells could react.  The spots were created using 0.1 µL MHC-peptide 
solution at 50 µg/mL per spot, with a resultant area of ~0.44 mm2 for each spot.  The short-term 
T cell line, which is about 13% specific for BZLF-1 by intracellular cytokine staining (not 
shown), was incubated on the chips at a density of 96,000 total cells per array (approximately 60 
                                                 
5 Note that for class I MHC proteins, the peptide termini typically bind within the MHC binding site, and each 
potential epitope must be present as a separate peptide. For class II MHC proteins, the peptide termini can extend 
from the site, and a single long peptide can be used to evaluate multiple potential epitopes. Thus, many more 
individual peptides must be evaluated to screen a protein sequence for class I as compared to class II epitopes. 
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specific cells per mm2) (Figure V.4C).  IFN-γ was specifically detected in the spots with 
previously identified EBV epitopes: peptide 196-220 in the overlapping peptide series (Figure 
V.4C, green), and the minimal peptide epitope QHY (Figure V.4C, red).  At these low cell 
densities, the inherent granularity of the assay is apparent, and the chips are more accurately 
analyzed by counting individual spots within the larger array spot areas, as in an ELISPOT 
analysis (Czerkinsky et al., 1988), instead of analyzing overall intensities.  Surface plots for a 
non-activating array element (BZLF-1 [221-245]) and the adjacent activating array element 
(QHY)  clearly show spikes corresponding to individual secreting cells, as opposed to higher 
density cell incubations where a more continuous peak is observed (compare surface plots in 
Figure V.4C to Figures V.4A-B).  The spots within each area were enumerated, and the average 
values for four experiments are shown in a bar graph with the same layout as the array (Figure 
V.4D).  The positive elements are readily apparent even at a low responding cell density.  An 
example of an identical array incubated with the EBV-specific T cell line at higher density can 
be seen in Figure V.6. 
Figure V.6  EBV-specific response 
from a short-term line can be 
detected by a mapping chip. A short-
term T cell line raised from a patient with 
acute infectious mononucleosis, which is 
about 13% specific for the EBV protein 
BZLF-1 by intracellular cytokine staining 
(not shown), was analyzed using a 
series of overlapping peptides covering 
EBV-specific CD4+ short-term T cell line
8 x 105 cells (13% specific)
the sequence of the protein, each in complex with HLA-DR1.  Cells were incubated on a 
chip at a density of 500 specific cells per mm2, or about 8 x 105 total cells per array. A 
map of the chip can be seen in Fig. 3C.  The fluorescence map obtained after 6-hour 
incubation with the polyclonal T cell line and detection of secreted IFNγ is shown.  IFN-γ 
was specifically detected most intensely in the spots with the previously identified EBV 
epitopes: BZLF-1 [196-220] in the overlapping peptide series and the minimal peptide 
epitope QHY (BZLF-1 [198-210]). 
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4. Sensitivity of cytokine secretion response   
 T cells responding to infection or vaccination often are present at low frequencies in the 
overall T cell population.  As a test of sensitivity of this technique, the VA55 3.13 T cell line was 
diluted into non-specific (allogeneic) PBMCs and tested on an array with specific and non-
specific HLA-A2 complexes.  Secretion of granzyme B, a cytotoxic T cell marker, was detected.  
Fig. 4 shows VA55 3.13 tested at dilutions ranging from 10% to 0.1% of the total cells, using in 
each case 2.5x106 cells, a sample size corresponding to 1-3 mL of blood.  A specific secretion 
signal was observed even after dilution to 0.1% of the total cells, a frequency of ~1000 specific 
cells per million (Fig. 4, 0.1% panel), or roughly 20-100 per spot assuming even distribution of 
cells around the array; however, at this level, interpretation is complicated by the relatively high 
non-specific background that approaches the sample-to-sample variability.  This sensitivity is in 
the range of other current T cell antigen screening assays such as MHC tetramer staining 
(Dunbar and Ogg, 2002) or ELISPOT assay (Czerkinsky et al., 1988); however, using the 
microarray assay, many epitopes can be assayed in a single well. 
Figure V.7  Detection of low-
frequency responses.  VA55 
3.13 CD8+ T cells (specific to HLA-
A2 in complex with MVA-74A) 
were diluted into allogeneic 
PBMCs, and granzyme B 
secretion was detected on the 
chips after incubation.  In each 
panel, the total number of cells per 
chamber was 2.5x106.  The spots  
 
are ~1 mm in diameter, for an average spot area of 0.75 mm2.  Average intensities of 
spots (n=2) and raw fluorescence image is shown after dilution of VA55 3.13 (left to 
right panels) to 10% of the total cells (100,000 per million), 1% of the total cells (10,000 
per million), and 0.1% of the total cells (1000 per million).  At the lowest level, the 
average spot intensity is less straightforward to interpret due to relatively high 
background, and more representative values may be obtained by counting individual 
ELISPOT-like secretion spots within the array areas. 
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5. Multiple cytokines can be tested simultaneously   
 The cytokine capture chips can be designed for simultaneous detection of multiple 
cytokines from a single responding T cell population.  In Figure V.8A, VA55 3.13 was screened 
in a four-chambered slide, with different capture antibodies immobilized in each chamber.  
Specific secretion of IFN-γ, granzyme B, and TNF-α, but not IL4, was observed.   These results 
replicate those observed in conventional bulk cytokine secretion ELISA experiments performed 
on the same cells (Figure V.8A).  In another approach, multiple cytokines can be distinguished 
using anti-cytokine antibodies labeled with different fluorescent probes.  Figure V.8B shows an 
array carrying both IFN-γ and IL4 capture antibodies along with specific and non-specific MHC-
peptide complexes.  Using two differently labeled cytokine detection antibodies, both IL4 and 
IFN-γ were detected in only the appropriate regions (Figure V.8B).  The two strategies of spatial 
separation and multiple fluorescent labels for detection could be applied concurrently to obtain 
large amounts of information from a single experiment.  Thus, very broad screens for functional 
responses could be carried out simultaneously with parallel screens of many different T cell 
epitopes. 
 
6. Non-fluorescent detection of cytokine capture   
 In some cases, it may be advantageous to detect the cytokine secretion in a manner 
visible to the naked eye by using enzyme-linked antibody and precipitating substrate, as in a 
traditional ELISPOT assay, rather than fluorescent detection.  Figure V.8C shows an array which 
was incubated with the CD8+ T cell line VA49 3.12, isolated from a vaccinia-immunized 
individual, which responds specifically to HLA-A2 in complex with the MVA-165 peptide (from 
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the vaccinia gene product “018L”), but not the MVA-74A peptide (Terajima et al., 2003).  The 
array was analyzed using biotinylated α-IFN-γ and peroxidase-coupled SA.  Visually apparent 
development can be seen in areas where specific A2-165 peptide complex or positive control α-
CD3 stimulus was immobilized, but not in areas with non-activating A2-74A complex (Figure 
V.8C).   
 
7. Other activation markers   
 MHC-peptide microarrays may be used to detect other activation markers in T cells.  For 
example, specific detection of transient calcium flux in cells on peptide-MHC tetramer arrays has 
been reported in murine T cells (Soen et al., 2003).  We investigated whether T cell surface 
markers, conventionally assayed in flow cytometry experiments, also could be evaluated in 
parallel on MHC-peptide and costimulatory microarrays.  Figure V.8D shows a 60x view of a 
single element of a MHC-peptide array with human CD4+ HA1.7 T cells specific for DR1-Ha 
(Lamb et al., 1982) adhering.  These cells have been stained with Hoechst nuclear stain, α-CD3-
PE, and α-CD69-FITC.  CD69 is a common early activation marker that is upregulated upon T 
cell activation (Testi et al., 1994), and CD3 is a component of the T cell receptor which is 
downregulated upon activation (Valitutti et al., 1997).  The HA1.7 T cells adhering to the 
specific DR1-Ha region are more numerous and clustered as seen by the blue Hoechst stain, and 
exhibit lowered CD3 expression (red) and substantial CD69 upregulation (green) as compared to 
cells in the non-specific DR1-PP16 region.  This technique could be applied to detect the 
expression of other cell-surface activation markers, or markers of intracellular signaling 
pathways.   
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Figure V.8  Analysis of multiple T cell 
functions.  (A) A multi-chamber LabTek II 
CC2 slide was prepared with a different 
capture antibody in each chamber, but 
identical MHC-peptide and α–CD11a 
patterns.  2.5x105 VA55 3.13 cells (specific 
to A2-74A) were incubated in each 
chamber, and then cytokine secretion was 
analyzed using the appropriate detection 
antibody.  Below each image is a bar 
graph showing the same cytokine detected 
by a bulk ELISA where VA55 3.13 T cells 
are stimulated with peptide-pulsed, HLA-
A2+ APCs.  (B) A chip was spotted with α–
IFN-γ and α-IL4 capture antibodies in 
different areas with the same MHC-peptide 
and α–CD11a stimuli co-immobilized.  The 
chip was incubated with 1x106 AC25 T 
cells (specific to DR1-PP16), and then 
stained with a mixture of biotinylated α–
IFN-γ pre-incubated with SA-Alexa 555 
and biotinylated α–IL4 pre-incubated with 
SA-Alexa 647.  The chip was scanned at 
both wavelengths: Alexa 555 is shown in 
red, and Alexa 647 is shown in green.  (C) 
Cytokine capture can be detected on the 
arrays using precipitating substrate.  The 
array shown was incubated with VA49 
3.12, a CD8+ T cell line specific to A2-165.  
IFN-γ secretion was detected in the 
regions containing α–CD3 and A2-165, but 
not A2-74A.  (D) Cell-surface protein 
upregulation in response to array elements 
can be detected using fluorescently 
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labeled antibodies.   HA1.7, a CD4+ T cell clone specific to DR1-Ha, was incubated on a 
microarray containing DR1-PP16 (null, top row) and DR1-Ha (activating, bottom row).  
Hoechst nuclear stain shows the presence of adhering cells, while α–CD3-PE and α–
CD69-FITC were used to show the relative levels of those activation-linked cell surface 
markers. 
 
D. Discussion 
 We have described a new technique that can be used to screen small samples of T cells 
for specific peptide-MHC binding as well as for functional responses in a microarray format.  
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Each array element consists of recombinant peptide-MHC complexes co-immobilized with co-
stimulatory antibodies and anti-cytokine antibodies to locally detect T cell adhesion and 
activation responses; these elements act as individual artificial antigen-presenting cells (Oelke et 
al., 2003) with each element presenting a different T cell epitope candidate.  The arrays are 
convenient to use with small volumes of cell suspension or staining solutions, allowing for 
reagent conservation, and are mass-producible with commercially available array spotters.  The 
arrayed MHC-peptide complexes are largely native and remain spatially distinct after multiple 
washes, incubations, and stainings.  The dry MHC-peptide arrays are stable for long periods in 
excess of 3 months at 4°C.  The functional responses induced when T cells recognize array 
elements, such as cytokine secretion or activation of cytolysis, are detected in a location-
dependent manner.  In previous work, MHC-peptide arrays were used to observe adhesion and 
calcium flux in murine CD4+ T cells (Soen et al., 2003).  Here, the combination of specific 
MHC-peptide complexes and costimulatory antibodies greatly enhances the detection of relevant 
specific functional responses. 
The advantages of array technology that have revolutionized gene expression research 
have already begun to be applied to important clinical problems of immunology and infection.  
Protein microarrays have been used to detect specific antibody responses in human serum 
(Bacarese-Hamilton et al., 2003), which may be applied conveniently to allergy testing, 
diagnosis of some diseases, and vaccine design for certain pathogens.  However, many infections 
are not eliminated by antibody responses (Aasa-Chapman et al., 2004; Khanna et al., 1995; 
Logvinoff et al., 2004), and in those cases, the ability to use array technology to analyze the 
cellular immune response would be beneficial.  Using antigen-presentation microarrays with live 
immune cells allows broad, multidimensional information to be obtained quickly and easily. The 
 118
ability to conveniently track T cells for specificity and functional response for many epitopes in 
parallel in small clinical samples has the potential to lend new levels to our understanding of the 
rise and fall of T cell populations during vaccination or infection.  
Artificial antigen-presenting arrays show promise as convenient tools with which to 
discover T cell epitopes and characterize T cell responses.  This technology is able to sensitively 
detect low-frequency responses as well as give extensive information on the nature of the 
response to different T cell epitopes.  This sort of data, conveniently and rapidly obtained, can be 
utilized to accelerate studies of the cellular immune response to novel pathogens and to promote 
development of safe, effective vaccines or other innovative immunotherapies.   
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VI. Conclusions and Future Directions for Research 
 
A. T Cell Activation Mechanism 
1. Multivalent T cell receptor binding is sufficient for activation processes 
 Chapters II-IV of this thesis showed that for both CD4+ and CD8+ T cells, simple cross-
linking of T cell receptors is adequate to induce activation processes.  This cross-linking may be 
achieved by cognate MHC-peptide complexes on the surface of an antigen-presenting cell, or by 
various soluble MHC-peptide reagents capable of binding to multiple T cell receptors 
simultaneously.  Cross-linking by non-physiological ligands such as antibodies to the T cell 
receptor or signaling subunits of the TCR complex can also trigger T cell signaling.   
 Chapter II presented a simple model based on multivalent binding equilibria that relates 
properties of the CD4+ T cell response such as MHC-ligand binding, TCR downregulation, 
CD69 upregulation, and CD25 upregulation using the binding parameter KD to describe 
monovalent MHC-TCR affinity, and KX to describe TCR cross-linking by subsequent MHC 
binding to TCR from the same oligomeric MHC complex.  The parameters KD and KX could be 
fit to the observed T cell activation after treatment with a series of soluble MHC-peptide 
oligomers of increasing size.  Different T cell clones recognizing identical MHC oligomers 
exhibit different binding and cross-linking parameters that could correlate with their sensitivity 
to the ligand.  These results suggest that information about the number of cross-linked receptors 
on the surface of the T cell induced by MHC oligomer binding is maintained through signaling 
cascades, and that cross-links can be directly converted into activation signals. 
 Chapter III discussed an important confounding feature in the activation of CD8+ T cells 
by soluble recombinant MHC-peptide molecules.  Peptide derived from soluble MHC complexes 
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added to CD8+ T cells can be loaded onto endogenous class I MHC molecules on the T cell 
surface, with cell-cell mediated presentation of the peptide-MHC complex sensitively triggering 
activation processes.  This phenomenon may be at play in all T cell triggering by soluble 
molecules, depending on the stability of the MHC-peptide complex and the relative proteolytic 
stability of released peptides.  Without contributions of cell-surface MHCs, CD8+ T cells were 
shown not to respond to soluble MHC monomer binding, as analyzed by allogeneic MHC-
peptide stimulation or syngeneic MHC-peptide stimulation of T cell chimeras that do not express 
cell-surface class I MHCs. 
 Chapter IV showed that CD8+ T cells respond to soluble oligomers of allogeneic MHC-
peptide complexes in a mode similar to CD4+ T cells.  Stimulation was seen by a soluble 
allogeneic class I dimer in naïve T cells with or without expression of the CD8 co-receptor.  For 
both CD4+ and CD8+ T cells, a soluble MHC-peptide monomer can antagonize responses to 
soluble MHC-peptide oligomers in activation assays, suggesting that monomeric binding cannot 
contribute to cross-link induced T cell signaling.  However, T cell triggering was observed when 
CD4+ T cells were treated with a heterodimer of MHCs including one cognate MHC-peptide and 
one non-specific MHC-peptide, whereas neither treatment with soluble cognate monomers or 
treatment with non-specific oligomers was able to induce a response.  These results show that T 
cells can respond very sensitively to specific MHC-peptide when it is accompanied by other 
interactions. 
 These results taken together argue for a T cell triggering mechanism involving 
multivalent ligation and cross-linking of T cell receptors.  However, questions regarding the 
manner in which receptor cross-linking results in an activation signal remain.  Recent studies 
have pointed to involvement of the TCR signaling subunits carrying intracellular ITAM 
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domains.  The soluble cytoplasmic domain of the TCR-zeta (ζ) subunit has shown a tendency to 
bind to acidic phospholipids; when TCRζ is lipid-bound, it is less accessible for phosphorylation 
by soluble tyrosine kinases (Aivazian and Stern, 2000).  Binding of activating antibody ligands 
to T cells has been shown to result in the rapid exposure of a new intracellular binding epitope 
for Nck on CD3-ε, an event which correlates well with productive signaling (Gil et al., 2002).  At 
high concentrations, soluble TCRζ has been shown to reversibly homooligomerize, as have other 
ITAM-containing cytoplasmic domains (Sigalov et al., 2004).  The geometry of the TCRζ 
homooligomerization interface is not known, and the interaction between cytoplasmic domains 
may or may not be possible in covalently-linked homodimers.  In addition, signaling subunits 
such as TCRζ homodimers have been observed on the T cell surface unassociated with the larger 
TCR complex after T cell stimulation in a process dependent upon the presence of src-family 
tyrosine kinases p56lck (Lck) and p59fyn (Fyn) known to be involved in T cell signaling (La Gruta 
et al., 2004).  A model may be synthesized from these data taken together, represented in Figure 
VI.1, whereby in resting T cell receptors, TCRζ cytoplasmic domains are held in a largely 
inaccessible arrangement, possibly lipid-bound.  T cell receptor clustering by multivalent ligand 
brings cytoplasmic signaling domains into high local concentration which drives release from the 
inhibited arrangement and homooligomerization of soluble domains.  These domains may then 
be substrates for cytoplasmic kinases and adaptor molecules.  The signaling complex may then 
separate from the antigen-binding chains, which become degraded, and remain on the surface as 
a scaffold for continued signal transduction.  A similar model has been presented as a general 
mechanism for all multichain ITAM-containing antigen receptors (Sigalov, 2004).  Continuing 
studies would focus on the ability to distinguish the order and causality for observed steps in the 
activation mechanism. 
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FIGURE VI.1  Model for T cell activation by 
multivalent ligand binding.  (A) Resting T cell 
receptors consisting of antigen-binding chains 
(gold) and signaling chains such as disulfide-
linked homodimer ζ-ζ (aqua on one receptor and 
blue on the other).  Signaling domains are held in 
an arrangement that has low accessibility for 
cytoplasmic tyrosine kinases—potentially bound 
to the acidic lipids in the membrane.  (B) Binding 
to multivalent ligand, whether soluble or 
presented on the surface of an APC, leads to 
receptor cross-linking or clustering.  This allows 
interaction of the cytoplasmic domains of TCRζ, 
including release from the inaccessible 
arrangement and homodimerization/ 
homooligomerization.  In this arrangement, the 
ITAMs on the cytoplasmic tails of TCRζ may 
expose a novel binding epitopes and become 
substrates for src family kinases Lck and Fyn.  
This results in tyrosine phosphorylation which 
may disallow re-binding to the lipid bilayer.  (C) 
The signaling chain homooligomers may 
dissociate from the antigen-binding chains of the 
TCR.  These chains are targeted for 
internalization and degradation.  The 
phosphorylated TCRζ complexes may stay on the 
surface, allowing adaptor molecules to bind and 
acting as a scaffold for signal transduction. 
 
2. Involvement of MHC co-receptor 
 While the MHC co-receptor has been shown both to bind extracellularly to MHC 
molecules and to associate intracellularly with kinases involved in TCR signaling, it is not 
certain what the role of the co-receptor is in T cell triggering.  CD4 has been shown to move 
away from TCRζ in stable immunological synapses in activated T cells (Krummel et al., 2000), 
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and activation has been seen in T cells that do not express MHC co-receptor; although these cells 
are less sensitive than T cells which do express the co-receptor (Ge et al., 2002).  T cells that 
bind their cognate MHC-peptide with high affinity do not appear to require co-receptor 
engagement for activation (Kerry et al., 2003).  It is unknown whether the main contribution lies 
in rapidly recruiting cytoplasmic kinases to engaged T cell receptors before MHC dissociation 
(Li et al., 2004; Xiong et al., 2001), or whether co-receptor binding is most helpful in increasing 
the affinity and half-life for binding of weak MHC-peptide agonists (Cho et al., 2001).  
However, the ability of CD8- T cells to be activated by a soluble MHC-peptide dimer (Chapter 
IV) shows that receptor cross-linking without involvement of co-receptor can initiate signal 
transduction. 
 
3. Does monovalent MHC-peptide binding to TCR initiate any signaling processes? 
 While monomeric MHC-peptide binding may not induce sustained signaling, there may 
still be certain events that are triggered when binding occurs.  Crystallographic studies have 
showed that for immunodominant epitopes, a conformational change can occur in the putative 
CD3-ε interface of the T cell receptor upon MHC-peptide binding.  Perhaps this change disturbs 
the association between TCR αβ and CD3-ε, exposing intracellular epitopes that can initiate 
signaling cascades.  Further studies on the potential for soluble MHC-peptide monomers to 
induce activation-linked makers such as exposure of the Nck-binding epitope (Gil et al., 2002) or 
incomplete phosphorylation of signaling subunits must be conducted in a system taking care to 
avoid the complication of peptide re-presentation at the T cell surface. 
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4. Role of co-stimulation and adhesion signals 
 It is known that co-stimulatory and adhesion signals contribute to full T cell activation 
(Chambers, 2001; McAdam et al., 1998; Pribila et al., 2004).  The presence of these antigen non-
specific interactions allows T cell activation to occur at lower specific peptide levels, resulting in 
increased apparent sensitivity (Irvine et al., 2002; Wulfing et al., 2002).  However, the specific 
mechanism by which these interactions contribute to specific recognition and signaling through 
the T cell receptor is not known.  The technique of cross-linking heterogeneous molecules, used 
in Chapter IV to attach an activating MHC-peptide complex specifically to a non-activating 
MHC-peptide complex, may be applied to linking MHC-peptide complexes to co-stimulatory 
molecules to further investigate the minimal requirements for T cell recognition. 
 
5. KD and KX differences between T cells subsets 
 Modeling of T cell binding and activation response to treatment with a soluble MHC-
peptide oligomer series could be extended to determine the parameter values for many different 
types of T cells.  For example, CD8+ T cells, thought to be more sensitive than CD4+ T cells, 
may express different values for these binding parameters.  Memory and effector T cells respond 
more sensitively to antigen than naïve T cells; perhaps the ability to cross-link receptors has 
changed during development, and higher avidity binding is seen after T cell maturation (Slifka 
and Whitton, 2001).  Anergized T cells, conversely, may have lowered the ability for their 
receptors to be cross-linked.  Measuring binding and activation using soluble MHC-peptide 
oligomer series and using mathematical modeling to derive the binding parameters related to the 
simple model studied in Chapter II may help us to understand how T cells with similar 
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monovalent affinity for MHC-peptide (or even identical receptors) respond very differently when 
presented with cell-bound or multivalent stimuli. 
 
B. Screening for T cell epitopes derived from vaccines or infectious agents 
1. Large-scale production of class I and class II MHC-peptide complexes 
 Chapter V in this thesis describes a technique for screening T cell reactivity to pathogen-
derived epitopes using MHC and co-stimulatory microarrays.  Efficient production of these chips 
involves the unique challenge of producing many recombinant biotinylated MHC-peptide 
complexes easily in parallel.  While only a small amount is required of each MHC-peptide 
complex for producing microarrays, a large number of different MHC-peptide complexes must 
be produced simultaneously.  Some development of these techniques has already begun. 
 Soluble class II MHC complexes such as HLA-DR1 can be recombinantly produced by 
insect cells without specific peptide loaded.  The MHCs can be made with a uniquely reactive 
cysteine at the C-terminus of either the α or β chain (Cameron et al., 2002; Cochran and Stern, 
2000).  The empty MHCs can be isolated using immunoaffinity chromatography, and the 
cysteine of the empty molecule can be modified using biotin maleimide (Sigma).  Large batches 
of empty, biotinylated MHC complexes can be obtained in this manner.  This material can then 
be split into small aliquots, and each aliquot can be loaded with a different peptide antigen by 
prolonged incubation at 37°C (Frayser et al., 1999).  Thus, the goal of small batches of many 
different peptide complexes is achieved.  Figure VI.2 shows a schematic for the production of 
these complexes with yields.  
 Class I complexes such as HLA-A2 are not conveniently produced without peptide 
loaded, and are generally refolded from urea-solubilized inclusion bodies in the presence of 
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peptide (Garboczi et al., 1992).  In order to produce class I MHC complexes with many different 
peptides, each on a small scale, the protocol has been tweaked such that small-scale refoldings 
are possible with good yield.  Figure VI.3 shows the method for making and purifying many 
class I MHC complexes in parallel. 
 
2. Applications of MHC microarrays 
 The technology discussed in Chapter V may be applied to the study of acute infection or 
vaccination.  Chips may be arrayed with MHC-peptide complexes produced as above, where the 
peptides are derived from the primary sequences of proteins from either a pathogen or from a 
vaccine.  Patient samples that are MHC-matched can be placed on the chips to determine which 
epitopes induce different responses, including adhesion, cell surface molecule modulations, and 
cytokine and effector molecule secretion.  The responses induced by different epitopes may be 
matched to the ability to control or clear infection.  This information can then be fed back into 
the design of new vaccines that elicit the most helpful responses. 
 127
Figure VI.2  Large scale parallel 
production of class II MHC-peptide 
complexes.  (A) Scheme for 
production of many different peptide 
complexes with biotinylated HLA-DR1.  
The final step may be carried out on 
very small scale, down to 5-20 µg of 
complex.  Overall yield of this 
procedure is 1-3 mg pure biotinylated 
DR1-peptide complex from each liter of 
induced S2 insect cells, which is 
enough to form between 50-600 
individual complexes.  (B) SDS-PAGE 
gel of crude peptide incubations with 
empty DR1 complexes.  Tightly-bound 
DR1-peptide complexes are SDS-
stable when not boiled, while empty 
DR1 or DR1-peptide boiled in SDS 
separates into alpha and beta chain 
subunits.  Lanes are labeled “NB” for 
not boiled, or “B” for boiled.  (C) SDS-
PAGE gel of purified DR1-peptide 
complexes formed using the scheme in 
(A), run not boiled “NB”, boiled “B”, or 
boiled plus excess streptavidin “B+SA”.  
The “B+SA” lane shows specific biotin 
incorporation on the DR1-alpha chain. 
A 
          
S2 / HLA-DR1 α-cys
and β chains
Empty bio-DR1
Empty reduced αcys-DR1
Empty αcys-DR1
Pure 
bio-DR1:peptide complex
Culture (~6-9L), induce, harvest
Immunoaffinity purification, reduction
Yield = 5-7 mg/L culture
G50 column to remove DTT
Yield = 60-70 %
Chemical biotinylation
Dialysis to remove biotin
Yield = 70-85 %
Incubation with peptide, size 
exclusion chromatography
Yield = 50-65 %
 
 
B     C 
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A
E. coli / HLA-A2 heavy chain 
or β2M light chain
pure bio-A2:peptide 
complex
A2 heavy chain and 
β2M light chain
Inclusion Bodies
native A2:peptide complex
Culture (10 L), induce, harvest
Yield: ~300 mg/L H.C.
~800 mg/L light chain
Folding in vitro with peptide
Size exclusion purification
Yield = 10-15 % heavy chain
OPTIONAL Size exclusion 
chromatography
Yield = 50-60 %
bio-A2:peptide complex
Buffer exchange, enzymatic 
biotinylation, removal of excess biotin
Yield = 90 %
C
+
-
-
-
+
-
+
+
+
-
+
+
-
+
+
+
+
+
+/-
+
+
+
+
+/-
+
+/-
+/-
+
17 kDa44158
Purified A2-BRLF-1
Light chain only
Heavy chain only
Refolding buffer only
MVA-103B: KMYACKNDM
MVA-198: FSEVMEDLFNYVN
MVA-189: KLLLWFNYL
MVA-183: ELLNILTEL
MVA-179: CIPFSFQTV
MVA-176: TLTIFYYFI
MVA-167: RVYEALYYV
MVA-163: NIIKFETML
MVA-158: GLIVILFIMFMLI
MVA-155: YLYNYTIAV
MVA-150: VLALYSPPL
MVA-138: KMIYDLNAV
MVA-129: VLPFDIKYI
MVA-126: VMAMMNITI
MVA-123: ILVCYILYI
MVA-119: KMLETEIVV
MVA-115: VLTAIGITV
MVA-103A: ILFRKPSLL
MVA-165: KVDDTFYYV
MVA-74A: CLTEYILWV
MVA-165 (crude): KVDDTFYYV
MVA-74A (crude):   CLTEYILWV
INF-MAT: GILGFVFTL
HIV-RT: ILKEPVHGV
Standards
B 
A2 heavy chain 
+ b2M
+ MVA-165 
peptide (crude)
A2 heavy chain 
+ b2M
Purified A2-
BRLF-1 peptide 
complex
MW Standards 670
158 44
17 1.35  kDa
Volume (mL)
5 6 7 8 9 10 11 12 13
 
Figure VI.3  Large scale parallel production 
of class I MHC complexes.  (A) Scheme for 
production of biotinylated HLA-A2 in complex 
with peptide from E. coli expression.  Overall 
yield of purified complex is 13-25 mg per liter of 
culture induction based on heavy chain, or 27-
40 mg if final purification is not required.  (B) 
Refolding can be tested by size exclusion 
chromatography.  The heavy chain and light 
chain in refolding mix do not refold without 
peptide (top trace).  The second trace shows a 
crude refolding mix with a binding peptide.  The 
third trace shows purified A2-peptide complex.  
Molecular weight markers are shown at the 
bottom.  (C)  Size exclusion chromatography 
may be automated using a robotic HPLC, 
allowing the purification of many A2-peptide  
complexes in parallel with little operator involvement.  A screen of different potential A2-
binding peptides was performed.  The appearance of a peak between 44 and 17 kDa 
when crude refolding mix is injected indicates refolded complex. 
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 Another benefit of the development of this technology will be the accumulation of data 
regarding MHC-peptide binding for different MHC alleles as well as which peptides create 
effective T cell epitopes.  This type of data may be used to improve and extend current prediction 
algorithms for MHC binding and T cell stimulation, which may in turn accelerate discovery of 
novel epitope, inhibitor, and antagonist peptides. 
 
3. Toward immobilized antigen-presenting cell arrays 
 Future development of microarray techniques may involve a modification of the artificial 
antigen-presenting cell design to take advantage of a patient’s own endogenous antigen-
presenting cells.  Peptide epitopes in some sort of gel or matrix could be microarrayed onto a 
surface coated with cytokine capture antibodies.  Antigen-presenting cells from the patient would 
then be cultured on top of this surface, which may include additional molecules to help 
immobilize the APCs in a single location.  The APCs would take up the peptide from the matrix, 
process and load it onto their MHC molecules, and present these molecules at their surface for 
recognition by the patient’s T cells.  This solution avoids the requirement for large production of 
recombinant MHC-peptide molecules, and expands the applicability, since only a small fraction 
of the total MHC alleles can be produced recombinantly.  There may be many technical 
challenges in setting up this system; however, evidence exists for the ability of cells cultured on 
top of a DNA microarray to take up and express the genes in a location-dependent manner 
(Ziauddin and Sabatini, 2001), giving hope for the eventual development of cell-based 
expression or presentation arrays.  
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A.1.a GROWING BL21 IN A 10 L FERMENTOR 
Protocol from Mia Rushe 
Procedure: 
 
Day 1: 
1. Streak an LB-amp (or kan if kanamycin resistant strain, chlor also if cells are pLyss) 
plate in the evening with BL21 cells of interest from frozen stocks.  Incubate at 37˚C 
overnight. 
Day 2: 
1. Put streaked plate at 4˚C in morning, sealed with parafilm. 
2. Autoclave assembled fermentor filled with 10 L of 1 x LB broth, 1 L of distilled H2O, 1 
L of 1 x LB broth, at least 150 mL 20 % glucose, and 3-125 mL Erlenmeyer flasks. 
3. In the early evening, add 83 mL sterilized LB broth to one of the sterile flasks. Add 83 
µL Ampicillin (50 mg/mL) and 1.2 mL 20 % glucose.  **IF the cells are kanamycin 
resistant, substitute 83 µL of a 50 mg/mL stock of kanamycin sulfate for ampicillin. If 
cells are pLyss, add 83 µL chloramphenicol (35 mg/mL).**  
4. Mix well and take a 1 mL blank sample for OD600 measurements.  You may want to add 
1 µL 20 % NaN3 to prevent growth in the blank sample.  Keep this blank in a plastic 
cuvette. 
5. The remaining LB solution will be split into different containers.  Pipet 2 mL into a 
sterile 15 mL conical tube, 20 mL into a 50 mL conical tube, and 20 mL into each of the 
remaining sterile Erlenmeyer flasks.  Label the flasks 1, 2 and 3. 
6. Pick one colony from your plate.  Add it to your 15 mL tube and vortex vigorously.  
Take 200 µL of that tube and add it to the 50 mL conical tube and vortex vigorously.  
Take 200 µL of that tube and add it to Erlenmeyer flask #1 and swirl a lot.  Take 200 µL 
from that flask and add it to Erlenmeyer flask #2 and swirl a lot.  Take 200 µL of that 
flask and add it to Erlenmeyer flask #3. 
7. Grow the 3 Erlenmeyer flasks on a shaker table at 37˚C overnight. 
 
 
200 µL 200 µL 200 µL 200 µL
500 
colonies/L
5 
colonies/L
0.05 
colonies/L
0.0005 
colonies/L
0.000005 
colonies/L
Flask #1 Flask #2 Flask #3
1 colony
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A.1.a GROWING BL21 IN A 10 L FERMENTOR (continued) 
Protocol from Mia Rushe 
 
Day 3: 
1. Measure the absorbance at 600nm of each flask compared to the blank you saved.  Pick the 
one that is less than 1.0 OD600, but still has measurable growth in it. (0.7 is about ideal.) 
2. Set up the fermentor:  Add 10 mL of Ampicillin, 50 mg/mL, 100 mL 20 % glucose 
(sterile), and 200 µL antifoam A.  **IF the cells are kanamycin resistant, substitute 10 mL 
of a 50 mg/mL stock of kanamycin sulfate for ampicillin.  If  the cells are pLyss, also add 
10 mL 35 mg/mL chloramphenicol.**  Mix well.  Remove 1 mL as a blank and store in a 
plastic cuvette, possibly with 1 µL 20 % NaN3. 
3. Run the mixer on the fermentor at ~700 rpm, and run the air at 15 psi and 5 LPM.  Watch 
for excessive foaming and add antifoam if it is necessary.  **If you have never set the 
fermentor up before, ask for help!! 
4. Seed the fermentor with 10 mL of the overnight flask you selected. 
5. Take samples and check the OD600 every hour until you get close to 1.0, and then check 
more frequently.  Do not overgrow! 
6. When the OD600 reaches 1.0, take a 1 mL sample “not induced.”  Spin down and re-
suspend in 1x urea-SDS loading buffer. Freeze at –20˚C. 
7. Add IPTG to 0.75 mM final concentration.  I use 10 mL of 0.75M IPTG stock (1000 x).  
Allow to grow for 2-5 hours with IPTG. (Longer for class I MHC subunits) 
8. Take a 1 mL sample “induced.”  Spin down and re-suspend in 1x urea-SDS loading buffer.  
Freeze at –20 ˚C until you are ready to check the “not induced” and “induced” samples on 
a gel by SDS-PAGE. 
9. Spin down all the cells at 8000 x g and discard the supernatant.  For inclusion bodies, you 
may freeze the pellet at –20˚C, or proceed with the inclusion body prep through the 
DNAse step and freeze at –20˚C. 
 
**NOTES: The above protocol is the “safe” protocol.  In addition to this, you may try a 
high density fermentation, where Terrific Broth is used instead of LB, and the cells are 
allowed to grow to 5-10 OD600 before induction.  For this protocol, take care when the 
cells become more dense that the temperature does not spike and kill your cells or make 
them shed their plasmid—cooling water should be used.** 
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A.1.a BL21 MEDIA RECIPES 
Protocol from Lauren Angelo 
 
  Modified LB      2x YT + Salts     Terrific Broth 
10 g/L tryptone   16 g/L tryptone   12 g/L tryptone 
5 g/L yeast extract   10 g/L yeast extract   25 g/L yeast extract 
0.4-1% glucose   0.4-1% glucose   0.4-1% glucose 
5 g/L NaCl    100 mL/L 10x Salts*   100 mL/L 10x Salts* 
5 g/L K2HPO4 
10 mM MgSO4 
1 mL/L Trace Elements 
 
 
  *10x Salts 
23.1 g/L KH2PO4 
125.4 g/L K2HPO4 
**filter-sterilize—do 
not autoclave. Add 
to media after other 
ingredients have been 
autoclaved** 
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 A.1.b INCLUSION BODY PREPARATION FOR HLA-DR1 SUBUNITS                                        
Protocol from Mia Rushe 
 
Procedure (for pellet from 10 L culture): 
1. Spin down cells at 5000 x g—collect supernatant into a container, sterilize with 1% 
Wescodyne for 10-20 minutes, and then dump down the sink. 
2. With a rubber spatula, re-suspend fresh bacteria into a single plastic container with ~200 
mL Sucrose Solution. 
3. Chop the solution briefly in a homogenizer or polytron. **Do not sonicate! 
4. If cells are not pLyss, add 1 mg dry lysozyme per mL suspension (0.2 g) and stir for 10 
minutes.  If cells are pLyss, just stir for 10 minutes. 
5. While stirring, add 500 mL Deoxycholate-Triton Solution.  Solution will become very 
viscous due to cell lysis and DNA release. 
6. Add 1 mL of 4 M MgCl2 Solution to make 5 mM final concentration. 
7. Add 2 mL DNAse Solution.  Stir until the solution is the viscosity of water. 
8. Freeze overnight at –20˚C, or until ready to complete the prep. 
9. Thaw solution in warm water bath. 
10. Stir an additional 10 minutes after thawing to allow the DNAse to work again. 
11. Spin down in 2 centrifuge bottles at 8000 x g for 20 minutes. Discard supernatant. 
12. Re-suspend pellets in 300 mL or more each Triton Solution.  Chop briefly, keeping the 
pellets on ice as much as possible.  Spin down at 8000 x g for 20 minutes and discard 
supernatant. 
13. Repeat step 12 three or more times. 
14. Re-suspend pellets into 300 mL or more each Tris Solution.  Chop briefly, keeping the 
pellets on ice as much as possible. Spin down at 8000 x g for 20 minutes and discard 
supernatant. 
15. Repeat step 14 two or more times. 
16. Re-suspend/dissolve the pellets and chop in ~ 200 mL Urea Solution. 
17. Spin down at 20˚C, 15,000 x g for 30 minutes.  Filter through a 0.2 µm filter. 
18. Freeze at –70˚C until ready to purify by Urea HQ. 
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A.1.b INCLUSION BODY PREPARATION FOR HLA-DR1 SUBUNITS                                        
Protocol from Mia Rushe 
 
Solutions (**NOTE: Do not add DTT until just before use!**): 
 
Name     Stock   For 1 L, 1x  For 1 L, 10x 
Sucrose Solution 
   50 mM Tris, pH 8.0   1 M Tris, pH 8.0 50 mL   N/A 
   25 % sucrose   dry, FW = 342.3 250 g    
   1 mM EDTA   0.5 M EDTA  2 mL 
   0.1 % NaN3    20 % NaN3  5 mL 
   10 mM DTT    dry, FW = 154.04 1.54 g 
Deoxycholate-Triton Solution 
   1 % Deoxycholic Acid  dry, FW = 414.6 10 g   100 g 
   1 % Triton X-100   100% solution  10 mL   100 mL 
   20 mM Tris, pH 7.5   1 M Tris, pH 7.5 20 mL   200 mL 
   100 mM NaCl   5 M NaCl  20 mL   200 mL 
   0.1 % NaN3     20 % NaN3  5 mL   50 mL 
   10 mM DTT    dry, FW = 154.04 1.54 g   N/A 
Triton Solution 
   0.5 % Triton X-100   100% solution  5 mL   50 mL 
   50 mM Tris, pH 8.0   1 M Tris, pH 8.0 50 mL   500 mL 
   100 mM NaCl   5 M NaCl  20 mL   200 mL 
   1 mM EDTA   0.5 M EDTA  2 mL   20 mL 
   0.1% NaN3    20 % NaN3   5 mL   50 mL 
   1 mM DTT    dry, FW = 154.04 0.154 g  N/A 
Tris Solution 
   50 mM Tris, pH 8.0   1M Tris, pH 8.0 50 mL   500 mL 
   1 mM EDTA   0.5 M EDTA  2 mL   20 mL 
   0.1% NaN3    20 % NaN3   5 mL   50 mL 
   1 mM DTT    dry, FW = 154.04 0.154 g  N/A 
Urea Solution 
   8 M Urea    dry, FW = 60.06 480.48 g  N/A 
   20 mM Tris, pH 8.0   1M Tris, pH 8.0 20 mL 
   0.5 mM EDTA   0.5 M EDTA  1 mL 
   10 mM DTT    dry, FW = 154.04 1.54 g 
DNAse Solution (**make 50 mL total, not 1L**) 
   75 mM NaCl   5 M NaCl  0.75 mL  N/A 
   50 % glycerol   100 % glycerol 25 mL    
   2 mg/mL DNAse   dry   100 mg 
        (Sigma D-5025 or DN25) 
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A.1.c UREA HQ INCLUSION BODY PURIFICATION FOR HLA-DR1 
Protocol from Mia Rushe 
 
Column: Perseptives HQ resin, bed volume ~17 mL 
 
Buffers: Solution A: 8 M urea, 20 mM tris, 1 mM DTT added just before use 
   Solution B: 8 M urea, 20 mM tris, 1 M NaCl, 1 mM DTT added just before use 
  For purifying A1S, both solutions should be pH 8.0 
  For purifying B1S, both solutions should be pH 9.0 
 
Procedure: 
1. Make approximately 3 L solution A and 1 L solution B, using the protocol for Making 
Urea Solutions.  Use the appropriate pH for the inclusion body you will be purifying.  If 
not using immediately, store at -20°C.  Do not add the DTT until just before use. 
2. Thaw urea-solubilized inclusion bodies.  For B1S, adjust the pH to 9.0 using NaOH. (pH 
should be 8.0 in frozen inclusion bodies) 
3. Equilibrate the HQ column in 1-5 column volumes solution A. 
4. Flow the inclusion body solution over the column.  If it is very concentrated, it may bind 
better if it is diluted 1:2 in solution A.  **NOTE: Save flow-through of the column, as 
the protein is very concentrated and may saturate the column.** 
5. Run a gradient of 0-30% solution B (1-300 mM NaCl) over 6 column volumes.  Collect 
fractions. 
6. Analyze fractions from all major peaks by SDS-PAGE.  **NOTE: If the protein peak of 
interest looks different when run on reducing vs. non-reducing SDS-PAGE, add more 
DTT to the final inclusion body pool to completely reduce the protein.** 
7. Pool peak fractions and measure the concentration of protein using absorbance at 280 nm 
against a blank of solution A.  **NOTE:   For A1S: 1.3 OD280 = 1 mg/mL.    For B1S: 
1.7 OD280 = 1 mg/mL. 
8. For B1S, adjust the pH back to 8.0.  Add EDTA to a final concentration of 5 mM (10 µL 
0.5M EDTA stock / mL inclusion body solution). 
9. Store in convenient aliquots at -80°C. 
 
**NOTES: A new HQ column has a protein binding capacity of about 5-10 mg / mL 
resin.  The capcity becomes significantly lower over time with this procedure, possibly in 
part due to EDTA.  Regeneration does not seem to be particularly helpful.  Thus, when 
loading protein, do it slowly and monitor the absorbance of the flow-through to determine 
when the protein is no longer binding to the resin.  The chromatograms will be very 
messy and inconsistent, but the refolding yield for inclusion bodies purified in this 
manner is much better.** 
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A.1.d REFOLDING HLA-DR1 FROM E. coli INCLUSION BODIES 
Protocol from Mia Rushe 
 
Procedure: 
 
1. Chill Refolding Mix without glutathione to 4˚C.  Refolding should be done in a container 
close to the size of the volume of liquid to reduce exposure to air.  De-gas solution by 
sparging with argon for about 20 minutes. 
2. Add glutathione (oxidized and reduced) and stir until just dissolved. 
3. Stir as rapidly as possible 
4. Add peptide—about 5-fold molar excess in a 1x refolding is good, so you should end up 
with a final peptide concentration of 0.4 µM.  You can use the same concentration 
peptide for a 2x re-folding.  **NOTE: If you want to re-fold empty DR1, simply omit the 
peptide.** 
5. Slowly (dropwise) add HQ-purified inclusion bodies in urea. Add 2 (1 x) or 4 (2x) mg of 
each inclusion body (alpha and beta) per liter of Refolding Mix. 
6. After everything is well mixed, cover tightly and store at 4˚C for at least 36 hours. 
 
 
Refolding Mix: 
   20 mM Tris, pH 8.5 
   0.5 mM EDTA 
   25 % glycerol 
   2 mM glutathione, reduced  ** Add just before use! 
   0.2 mM glutathione, oxidized ** Add just before use! 
 
Example 2 x re-folding, 4 L total volume: 
   80      mL of 1 M Tris, pH 8.5 
4        mL of 0.5 M EDTA 
1000  g glycerol 
2.45  g glutathione, reduced 
0.488 g glutathione, oxidized 
16 mg DRA1S inclusion bodies (8 mL of 2 mg/mL stock, Urea HQ pure) 
16     mg DRB1S inclusion bodies (16 mL of 1 mg/mL stock, Urea HQ pure) 
1.6     µmoles Ha peptide (800 µL of 2 mM Ha peptide stock) 
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A.1.e PREPARATION OF ANTIBODY-COUPLED MATRIX 
Protocol from Mia Rushe  
 
1. Spin Immobilized Protein A (RepliGen) 2000 rpm for 5 minutes, remove supernatant, 
and wash with Binding Buffer. Your volume will be 50% of the original volume after the 
wash. 
2. Mix 1 mL Antibody Stock Solution per 1 mL  Immobilized Protein A beads (or 1 mL 
Antibody Stock Solution per 2 mL original 50% Immobilized Protein A slurry). **Take 
20 µL sample of mixture: “TOTAL” 
3. Incubate on nutator at room temperature for 1 hour or longer. 
4. Spin mixture at 2000 rpm for 5 minutes. Save the supernatant in the fridge in case you 
got low binding. **Take 20 µL sample of supernatant: “NON-BOUND” 
5. Re-suspend pellet in 50 mL Borate Solution. Spin 2000 rpm for 5 minutes, remove and 
discard supernatant. 
6. Re-suspend pellet to original volume of antibody/slurry mixture with fresh Borate 
Solution. **Take 20 µL sample of mixture: “BOUND”  
7. Add a 1/10 dilution Dimethylpimelimidate Stock Solution (200 mM) to 20mM final. 
Incubate on nutator at room temperature for 30 minutes. 
8. Spin 2000 rpm, 5 minutes, remove supernatant and check pH—should be above 8.0! 
9. Re-suspend pellet in 50 mL Ethanolamine Solution and incubate at room temperature on 
nutator for 30 minutes or more. 
10. Spin 2000 rpm, 5 minutes, remove and discard supernatant. 
11. Perform the following washes: 
a. 50 mL Ethanolamine Solution 
b. 50 mL Borate Solution 
c. 50 mL Binding Buffer  **Take 20 µL sample of mixture: “WASH” 
d. 50 mL CAPS Solution 
e. 50 mL Binding Buffer—repeat until supernatant has neutral pH. 
12. Re-suspend pellet to original volume of antibody/slurry mixture in fresh Binding Buffer. 
**Take 20 µL sample of mixture: “NON-COUPLED”  
13. Store matrix at 4°C—making sure that Binding Buffer contains 0.02% NaN3. 
14. Analysis of coupling: Boil all samples with 5 µL 5x Reducing Laemlli Load Buffer and 
spin down any matrix. Run 10% SDS-PAGE gel of samples.  You should be able to see 
heavy and light chains in “TOTAL” and “BOUND” and nothing in “NON-BOUND”, 
“WASH”, or “NON-COUPLED”.  If there is any protein in “NON-BOUND”, try a 
different binding buffer. If there is any protein in “NON-COUPLED”, cycle the matrix 
back through all the binding and elution conditions that will be used for the affinity 
purification procedure.  **Make sure to use fresh Dimethylpimelimidate!    
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A.1.e PREPARATION OF ANTIBODY-COUPLED MATRIX 
Protocol from Mia Rushe  
 
 
Materials: 
     Borate Solution: 200 mM Borate, pH 9.0 **MAKE FRESH!! 
     Ethanolamine Solution: 200 mM Ethanolamine, pH 8.0 **MAKE FRESH!! 
     Antibody Stock Solution: 2 mg/mL antibody, will add 10 g antibody per 5 mL matrix 
     Immobilized Protein A (RepliGen): use 5 mL beads/column—comes as a 50% slurry 
     Binding Buffer: PBSZ, 1x PBS with 0.02% NaN3, make at least 500 mL 
     Dimethylpimelimidate Stock Solution: 200 mM, use fresh 250 mg vials (MW = 259) 
 
Borate Solution         Dimethylpimelimidate Stock Solution           Ethanolamine Solution  
     1.86 g Borate  250 mg Dimethylpimelimidate  1.2 mL Ethanolamine 
     to 150 mL ddH2O  4.83 mL ddH2O    to 100 mL ddH2O 
     to pH 9.0 with NaOH       to pH 8.0 with HCl 
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A.1.f IMMUNOAFFINITY PURIFICATION OF DR1 
Protocol from Mia Rushe  
 
Procedure: 
1. Concentrate folding mix and switch buffers into 1x PBS, pH ~7.  Make sure there is 
no glutathione, as that will ruin the antibody column! If the DR1 is from an insect 
cell prep instead of an E.coli refolding, make sure the supernatant has been filtered 
through a 0.2 µM filter. 
2. Flow the protein solution over a Protein A sepharose pre-column and then the 
LB3.1 or L243 column by gravity. Be sure to use a safety loop so that the columns 
don’t dry out. Save the flow-through to check on a gel. 
3. Wash with at least 10 column volumes of cold PBS 
4. Elute using high pH for DR1.  Use ~5 column volumes of 50 mM CAPS, pH 11.5 
and collect 1 mL fractions into tubes with 300 µL of 300 mM NaPi, pH 6.0 to 
neutralize them.  Make a blank fraction for zeroing the UV-VIS. (**Note: low pH 
may be used to elute, using 5 column volumes 50 mM glycine, pH 2.6, and 
collecting 1 mL fractions into tubes containing 300 µL of 300 mM Tris, pH 8.0 in 
them. This will give a lower yield for DR1, but may be better for other alleles.) 
5. Clean the column with pH swings: 
i. 3 column volumes 50 mM glycine, pH 2.6 
ii. 3 column volumes 50 mM CAPS, pH 11.5 
iii. 3 column volumes 50 mM glycine, pH 2.6 
6. Wash the column with at least 10 column volumes of PBSZ—until the pH is 
neutral. 
7. Check the Abs280 of the fractions and pool the protein-containing fractions. You 
may add azide to 0.02%, add peptide if the complex is empty and you wish to load a 
particular peptide, or dialyze/concentrate into 20 mM tris, pH 8.0 if you wish to 
further purify by ion exchange. 
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A.1.g LOADING PEPTIDE ONTO EMPTY MHC CLASS II 
Protocol from Zarixia Zavala-Ruiz 
 
Procedure: 
 
1. Obtain the empty MHC at a concentration of ~ 1 mg/mL, about 20 µM, in a suitable 
buffer such as PBS pH 7.0 with 0.02% sodium azide and 5 mM EDTA as protease 
inhibition. 
2. Add the peptide of choice to a final concentration of at least 100 µM, or 5-fold molar 
excess. 
3. Incubate the mixture at 37°C for 3 days.   
4. Purify the peptide-loaded complex by gel filtration. **NOTE: Make sure to save a 
sample of the unloaded complex to test by SDS-PAGE and analytical gel filtration.  
Peptide loading will shift the MHC complex to a later time on a gel filtration column, and 
it will often cause SDS stability in a gel, as opposed to the empty MHC, which will break 
down into subunits.** 
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A.1.h INCLUSION BODY PREPARATION FOR CLASS I MHC SUBUNITS                                    
Protocol from Jenny Cochran 
 
Procedure (for pellet from 10 L culture): 
 
1. Spin down cells at 5000 x g—collect supernatant into a container, sterilize with 1% 
Wescodyne for 10-20 minutes, and then dump down the sink. 
2. With a rubber spatula, re-suspend fresh bacteria into a single plastic container with ~200 
mL Sucrose Solution. 
3. Chop the solution briefly in a homogenizer or polytron. **Do not sonicate! 
4. If cells are not pLyss, add 1 mg dry lysozyme per mL suspension (0.2 g) and stir for 10 
minutes.  If cells are pLyss, just stir for 10 minutes. 
5. While stirring, add 500 mL Deoxycholate-Triton Solution.  Solution will become very 
viscous due to cell lysis and DNA release. 
6. Add 1 mL of 4 M MgCl2 Solution to make 5 mM final concentration. 
7. Add 2 mL DNAse Solution.  Stir until the solution is the viscosity of water. 
8. Freeze overnight at –20˚C, or until ready to complete the prep. 
9. Thaw solution in warm water bath. 
10. Stir an additional 10 minutes after thawing to allow the DNAse to work again. 
11. Spin down in 2 centrifuge bottles at 8000 x g for 20 minutes. Discard supernatant. 
12. Re-suspend pellets in 300 mL or more each Triton Solution.  Chop briefly, keeping the 
pellets on ice as much as possible.  Spin down at 8000 x g for 20 minutes and discard 
supernatant. 
13. Repeat step 12 three or more times. 
14. Re-suspend pellets into 300 mL or more each Tris Solution.  Chop briefly, keeping the 
pellets on ice as much as possible. Spin down at 8000 x g for 20 minutes and discard 
supernatant. 
15. Repeat step 14 two or more times. 
16. Re-suspend/dissolve the pellets and chop in ~ 200 mL Urea Solution. 
17. Spin down at 20˚C, 15,000 x g for 30 minutes.  Filter through a 0.2 µm filter. 
18. Measure protein concentration by absorbance at 280nm.  Aliquot inclusion bodies and 
freeze at -80°C. 
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A.1.h INCLUSION BODY PREPARATION FOR CLASS I MHC SUBUNITS                                    
Protocol from Jenny Cochran 
 
Solutions (**Note: Do not add DTT until just before use!): 
 
Name     Stock   For 1 L, 1x  For 1 L, 10x 
Sucrose Solution 
   50 mM Tris, pH 8.0   1 M Tris, pH 8.0 50 mL   N/A 
   25 % sucrose   dry, FW = 342.3 250 g    
   1 mM EDTA   0.5 M EDTA  2 mL 
   0.1 % NaN3    20 % NaN3  5 mL 
   10 mM DTT    dry, FW = 154.04 1.54 g 
Deoxycholate-Triton Solution 
   1 % Deoxycholic Acid  dry, FW = 414.6 10 g   100 g 
   1 % Triton X-100   100% solution  10 mL   100 mL 
   20 mM Tris, pH 7.5   1 M Tris, pH 7.5 20 mL   200 mL 
   100 mM NaCl   5 M NaCl  20 mL   200 mL 
   0.1 % NaN3     20 % NaN3  5 mL   50 mL 
   10 mM DTT    dry, FW = 154.04 1.54 g   N/A 
Triton Solution 
   0.5 % Triton X-100   100% solution  5 mL   50 mL 
   50 mM Tris, pH 8.0   1 M Tris, pH 8.0 50 mL   500 mL 
   100 mM NaCl   5 M NaCl  20 mL   200 mL 
   1 mM EDTA   0.5 M EDTA  2 mL   20 mL 
   0.1% NaN3    20 % NaN3   5 mL   50 mL 
   1 mM DTT    dry, FW = 154.04 0.154 g  N/A 
Tris Solution 
   50 mM Tris, pH 8.0   1M Tris, pH 8.0 50 mL   500 mL 
   1 mM EDTA   0.5 M EDTA  2 mL   20 mL 
   0.1% NaN3    20 % NaN3   5 mL   50 mL 
   1 mM DTT    dry, FW = 154.04 0.154 g  N/A 
Urea Solution (adjust pH to 6.0) 
   8 M Urea    dry, FW = 60.06 480.48 g  N/A 
   25 mM MES, pH 6.0  dry, FW = 213.3 5.33g 
   10 mM EDTA   0.5 M EDTA  20 mL 
   0.1 mM DTT   dry, FW = 154.04 15.4 mg 
DNAse Solution (**make 50 mL total, not 1L**) 
   75 mM NaCl   5 M NaCl  0.75 mL  N/A 
   50 % glycerol   100 % glycerol 25 mL    
   2 mg/mL DNAse   dry   100 mg 
        (Sigma D-5025 or DN25) 
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A.1.i REFOLDING OF CLASS I MHC PROTEINS 
Protocol modified from NIH Tetramer Facility 
 
Procedure: 
 
1. Pre-chill 1 L of Folding Buffer in a 1.5 L beaker to 10°C.  
2. Add 5 mM reduced glutathione, 0.5 mM oxidized glutathione, and 0.2 mM PMSF to cold 
Folding Buffer, stirring quickly. **NOTE: Avoid foaming! 
3. Calculate 1 µM heavy chain urea-solubilized subunit and add to 4 mL of Injection 
Buffer. 
4. Calculate 2 µM β2M urea-solubilized subunit and add to 4 mL of Injection Buffer. 
5. Weigh out 30 mg of peptide and dissolve in 0.5 mL DMSO or water, depending on 
sequence. 
6. Add peptide solution dropwise to rapidly stirring Folding Buffer. 
7. Forcefully inject heavy chain and β2M to the stirring reaction through a 26-gauge needle 
as close to the stir-bar as you can.  There may be some precipitation or light foaming. 
8. Replace the mixture at 10°C and incubate overnight. 
9. In the morning, inject heavy chain ONLY in Injection Buffer into the cold, quickly-
stirring mixture as above (1 µM more, now 2 µM total concentration heavy chain). 
Replace at 10°C. 
10. In the evening, once again inject heavy chain ONLY in Injection Buffer into the cold, 
quickly-stirring mixture as above (1 µM more, now 3 µM total concentration heavy 
chain). Replace at 10°C and incubate overnight 
 
Solutions: 
  
Folding Buffer (pH 8.0)    Injection Buffer (pH 4.2)  
400 mM L-Arginine (Sigma A5949)   3 M Guanidine-HCL 
100 mM Tris, pH 8.0     10 mM Sodium Acetate 
2 mM EDTA      10 mM EDTA 
 
 
Other Materials 
Urea-solubilized heavy chain and light chain (β2M) 
Peptide of choice 
Reduced glutathione (Sigma G4705) 
Oxidized glutathione (Sigma G4501) 
100 mM Phenylmethylsulfonyl fluoride (PMSF—Sigma P7626) 
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A.1.j PURIFICATION OF FOLDED CLASS II MHC-PEPTIDE COMPLEXES USING 
DEAE BEADS 
Procedure from M. Rushe and J. Cochran 
 
Reagents: 
 20 mM Tris, pH 8.5 (add 5 mM DTT for cys-modified protein) **make 1 L** 
 20 mM Tris, pH 8.5, 0.5 M NaCl (add 5 mM DTT for cys-modified protein) **make 500  
  mL** 
 20 mM Tris, pH 8 (add 5 mM DTT for cys-modified protein) 
 
 Buffer A: 20 mM Tris (pH 8) 
 Buffer B: 20 mM Tris (pH 8), 1 M NaCl 
 
Protocol: 
1. Add DEAE Sephadex A-50 beads (A-50-120 Sigma-Aldrich) to 2 g / L refolding mix.  
Allow the beads to swell and adsorb refolded protein for at least 12 hours. 
2. Collect the beads on a large Büchner funnel using vacuum filtration. 
3. Rinse the beads with 1 L of 20 mM Tris, pH 8.5 (containing 5 mM DTT for cys-modified 
protein). 
4. Elute protein from the beads by adding 20-30 mL aliquots of 20 mM Tris, pH 8.5, 0.5 M 
NaCl (containing 5 mM DTT for cys-modified protein).  Allow the beads to sit in the 
buffer for a few minutes before applying vacuum.   
5. Repeat the elution using 20-30 mL salt-containing buffer at a time until you have added 
all of the solution.  **NOTE: The beads will shrink quite a bit with water loss the first 
few times you add the salt.  This is normal.** 
6. Filter the eluate through a 0.2 µm filter unit. 
7. Concentrate the eluate as far as you can go—to about 20 mL. To achieve this, you may 
use a Pellicon-30 XL Filter (PXC03050 Millipore), although any concentration method 
should work. 
8. Dilute the mixture 1:10-1:12 with 20 mM Tris, pH 8.0 (containing 5 mM DTT for cys-
modified protein) and re-concentrate back down to the minimal volume.  Repeat this for 
2 full washes. **NOTE: This step is required to remove salt from the solution, as the salt 
will prevent binding of the protein to the anion exchange column later.** 
9. Rinse the concentrator membrane with ~50 mL 20 mM Tris, pH 8.0 (containing 5 mM 
DTT for cys-modified protein) and pool the concentrated protein solution and the 
membrane rinse. 
10. Filter the protein pool through a 0.2 µm filter unit. 
11. Purify concentrated folding reaction by anion-exchange (HQ column) using Buffers A 
and B (Do not include DTT in these buffers!).  Folded Class II will elute with ~ 200 mM 
NaCl.    
 
**NOTE: This procedure is not used for empty class II MHCs or weak-binding peptide 
complexes. In those cases, use a combination of immunoaffinity purification and size exclusion 
chromatography to purify the protein.** 
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A.1.j PURIFICATION OF FOLDED CLASS II MHC-PEPTIDE COMPLEXES—
ALTERNATIVE PROCEDURE 
Procedure adapted from M. Rushe 
 
Reagents: 
 20 mM Tris, pH 8 (add 5 mM DTT for cys-modified protein) 
 
 Buffer A: 20 mM Tris (pH 8) 
 Buffer B: 20 mM Tris (pH 8), 1 M NaCl 
 
Protocol: 
1. Concentrate the refolding mix as far as you can go—to about 200 mL. To achieve this, 
you may use an Amicon Spiral Concentrator, although other concentration methods 
should work. 
2. Dilute the mixture 1:10-1:12 with 20 mM Tris, pH 8.0 (containing 5 mM DTT for cys-
modified protein) and re-concentrate back down to the minimal volume.  Repeat this for 
2-3 full washes. **NOTE: This step is required to remove glycerol and glutathione from 
the solution, as these components are bad for the anion exchange column later.** 
3. Filter the protein through a 0.2 µm filter unit. 
4. Purify concentrated folding reaction by anion-exchange (HQ column) using Buffers A 
and B (Do not include DTT in these buffers!).  Folded Class II will elute with ~ 200 mM 
NaCl.    
 
**NOTE: This procedure gives much better overall yield from the refolding; however, the 
lifetime of the anion exchange column seems to be diminished by components in the refolding 
mix which are not fully removed.  It may be advantageous to use less expensive disposable 
columns from Pharmacia such as HiTrap columns for this purification, especially since the 
protein is fairly pure already and does not require very high resolution.** 
 
**NOTE: This procedure is not used for empty class II MHCs or weak-binding peptide 
complexes. In those cases, use a combination of immunoaffinity purification and size exclusion 
chromatography to purify the protein.** 
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A.1.j PURIFICATION OF FOLDED CLASS II MHC-PEPTIDE COMPLEXES 
(continued) 
Procedure from M. Rushe and J. Cochran 
 
Sample trace from anion-exchange purification of DR1-Ha with a NaCl gradient using POROS 
20 HQ resin 
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A.1.k BIOTIN LIGASE PURIFICATION 
Protocol from Kai Wucherpfennig  
 
1. Inoculate a 50 mL culture (LB/Amp 50µg/mL) with E. coli (BL21 (DE3)) transformed 
with pET22b-BirA-(His) tag. Grow O.N, 37ºC, shaker. 
2. Inoculate 2 liters of LB/Amp (50µg/mL) with the O/N culture.  Grow at 37ºC, 225 rpm, 
to an OD600 of ~0.6 (start monitoring OD after 3 hours). 
3. IPTG induction: add IPTG to 1mM.  Grow O/N at RT on shaker.  The yield of soluble 
biotin ligase is greatly increased by growth at RT rather than 37ºC. 
4. Harvest 2L culture; Spin 3000 rpm, 4ºC, 30’. 
5. Resuspend in ~25mL sonication buffer:  30 mM Tris, pH 8.0 
       150 mM NaCl 
       1 mM PMSF 
6. Sonicate resuspended pellet on ice. Settings for sonication:  Timer: Hold 
         Output cycle: 5 
         Input cycle: 50 
      Sonicate 4-5 times for 1’ 
7. Spin in ultracentrifuge to remove all insoluble material: 25,000rpm, 4ºC, 30’, SW28 
rotor.  Set temperature well in advance; it takes a while to reach 4ºC.  Make sure that the 
tube (Beckman Ultra-ClearTM, Cat # 344058) is filled almost all the way to the top or else 
it will collapse! 
8. Save supernatant on ice 
9. Repeat resuspension, sonication, and centrifugation on the pellet from the 
ultracentrifugation spin. 
10. Equilibrate Ni-NTA column (7.5 mL bed volume) with 30 mM Tris, pH 8.0, 150 mM 
NaCl. 
11. Load supernatant onto column (0.8 mL/min, cold room) 
Wash column with ~2 bed volumes:  30 mM Tris, pH 8.0  
     150 mM NaCl 
Imidazole wash (30 mL): 30 mM Tris, pH 8.0 
    150 mM NaCl 
    10 mM Imidazole 
The imidazole wash removes a lot of contaminating proteins 
 
Elution: 40 mL  30 mM Tris, pH 8.0 
    150 mM NaCl 
    25 mM Imidazole 
  40 mL  30 mM Tris, pH 8.0 
    150 mM NaCl 
    40 mM Imidazole 
  30 mL  30 mM Tris, pH 8.0 
    150 mM NaCl 
    60 mM Imidazole 
12. Fractions eluted with 60 mM Imidazole are quite pure.  Fractions from 25 and 40 mM 
elutions still have contaminating proteins.  These can be removed using a cation 
exchange HPLC column. 
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13. Buffer exchange using PD-10 column prior to HPLC.  Add 2.5 mL of fraction to the 
column and load by gravity flow. 
To elute, add 3.5 mL of 30 mM Tris (HPLC buffer A), elute by gravity flow.  
14. HPLC Poros HS column: 
Buffer A: 30 mM Tris, pH 8.0 
Buffer B: 30 mM Tris, pH 8.0 + 1.0 M NaCl 
Load sample using 5mL loop 
Gradient of buffer B from 0-100% in 20 minutes (protein elutes at ~12 minutes)  
15. Exchange buffer using PD-10 columns; elute in 50 mM Bicine, pH 8.3 (storage buffer) 
16. Aliquot and store at -80ºC (glycerol can be added to 5%) 
 
 
 
 
Induction gel of Bir A enzyme 
 
 
Gel of Ni-NTA column fractions 
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A.1.l S2 CELL CULTURING 
Protocol from Tom Cameron 
 
S2 cells, also called Schneider Cells, are a Drosophila melanogaster cell line available from 
ATCC, CRL-1963.  They are smaller than Sf9 cells.  They double every 24-48 hours, and they 
are somewhat adherent to plastic.  They can usually be removed by pipetting up and down.  
**Incubate cells at 25ºC or room temperature. 
 
Serum Media, 100 mL:  Serum-Free Media, 100 mL:  Freezing Media: 
Schneider’s or Grace’s  Sf-900, Ex-cell, or BaculoGold 90% Serum Media 
    Pre-made media        Pre-made media   10% DMSO 
1 mL Penn-Strep    1 mL Penn-Strep   **freeze cells at 
1 mL Glutamine   1 mL Glutamine       3-4 million cells 
1 mL Fungizone   1 mL Fungizone       per mL. 
10 mL FBS 
 
Split cells 1:2 or 1:3 every 3-4 days, keeping density between 0.5-4 million cells/mL in plates or 
flasks.  In order to pass from flasks to spinners, let the cells overgrow two T-75 flasks or one T-
150 flask to make sure plenty are not sticking to the plastic.  Pipet vigorously to remove adherent 
cells, and transfer to a 100 mL spinner flask.  In spinner flasks, the cells can grow happily up to 
10 million cells/mL, and can reach up to 20 million cells/mL. 
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 A.1.m MATERIALS FOR S2 CELL TRANSFECTION 
From Invitrogen 
 
Calcium Phosphate Transfection 
 
Material (kept sterile)     Amount required per construct transfected 
Thawed, growing, untransfected S2 cells  3 million 
S2 media with serum     ~ 30 mL 
2 M CaCl2      18 µL 
2x Hepes Buffered Saline (HBS)   150 µL 
Construct plasmid     5 µg per plasmid 
pNeo (G418 resistance)    0.25 µg 
S2 media with 1.5 mg/mL G418   >30 mL 
0.5 M CaSO4 solution (1000x, sterile)  1 mL per liter induction 
 
 
 
Lipofectin Transfection 
 
Material (kept sterile)     Amount required per construct transfected 
Thawed, growing, untransfected S2 cells  3 million 
S2 media with 10% serum, PSFQ   0.3 mL for overnight plating, ~30 mL other 
Sf-900 II media with PSFQ    2.7 mL 
Sf-900 II media with Q only    6.0 mL, no antibiotic, for transfection 
Construct plasmid     3 µg per plasmid 
pNeo       0.2 µg 
Lipofectin Reagent     20 µL (diluted into 80 µL Sf-900 II + Q) 
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A.1.n CALCIUM PHOSPHATE S2 CELL TRANSFECTION 
Protocol from Tom Cameron and Invitrogen 
 
1. Buy Invitrogen Calcium Phosphate Transfection Kit (K2780-01). 
2. Plate 3 million cells per well untransfected S2 cells into 6-well plates and allow to sit 
overnight. 
3. In the morning, spin the 6-well plates at 1500 rpm for 5 minutes, aspirate out the media, 
and add 5 mL per well fresh media.  Allow to sit another two hours or more while you set 
up your DNA solutions. 
4. Sterilize your DNA with sterile Spin-X eppendorf filters.  You will need approximately 5 
µg of each plasmid that will produce protein and 0.25 µg pNeo for a selection tag in each 
transfection well. 
5. In the tissue culture hood, add plasmid and sterile water to 132 µL.  Add 18 µL 2 M 
CaCl2 Solution to give 150 µL total volume.  Label this with the transfection name and 
“Solution A.” 
6. In a separate 15 mL conical tube, add 150 µL 2x Hepes Buffered Saline (HBS), and label 
this with the transfection name and “Solution B.” 
7. While vortexing “Solution B” (still in the tissue culture hood), add “Solution A” 
dropwise slowly over the course of 1-2 minutes.  This will ensure the finest possible 
precipitate. 
8. Allow the mixture to sit at room temperature for 30 minutes. 
9. Add the mixture to the cells in the 6-well plate dropwise while swirling.  Allow to sit for 
24 hours. 
10. The next day, pipet the cells up and down well and transfer them to 15-mL conicals and 
wash 1 time with fresh media before re-suspending in fresh media. 
11. Meanwhile, rinse the plate wells out with fresh media several times, swirl and aspirate. 
12. Re-plate the washed cells into the same 6-well plate (same wells). 
13. Allow cells to sit 2 days at room temperature to incorporate DNA. 
14. After 2 days, add 1.5 mg/mL Geneticin, or G418.  This antibiotic will cause cells that 
have not incorporated pNeo to die over the course of 3-4 weeks.   
15. Maintain cells in G418-containing media, rinsing often into fresh media for 3 weeks in 
the same wells.   **At some point during this time, you may wish to do a test induction of 
protein, growing up some of the cells in CuSO4-containing media for several days and 
testing the supernatant for protein expression using an ELISA protocol. 
16. At the end of 3 weeks, start expanding the lines, maintaining the G418 until you get to a 
100 mL spinner flask.  **At this point, make multiple freezes at 3-4 million/mL.  **Once 
you are getting past the 100 mL spinner flask, you may start phasing out the G418 
because the cell line should be stable with the resistance. 
 
**NOTE: If you are only doing a transient tranfection, you can add 0.5 mM sterile CuSO4 after 
step 12 to induce protein production.  Maintain cells in CuSO4-containing media for 4-5 days 
before harvesting. 
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A.1.o LIPOFECTIN S2 CELL TRANSFECTION 
Protocol from Tom Cameron and Invitrogen 
 
1. Buy Lipofectin Reagent from Invitrogen (18292-011). 
2. Grow nice, untransfected S2 cells in serum-containing media to 3 million per transfection 
well. 
3. Spin cells down and aspirate media. Resuspend in an appropriate volume to give 3 mL 
per transfection well of 90% Sf-900 II with PFSQ and 10% S2 media with PFSQ, 10% 
FBS (giving 1% serum final).  Allow cells to sit overnight. 
4. Prepare 3 µg of each transfection plasmid and 0.2 µg of pNeo for each transfection and 
sterilize using a sterile eppendorf Spin-X filter.  Dilute to 100 µL total volume in Sf-900.  
Label with construction name and “Solution A.”  Allow to stand at room temperature for 
30-45 minutes. 
5. Prepare 20 µL of Lipofectin Reagent and 80 µL Sf-900 (1:5 dilution). Label as “Solution 
B.” 
6. Add “Solution A” to “Solution B” and incubate at room temperature for 15 minutes. 
7. Spin cell plates at 1500 rpm for 5 minutes and aspirate media.  Add Sf-900 and swirl.  
Spin plates again, aspirate media, and add 3 mL/well Sf-900 + Q and swirl. 
8. Add the mixture of Solutions A and B to the plate. Swirl vigorously or pipet-mix. 
9. Allow transfections to sit overnight at 25˚C 
10. The next day, spin cell plates at 1500 rpm, 5 minutes, aspirate media, and replace with 5 
mL of S2 media with serum and PSFQ.  Allow to sit for 48 hours. 
11. After 48 hours, spin cell plates at 1500 rpm, 5 minutes, aspirate media, and replace with 5 
mL S2 media with serum, PFSQ, and 1.5 mg/mL Geneticin (G418). 
12. One week after the transfection, spin plates and replace old media with fresh G418-
containing media. 
13. At some point (perhaps weekly between weeks 1 and 4) do some test protein expressions 
(ELISA). 
14. Continue to simply replace the media with fresh media until the cells are starting to grow 
dense and happy (low death).  Then begin to expand the cells.  The lines should be stable 
and G418 resistant at 4 weeks.  Make many freezes at 3-4 million cells/mL. 
15. After you have plenty of freezes, you can begin to reduce the G418 and passage into Sf-
900 II + PSFQ (no media), expand up to spinner flasks, and begin serious protein 
production. 
 
 
 
**NOTE: If you are only doing a transient tranfection, you can add 0.5 mM sterile CuSO4 after 
step 10 to induce protein production.  Maintain cells in CuSO4-containing media for 4-5 days 
before harvesting. 
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A.1.p PROTEIN PRODUCTION IN S2 CELLS 
Protocol from Tom Cameron, Liying Lu, and J. Stone 
**NOTE: This protocol is for constructs using a metallothionine promoter, e.g. pRMHA-3** 
 
Protocol: 
1. Grow the S2 cell line in a plate or T flask, maintaining selection marker if applicable, 
until they are sufficiently dense to switch to a shake flask. Grow the cells between 24-
27°C with adequate aeration (no CO2 required).  They can grow to ~4-6 x 106/mL in the 
T flask. 
2. Split the cells into a sterile, capped Erlenmeyer flask (can use disposable flasks or 
autoclaved glass flasks provided they are only washed with 7x detergent, not Alconox!!).  
Use a volume ~1/3 of the total flask volume for cells and media, e.g. 160 mL in a 500 mL 
flask.  Do not split the cells so they are below 1 x 106/mL!   
3. Grow these flasks on a shaker table at 100-120 rpm at 27°C, making sure the cap is loose 
to allow for aeration.  **NOTE: there may be a lag at this stage before the cells begin 
doubling again, but once they take off, they will grow VERY QUICKLY!!** 
4. Increase the volume of the shaking culture by splitting the cells into larger flasks or 
multiple flasks, keeping the cell density between 1-6 x 106/mL.  They can grow denser, 
but since the idea is to increase the culture, there is no need to wait until they are very 
dense.  During this phase, it is possible to stop adding the selecting agent (e.g. G418).  
You should check the cells every day, since they will double every 30 or so hours. 
5. When the culture has reached the size you would like (e.g. 1.5 L in a 4 L flask), allow the 
cells to reach an appropriate density.  A good induction density is 6-10 x 106/mL, with an 
optimum around 8 x 106/mL. 
6. Add a 1:1000 dilution of 1 M CuSO4 sterile stock solution to the culture.  The media 
should look dark green. 
7. Replace the induced cells on the shaker table.  Incubate another 2-5 days.  Optimal 
expression time may vary, but will generally be within this range.  3 days is usually good. 
8. After induction period, spin down the cells at 5000 x g and harvest the supernatant for 
soluble proteins. 
9. Check the supernatant by ELISA or Western Blot if possible to ensure production was 
successful. 
10. Concentrate the supernatant down to 200-500 mL unless a large amount of precipitation 
is found.  (Generally this is due to excess glutamine in the media.)  Filter the supernatant 
through a 0.2 µm filter. 
11. Add the following components: sodium azide to 0.2%, EDTA to 5 mM, PMSF* to 1 mM, 
and Iodoacetamide* to 1 mM.  Stock solutions are described on the next page. 
12. Store the supernatant in the fridge or freezer until ready to purify by immunaffinity. 
 
1 M CuSO4, 50 mL (1000x):   Additions to supernatant: 
7.98g CuSO4 (Sigma C1297)   NaN3 to 0.02% (1:1000 dilution of 20% stock)  
fill to 50 mL with ddH2O    5 mM EDTA (1:100 dilution of 0.5 M stock) 
filter-sterilize with 0.2 µm filter   *PMSF to 1 mM (Sigma P7626, make a 200 mM  
stock solution in ethanol, dilute 1:200) 
      *Iodoacetamide to 1 mM (Sigma I6125, make a  
       500 mM stock solution, dilute 1:500) 
                                                 
* If the protein being produced has a free cysteine, do not add PMSF or Iodoacetamide to the supernatant. 
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A.2.a FLUORESCEIN-LABELING OF PROTEINS AND ANTIBODIES 
Protocol modified from J. Cochran and Molecular Probes 
 
Reagents: 
 Fluorescein-isothiocyanate (FITC) 3 mg/ml in DMSO  
 50 mM NH4Cl 
 0.1 M sodium carbonate, pH 9 
 
Protocol: 
1. Exchange buffer in protein of interest to 0.1 M sodium carbonate, pH 9 and concentrate 
to ~2.5 mg/ml. 
2. Add 10 µl of FITC stock to each sample and incubate overnight at 4 °C in the dark. 
3. Add NH4Cl to 50 mM.  Incubate for an additional 2 hours. 
4. Separate FITC-labeled protein from unreacted FITC by size exclusion chromatography 
(G50 column) 
5. Measure OD of fractions at 280nm and 495nm.  Calculate the ratio of 495nm/280nm and 
pool fractions containing a similar ratio. 
 
Estimation of degree of FITC labeling in an antibody by UV absorbance scanning of the labeled 
complex: 
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Assume: ε495FITC= 69,000 M-1 cm-1  
 ε280FITC= (0.274)(69,000) M-1 cm-1  
 ε280Ab= 210,667 M-1 cm-1  
 ε280MHC class II= 54,000 M-1 cm-1  
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A.2.b MODIFYING FREE CYSTEINES IN A PROTEIN 
USING MALEIMIDE REACTIVE GROUPS                                                   
Protocol synthesized from experience and Jennifer Cochran, Liying Lu, Molecular Probes and Pierce 
 
Procedure: 
1. If the protein is not freshly reduced, add DTT to 5 mM and incubate the protein for 1 hr 
at room temperature. **Note: If the protein has been stored in DTT and is freshly purified 
by anion exchange, there is no need to re-reduce. Skip to step 3. 
2. Either column-purify, dialyze, or concentrate/switch buffers to remove DTT and put 
protein in reaction buffer (PBS, tris, or some buffer with pH 7-8--if the pH is too high, 
the maleimide reagent will also modify amines such as lysine).  
3. Immediately check the concentration of the protein—should be no higher than 20 µM. 
4. Add the maleimide reagent (commonly used reagents: fluorescein maleimide or biotin 
maleimide) to a final concentration of 100 µM.  Your stock solution should be in DMSO, 
since the maleimide groups are water-labile, and the stock concentration should be such 
that you can dilute 1:10 or 1:20 at least into the protein solution (1 mM or more 
concentrated). 
5. Mix well and store the solution at room temperature for 1-2 hours. If the probe is 
fluorescent, store the solution in the dark to prevent quenching. 
6. After the incubation, add DTT to a final concentration of 5 mM to quench any remaining 
unreacted maleimide. 
7. Either column-purify, dialyze, or concentrate/switch buffers to remove the maleimide 
probe and the excess DTT. 
8. Measure the final concentration and, if possible, the labeling stoichiometry. 
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A.2.c BIOTINYLATION OF MHC PROTEINS USING THE BIRA ENZYME 
Adapted from instructions from Avidity (Denver, Colorado) 
 
Reagents: 
 BirA enzyme (1mg/ml stock) in: 
 50 mM imidazole (pH 6.8), 50 mM NaCl, 5% glycerol, 5 mM mercaptoethanol 
 5000 Units/µg. 1 Unit is the amount of enzyme that will biotinylate 1 pmol of peptide  
  substrate in 30 min at 30 °C using the provided buffers and 38 µM of substrate. 
 
 Biomix A: 
 0.5 M Bicine buffer (pH 8.3) 
 
 Biomix B: 
 100 mM ATP 
 100 mM MgOAc 
 500 µM biotin 
 
**NOTES: Biomix A and B can be stored at –20 °C with repeated thawing and refreezing 
BirA should be stored at –80 °C.  It retains >90% of its activity for > 3 months when stored at 4 
°C.** 
 
**It is recommended for every 10 nmol of substrate (at 40 µM), to use 2.5 µg of birA enzyme to 
complete the biotinylation in 30-40 minutes at 30 °C.  Final reaction mixture should contain 1 
part Biomix A, 1 part Biomix B, and 8 parts protein.** 
 
**NaCl, glycerol, and ammonium sulfate inhibit the activity of the birA.** 
 
**Substrate should be as concentrated as possible (up to 40 µM).** 
 
1. Dilute 1 mg of MHC-peptide complex containing the biotinylation sequence to a 
concentration of 1.8 mg/ml (1 mg per 560 µL).  Protein should be in 10 mM Tris (pH 8). 
2. Add 70 µL of Biomix A and 70 µL of Biomix B to the protein solution.  
3. Add 7 µg of birA enzyme (7 µL of 1 mg/ml stock) to the mixture from step 2. 
4. Incubate at room temperature 16-20 hours or 1 hour at 30°C (reduces aggregation and 
protein loss). 
5. Concentrate and purify by size exclusion chromatography. 
6. Pool fractions, and freeze at –80 °C in aliquots to help prevent proteolysis. 
  
To estimate extent of biotinylation, use the protocol “Biotinylation Yield Test” in this thesis.   
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A.2.d BIOTINYLATION YIELD TEST 
Protocol worked out with Tom Cameron and Liying Lu 
 
Procedure: 
1. Set up to do reducing SDS-PAGE using a 12% polyacrylamide gel (or other percentage if 
it is appropriate). 
2. Assemble the following samples in reducing SDS laemlli loading buffer—your protein 
should be boiled if required to separate into individual subunits (such as HLA-DR1 with 
tight-binding peptide).  Samples b-f should be brought to the same volume: 
a. Protein MW standards 
b. Unbiotinylated monomer, 2 µg 
c. Unbiotinylated monomer, 2 µg 
d. Biotinylated monomer, 2 µg 
e. Biotinylated monomer, 2 µg 
f. 1x PBS or similar buffer 
3. Cool all boiled samples to at least room temperature. Then add 2µg of streptavidin to 
samples c, e, and f, and an equivalent volume of PBS or similar buffer to samples b and 
d.  Allow samples to sit at least 10-15 minutes to allow streptavidin-biotin interaction to 
occur. 
4. Run samples on gel, then stain with Coomassie.  The band corresponding to the 
biotinylated chain of your monomer should disappear in sample e, and larger bands will 
appear indicating binding to streptavidin.  The yield of biotinylation can be determined 
by determining the fraction of monomer chain remaining after streptavidin was added. 
 
**NOTE: make sure your reducing laemilli load buffer in which the samples are boiled in step 2 
is concentrated enough to run the samples after the additional volume of streptavidin or PBS is 
added in step 3. 
 
Schematic of results of HLA-DR1 with a biotinylation site on the alpha chain: 
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A.2.e DIMERIZING PROTEINS THROUGH FREE CYSTEINES 
BY CREATING A DISULFIDE BOND                                                   
Protocol from Jennifer Cochran 
 
 
Procedure: 
1. If the protein is not freshly reduced, add DTT to 5 mM and incubate the protein for 1 hr 
at room temperature. 
2. Either column-purify, dialyze, or concentrate/switch buffers to remove DTT and put 
protein in PBS or HEPES reaction buffer, pH ~ 7.4. 
3. Make sure the protein is concentrated—at least 1 mg/mL. 
4. Add HEPES to a concentration of 50 mM if another buffer was used. 
5. Add 1,10-phenanthroline to 1.3 mM. 
6. Add CuSO4 to 0.25 mM. 
7. Incubate for at least 1 hour at room temperature or 30 minutes at 37°C. 
8. Either column-purify, dialyze, or concentrate/switch buffers to remove copper and 
phenanthroline and put protein into desired buffer.  **Note: Reducing agents will un-do 
the dimerization. 
9. Assay the extent of dimerization by size exclusion chromatography or SDS-PAGE gel 
(non-reducing).  If purified dimer is desired, usually size exclusion chromatography can 
be used. 
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A.2.f CROSS-LINKING PROTEINS USING Pep2x, Pep3x, and Pep4x (and relatives) 
Protocol by J. Stone, based on method used by J. Cochran 
 
Procedure: 
 
1. Immediately before use, dissolve lyophilized peptide-based cross-linker in small 
volume 1x PBS, pH 7.0 (around 50µL).  Store on ice to minimize hydrolysis of 
maleimide before reaction with cysteine from protein.  Take absorbance scan of 1µL 
diluted 1:100 at 495nm.  
[cross-linker]=100*Abs495/69,000 
2. Calculate amount to add to freshly-purified cysteine-containing protein. **There can 
be no DTT present in the protein sample at this stage.**  Save a sample of 
unreacted protein to run on a gel. 
moles cross-linker = moles protein / valency of cross-linker 
3.  Divide the volume of cross-linker that must be added into 4 equal-volume aliquots.  
Add ¼ of total cross-linker to the protein and allow the mixture to react in the dark at 
room temperature for 1 hour.  Repeat with the other three aliquots. 
4. Take a small sample of the reaction mixture to run on a gel. 
5. Purify by size exclusion chromatography.  For DR1 MHC protein, use two Superdex 
200 columns in series to achieve required resolution.  
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A.2.g HETEROGENEOUS CROSSLINKING 
Protocol by J. Stone 
**NOTE: To use this protocol, your protein must be stable for short periods at low pH at 4°C. 
 
Procedure: 
1. Store small aliquots (~ 20 µL) stock solutions of cross-linker reagents 3-
bromopyruvate (3-BP, Aldrich Cat. #238341) and N-(ß-Maleimidopropionic acid) 
hydrazide (BMPH, Pierce Cat. #22297) at 300 mM in DMSO at -20°C. 
2. Prepare both freshly reduced, cysteine containing samples (A and B) separately into 
either 1x PBS, pH 7.4 or 20 mM Tris, pH 8.0.  **There can be no DTT present in 
the protein sample at this stage.**  Save a sample of unreacted protein to run on a 
gel. Calculate the concentration of the protein—it should be between 0.1-0.5 mg/mL, 
or 5-10µM. 
3. Calculate the amount of each cross-linker to add to the proteins. Do not allow the 
final volume of cross-linker to be greater than 10% of the total volume. 
moles 3-BP = (20-30)* moles protein A 
moles BMPH = (20-30)* moles protein B 
4. Add the appropriate amount of 3-BP to sample A and BMPH to sample B (keep 
separated).  Allow to react at room temperature for approximately 1 hour at room 
temperature.  Take a small sample of each reaction mixture to run on a gel. 
5. Rinse both samples (separately) well in concentrators (Amicon Ultra-4, for example) 
to remove excess cross-linker reagent.  Usually 3 washes (200 µL Æ 4 mL in PBS 
and concentrated back down) are enough to reduce the concentration of free cross-
linker down far below the concentration of the protein (2 orders of magnitude). 
6. Check the concentration of each protein.   
7. Add equal molar amounts of A-3BP and B-BMPH together in the same concentrator 
and dilute to 4 mL with 30 mM acetate, pH 4.5, 150 mM NaCl.  Concentrate in a 
centrifuge for 1.5 hours at 4°C. 
8. Dilute back to 4 mL with 50 mM phosphate, pH 7.4, 150 mM NaCl.  Concentrate in a 
centrifuge for 40 minutes at 4°C. 
9. Add DTT to 5 mM and incubate 20-30 minutes at room temperature to reduce any 
disulfide-linked dimers from unreacted cysteines on A or B (or both). 
10. Filter the sample and purify by size exclusion chromatography.  For DR1 MHC 
protein, may wish to use two Superdex 200 columns in series to achieve required 
resolution.  
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A.2.g HETEROGENEOUS CROSSLINKING (continued) 
Protocol by J. Stone 
 
 
Label each protein by the uniquely-reactive cysteine with a different cross-linker  
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                                BMPH from Pierce
N N
H
NH3+
OO
O
-O CF3
O
H+
ACSHa S-
ACSHa S
N N
H
NH3+
OO
O
H
 
 
Combine the two cross-linker labeled proteins at high concentration, pH 4.5 for 1.5 
hours at 4 °C 
ACSHa S
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H
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O
H
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H
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+
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A.2.g HETEROGENEOUS CROSSLINKING (continued) 
Protocol by J. Stone 
 
 
Non-reduced gel of reaction mixtures between ACS-
A2-3BP and BCL-HA-BMPH.  Both Alpha and Beta 
chains should be present when the complex is boiled, 
but the cross-linked chains should hold together. 
 
 
 
 
 
 
 
 
Reduced gel of the reaction mixture.  The dimer is 
not DTT-sensitive, and forms in the largest amount 
at pH 4.5 
 
 
 
 
 
 
 
Gel filtration trace of reaction mixture on double Superdex 200 columns.  Heterodimer is 
around 94 kDa and monomer is around 47 kDa—easily separable. 
 
 
 
158,000  
Da
670,000  
Da
44,000 
Da
17,000 
Da
1350 
Da
Heterodimer 
Monomer
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A.2.h SYNTHESIS OF PEPTIDE-BASED CROSSLINKERS 
Protocol modified from J. Cochran 
 
Peptide synthesis: 
1. Synthesize peptides by FMOC chemistry on a solid phase peptide synthesizer.  TentaGel S 
RAM Fmoc resin (Advanced ChemTech) should be used to give a C-terminal amide upon 
cleavage.  **NOTE: If crosslinkers are to be fluorescently-labeled, β-alanine should be used 
as the N-terminal amino acid to prevent thiazolidone formation and release of fluorescein 
during peptide deprotection.** 
2. Cap peptides at their N-termini by reaction with excess fluorescein isothiocyanate (FITC) or 
EZ-link NHS-LC-LC-biotin (Pierce) dissolved in DMF. 
3. Cleave peptides from the resin and deprotect side-chains with 88% trifluoroacetic acid 
(TFA), 2% triisopropylsilane, 5% dithiothreitol, shaking for at least 4 hours at RT. 
4. Evaporate off as much TFA as possible, heating at 37 °C and gently blowing with a 
continuous stream of nitrogen. 
5. Precipitate the peptide with cold ether  (overnight in freezer is best). Wash the peptide twice 
with cold ether to remove cleavage products and cleavage reagent.  
6. Purify peptides by reverse phase HPLC using a shallow acetonitrile gradient in 0.1% TFA 
and a C18 column (Vydac).  Verify molecular weight of peptide by mass spectrometry.  This 
purification may seem like an extra step, but it is important to remove all traces of DTT 
before addition of modification reagents. 
 
Modification of cysteine residues to include aldehyde groups (for heterocrosslinkers):  
1. Dissolve purified peptides (2-5 mg) in 500 ml of 20 mM Na-phosphate buffer (pH 7), 150 
mM NaCl. 
2. Prepare a 5-fold molar excess solution of 3-bromopyruvate (3BP). 
3. Mix together peptide and crosslinker and incubate at RT for approximately 1.5 hours (in the 
dark).  Crosslinker will react through an SN2 reaction with the sulfhydryl, eliminating 
bromide. 
4. Purify modified peptides by reverse-phase HPLC as above.  Confirm appropriate number of 
aldehyde functional groups with mass spectrometry.  
 
**NOTE: If making heterocrosslinkers, modification of cysteines must be done before 
modification of lysines, since free sulfhydryl groups can also react with the lysine 
modification reagents.  When using heterocrosslinker, react first through the maleimide to 
attach to a free cysteine on the protein, then couple the crosslinker and protein to a second, 
BMPH-modified protein.  For details, see the protocol for “Heterogeneous Crosslinking”** 
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A.2.h SYNTHESIS OF PEPTIDE-BASED CROSSLINKERS (continued) 
Protocol modified from J. Cochran 
 
Modification of lysine residues to include maleimide groups (all peptide-based crosslinkers):  
1. Dissolve purified peptides (2-5 mg) in 500 ml of 20 mM Na-bicarbonate buffer (pH 9), 150 
mM NaCl. 
2. Prepare a 5-fold molar excess solution of either N-[ε-maleimidocaproyloxy] succinimide 
ester (EMCS, Pierce) or succinimidyl-4-[N-maleimidomethyl]-cyclohexane-1-carboxy-[6-
amidocaproate] (LC-SMCC, Pierce) in N,N -dimethylformamide (DMF). 
3. Mix together peptide and crosslinker and incubate at RT for approximately 1.5 hours (in the 
dark).  Crosslinker will react through the succinimide ester to the lysine ε-amino groups on 
the peptide.   Solution may turn a bit cloudy during the course of the reaction, as crosslinker 
is not very soluble in buffer.  This is not cause for alarm as the reaction should take place 
very quickly after mixing reagents. 
4. Purify modified peptides by reverse-phase HPLC as above.  Confirm appropriate number of 
maleimide functional groups with MALDI-TOF.  
 
Peptide sequences used for making crosslinkers: (can also be made without fluorescein) 
 
Name Sequence 
pep2* fluorescein-βA-E-K-S-G-S-K-G-NH2 
pep3 fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-K-G-NH2 
pep4 fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-K-S-S-E-G-K-G-NH2 
het2# fluorescein-βA-E-K-S-G-S-C-G-NH2 
het3a fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-C-G-NH2 
het3b fluorescein-βA-E-K-S-G-S-G-C-S-G-E-S-K-G-NH2 
het4a fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-K-S-S-E-G-C-G-NH2 
het4b fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-C-S-S-E-G-K-G-NH2 
het4c fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-C-S-S-E-G-C-G-NH2 
het4d fluorescein-βA-E-K-S-G-S-G-C-S-G-E-S-K-S-S-E-G-C-G-NH2 
*“pep” crosslinkers are homogeneous.  Modified peptide crosslinkers are called pep(n)x, where 
(n) is the valency of the crosslinker 
#“het” crosslinkers are heterogeneous.  Modified peptide crosslinkers are called het(n)(arr)x, 
where (n) is the total valency of the crosslinker, and (arr) is an optional letter corresponding to 
the arrangement of different moieties in higher-order oligomers. 
 
 
 182
A.3.a MEDIA RECIPES FOR TISSUE CULTURE 
 
Complete Tumor Medium (CTM) 
 Used for HA1.7 Hybridoma cells 
 
30 mL Tumor Cocktail (TC)  
50 mL Fetal Calf Serum (heat inactivated) Fill to 500 mL with S-MEM 
**Filter sterilize (0.2 µm) and store at 4°C. 
 
 
Tumor Cocktail (TC) 
 
351 mL S-MEM (Gibco 11380-037) 
7.5 g Dextrose (Fisher BP350) 
3.361 g L-Glutamine (Sigma G-8540) 
75 mL Essential Amino Acids (50x, Gibco  
11130-051) 
140 mL Non-Essential Amino Acids (100x,  
Gibco 11140-050) 
100 mL Sodium Pyruvate (100x, Gibco  
11360-070) 
**Mix and adjust pH to 7.0 with 10N NaOH 
Then, add: 
8.5 g Sodium Bicarbonate (Fisher S233) 
500 mg Gentamycin Sulfate (Sigma  
G-3632) 
600 mg Penicillin G Sodium Salt (Sigma  
P-3032) 
1 g Streptomycin Sulfate (Sigma S-9137) 
34 µL 2-mercaptoethanol (Sigma M-7522) 
**Filter sterilize (0.2 µm), aliquot into 30 mL, and store at -20°C. 
 
 
EBV Medium 
 Used for EBV-transformed B cell lines such as LG2, Priess, and EBV 1.24 
 
50 mL Fetal Calf Serum (heat inactivated) 
5 mL Hepes  
5 mL Penn-Strep  
5 mL L-Glutamine  
Fill to 500 mL with RPMI 1640 
**Filter sterilize (0.2 µm) and store at 4°C. 
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A.3.a MEDIA RECIPES FOR TISSUE CULTURE (continued) 
 
751P Medium 
 Used for fibroblasts such as 751P 
 
50 mL Fetal Calf Serum (heat inactivated) 
5 mL Glutamine 
5 mL Penn-Strep 
Fill to 500 mL with DMEM 
**Filter sterilize (0.2 µm) and store at 4°C. 
 
 
 “K” Medium 
 Used for P815 cells 
 
500 mL EBV Medium 
5 µL 2-mercaptoethanol 
**Filter sterilize (0.2 µm) and store at 4°C. 
 
 
“C” Medium 
 Used for murine CD8+ 2C clone L3.100 
 
5 mL Rat ConA Sup (equivalent to 30 U/mL  
mouse rIL2) 
3 mL a-methylmannoside (Sigma M6882,  
20% stock in Hank’s, Invitrogen  
14175095) 
 
 
THP-1 Medium 
 Used for THP-1 macrophage pre-cursor line 
 
5 mL 100x Sodium Bicarb/Gluc Sol’n*  
5 mL Hepes 
5 mL L-Glutamine 
5 µL 2-mercaptoethanol 
50 mL Fetal Calf Serum (heat inactivated) 
Fill to 500 mL with RPMI-1640 
**Filter sterilize (0.2 µm) and store at 4°C. 
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A.3.a MEDIA RECIPES FOR TISSUE CULTURE (continued) 
 
100x Sodium Bicarb/Gluc Sol’n  
 
75 g sodium bicarbonate  
225 g glucose 
Fill to 500 mL with ddH2O 
**Filter sterilize (0.2 µm) and store at 4°C. 
 
 
Drosophila (S2) Medium 
 For newly thawed insect cells 
 
5 mL Penn-Strep-Fungizone (also called  
Antibiotic/Antimycotic) 
5 mL L-Glutamine 
50 mL Fetal Calf Serum (heat inactivated) 
Fill to 500 mL with Schneider’s or Grace’s 
**NOTE: you can also use Sf-900 II as a  
base medium and add these  
supplements for a very rich medium 
**Filter sterilize (0.2 µm) and store at 4°C. 
 
 
Serum-Free S2 Medium 
 Used for insect cells that will be secreting protein 
 
5 mL Penn-Strep-Fungizone (also called 
 Antibiotic/Antimycotic) 
5 mL L-Glutamine 
Fill to 500 mL with Sf-900 II medium 
**Filter sterilize (0.2 µm) and store at 4°C. 
 
 
Serum-Free S2 Selecting Medium 
 Used for insect cells that have been transfected with the pNeo selection marker for 
Geneticin (G418) resistance 
 
5 mL Penn-Strep-Fungizone (also called 
 Antibiotic/Antimycotic) 
5 mL L-Glutamine 
5 mL 50-150 mg/mL Geneticin (G418) 
Fill to 500 mL with Sf-900 II medium 
**Filter sterilize (0.2 µm) and store at 4°C. 
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A.3.a MEDIA RECIPES FOR TISSUE CULTURE (continued) 
 
Freezing Medium (generic) 
 Can be used for almost any tissue culture cells 
 
9 mL Fetal Calf Serum (heat inactivated) 
1 mL DMSO 
**Freeze cells at ~4-5 million/mL at least 
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A.3.b T CELL MAINTENANCE—CD4+ CLONES AND LINES 
Protocol from Jennifer R. Cochran 
 
Procedure: 
1. Pool T cells in a conical tube. **If you are freshly thawing, wash 1 time to remove 
DMSO.  
2. Count a small aliquot to determine T cell density. You will need to re-stimulate at a 
density of 7 x 105-106 cells per well in a 24-well plate. Spin cells down and re-suspend to 
the proper density in T cell medium (7 x 105-106 per mL). Keep cells on ice. 
3. Count HLA-matched EBV-immortalized B cells (maintain in B cell medium, keeping 
density between 0.3-1.0 x 106/mL). You will need 1-2 x 106 per well, so you must take 
enough to match the number of T cell wells you will have. Spin down the appropriate 
volume of cells and re-suspend in plain RPMI to the proper density (1-2 x 106 per mL). 
4. Add sterile peptide to a concentration of 1 µM for tight binders, higher for weak binders. 
Incubate the B cells with the peptide at 37°C for 1-2 hours. 
5. Spin the peptide-pulsed B cells at 1500 rpm for 5-10 minutes and re-suspend in fresh T 
cell medium at 1-2 x 106 per mL. 
6. Thaw feeder cells (PBMC’s—Peripheral Blood Mononuclear Cells) from three different 
donors. You need 1-2 x 106 per well. Wash the feeders 1 time to remove DMSO, count, 
spin down cells, and re-suspend to the appropriate volume in fresh T cell medium (final 
density 1-2 x 106 per 100 µL). 
7. Irradiate B cells and feeder cells: 
a. PBMC’s = 5000 rads 
b. B cells    = 10,000 rads 
8. Set up wells in 24-well plate for re-stimulation. Add 1 mL T cell suspension (7 x 105-106 
cells), 1 mL peptide-pulsed, irradiated B cell suspension (1-2 x 106 cells), and 100 µL of 
irradiated PBMC’s (1-2 x 106 cells). 
9. Incubate plate at 37°C, 5-7% CO2 overnight. 
10. The next day, supplement each well with 20 Cetus units (120 IU) per mL of recombinant 
human IL-2. (240 IU per well). 
11. Leave cells at 37°C, 5-7% CO2 for approximately 7 days or until T cells are resting 
(appear round, not elongated, under the microscope). **If T cells look overcrowded on 
day 4 or 5, split the wells 1:2, adding 1 mL fresh T cell medium to 1 mL re-suspended T 
cell solution without adding IL-2. 
12. Once the T cells are resting, they can be used in assays, frozen, or re-stimulated. 
 
Media: 
T cell Medium     B cell Medium 
5% Human Serum (heat inactivated)   10% Fetal Calf Serum (heat inactivated) 
5% Fetal Calf Serum (heat inactivated)  5 mL 100x HEPES, pH 7.0 
5 mL 100x HEPES, pH 7.0    5 mL 100x Glutamine 
5 mL 100x Glutamine     5 mL 100x Penn-Strep 
2.5 mL 100x Penn-Strep    fill to 500 mL with RPMI medium 
fill to 500 mL with RPMI medium   Filter and store at 4°C 
Filter and store at 4°C 
     **sera from Sigma, other media ingredients from Gibco 
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 A.3.b T CELL MAINTENANCE—CD4+ CLONES AND LINES 
Protocol from John Cruz, University of Massachusetts Medical School 
 
Procedure: 
1. Pool T cells in a conical tube. **If you are freshly thawing, wash 1 time to remove 
DMSO.  
2. Count a small aliquot to determine T cell density. You will re-stimulate at a density of 1 x 
106 cells per mL.  Spin cells down and re-suspend to the proper density in PHA medium. 
Keep cells on ice until you are ready to plate them out. 
3. Thaw 3 x 106 allogeneic feeder cells (can use PBMC’s from 2-3 different donors) per mL 
of T cells being stimulated. Spin them down and re-suspend them to 3 x 107 cells per mL 
in Maintenance medium.   
4. Irradiate the feeder cells for 5,000 rads (about 1 hour in an 80 rad/min machine). 
5. Plate out the T cells and feeders in a 24-well plate. Add 1 mL of T cells in PHA medium 
and 100 µL of feeder cells in Maintenance medium to each well. **Make sure 
surrounding wells are filled with sterile RPMI or PBS to prevent excess evaporation.  
6. Incubate plate at 37°C, 5-7% CO2 overnight. 
7. On day 4, expand 1:2 using 2x Maintenance medium. 
8. On days 7 and 11, count the cells. If they are dense (>2 x 106 per mL), expand them 1:2 
into new wells, using 2x Maintenance medium.  If they are not very dense, then simply 
remove 1 mL of medium from each well and replace with 2x Maintenance medium. **T 
cells can be used for assays or for freezing on days 7-14. 
9. Re-stimulate on day 14. 
 
Media: 
PHA Medium      2x Maintenance Medium 
50% 2x Maintenance Medium   30% Fetal Calf Serum (heat inactivated) 
3 µg per mL PHA  (1:100 dilution of stock sol’n) To 100% with AIM V medium (Gibco) 
To 100% with AIM V medium (Gibco)  Filter and store at 4°C 
       **Before use, add 100-300 units/mL rIL2  
(BD Collaborative Research) 
 
**For 1x Maintenance Medium, dilute complete 2x Maintenance Medium 1:2 with AIM V 
medium (no addititives). 
**AIM V medium contains strep, gent, and glutamine 
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A.3.b T CELL MAINTENANCE—CD4+ CLONES AND LINES 
Protocol from Melissa Precopio, University of Massachusetts Medical School 
 
Procedure: 
1. Pool T cells in a conical tube. **If you are freshly thawing, wash 1 time to remove 
DMSO.  
2. Count a small aliquot to determine T cell density. You will re-stimulate at a density of 1 x 
106 cells per mL.  Spin cells down and re-suspend to the proper density in OKT3 
medium. **Another anti-CD3 antibody such as 12F6 (from Johnson Wong, 
Massachusetts General Hospital) or UCHT-1 (available from BD Pharmingen) can be 
used instead.  Keep cells on ice until you are ready to plate them out. 
3. Thaw 3 x 106 allogeneic feeder cells (can use PBMC’s from 2-3 different donors) per mL 
of T cells being stimulated. Spin them down and re-suspend them to 3 x 107 cells per mL 
in Growth medium.   
4. Irradiate the feeder cells for 5,000 rads (about 1 hour in an 80 rad/min machine). 
5. Plate out the T cells and feeders in a 24-well plate. Add 1 mL of T cells in OKT3 medium 
and 100 µL of feeder cells in Growth medium to each well. **Make sure surrounding 
wells are filled with sterile RPMI or PBS to prevent excess evaporation.  
6. Incubate plate at 37°C, 5-7% CO2 overnight. 
7. On day 4, expand 1:2 using 2x Growth medium. 
8. On days 7 and 11, count the cells. If they are dense (>2 x 106 per mL), expand them 1:2 
into new wells, using 2x Growth medium.  If they are not very dense, then simply remove 
1 mL of medium from each well and replace with 2x Growth medium. **T cells can be 
used for assays or for freezing on days 7-14. 
9. Re-stimulate on day 14. 
 
Media: 
OKT3 Medium     2x Growth Medium 
50% 2x Growth Medium (including rIL2)  20% Fetal Calf Serum (heat inactivated) 
1-5 µg/mL OKT3     2x Glutamine 
To 100% with RPMI 1640 medium (Gibco)  2x HEPES 
       2x Gent 
    To 100% with RPMI 1640 medium (Gibco) 
       **Before use, add 100-300 units/mL rIL2  
(BD Collaborative Research) 
 
**For 1x Growth Medium, dilute complete 2x Growth Medium 1:2 with RPMI 1640 medium 
(no addititives). 
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A.3.c T CELL MAINTENANCE—MURINE CD8+ 2C CLONE L3.100 
Protocol from Carol McKinley, Herman Eisen’s Lab 
 
Procedure: 
1. Count P815 cells (maintained by splitting frequently in “K” medium). Pool 6 x 106 cells 
in a tube, spin down, and re-suspend in 10 mL “C” medium. 
2. Irradiate P815 cells on ice Æ 20,000 rads. 
3. In a 50 mL centrifuge tube, pool several wells of day 7 post stimulation L3.100 cells.  
Count cells, and take 6 x 106 cells. Centrifuge cells at 1000 x g for 5 minutes at room 
temperature. Aspirate all but 5 mL of old medium.  
4. Combine P815 cells with L3.100 cells in the 50 mL tube. Bring volume up to 48 mL with 
“C” medium and distribute 2 mL per well in a 24-well plate. 
5. Incubate L3.100 cells in 24 well plate for 7 days at 37°C, 5% CO2. 
 
Media: 
“K” Medium     “C” Medium 
10% Fetal Calf Serum (heat inact.)  “K” medium containing 
10 mM HEPES, pH 7.0   5% Rat ConA Sup (equivalent to 
2 mM L-glutamine          30 U/mL recombinant mouse IL2) 
100 U/mL Penicillin    3% a-methylmannoside (Sigma M6882) 
100 µg/mL Streptomycin         (20% stock in Hank’s, Invitrogen 14175095)  
50 mM of β-mercaptoethanol 
in RPMI 1640 Medium 
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A.3.d LEUKOPACK PROCESSING 
Protocol from Jennifer R. Cochran 
 
Procedure: 
 
1. Set the temperature on the centrifuge to 25˚C (room temperature). 
2. Add 15 mL Ficoll to Accuspin tubes  
3. Centrifuge for 2 minutes at 500 RPM to get the Ficoll below the frit. 
4. Aspirate off residual Ficoll remaining on top of the frit.  
5. Add a 35 mL or less of leukopack blood (undiluted) per tube. 
6. Centrifuge at room temperature at 1800 RPM for 20 minutes.  **Turn the brake off on 
the centrifuge for this spin to avoid disrupting your gradient. 
7. **After removing the Accuspin tubes from the centrifuge, turn the brake back on, and set 
the temperature back down to 4˚C and allow it to begin cooling. 
8. Remove the leukocyte layer from the Accuspin tubes.  The leukocytes from 2 Accuspin 
tubes can go into a single 50 mL conical tube.  The bottom layer will be red blood cells 
(red), followed by Ficoll (colorless), leukocytes (cloudy thin layer), and serum (yellow). 
9. Fill the remaining space in the conical tube with RPMI (without any additives).  
Centrifuge at 1500 RPM at 4˚C to pellet the cells. 
10. Wash a second time with RPMI. 
11. Resuspend pellet in a small volume (around 5 mL).  Count a 1:100 dilution of this 
mixture.  Your final concentration will be 1-2 x 107 cells/mL. 
12. Dilute concentrated cells in RPMI to appropriate concentration in Freezing Media. (Note: 
If your dilution will be less than 1:8, re-pellet the cells and take up directly into Freezing 
Media.) 
13. Aliquot cells into cryovials, adding 1 mL cells per vial. 
14. Freeze vials of cells slowly at -70˚C overnight. 
15. Transfer vials to liquid nitrogen dewar. 
 
 
***25 mL of leukopack blood will yield 200-500 million cells. 
 
 
Materials: 
 
Accuspin Tubes – Sigma Diagnostics (A2055) 
Ficoll-Paque – Pharmacia Biotech (17-0840-02) 
Freezing Media – 90% Fetal Calf Serum, 10% DMSO, filtered 
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A.3.e QUICK FICOLL GRADIENT PURIFICATION 
Protocol from Sriram Chitta 
  
Procedure: 
 
1. Set centrifuge to 21°C, 1500 x g (rcf), brake = 0 
2. Resuspend cells 3 mL (10 mL) in RPMI, 10% FCS in a 15 mL (50 mL) tube.  Count live 
cells with Trypan Blue. 
3. Add 7 mL (30 mL) sterile Hanks Balanced Salt Solution or PBS and mix. 
4. Add 2 mL (10 mL) of sterile Ficoll-Paque SLOWLY at the bottom of the tube.  Should 
form a discrete layer. 
5. Spin cells (balanced) for 20 minutes at 20°C, 1500 x g, NO BRAKE. 
6. After the spin, there should be a buffy layer of leukocytes around the 2.5 mL ( mL) mark 
on the tube. With a pipet, carefully recover that layer and dilute into medium.  Try not to 
get much Ficoll, as that will spin down when you wash the cells. 
7. Wash cells twice with medium to remove remaining Ficoll. 
8. Resuspend and count cells.  Debris and dead cells should be absent by Trypan Blue. 
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A.3.f SINGLE CELL SUSPENSIONS FROM MOUSE ORGANS 
Protocol from Airiel Davis 
 
**Note: save the supernatants from every step of this protocol until you are finished and know 
you have enough cells. 
 
Procedure: 
 
1. Collect the mouse organs (lymph nodes, spleen, etc.) in a Petri dish with 3-5 mL 
RPMI, 2% FCS. 
2. Crush the organs between the frosted handles of two glass slides (sterilized).  Start 
with the smallest organs, as the solution will become cloudy and the small organs will 
be difficult to see later. 
3. Spin down cells at 1500 rpm, 10 minutes. Ensure that a pellet has formed! Remove 
supernatant and retain in a separate tube. 
4. Resuspend cells in 2-3 mL room temperature RBC lysis buffer per mouse. Allow to 
sit 1-5 minutes—no longer! **NOTE: If you have trouble with losing cells in this 
step, try a Ficoll gradient to isolate the white blood cells instead of lysing the RBC’s. 
5. Dilute with 10 mL/mouse RPMI, 2% FCS and spin down at 1500 rpm, 10 minutes. 
Ensure that a pellet has formed! Remove supernatant and retain in a separate tube. 
6. Resuspend cells in RPMI, 2% FCS and count total number.  
 
To purify TCR transgenic CD8 T cells with Dynal Magnetic Beads: 
 
1. Calculate from the total cell number the number of B cells/APCs expected and determine 
the volume of B220 beads (Dynal cat. # 114.01) to add such that there are at least four 
beads per cell.  Do the same calculation for CD4+ T cells to determine the volume of 
CD4 beads (Dynal cat # 114.05) to add. 
2. Add the appropriate volume of beads into PBS, 1% FCS in a tube to rinse away azide. 
3. Place the tube into the magnetic concentrator (Dynal cat. # 120.01) and allow the beads 
to stick to the side of the tube.  Remove the PBS solution. 
4. Pipet the resuspended lymph node cells into the tube with the beads.  Remove the tube 
from the concentrator, cap tightly, and agitate at 4°C for 20 minutes. 
5. Place the tube back into the magnetic concentrator and allow the beads and cells bound to 
them to stick to the side of the tube, depleting CD4+ T cells and B cells/APCs. 
6. Remove the cells still in solution with a pipet, place into a new tube, and count. 
 
from Lymph Nodes (20% B cells/APCs, 2-5% CD4+) 
 
µL B220 beads = 2*(# million cells total) 
µL CD4 beads = 0.5*(# million cells total) 
 
from Spleen  (up to 60% B cells/APCs, up to 30% CD4+) 
 
µL B220 beads = 6*(# million cells total) 
µL CD4 beads = 3*(# million cells total) 
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A.3.f SINGLE CELL SUSPENSIONS FROM MOUSE ORGANS (continued) 
Protocol from Airiel Davis 
 
Solutions: 
 
160 mM NH4Cl  170 mM Tris, pH 7.65 RBC lysis buffer, pH 7.2 
   8.45 g. NH4Cl     20.6 g. Tris base     90 mL 160 mM NH4Cl 
   to 1 L with ddH2O     115 mL 1M HCl     10 mL 170 mM Tris, pH 7.65 
   sterile filter      pH to 7.65 in 1L total    sterile filter 
       sterile filter  
 
**Since the RBC lysis is a very sensitive step (as I have lost all my cells multiple times at this 
point), it may be worth A) testing a small part of the cells before lysing all of them and/or B) 
purchasing the RBC lysis buffer from Roche (cat. # 1814389). 
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A.3.g MAKING MACROPHAGES OUT OF PBMC MONOCYTES 
Protocol from Sriram Chitta 
 
Procedure: 
1. Take PBMC’s in RPMI-based medium with 10% serum, Penn-Strep, Glutamine, and 
Hepes. Plate them onto a cell-culture polystyrene surface at high density. 
2. Allow cells to sit at 37°C for 2 hours. 
3. After incubation, swirl medium and remove non-adherent cells. **You may wish to keep 
these in a separate tube, depending upon what you are going to do. 
4. Wash the adherent cells 2x with sterile PBS, swirling each time. 
5. Add fresh RPMI-based medium (described above) with 25 ng/mL M-CSF. 
6. On 3rd day, remove ½ medium from the plated cells and replace with new RPMI medium 
with 25 ng/mL M-CSF. 
7. On day 6, the monocytes should have transformed into macrophages. To remove, soak in 
PBS with 1 mM EDTA for 10 minutes at room temperature, use a cell lifter to gently 
remove cells, and wash the cells well to remove the EDTA. 
8. The cells can be re-plated on a new surface—they should re-adhere within 2 hours at 
37°C. 
 
Donor C PBMC’s, Day 1 Donor C PBMC’s, Day 4 
 
High magnification 
 
High magnification 
 
Medium magnification 
 
Medium magnification 
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A.3.h COUNTING TISSUE CULTURE CELLS 
Protocol from Jennifer Stone 
 
 
 
 
SPLITTING TISSUE CULTURE CELLS 
 
1. Count your cell suspension and find the density (Di) 
2. Determine the final cell density you would like (Df) 
3. Determine the final volume of suspension you would like (Vf) 
4. Calculate the volume of current suspension to add using the following equation: 
i
ff
i D
VDV =  
 Where Vi is the volume you will keep from your initial cell suspension 
5. The cells should be split using Vi from the initial cell suspension and Vm of fresh media, 
where Vm = Vf - Vi 
 
 
 
Count cells 
touching top 
or left line
Do NOT count cells touching 
right or bottom line
Volume 
= 0.1 µL
**Dilute cells 1:2 with trypan
blue, e.g. add 10 µL cell 
suspension to 10 µL trypan
blue.
**Add mixture to 
hematocytometer under the 
coverslip (takes about 10 µL)
**Count cells in 2 squares the 
size of the red outlined 
portion—add numbers 
together
**Multiply result by 104 to get 
# cells/mL
EXAMPLE:
square 1: 31 cells
square 2: 34 cells
TOTAL= 65 cells in 0.1 mL
Density=0.65x106cells/mL
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A.3.i GENERAL T CELL ACTIVATION ASSAY 
Protocol and notes by J. Stone 
 
**NOTE: PLANNING is the most crucial part of a successful T cell assay.  Overdocument 
everything in advance so you are not grasping for materials or performing last-minute 
calculations—that WILL result in errors.  For long assays (24 hours or more), it is important to 
keep everything sterile-filter all protein solutions and buffers and perform everything in the 
biosafety cabinet.  For a shorter assay, sterility is less crucial, especially since the T cell 
stimulation is performed in media that generally contains antibiotics.** 
 
Protocol: 
1. Select a plate or plates that will hold all of your samples.  In general, polystyrene round 
bottom 96-well plates are useful, although flat-well plates may be better for immobilized 
stimuli.  For ELISPOT assays, you will normally perform the assay in commercially 
available plates with wells (usually with a nitrocellulose membrane bottom) pre-coated 
with cytokine or chemokine capture antibody, although you can replicate this yourself. 
2. Plan your assay, including concentrations and assay volumes.  An assay volume for a T 
cell stimulation may be as low as 20 µL per well if reagent conservation is a high 
priority, although larger volumes (50 µL or so) may be more convenient to manipulate.  
For later ELISA analysis of the supernatant to determine cytokine secretion, even larger 
volumes (100-200 µL/well) may be desired so there is enough supernatant at the end of 
the incubation to perform the ELISA experiment. 
3. Perform any surface coating for immobilized stimuli first.  Put the proteins at the 
appropriate concentrations in the well in PBS and incubate 2 hours at room temperature 
or overnight at 4°C. 
4. Block the plate using 1% BSA or 4% FBS in PBS or RPMI.  Fill each well with 200-300 
µL of the block solution and incubate 2 hours at room temperature or overnight at 4°C. 
5. Remove the block solution by aspiration or flicking. (Flicking is a useful technique that is 
fast and results in low cell loss during wash steps. I recommend it!) 
6. Plate out soluble stimuli and control wells with media alone.  Perform dilutions very 
carefully.  Replicates of different conditions are always useful if you have enough of the 
cells and stimulus.  If cells are to be used as a stimulus, make sure they are pulsed with 
any peptides or chemicals in advance (usually incubated 2 hours at 37°C) and washed 
into fresh media. 
7. Count your T cells and determine what volume of fresh media to resuspend them into so 
that at the volume of T cell you will add (VT) will contain the appropriate number of T 
cells.  Generally, you will want to make sure your assay wells each contain 50,000-
200,000 T cells, with a clonal population of T cells requiring fewer cells per condition 
and a mixed T cell population requiring more. 
8. Add the T cells to the wells, taking care not to carry stimulus from one well to another.  If 
you have difficulty here, use fresh pipet tips for each well.  Do not lose your place—
check carefully to make sure you added stimulus or media and T cells to each well. 
9. Incubate the T cells with the stimulus at 37°C, 5% CO2 for an appropriate time to detect 
your desired activation marker.  If fluorescently labeled stimulus is being used, take care 
to keep the assay plate in the dark.  For CD8+ T cells, many cell surface proteins detected 
by flow cytometry are modulated in the first 3-6 hours (CD3 and CD69 are more rapid, 
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and CD25 and CD71 are more slow), while for CD4+ T cells, those proteins are more 
slowly modulated—on the order of 12-24 hours.  Cytokine secretion assays (ELISA or 
ELISPOT) may be detected between 16-72 hours of incubation, depending on the cells 
and the cytokine desired.  For your particular marker, you may need to perform a time 
course to determine the optimal incubation time, or consult the literature. 
 
FOR ELISPOT: 
 After incubation, lyse and remove cells, and detect cytokines following the protocol for 
your kit (or your own protocol that you have worked out), developing spots for secreting cells 
with precipitating substrate. 
 
FOR ELISA: 
 After incubation, spin down cells, remove and retain supernatants for detection of bulk 
cytokine secretion, usually by sandwich ELISA with matched pairs of monoclonal antibodies. 
 
FOR PROLIFERATION USING 3H-THYMIDINE: 
 After incubation for several days, add 1µCi of 3H-thymidine to each well and allow cells 
to continue incubating for another 12 hours (overnight).  Harvest cells onto a glass fiber filter 
and count associated radioactivity (see separate protocol for 3H-Thymidine assay). 
 
FOR FLOW CYTOMETRY: 
 After incubation, chill cells on ice for 5 minutes or so to halt membrane turnover.  
Prepare your antibodies to add to the cells, using the same strategy for planning as you did to 
resuspend your T cells for the assay—always plan enough antibody mixture for 5-10 more 
samples than you need, as you are likely to run short after many samples.  You may use as many 
differentially labeled fluorescent antibodies as you can detect on your flow cytometer 
simultaneously in each sample.  For small incubation volumes, you can add fluorescent 
antibodies directly to the assay media, pipet-mixing well to ensure adequate staining.  For larger 
volumes, you may wish to spin down the cells, flick out the media, and resuspend each well in an 
antibody cocktail made up in FACS buffer (0.02% azide, 1% FBS in 1x PBS).  You may have to 
titrate your fluorescent antibodies to determine the proper amount to add to each well, although 
generally it will be 1-5 µL.  Allow the cells and antibodies to sit on ice in the dark for 30-60 
minutes.  Then, spin down and wash the cells 2-3 times (resuspend, pipet-mix, spin down, and 
flick out supernatant) with FACS buffer and finally resuspend in a small volume (50-100 µL—
the higher the volume, the more slowly the flow cytometer will analyze the sample) of FACS 
buffer (may add very small concentration of ethidium bromide if you will be using that channel 
to gate out dead or lysed cells) or Fixing buffer (1% paraformaldehyde in PBS—all cells are 
dead, so you can’t use ethidium bromide, but the cells may sit for up to a week at 4°C before 
analysis).  Move the samples into labeled FACS tubes which can be used on your flow 
cytometer. 
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A.3.i GENERAL T CELL ACTIVATION ASSAY (continued) 
Protocol and notes by J. Stone 
 
Sample calculation for plating stimulus and cells: 
Tstimf VVV +=                                                                       (1) 
where Vf is the final volume in the assay well, Vstim is the volume of the solution containing the 
stimulus in each well, and VT is the volume of T cell suspension added to each well.  In general, I 
add the T cells to the assay well last before the incubation.  To calculate what volume to 
resuspend your T cells into so that you can add VT to each well and have the appropriate number 
of cells added:  
well
tot
Tresuspend N
N
VV *=                                                               (2) 
where Vresuspend is the volume of fresh media to resuspend all your T cells into, Ntot is the total 
number of T cells you have, and Nwell is the total number of T cells you will add to each well.  
**NOTE: Ntot/Nwell MUST be greater than the number of samples you are planning by at least 5-
10.  ALWAYS calculate enough cell suspension that you will be left with enough volume for 5-
10 extra samples at the end.  When pipetting samples such as these, often using a multipipettor, 
you will never end up with the exact right volume, and you will always come up short if you 
don’t plan for extra.**  Then, to calculate the concentration of stimulus to plate out in the 
stimulus solution before adding the T cells: 
stim
f
fstim V
V
CC *=                                                                     (3) 
where Cstim is the concentration of the reagent in the stimulus solution before T cells are added, 
Vstim is the volume of the stimulus solution without T cells, and Cf and Vf refer to the final 
concentration of the stimulus reagent and final volume of the assay with T cells added, 
respectively.  Then, using those values and the concentration of your stock solution, you can 
concentrate the volume of stock solution to add to the well: 
stock
stim
stimstock C
C
VV *=                                                                  (4) 
where Vstock is the volume stock solution to add, and Cstock is the concentration of the stimulus in 
the stock solution.  To find the amount of media, Vmedia, to add to the stimulus solution: 
stockstimmedia VVV −=                                                                 (5) 
**NOTE: If you plan to do serial dilutions of some top concentration of stimulus, you will 
calculate your Cstim the same way for the top concentration.  However, for making your 
stimulation solution in equations (4) and (5), use a V’stim that is larger—enough that you will 
have the original Vstim after you remove a portion to dilute into fresh media for the first dilution.  
For example, if you will do 1:3 dilutions of stimulus, add the volume of your Vstim in fresh media 
to all but the top well.  Your V’stim (top well) will be equal to 3/2*Vstim in equations (4) and (5).  
Then, you can take a volume equal to 1/2Vstim from the top concentration well (leaving Vstim) and 
dilute it into the next well for a 1:3 dilution, and mix well.  Repeat this for as many dilutions as 
you plan to make.  Finally remove a volume of 1/2Vstim from the lowest concentration well after 
the dilution so that you are left with Vstim in that well.  Put the excess solution in the waste. 
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A.3.i GENERAL T CELL ACTIVATION ASSAY (continued) 
Protocol and notes by J. Stone 
 
For planning assays in a 96-well plate: 
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A.3.j ANERGIZING T CELLS 
Protocol by T. Cameron, based on experiment of 4/9/01 
 
Procedure: 
 
Day 1: 
Plan experiment and calculate the number of wells and cells you will need. (Plan 
triplicate samples for proliferation assays.) 
 
To anergize using OKT3 on a plate, dilute Ab in PBS to 5 µg/ml and add 150 ml/well in 
a flat-bottomed 96-well plate.  Incubate 2 hrs at room temperature.  Wash several times 
with PBS or RPMI, making sure wells do not dry out. 
 
Wash T cells and resuspend in T cell media to 1.333 x 106 cells/ml.  Add 150 µl/well. 
 
Add Anergizing Stimulus (5 µM control or specific peptide) or activating stimulus (EBV 
+ peptide, PMA/Ionomycin, or PHA/IL-2) for wells without OKT3. 
 
Incubate overnight or ~24 hours at 37°C with 7% CO2. 
 
Day 2: 
Warm some T cell media.   
 
In a flat-bottomed 96-well plate, prepare the activation stimuli (peptide, PMA/Ionomycin, 
PHA/IL-2) at 3x concentration. Prepare 50 µl for each final stimulated well you will have 
of that stimulus. 
 
Collect healthy EBV 1.24 (DR1+) cells in T cell media to 2 x 106 cells/ml.  Irradiate with 
10 krads. 
 
Collect anergized T cells in 15 ml conicals, spin down, aspirate (leave some liquid, and 
do not suck up the pellet), and resuspend to 2 x 106 cells/ml.  Add 50 µl T cells and 50 µl 
EBV’s to each well in 96-well round-bottom plate.   
 
Add 50 µl stimulation reagent to each well.  Pipet-mix briefly. 
 
Incubate for desired time at 37°C with 7% CO2. 
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A.3.j ANERGIZING T CELLS 
Protocol by T. Cameron, based on experiment of 4/9/01 
 
Solutions/Reagents: 
 
Ha and Tfr: Specific and null peptides.  Use at 5 µM (15mM in preparation well). 
 
PMA: 0.05 mg/ml aliquots, 10,000x. Best results when adding 0.25 µl/ml, or 0.75 µl/ml in  
preparation well (12.5 ng/ml final). 
 
Ionomycin: 0.4 mg/ml aliquots, 1000x. Best results when adding 2.5 µl/ml or 7.5 µl/ml in  
preparation well (1000 ng/ml final). 
 
PHA: 0.2 mg/ml aliquots. Add 10 µl/ml or 30 µl/ml in the preparation well (2 µg/ml final). 
 
IL-2: 22,000 units in 50 µl RPMI aliquots.  Add 0.091µl/ml, or 0.273 µl/ml in preparation well  
(40 units/ml final). 
 
OKT3: α-CD3 mAb, used clinically. 
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A.3.k INTRACELLULAR CYTOKINE STAINING 
Protocol by T. Cameron, synthesized from protocols at BD, Caltag, Zoran, and websites 
 
Procedure and approximate time scale: 
 
9:00 AM 
Wash cells, resuspend in T cell media, add ~100,000 cells/well into a round-bottom 96-
well plate with stimulus (EBV’s, PMA/Ionomycin, PHA/IL-2). Incubate at 37°C with 7% 
CO2 for 2-3 hours. 
 
11:30 AM 
Add 46.7 µl T cell media to 20 µl aliquot of 5 mg/ml BFA. Add 1 µl per well (150 ml 
stimulated cells) to final concentration of 10 µg/ml.  Incubate at 37°C with 7% CO2 for 4 
more hours. 
 
3:30 PM 
Spin down (5 min at 1500 rpm) and flick out supernatant.  Resuspend in 20-50 µl cold 
FACS buffer WITH EDTA containing α−CD4-APC at 1:50 dilution.  Stain for 15 
minutes at 4°C.  Add 150 µl Fixing Solution per well after 15 minutes and incubate 15 
more minutes at 4°C.   
 
4:00 PM 
Spin down, flick, and resuspend in 200 µL FACS buffer (without EDTA).  Spin down 
again, flick, and resuspend in 20 µl Permealization Solution.  Incubate 10 minutes at 4°C.  
Split samples into 2 wells (10 µl and 10 µl) each—to one set, add 20 µl α-cytokine (α-
IL-2) antibody, and to the other set, add 2.5 µl of a 1:4 dilution (200 µg/ml stock, 50 
µg/ml dilution, 10 µg/ml final in well) the isotype control.  Incubate 30 minutes at 4°C. 
 
5:00 PM 
Add 150 µl Permealization Solution.  Spin down, flick, resuspend in 200 µl 
Permealization Solution, spin down, and flick again.  Resuspend in 50 µl FACS buffer.  
Analyze on FACSCalibur Flow Cytometer. 
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A.3.k INTRACELLULAR CYTOKINE STAINING 
Protocol by T. Cameron, synthesized from protocols at BD, Caltag, Zoran, and websites 
 
Solutions/Reagents: 
 
BFA: Brefeldin A, Sigma B7651.  Make stock solution 5 mg/ml in DMSO.  Freeze at –20 or        
-80°C in 20 µl aliquots.  Use at a final concentration of 10 µg/ml. 
 
Fixing Solution: 4% Paraformaldehyde in 1x PBS, stored at 4°C, less than 1 month old.  To  
make, add dry paraformaldehyde with PBS at 56-66°C stirring for 30-60 minutes.  Cool, 
adjust pH to 7.2-7.4, and filter. 
 
Permeabilizing Solution: 1% FBS, 0.1% NaN3, and 0.1% Saponin (Sigma S-4521) in 1x PBS,  
adjust pH to 7.2-7.4, filter, and store cold. 
 
FACS Buffer (without EDTA): 1% FBS and 0.1% NaN3 in 1x PBS. 
 
FACS Buffer WITH EDTA: 1% FBS, 0.1% NaN3, and 5 mM EDTA in 1x PBS. 
 
α-cytokine mAb: Use BD Cat # 340448, Clone 5344.111, α-Hu-IL-2-FITC 
 
Isotype control mAb: Use Sigma IgG1-FITC Isotype Control F-6397.  Comes at 200 µg/ml— 
dilute 1:4 in permeabilizing solution to 50 µg/ml, and add 2.5 µl/well to a final 
concentration of 10 µg/ml. 
 
α-CD4 mAb: Use Diatec α-CD4-APC Cat # 3023 
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A.3.l PROLIFERATION ASSAY FOR T CELLS (3H-Thymidine Incorporation) 
Protocol by Jennifer Cochran 
 
Procedure: 
 
Day 1: 
Set up T cell assay in 96-well plate. Stimulate with stimulus of choice. (See Day 2 of 
“ANERGIZING T CELLS” Procedure.)  Incubate plate 36-48 hours at 37°C with 7% 
CO2. 
 
Day 3: 
 Add 1 microcurie of 3H-Thymidine to each well.  For a 1 mCi/ml stock, this will be 20 µl  
of a 1:20 dilution.  Rinse out pipet tips in wells to quantitatively dispense all the reagent. 
 
Incubate overnight (~ 12 hours) at 37°C with 7% CO2. 
 
Day 4: 
 Harvest cells onto glass fiber filters and count radioactivity. 
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A.3.m COUNTING 3H-THYMIDINE INCORPORATION INTO CELLS 
Protocol by Sriram Chitta 
 
Procedure: 
 
1. Get plates that have been incubated with 3H-thymidine for at least 12 hours.  Take them 
to the radioactivity room with the scintillation counters (door code 1-3-5). 
2. To harvest cells, first turn on the two vacuum pumps (grey), and then turn on the 
harvester itself (switch on right).  **Make sure the water reservoir is at least half-full 
before you begin (white plastic tank to the right of the harvester). 
3. Turn toggle switch on the trap (on the left near sink) to the “TRAP” setting—a green 
light will display. 
4. Place a dummy glass filter in the filter press and use a deep tray full of water on the plate 
tray with the wash/aspirator tips.  **A1 goes in the upper left, and the filter should touch 
the rubber gaskets at the top and right.  Pull the press down and lock it over the filter by 
pulling the metal bar toward you until it is horizontal. 
5. Press pulse wash—it will wash once, and then the light will flash. Press it again, and it 
will continue with three more washes.  The red light will go off when it is done. 
6. Remove the tray of water and replace it with a dummy 96-well plate (empty), and place it 
up around the wash/aspirator tips. 
7. Press pulse wash—it will wash once, and then the light will flash. Press it again, and it 
will continue with three more washes.  The red light will go off when it is done. 
8. Remove the dummy filter and replace it with your assay glass filter—make sure it is 
marked with indelible ink or by notching the filter so you can identify it later. **A1 goes 
in the upper left, and the filter should touch the rubber gaskets at the top and right.  Pull 
the press down and lock it over the filter by pulling the metal bar toward you until it is 
horizontal. 
9. Press pulse wash—it will wash once, which will serve to pre-wet your experimental 
filter. DO NOT PRESS PULSE WASH THE SECOND TIME—leave it flashing. 
10. Remove the dummy plate and replace it with your experimental 96-well plate. Raise it up 
around the wash/aspirator tips. 
11. Once the experimental plate is in place, press the pulse wash button again, which should 
be flashing. It will harvest the cells from the experiment and then wash. The red light will 
go off when it is done. 
12. Remove the filter onto which you harvested the cells when the pulse wash is done.  Keep 
it to the side and allow it to completely dry while you clean the harvester.  Replace the 
dummy filter into the filter press.  Close and lock the press. 
13. Press pulse wash—it will wash once, and then the light will flash. Press it again, and it 
will continue with three more washes.  The red light will go off when it is done. 
14. Remove the experimental plate and replace it with a dummy 96-well plate (empty), and 
place it up around the wash/aspirator tips. 
15. Press pulse wash—it will wash once, and then the light will flash. Press it again, and it 
will continue with three more washes.  The red light will go off when it is done. 
16. Remove the dummy plate and replace the water tray.  Make sure it is raised so the 
wash/aspirator tips are in the water so they do not dry out. 
17. Remove the dummy filter from the filter press. Leave the metal bar vertical (unlocked) so 
the gaskets are not under pressure. 
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18. Toggle the switch on the trap to the “DRAIN” position.  Stand away from the sink to 
avoid any splashing when the water begins to drain.  Once the trap has stopped draining, 
place the switch on the trap to the neutral position—directly in the center. 
19. Turn off the harvester. 
20. Turn off both vacuum pumps. 
21. Make sure your experimental filter paper is dry. If it is not, use a hair dryer to finish 
drying it. 
22. Place the filter paper in a plastic sample bag and seal the edges close to, but not right on 
top of, the filter.  Make sure there is enough room for you to cut and re-seal one corner! 
23. Cut one corner off the plastic bag and add 5 mL of BetaScint solution. Spread it around 
evenly such that the entire filter paper is wet inside.  Make sure there is no excess 
solution and there are no bubbles. 
24. Re-seal the corner of the plastic bag.  Make sure it is not leaking scintillation fluid. 
25. Place the filter in the plastic bag into a carriage for reading in the Microbeta Trilux 
scintillation counter.  Make sure the 96-well demarcations line up with the holes in the 
carriage. 
26. Use the bar code for protocol 08 on the first carriage and no bar codes for subsequent 
carriages that you will also count. 
27. Place the carriages inside the Microbeta from the bottom shelf (1) upwards. Place an 
empty carriage with a “STOP” protocol bar code in the shelf immediately following your 
sample carriages. 
28. Open the Microbeta Workstation window on the computer. Click on the large “Protocols” 
icon.  Select “General” in the menu that pops up.  Then, select “sriram” (not “sriram Cr”).  
Use protocol “8” on the screen.  Check the plate map to make sure it will count all the 
wells in which you had samples.  When the plate map is appropriate, click on start next to 
the protocol number.  It will then say “READY” on the bottom of the screen.  Then, click 
the large “Start” icon with the green light. 
29. If you are counting a plate, it will usually give a live display.  If you would like to check 
a previous plate, you may by clicking the “Prev” button to the right of the plate display. 
30. MAKE SURE YOU DISPOSE OF ALL RADIOACTIVE MATERIAL PROPERLY!! 
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A.3.n STAINING CD4+ T CELLS WITH DR TETRAMERS 
Protocol from Tom Cameron 
 
Reagents: 
 DR1-pep: Biotinylated DR1-peptide of choice in PBS. 
 SA-PE: R-phycoerythrin conjugated Streptavidin from BioSource, Inc 
 PBS, 1x 
 RPMI  
 T cell Media 
 T cells and/or PBMCs 
 FACS buffer: 1x PBS, 1% BSA or FBS, 0.02% sodium azide 
 Fixing Solution: 1x PBS, 1% paraformaldehyde (must be dissolved at 60°C) 
 Fluorescent antibodies to cell-surface markers: 
  α-CD4-APC 
  α-CD14-PerCP (optional, good for PBMCs),  
  α-CD3-Fitc (optional, but good, esp for clones). 
 
Make the Oligomer Reagent (for 50 µl): 
 **NOTE: this procedure is generally completed on ice, although it may be done at  
 room temperature.  The reagent should be made up fresh for each stain.** 
 
1. Aliquot 1.5 µg DR1-pep into an eppendorf tube. 
2. In a separate tube, dilute 2 µL SA-PE with 4 µL PBS 
3. Add 2 µL of diluted SA-PE mixture to the tube with DR1-pep and pipet-mix well 
4. Wait 2 minutes 
5. Add 2 µL of diluted SA-PE mixture to the tube with DR1-pep and pipet-mix well 
6. Wait 2 minutes  
7. Add the rest of the diluted SA-PE mixture to the tube with DR1-pep and pipet-mix well 
8. Wait 2 minutes Æ complex should form between biotinylated DR1-pep and SA-PE: 
DR1-SAPE oligomer 
9. Dilute DR1-SAPE oligomer with RPMI or T cell media to a final volume of 50 µL. 
 
 **NOTES: This is called a 60 ug/ml reagent, approximately half DR1-pep and half SA-
PE (by weight).  Since SA-PE is a poorly characterized heterogeneous reagent, that isn’t 
very precise.  Different lots of SA-PE should be titrated with DR1-pep to find the optimal 
ratio between the two reagents.  For Lot 1401 from BioSource, Tom Cameron found 
experimentally that the optimal ratio was 1.3 µL SA-PE per 1 µg DR1-pep.  In general, 
approximately 1 µL SA-PE per 1 µg DR1-pep should give decent staining. ** 
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A.3.n STAINING CD4+ T CELLS WITH DR TETRAMERS (continued) 
Protocol from Tom Cameron 
 
 
Staining CD4+ T Cells: 
1. Collect cells in a 15 ml conical tube and spin down 5 minutes, 1500 rpm 
2. Aspirate as much of the media as you can. 
3. Resuspend the cells in a very small volume of media. You will want to have a final 
volume such that you use 10 µL cell suspension for each stain you would like to do.  
(example: staining with one specific tetramer and one control tetramer Æ resuspend cells 
in 20 µL) 
4. Aliquot 10 µl cell suspension into one well of a 96-well round-bottom plate for each 
staining experiment.  **NOTE: avoid outer wells and if possible, fill the wells 
surrounding the experiment with 200 µL RPMI to prevent evaporation during the 
assay.** 
5. Add 5 µl of DR1pep-SAPE oligomer reagent (tetramer) to the cell suspension in 
appropriate wells. 
6. Incubate the plate at 37°C for 3-5 hours.  In general, use a hydrated 37°C incubator with 
5% CO2. 
7. Chill plate on ice 5 minutes. 
8. Prepare a cocktail of desired fluorescent antibodies.  Typically use 1 or 2 µl of each 
antibody per well and dilute with T cell media, RPMI or PBS so that you will add 5 µL 
cocktail per sample. 
9. Add 5 µl of fluorescent antibody cocktail to each sample. Pipet mix well. 
10. Incubate on ice for 20-45 minutes. 
11. Add 200 µl cold FACS buffer to each sample.  Spin plate at 4°C for 5 minutes, 1500 
rpm.  **NOTE: it can be reassuring to look at the bottom of the plate to make sure cell 
pellets have formed in your sample wells. 
12. Aspirate supernatant with pipet tip or flick plate into sink. 
13. Wash with 200 µl cold FACS buffer and pipet mix well.  Spin plate at 4°C for 5 minutes, 
1500 rpm. 
14. Aspirate or flick supernatant 
15. Resuspend samples in either FACS buffer or Fixing Solution. 
16. Analyze by flow cytometry. 
 
**NOTES: Remember to include plenty of controls including single-stained cells for 
compensation adjustment, control tetramers, control cells if available.  Try to keep 
samples cold after the 37° staining incubation is over, since α-CD3 antibody can 
stimulate the cells at RT or 37°C, resulting in odd results (downregulated TCR, maybe 
CD4, etc.).** 
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A.3.o T CELL—T CELL ACTIVATION ASSAY 
Used for 2C T cell assays using Class I MHC monomers or peptide alone 
Protocol by J. Stone and Q. Ge 
 
Procedure and approximate time scale: 
 
Night Before 
Block enough V-bottom FACS plates for your experiment with 150µL/well of 1%BSA in 
PBS—incubate overnight at 4°C. 
 
6:30 AM 
Kill naïve 2C mice with and without GFP and purify cells for low CD44 expression with 
magnetic beads (keeping + and – GFP cells separate).  Count both sets of cells, and re-
suspend each set in T cell media to a volume that gives 50,000-100,000 in 24µL. These 
cells should be ready around 11:00AM-12:00PMish.  Store cells on ice until needed. 
 
7:00 AM 
Check monomer by analytical gel filtration, and check concentration of monomer and 
peptide by UV absorbance. Calculate dilutions for assay—you will need to start with 
1.857x of your first concentration in the first well—made up by dilution in T cell media 
just before the assay begins. 
 
11:30 AM 
On ice, add 32µL of 1.857x of your first concentration in T cell media to the first well, 
and perform 1:8 dilutions of 4µL into 28µL down the row, mixing well at each stage. 
Throw 4µL away at the end of the row to leave 28µL in each well.  Add 28µL media 
alone to any control wells you have planned.  Add 24µL GFP- cells to each well.  
Incubate at 37°C  for 3 hours.  
 
2:30 PM 
Spin cells down in plate, flick, and wash 4x by resuspending in wash buffer and/or media.  
After 4 washes, resuspend all wells in 28µL.  Add 24µL GFP+ cells to assay wells, 
making sure you have some control wells for these cells, as well.  Incubate another 3 
hours at 37°C.  
 
5:30 PM 
Chill cells on ice. Stain with aCD8-APC and either αTCR-PE or αCD69-PE at a 1:100 
final dilution. (Make up 48µL/well, 1µl Ab/well, in FACS buffer with azide.)  Stain on 
ice for 1 hour. 
 
6:30 PM 
Spin down cells, and wash in FACS buffer twice.  After last wash, resuspend in FACS 
buffer containing Propidium Iodide, about 60µL/well, and transfer into FACS tubes. 
Analyze on the FACSCalibur Flow Cytometer. 
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A.3.p ASSAY OF ERK PHOSPHORYLATION 
Protocol from Leslie Berg’s lab, from papers by Karen Liu and Steve Bunnel 
 
Reagents: 
 PMA and Ionomycin: Final concentrations 2.5ng/mL and 375ng/mL, respectively. 
 RPMI 
Stopping Solution: 20 mM NaF and 1 mM Na3VO4 in 1x PBS. Make solution fresh 
using 15 mL PBS, 75 µL Na3VO4 stock solution, 600 µL NaF stock solution. 
 NaF Stock Solution: 0.5 M in DMSO, store aliquots at -20°C 
 Na3VO4 Stock Solution: 0.2 M in DMSO, store aliquots at -20°C 
Lysis Buffer: 25 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% 
Triton X-100, 1 mM PMSF, 10 µg/mL leupeptin, and 1 mM Na3VO4.  Make 15 mL 
aliquots of solution without Na3VO4 and store at -20°C.  When ready to use, thaw 
aliquot and add 75 µL Na3VO4 stock solution fresh. 
Phospho-p44/42 MAP Kinase: detects phosphorylated ERK, from Cell Signaling 9101S 
p44/42 MAP Kinase: detects total ERK, from Cell Signaling 9102 
HRP-secondary antibody: choose any polyclonal antibody reagent against the proper 
species. For ERK, use goat anti-rabbit HRP. 
**NOTE: Can also use Phospho SAPK/JNK or other markers in this protocol.** 
 
Procedure: 
1. Plan experiment to study T cell stimuli, being sure to include a positive control such as 
PMA and Ionomycin and negative controls including T cells with no stimulus and lysis 
buffer alone. 
2. Incubate 3-5 x 106 T cells with each of the stimuli you plan to study at 37°C for 0 sec., 30 
sec., 2 min., 5 min., 10 min., and 15 min.  Volume should be ~120 µL/sample. 
3. Add 1 mL/sample ice-cold stopping solution to stop reactions. 
4. Spin cells and remove supernatant. 
5. Resuspend in a small volume of cold lysis buffer (~100 µL) and incubate for 15 minutes 
on ice. 
6. Clear lysates by spinning 10,000 x g for 10 minutes. 
7. Analyze by SDS-PAGE, and transfer to an Immobilon-P membrane (Millipore) 
8. Block, blot for phospho-p44/42 MAP Kinase, detect with an HRP-labeled goat anti-rabbit 
reagent, and develop using ECL reagents (for example, Chemicon 2600: 
Chemiluminescent Blot Detection System). A sample protocol can be seen in “Western 
Blot—ECL Detection” 
9. After detection, strip using an ECL-approved stripping protocol (for example, Chemicon 
2504: Re-Blot Plus Strong Ab. Stripping Solution) and re-probe the same membrane for 
total p44/42 MAP Kinase. 
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A.3.q MAKING MHC AND CO-STIMULATORY ARRAY CHIPS 
Protocol by Jennifer D. Stone, Modified from B.D. Pharmingen ELISPOT Protocol 
 
Procedure: 
1. Take a 25 mm x 75 mm slide (works best on polystyrene or LabTek II CC2 chamber 
slides).  For hand-spotting, mark the array pattern on the back using a pre-printed 
template, leaving the frosted/rough handle area free.  **LABEL YOUR SLIDE WELL. 
2. If you are not using a chamber slide, surround the array area on the front of the slide with 
your hydrophobic barrier of choice; for example, paint hydrophobic ink around the array 
area and allow to dry (works best on glass), or use an adhesive-backed rubber gasket cut 
to surround the area (Molecular Probes P-24745).  Place this type of slide into a 
secondary container such as a petri dish to catch any spills that may occur. 
3. Dilute your monoclonal cytokine capture antibody (not biotinylated) 1:25 (40 µg/mL 
final) into 1x PBS, pH 7.4.  
4. If hand-spotting, place one spot of the capture antibody solution (0.1-0.5 µL) in each 
location.  If automatically spotting, spot one layer of the pattern (0.05-0.1 µL per spot). 
Allow to dry completely at room temperature. 
5. Repeat the spotting of the capture antibody solution in the same pattern 3 more times, 
allowing to dry each time between layers. Total layers of capture antibody solution = 4 in 
each spot. 
6. Spot your MHC and/or antibody solutions onto the slide in the pattern of your choice on 
top of the dry capture antibody spots.   
a. As a control, it is good to use anti-CD3 in some spots, which should stimulate all 
T cells.   
b. Combining the anti-CD3 or MHC-peptide complex with a co-stimulatory 
antibody such as anti-CD11a, anti-CD28, or anti-CD2 will enhance the activation 
seen, but will not cause activation by non-specific peptide-MHC complexes.  
c. Concentrations should be 1 µM or approximately 50 µg/mL of MHC-peptide 
complex, and/or 5 µg/mL of anti-CD3 or co-stimulatory antibody.   
d. It is generally beneficial to tetramerize MHC-peptide complexes by biotinylating 
the soluble monomers and adding them to streptavidin in a 4:1 ratio. The final 
MHC concentration should remain 50 µg/mL in the spot. 
7. Allow the spots to dry completely. 
8. Store the array slide at 4°C in a dessicator until you are ready to use it. 
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A.3.r T-CELL EPITOPE DETECTION EXPERIMENT USING MHC AND CO-
STIMULATORY ARRAYS 
Protocol by Jennifer D. Stone, Modified from B.D. Pharmingen ELISPOT Protocol 
 
Procedure: 
1. Take a dry, arrayed slide with the appropriate MHC-costimulatory-capture antibody 
pattern and allow to come to room temperature.  **Note: it is useful to keep the array 
inside the petri dish if it is not a chambered slide. 
2. Block the slide by incubation with T cell medium containing 10% FCS for 30 minutes at 
room temperature. 
3. Re-suspend and count your T cell sample. You will want to add enough T cells that you 
would expect at least 1 x 104 specific cells to be present on the array.  Take the 
appropriate amount of the T cell solution and spin down the cells at 1500RPM for 10 
minutes at 4°C. 
4. Aspirate the supernatant. 
5. Re-suspend the pellet in 1-2 mL T cell medium.  **Note: for some cell lines or for 
precipitating substrate development, you may wish to use 5 ng/mL PMA to enhance the 
antigen-specific activation you will see.  The PMA alone will not cause activation in the 
T cells.  Generally, this is not required. 
6. Aspirate the T cell medium from the MHC-peptide array that was blocking the surface.  
Add the freshly re-suspended T cells in medium to the surface of the array inside the 
hydrophobic barrier, making sure the entire area is covered. 
7. Carefully place the array with the T cells inside a 5% CO2, 37°C incubator, being careful 
not to spill the T cell solution, and making sure that the array is level inside the incubator. 
**Note: Make sure the incubator is well-humidified to reduce evaporation during the 
incubation. 
8. Incubate the array at 37°C, 5% CO2 for 4-16 hours, depending on the cytokine you wish 
to analyze and the type of T cell (CD4+ or CD8+, murine or human, etc.).  For IFN-γ 
response, 6 hours is best for fluorescent detection, and 16 hours is best for precipitating 
substrate detection. 
9. Pre-incubate your monoclonal cytokine detection antibody (biotinylated) with either 
fluorescent streptavidin (SA-CY3, -CY5, -Alexa 555, or -Alexa 647, 2 mg/mL, for 
fluorescent detection) or enzyme-linked streptavidin (SA-HRP, 2 mg/mL, for 
precipitating substrate detection) at high concentration for ≥ 30 minutes.  Your final 
dilution will be 1:250 for the detection antibody and 1:1000 for the streptavidin at 2 
mg/mL in Dilution Solution containing excess biotin. 
10. After the incubation, carefully remove the array from the incubator.  Aspirate off the cell 
solution and observe for cell adhesion to the spotted pattern. **Note: it is possible to 
analyze the array for adhesion only under a microscope—see protocol for Detecting 
Adherent Cells on MHC-costimulatory Arrays.   
11. Spread ddH2O inside the hydrophobic barrier. Allow the array to sit for 5 minutes at 
room temperature. This will help lyse any remaining cells. 
12. Aspirate the ddH2O and repeat with another 5 minute ddH2O wash. 
13. Aspirate the ddH2O and wash the slide 3 times with TBST, aspirating the buffer off after 
each wash. 
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14. Dilute your pre-incubated detection antibody and streptavidin mixture into Dilution 
Solution containing 100 µM d-biotin to prevent non-specific binding to streptavidin-
containing spots.  Apply this solution (1.0-1.5 mL/array) inside the hydrophobic barrier. 
Allow the array to incubate with the detection antibody solution for 2 hours at room 
temperature. 
15. After the incubation, aspirate the detection antibody solution and wash 3 times with 
TBST. 
 
16. FOR FLUORESCENT DETECTION: Wash 2 additional times with ddH2O, then dry 
completely.  Remove the chamber if using a chambered slide array (LabTek II CC2).  
Scan using an array scanner. 
 
 
17. FOR PRECIPITATING SUBSTRATE DETECTION: No more than fifteen minutes before 
you are ready to use it, prepare the AEC substrate solution by adding 20 µL of substrate 
per milliliter of PBS and mixing well. 
18. Wash 2 additional times with PBS—NO AZIDE. Azide will inhibit the enzyme. 
19. Spread 1.0-1.5 mL of the AEC substrate solution on the array, making sure the entire area 
is covered evenly. Allow this reaction to proceed in the dark for 5-60 minutes, checking 
the progress periodically. 
20. To stop the reaction, aspirate the AEC solution and wash 2 times with ddH2O. Allow to 
dry completely in the dark. 
21. Observe the spots by eye and under a dissection microscope. The AEC precipitate 
photographs very well, but will fade over time, especially if exposed to light. 
 214
A.3.r T-CELL EPITOPE DETECTION EXPERIMENT USING MHC AND CO-
STIMULATORY ARRAYS (continued) 
Protocol by Jennifer D. Stone, Modified from B.D. Pharmingen ELISPOT Protocol 
 
Solutions and Reagents: 
 
T cell medium (for assay)   TBST:    Dilution Solution:  
   10% Fetal Bovine Serum, heat inact.     50 mM Tris, pH 7.5     TBST   
   1:100 Penn-Strep solution (Gibco)     150 mM NaCl     0.3% BSA   
   1:100 Glutamine solution (Gibco)     0.1% Tween-20            100 µM d-biotin  
   1:100 Hepes solution (Gibco)     filter and store at 4˚C    filter and store at  
   Fill with 1x RPMI with phenol red (Gibco)     4˚C  
   Filter and store at 4°C 
 
Company Catalogue # Description 
Nalge Nunc 
International 
160004 Polystyrene Cell Culture Slide—25 mm x 75 mm, 
one end frosted, 20/pack. Buy through VWR or 
Fisher 
Nalge Nunc 
International 
154739  (1 chamber) 
154917 (4 chambers) 
LabTek II CC2 Chamber Slides with cover, 
16/pack. Buy through VWR or Fisher. 
Molecular Probes P-24742 Press-to-Seal silicone isolator with adhesive, 24 
wells, 2.5 mm diameter, 2.0 mm deep, 25/pack 
Molecular Probes P-24745 Press-to-Seal silicone sheet with adhesive, 13 
cm x 18 cm, 0.5 mm thick, 5/pack 
Molecular Probes S32355 Streptavidin-Alexa 555 
Molecular Probes S32357 Streptavidin-Alexa 647 
Sigma S5512 Streptavidin-HRP 
Sigma B3399 d-biotin 
Ted Pella, Inc. 22309 Super Pap Pen Liquid Blocker—hydrophobic ink 
Avery (Office Supply) 8665 Clear Full Sheet Labels 
B.D. Pharmingen 551884 Anti-human IL2 monoclonal antibody pair, 
detection antibody biotinylated 
B.D. Pharmingen 551873 Anti-human IFNγ monoclonal antibody pair, 
detection antibody biotinylated 
B.D. Pharmingen 551881 Anti-mouse IFNγ monoclonal antibody pair, 
detection antibody biotinylated 
B.D. Pharmingen 551950 Avidin-HRP, 100x, 1 mL 
B.D. Pharmingen 551951 AEC precipitating substrate set, to use with 
Avidin-HRP 
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A.3.s QUANTITATION OF CELL SURFACE RECEPTORS BY FLOW CYTOMETRY 
Protocol from J. Cochran 
 
**NOTE: In order to quantitate receptor number you must know how many FITC or PE 
molecules are present per antibody molecule.  For FITC, you can estimate this value using the 
protocol “Fluorescein labeling of proteins and antibodies” in this thesis.  For PE you can try to 
get this number from the manufacturer, or calculate a value from comparison to the levels 
obtained with a FITC labeled version of the same antibody.** 
 
1. After performing FACS assay and running tubes through the flow cytometer, run a 
sample containing diluted SPHERO Rainbow Calibration Particles (RCR-30-5; 
Spherotech, Inc.) through the flow cytometer. 
2. Plot up histograms of mean FITC and PE.  You should see 6 peaks on your histogram 
(see next page for an example). Obtain mean fluorescence values for each peak. 
3. Plot up a standard curve of Mean FITC versus Mean equivalents of fluorescein (MEFL). 
Repeat for Mean PE versus Mean equivalents of PE (MEPE). 
 
         Peak  MEFL  MEPE 
1  100  70                                                                                                                    
 2  4700  3800       
 3  15000  12000       
 4  40000  34000       
 5  140000 124000      
 6  330000 300000 
 
4. Obtain mean fluorescence values for each samples of interest.  Using linear regression    
of your standard curve, calculate Mean equivalents of fluor present on the cell surface. 
5. Divide the Mean equivalents by the number of fluors present per antibody to obtain 
number of cell surface receptors present. 
 
 
See the following page for an example of flow cytometry data and standard curve 
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          FITC 
Marker          Mean FITC 
   M1      1.23 
   M2     20.45 
   M3     56.76 
   M4    150.17 
   M5    521.86 
   M6   1213.52 
            PE 
Marker    Mean PE 
   M1       2.53 
   M2      99.10 
   M3     291.64 
   M4     791.48 
   M5    2864.38 
   M6    7169.17 
M1 M2
M3 M4
M5
M6
M1
M2
M3
M4
M5
M6
0
1 105
2 105
3 105
4 105
0 400 800 1200 1600
FITC standard curve
y = -781.39 + 272.14x   R= 0.99999 
M
E
FL
Mean FITC
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A.4.a AGAROSE GEL ELECTROPHORESIS                                                    
Protocol from Applied Molecular Biology at the University of Maryland and Tom Cameron 
 
Procedure: 
 
1. Prepare 100 ml of a 1% agarose solution.  (Measure 1 g agarose into a glass beaker or 
flask and add 100 ml 1X TBE or TAE.) 
2. Microwave or stir on a hot plate until agarose is dissolved and solution is clear.  
**NOTE: the solution may boil rapidly after microwaving, so be careful handling it.  
3. Allow solution to cool to about 55˚C before pouring. (Ethidium bromide can be added at 
this point to a concentration of 0.5 µg/ml.)  
4. Prepare clean gel tray by sealing ends with tape or other custom-made dam.  
5. Place comb in gel tray about 1 inch from one end of the tray and position the comb 
vertically such that the teeth are about 1-2 mm above the surface of the tray.  
6. Pour 50˚C gel solution into tray to a depth of about 5 mm. Allow gel to solidify about 20 
minutes at room temperature.  Excess agarose can be stored at room temperature and re-
melted in a microwave.  
7. To run, gently remove the comb, place tray in electrophoresis chamber, and cover (just 
until wells are submerged) with electrophoresis buffer (the same buffer used to prepare 
the agarose).  
8. To prepare samples for electrophoresis, add 1 µl of 6x gel loading dye for every 5 µl of 
DNA solution. Mix well. Load 5-12 µl of DNA per well (for minigel).  
9. Electrophorese at 50-150 volts until dye markers have migrated an appropriate distance, 
depending on the size of DNA to be visualized.  
10. If the gel was not stained with ethidium during the run, stain the gel in 0.5 µg/ml 
ethidium bromide until the DNA has taken up the dye and is visible under short-wave UV 
light, if the DNA will not be used further, or with a hand-held long-wave light if the 
DNA is to be cloned. 
   
 
Materials: 
     agarose solution in TBE or TAE (generally 0.7-1%)  
     1X TBE or TAE (same buffer as in agarose)  
     gel loading dye  
     10 mg/ml ethidium bromide  
 
50x TAE (fill to 1L with ddH2O)   6x gel loading buffer  
     242 g Tris base           0.25% Bromophenol blue  
     57.1 g glacial acetic acid          0.25% Xylene cyanol FF 
     100 ml 0.5 M EDTA          33% glycerol  
10x TBE (fill to 1L with ddH2O)        18% 50x TAE  
     108 g Tris base           49% ddH2O 
     55 g boric acid  
     40 ml 0.5 M EDTA, pH=8     
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A.4.b TRANSFORMING COMPETENT E. coli (DH5α, BL21) 
Procedure from Tom Cameron and Lawrence Stern 
 
Make sure you have enough LB-agar plates for all of your samples, containing the antibiotic you 
will be using to screen (for example, ampicillin or kanamycin).  You will also need roughly 
sterile eppendorf tubes, pipet tips, and a spreader or autoclaved spreading beads. 
 
Thaw an aliquot of competent cells on ice. 
 
Pre-heat a water bath to 42°C. 
 
For each sample, add 1-100 ng plasmid to 25 µL competent cells in a roughly sterile eppendorf 
tube.  **Whenever doing a transformation, make sure to perform at least two controls: a known 
plasmid with the antibiotic resistance tag you will be using (such as pLM1 for ampicillin 
resistance), and cells with no DNA added. 
 
Incubate on ice 5-15 minutes.   
 
Place tubes in the water bath at 42°C for 45-90 seconds.  **Do not allow the bath to get too hot! 
 
Return the tubes to ice for another 2 minutes.   
 
Add ~9 x volume of sterile LB media to each tube and mix by inverting.  There should be no 
antibiotic in the media at this stage.   
 
Incubate the cells at 37°C for 10-30 minutes.  This allows recovery from the heat shock in the 
water bath.   
 
Plate the cells onto LB plates containing the antibiotic you are using to screen (for example, 
ampicillin or kanamycin).  Use a spreader or autoclaved spreading beads.  If using a spreader, 
sterilize it well between each sample by rinsing with 70% EtOH and flaming over a Bunsen 
burner.  Be careful not to get any bacteria from one sample onto another plate. 
 
Incubate plate overnight at 37°C.  **You should have colonies on your positive control plasmid 
plate (such as pLM1), and no colonies on your “no DNA” plate.  **Note: If you get too many 
colonies or a “lawn” on your transformation plates, use a smaller volume of the transformation 
mixture to spread onto your plates. 
 
To test protein induction in BL21 or other production strain, grow several colonies from the 
transformed plate in 5 mL of 1x LB medium, 50 µg/mL ampicillin (or appropriate amount of 
kanamycin or other selective agent), 0.2-0.5% glucose until the cultures reach an OD600 of ~0.7.  
Take a “Not Induced” sample from each culture.  Add IPTG to 0.75 mM final concentration and 
allow to grow another 1-3 hours at 37°C.  Take an “Induced” sample of the same volume from 
each culture.  Run an SDS gel of the samples against molecular weight markers to test protein 
induction in each culture.  Freeze down the cultures that induce in 1x LB with 30% glycerol. 
Store at -80°C. 
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A.4.b TRANSFORMING COMPETENT E. coli (DH5α, BL21, continued) 
Procedure from Tom Cameron and Lawrence Stern 
 
Calculating Efficiency of Transformation: 
 
for your positive control plasmid, 
 
           # colonies/plate 
    Efficiencymax (colonies/µg)   = ----------------------------------------------- 
        (µL plasmid added)  (µg/µL plasmid) 
 
for your plasmid of interest, 
 
           # colonies/plate 
    Efficiencyactual (colonies/µg)  = ----------------------------------------------- 
        (µL plasmid added)  (µg/µL plasmid) 
 
relative efficiency 
 
              Actual transformation (colonies/µg) 
   Efficiencyrel  =     -------------------------------------------------- 
            Maximum transformation (colonies/µg) 
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A.4.c VARIOUS AND SUNDRY NOTES AND TIPS ON MOLECULAR BIOLOGY 
Collected from Tom Cameron, Lawrence Stern, and personal experience 
 
Cloning Genes into Plasmids: 
Vector Piece: 
• Grow a large amount of plasmid and purify using something like Qiagen midi prep.  If 
the plasmid is not clean enough, the digestions will not work well, and you may have to 
clean the prep using a Qiagen mini prep or Qiaquick kit. 
• Run test digestions to find what concentrations of enzyme completely cut the plasmid.  
You will want to use about a 3-fold excess of each enzyme in your actual reaction mix to 
try to ensure complete cleavage.  It can be useful if the plasmid you are starting with has 
a gene in it so the doubly cleaved band can be easily identified on a gel. **NOTE: the 
New England Biolabs (NEB) catalogue has tons of useful information about setting up 
digestions.** 
• Digest about 3 µg of vector for your cloning experiment.  Keep your DNA concentration 
around 0.2 µg/µL, and do not allow the enzyme volume to be more than 10% of the final 
reaction volume, as the glycerol will inhibit the reaction.  **NOTE: to reduce 
recyclization of vector, you can add a phosphatase (CIP) into the reaction. 
• For reaction volumes greater than 30 µL, clean up the plasmid using a Qiaquick kit so 
that your sample can be loaded into a single well on an agarose gel. 
• Run the digested vector on a 1% agarose gel, making sure everything is clean.  Keep the 
voltage low (~70 volts), and run for 3-4 hours until you get clear separation.  **NOTE: 
Do not use a bright or short wavelength UV source to look at the gel, as it will cause 
mutations in the fragment.  Use a dim, long wavelength source, and keep the exposure 
time short.** 
• Identify the vector band and cut it out using a brand-new razor blade. 
• Purify the digested vector using the Qiaquick kit gel extraction directions.  Check a small 
aliquot of the product on an agarose gel to estimate the concentration and confirm that it 
is the right size. 
• Yield will be about 0.5 µg from an initial 3 µg of uncut vector. 
  
Gene Insert: 
• From PCR Product: 
o Estimate the concentration of your PCR product on an agarose gel. 
o Digest the PCR product if necessary to create appropriate sticky ends.  If the 
digestion does not work in the PCR reaction mixture, run a Qiagen PCR clean-up 
kit before the digestion. 
o Gel-purify 3-10 µg using a Qiaquick kit as above. 
• From another vector: 
o Digest 5-8 µg DNA, keeping concentration around 0.2 µg/µL.  Use excess 
enzyme as described above (Vector Piece).  **NOTE: This may require a large 
reaction volume.** 
o Use Qiaquick to concentrate the sample before loading on gel. 
o Gel Purify the reaction using a Qiaquick kit as above. 
• Cloning from Primers:  
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o If you used CIP in your vector prep, kinase the primers each separately and heat 
inactivate the kinase when done.  
o Mix the primers at an equimolar ratio at ≥ 10 µM in a restriction enzyme buffer 
(e.g. NEB buffer 1).  Heat up to 90-100°C and allow to cool slowly to room 
temperature using the PCR machine or bring to boiling in a water bath and allow 
to cool.  Store in the freezer. 
o When ready to use, dilute to 1-100 fM (1-100 nmol/µl) and use 1 µl in ligation 
reaction. 
 
Ligation Reaction: 
• Use about 200 ng for a new vector, about 50 ng for an already tested/proved vector. 
• Use between 1-5 fold molar excess insert (about 100 ng is good—the insert is often 
around 1/10 the weight of the vector). 
• Set up control samples including vector without insert and insert alone along with your 
samples of vector with (various) inserts. 
• Plan the ligation reaction in 12-20 µL usint ~1 µL T4 DNA Ligase.  Leave at 16°C for 
12-24 hours.  **NOTE: faster ligations are possible at room temperature using fast 
ligation enzymes from NEB.** 
• Use 2-4 µL to transform 25 µL competent DH5α cells. (See method for “Transforming 
Competent E. coli”) 
 
 
Picking colonies, Growing, and Sequencing: 
• If you have 2-fold more colonies on your plates with vector plus insert vs. your vector 
alone sample, your cloning may have worked.  (The higher the ratio, the better chance 
that you got the appropriate ligation.) 
• Pick between 2-10 colonies (including two from the vector alone plate).  Grow 5 mL 
overnight cultures of each colony in LB/selecting agent (e.g. ampicillin). 
• Freeze down a small aliquot of each sample (0.5 mL culture with 0.5 mL autoclaved 30% 
glycerol in LB) and store at -80°C. 
• Do a Qiagen Mini-prep kit to isolate plasmid. 
• Digest about 1 µg of each plasmid (assume about 1 µg plasmid per mL of culture) with 
the cloning enzymes and check on an agarose gel.  You should be able to see your insert 
at the right size.  You may want to also do a digest that cuts in the middle of the insert.  
• If you have clones that look right, Qiagen purify 5-100 µg and send out for DNA 
sequencing. 
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A.4.d SDS-PAGE GEL                                                    
Protocol from Mia Rushe 
 
Procedure: 
 
1. Assemble the gel apparatus, being careful to avoid leakage. 
2. Select the percentage of Separating Gel you would like to pour. (Lower percentage gels 
allow higher molecular weight proteins to separate further.) 
3. Add the ingredients in the order listed—mix well between each step. 
4. After the temed and APS, move quickly, since the acrylamide will try to begin 
polymerizing.  
5. Pour about 2.5-3 mL of acrylamide mixture into the space between the gel plates. 
6. Slowly layer a small amount of water on top of the acrylamide mixture using a syringe.  
The acrylamide polymerizes faster in anaerobic conditions. 
7. Allow the Separating Gel to polymerize for about 45 minutes. 
8. Remove the water layer from the top of the gel by tilting and using a paper towel. 
**Note: if the gel itself moves when you tilt the apparatus, allow it to polymerize for 
longer. 
9. Mix the ingredients for the Stacking Gel (shown below) in order, mixing after each one. 
10. Layer the Stacking Gel mixture on top of the Separating Gel. Fill all the way to the top. 
11. Insert a comb into the stacking gel to create lanes for loading your samples. 
12. Allow the Stacking Gel to polymerize for about 45 minutes.  
13. Remove the comb. 
14. At this point, you can either place the gel into the electrophoresis chamber covered with 
SDS Running Buffer, load samples in 1x SDS Loading Buffer, and run the gel, or you 
can store the gel at 4˚C by wrapping in several soaked paper towels and then surrounding 
it with Saran Wrap. The gel should keep stored this way for a week or two. 
15. After running your samples, disassemble the apparatus and place the gel into Coomassie 
Stain (or use other stain protocol). Allow to shake for >1 hour at room temperature.   
16. Remove the stain and place gel into Destain on shaker. Observe on light box. 
 
SDS-PAGE Gel Recipes: 
Separating Gel 
   7.5%   10%   12.5%   15% 
30% Acrylamide     1 mL   (4) 1.3 mL  (5.2)        1.7 mL  (6.8)      2 mL   (8) 
ddH2O          2 mL   (8) 1.7 mL  (6.8)        1.3 mL  (5.2)      1 mL   (4) 
4x Lower Buffer     1 mL   (4) 1    mL  (4)        1    mL  (4)      1 mL   (4) 
temed          10 µL (40) 10  µL   (40)        10  µL   (40)      10 µL  (40)  
10% APS         20 µL (80) 20  µL   (80)        20  µL   (80)      20 µL  (80) 
 
Stacking Gel 
30% Acrylamide     0.3 mL   (2)  
ddH2O          1.2 mL   (8)  
4x Upper Buffer      0.5 mL   (4)  
temed          5    µL    (20)  
10% APS         20  µL    (80)  
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A.4.d SDS-PAGE GEL                                                    
Protocol from Mia Rushe, 2x SDS Sample Buffer from Alistair Easterfield 
 
Solutions: 
 
4x Lower Buffer   4x Upper Buffer   10x Running Buffer 
181.7 g Tris base   60.6 g Tris base   30.3   g Tris Base 
4.0     g SDS               4.0   g SDS    10.0   g SDS 
Fill to 1L with ddH2O              Fill to 1L with ddH2O   144.0 g glycine 
Adjust pH Æ 8.8              Adjust pH Æ 6.8   Fill to 1L with ddH2O 
          Do Not Adjust pH! 
 
5x Laemlli Load Buffer             Coomassie Blue Stain   Destain 
60     mM Tris, pH 6.8             0.25% CBBR-250   15% Methanol 
100   mM DTT (if reducing)             15%    Methanol   10% Acetic Acid 
1       %    SDS              10%    Acetic Acid     in ddH2O 
10     %    glycerol                  in ddH2O 
0.001% bromophenol blue              **Note: Dissolve CBBR  
    in ddH2O                in Methanol first, then add 
**Freeze in 1 mL aliquots                   acid and water. Filter. 
at –20˚C 
 
2x SDS Sample Buffer 
6.67  g SDS 
20     g Sucrose 
0.3    g Tris base 
1.03  g DTT 
**Note: Dissolve in 80 mL 
ddH2O, pH to 7.5 with HCl, 
then make up to 100 mL 
with ddH2O 
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A.4.e FOLDED DR1 ELISA 
Protocol from Mia Rushe 
 
Procedure: 
1. Coat Immulon IV plate (from Dynex) with 100 µL per well α-DR monoclonal antibody 
LB3.1 or L243, diluted 1:1000 in plain PBS.  Stock is 1.8 mg/mL in PBS, 0.02% NaN3.  
Incubate plate on nutator for 2 hours at 37˚C or overnight at 4˚C. 
2. Wash each well 3 times with PBST Solution. 
3. Block the plate by filling each well to the top with Block Solution. Incubate at least one 
hour on nutator at 37˚C.  The plate can be stored at this point if the Block Solution is 
replaced by Dilution Solution.  Store plates at 4˚C, covered in packing tape and 
surrounded by plastic wrap. 
4. Remove Block Solution or Dilution Solution in stored plates.  Add 50 µL fresh Dilution 
Solution to each well. 
5. Make up standards of folded DR1 in dilution solution.  Make high concentration of 2 
ng/µL as the high concentration, and dilute 1:2 down to 0.002 ng/µL.  Add 50 µL of 
standard per well, giving 100-0.1 ng/well—make sure to do duplicate measurements of 
the standards.  Also, include a blank measurement. 
6. Add samples and diluted samples into wells.  A good way to test most refolding mixes is 
to add 50 µL, 5 µL, and 2.5 µL of sample to give the dilutions, making up the difference 
to 50 µL with dilution solution (0 µL, 45 µL, and 47.5 µL). 
7. Incubate plate on nutator for 1 hour at 37˚C, 2 hours at room temperature, or overnight at 
4˚C. 
8. Carefully wash each plate 3 times with PBST, avoiding spillover from neighboring wells. 
9. Add 100 µL/well of rabbit CHAMP polyclonal α-DR1 antibody diluted 1:25,000 (or 
1:500 of a 1:50 stock solution) in Dilution Solution.  Incubate plate on nutator for 1 hour 
at 37˚C, 2 hours at room temperature, or overnight at 4˚C. 
10. Wash wells 3 times with PBST.  ** Follow Alternate Procedure after this point for 
Europium Staining (following page) 
11. Add 100 µL goat α-rabbit IgG peroxidase (HRP) conjugate (from Roche) diluted 1:4000 
in dilution solution.  No azide should be present at this step, as it inhibits the enzyme.  
Incubate on nutator 0.5-2 hours at room temperature or 37˚C.  **Background increases if 
this step is allowed to sit overnight at 4˚C. 
12. Wash wells 3 times with PBST. 
13. Add 200 µL ABTS Solution to each well. 
14. Read absorbance in ELISA plate reader at 405 nm. 
15. To stop plate from developing, add 50 µL Stopping Solution to each well. 
16. Try several absorbance readings to catch the solutions at the most informative stage of 
developing—before saturation. 
17. Use a 4-parameter curve fit to the standards to determine the MHC class II concentration 
of the samples. 
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A.4.e FOLDED DR1 ELISA—EUROPIUM PROCEDURE 
Protocol from Mia Rushe 
 
Follow steps 1-10 on the previous page—FOLDED DR1 ELISA 
11. Add 100 µL/well of 1:1000 diluted goat α-rabbit Europium conjugate (from Perkin 
Elmer Life Sciences, AD0105).  Incubate on the nutator for 1 hour at 37˚C or 2 hours at 
room temperature. Don’t leave this step overnight, as background will increase. 
12. Wash 5x with PBST. 
13. Add 100 µL/well of DELFIA Assay Buffer (from Perkin Elmer Life Sciences, 1244-
111).  Incubate on nutator for 30 minutes at 37˚C. Meanwhile, thaw DELFIA 
Enhancement Solution (from Perkin Elmer Life Sciences, 1244-105) and allow to reach 
room temperature. 
14. Wash 7x with PBST. 
15. Add 200 µL/well of DELFIA Enhancement Solution and allow to sit at room 
temperature for 15-20 minutes. 
16. Read on Victor 1420 Multilabel Counter using standard Europium protocol. 
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A.4.e FOLDED DR1 ELISA 
Supplies and Solutions--Protocol from Mia Rushe 
 
PBST:    Dilution Solution:   Block Solution: 
   1x PBS       1x PBS     1x PBS 
   0.05% Triton X100      0.3% BSA     3% BSA 
   filter and store at 4˚C     0.1% Triton X-100    0.02% NaN3 
       filter and store at 4˚C   filter and store at 4˚C 
 
ABTS Solution:        Stopping Solution: 
   5 mL 10x ABTS Solution           20% SDS 
       (From Roche—stored at –20˚C, 5mL aliquots)       50% DMF 
   45 mL ddH2O           in ddH2O 
   1 ABTS tablet (Roche)—allow to dissolve completely 
       **unused portion may be stored in dark at 4˚C, ~ 2 weeks 
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A.4.e FOLDED DR1 ELISA 
Data Treatment--Protocol from Mia Rushe 
 
Equations to fit ELISA standards: 
m2
)
m3
x(1
m2m1y
m4
+
+
−=  
 
where m1-m4 are constants that will be fit to the data.  When inputting this fit into Kaleidograph, 
the following format should be used, including guesses for each constant, substituting “m0” for 
“x”, and adding partial derivatives to the fitting algorithm. 
 
In the “General Curve Fit” window, type: 
 
 ((m1-m2)/(1+(m0/m3)^m4))+m2; m1=0.7; m2=0; m3=2; m4=-0.5 
 
In the “dF/dM1” window, type: 
 
 1/(1+(m0/m3)^m4) 
 
In the “dF/dM2” window, type: 
 
 1-(1/(1+(m0/m3)^m4)) 
 
In the “dF/dM3” window, type: 
 
 (m1-m2)*(1+(m0/m3)^m4)^(-2)*(m4*(m0/m3)^(m4-1))*m0/m3^ 2 
 
In the “dF/dM4” window, type: 
 
 (m2-m1)*(1+(m0/m3)^m4)^(-2)*(m0/m3)^m4*ln(m0/m3) 
 
Sample ELISA standards curve fit: 
0.1
0.2
0.3
0.4
0.5
0.6
0.001 0.01 0.1 1 10 100
DR1 ELISA 10-5-01 Standards
Reading 2:29 PM
Avg Abs
A
bs
or
ba
nc
e 
40
5n
m
ng DR1 per well
y = ((m1-m2)/(1+(m0/m3)^m4))...
ErrorValue
0.011420.53583m1 
0.00870210.16082m2 
0.355243.9167m3 
0.25378-1.7738m4 
NA0.0022776Chisq
NA0.99622R
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A.4.f WESTERN BLOT—ALKALINE PHOSPHATASE DETECTION 
Procedure from L. Stern 
 
**Note: This procedure will detect human DR1 proteins.  If using another protein, the antibodies 
used will vary, but the procedure should still work. 
 
Run an SDS gel using pre-stained molecular weight markers with two copies of each lane 
(including the markers).  The duplicates should be arranged so you can cut the gel in half and get 
identical lanes on each half.  
 
After running the gel, cut off part of the loading gel so that only nubs from the comb region 
remain. 
 
Wet a gel-sized rectangle of transfer membrane with 70% EtOH. 
 
Soak the membrane and 6 gel-sized rectangles of filter paper in transfer buffer. 
 
Place the transfer membrane flat on the gel.  Remove any bubbles gently.   
 
Sandwich the transfer membrane and the gel between the filter paper rectangles soaked in 
Transfer Buffer—3 sheets on each side.  Remember which side has the transfer membrane! 
 
Place the sandwich flat on the blotter with the membrane on the cathode (+) side, and the gel on 
the anode (-) side.  Once again, gently remove any bubbles.   
 
Close the blotter and use screws to create even, light pressure between the plates.  Do not over 
tighten screws.   
 
Run the blotter at constant amperage: 400mamps for about ½ hour, or until most of the protein is 
transferred from the gel to the membrane (watch the pre-stained MW markers).  When it is done, 
turn off the power source and open the blotter. 
 
Remove the gel and the membrane from the blotter.  Cut the transfer membrane into the 2 
identical halves. 
 
Place ½ of the membrane into Coomassie stain in a clean petri dish. 
 
Place the other ½ of the membrane into Block Solution in a clean petri dish.  Leave both on a 
shaker table at room temperature for 1 hour to overnight. 
 
Place the membrane from the Coomassie into 50% methanol or isopropanol and 50% normal gel 
de-stain.  Leave this membrane on the shaker table at room temperature, changing the de-stain 
mixture periodically, until it has de-stained properly.  **This may take a long time! 
 
Rinse the membrane in the Block Solution with TBST.   
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Add a 1:25,000 dilution of Champ in TBST to the petri dish and membrane.  Leave on the shaker 
table for 1 hour at room temperature. 
 
Wash WELL with TBST—4 times, 5 minutes each on the shaker table. 
 
Add a 1:1000 dilution of anti-rabbit polyclonal antibody linked to alkaline phosphatase in TBST 
to the petri dish and membrane.  Leave on the shaker table at room temperature for ½ hour. 
 
Wash WELL with TBST—4 times, 5 minutes each on the shaker table. 
 
Add 10 mL Alkaline Phosphatase Buffer with 70 µL NBT and 70 µL BCIP.  The color should 
begin to develop on the membrane almost immediately.  **Do not overdevelop! 
 
Stop the reaction by rinsing with ddH2O.  Enjoy! 
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A.4.f WESTERN BLOT—ALKALINE PHOSPHATASE DETECTION 
Procedure from L. Stern 
 
Solutions/Materials: 
 
70% EtOH   SDS gel and equipment  Filter paper 
Coomassie Stain  Clean petri dishes   Methanol/Isopropanol 
De-stain   Blotter/power supply   Shaker table 
NBT stock   BCIP stock 
 
Transfer Buffer:     Transfer Membrane: 
 50 mM CAPS, pH 11.0    Millipore Immobilon-P Transfer 
 20% MeOH      membranes,  IPUH 304 FO 
 
TBST:       Block Solution: 
 50 mM Tris, pH 7.5     3% BSA 
150 mM NaCl      0.02% NaN3   
0.1% Tween-20     in 1 x PBS 
 
Alkaline Phosphatase Buffer: 
 100 mM Tris, pH 9.0-9.5 
 100 mM NaCl 
 5 mM MgCl2  
 
 
Antibodies for HLA-DR1 detection: 
 
CHAMP – rabbit anti-HLA-DR1 polyclonal antibody serum.  Use at 1:25,000 dilution 
 
Anti-Rabbit Polyclonal linked to Alkaline Phosphatase enzyme 
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A.4.g WESTERN BLOT—ECL DETECTION 
Procedure from Alistair Easterfield 
 
1. Run an SDS gel using pre-stained molecular weight markers.  
2. After running the gel, cut off part of the loading gel so that only nubs from the comb 
region remain. 
3. Wet a gel-sized rectangle of transfer membrane with 70% EtOH. 
4. Soak the membrane and 6 gel-sized rectangles of filter paper in transfer buffer. 
5. Place the transfer membrane flat on the gel.  Remove any bubbles gently.   
6. Sandwich the transfer membrane and the gel between the filter paper rectangles soaked in 
Transfer Buffer—3 sheets on each side.  Remember which side has the transfer 
membrane! 
7. Place the sandwich flat on the blotter with the membrane on the cathode (+) side (up), 
and the gel on the anode (-) side (down).  Once again, gently remove any bubbles.   
8. Close the blotter and use screws to create even, light pressure between the plates.  Do not 
over tighten screws.   
9. Run the blotter at constant amperage: 400mamps for about 25-30 minutes, or until most 
of the protein is transferred from the gel to the membrane (watch the pre-stained MW 
markers).  When it is done, turn off the power source and open the blotter. 
10. Remove the gel and the membrane from the blotter. 
11. Place the membrane into freshly-made Block Solution (5% dry milk, 0.1% Tween-20 in 
1x PBS) in a clean petri dish.  Leave on a shaker table at room temperature for 1 hour to 
overnight. 
12. Rinse the membrane in the Block Solution with TBST.   
13. Add your primary antibody at an appropriate dilution in dilution solution.  Leave on the 
shaker table at room temperature for 2 hours to overnight. 
14. Wash WELL with TBST—4 times, 5 minutes each on the shaker table. 
15. Add your secondary antibody at an appropriate dilution in dilution solution.  Leave on the 
shaker table at room temperature for ½ hour. 
16. Wash WELL with TBST—6 times, 5 minutes each on the shaker table. 
17. Add freshly-prepared ECL detection solution (4-10 mL, 1:1 mixture of supplied 
reagents).  Incubate for 1-3 minutes in this solution, and then drain excess, tapping corner 
on a paper towel. 
18. Sandwich the membrane between 2 sheets of transparency film, cut to size. Remove any 
bubbles carefully. 
 
PERFORM FOLLOWING IN DARK ROOM WITH SAFETY RED LIGHT ON ONLY!! 
 
19. Open film box and remove one sheet. Mark the sheet so you can tell the orientation in 
which you use it (i.e. clip one corner). DO NOT TRY TO DEVELOP THE 
CARDBOARD! Make sure the package with the film is closed again when you have 
removed your sheet. 
20. Lay the film and the membrane in an ECL development cartridge in defined spots for 
pre-set periods of time, i.e. 10 seconds, 1 minute, 2 minutes, 5 minutes, 20 minutes, 1 
hour.  Move the membrane between each exposure. DO NOT TURN THE LIGHT ON 
DURING THIS TIME!! 
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21. Replace the film in the package and close it again. You may then turn on the light, 
making sure to turn off the safety red light. 
TAKE THE EXPOSED FILM TO ROOM S5-126. SIGN UP ON SHEET, THEN ENTER 
DARK ROOM. 
 
22. Take the film in the closed box to the development room. TURN ON THE SAFETY 
RED LIGHT AND TURN OFF THE WHITE LIGHT!! 
23. Remove your film and place it into the developer with the long side of the film along the 
left side of the tray.  Push it all the way forward and the rollers should pull it in.  If not, 
try turning the machine off and on several times. 
24. Once the film is completely within the developer, a beep will sound, indicating you can 
place your next film in OR turn on the white light. 
25. Before leaving the dark room, turn on the white light and turn off the red light. 
26. Your developed films will appear right outside the dark room on the developer tray. 
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A.4.g WESTERN BLOT—ECL DETECTION 
Procedure from Alistair Easterfield 
 
 
Solutions/Materials: 
 
70% EtOH   SDS gel and equipment  Filter paper 
Immobilon Membrane Clean petri dishes   Methanol/Isopropanol 
Antibodies   Blotter/power supply   Shaker table 
Dilution Solution  TBST     Block Solution 
ECL Reagents   BioMax XAR film   Light-blocking cartridge 
Transparency film 
 
Transfer Buffer:     Transfer Membrane: 
 50 mM CAPS, pH 11.0    Millipore Immobilon-P Transfer 
 20% MeOH      membranes,  IPUH 304 FO 
 
TBST:       Block Solution: 
 50 mM Tris, pH 7.5     5% Non-Fat Dry Milk 
150 mM NaCl      0.1% Tween-20   
0.1% Tween-20     in 1 x PBS 
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A.4.h DETERMINATION OF APPARENT MOLECULAR WEIGHT FROM SIZE 
EXCLUSION CHROMATOGRAPHY 
 
Procedure: 
1. Run molecular weight standards (Bio-rad) containing thyroglobulin (670 kDa), γ-globulin 
(158 kDa), ovalbumin (44 kDa), and myoglobin (17 kDa) under the same conditions as 
you would your sample. 
2. Run the samples of interest. **NOTE: if you take the column off the HPLC for any 
reason, or introduce air in to the lines you cannot compare the samples or the standard 
curve and need to start over.** 
3. Determine the elution volume (mL) of the peak for both your standards and samples. 
4. For the standards, make a plot of elution volume versus log MW. 
5. Determine the log MW for the samples by linear regression, and convert to MW to obtain 
the apparent molecular weight (MWapp).   
 
 
Sample standard curve for Bio-Rad molecular weight markers 
 
4
4.5
5
5.5
6
15 20 25 30
y = 7.7059 - 0.11865x   R= 0.99991 
Elution volume (ml)
thyroglobulin 
γ-globulin 
ovalbumin
myoglobin 
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A.4.i HYDRODYNAMIC CALCULATIONS FOR MHC OLIGOMERS 
from J. A. Zarutskie  
Calculations may be found in: 
Zarutskie et. al. (1999) A conformational change in the human major histocompatibility  
complex protein HLA-DR1 induced by peptide binding. Biochemistry 38:5878-87  
 
Calculations: 
The partial specific volume of DR1-Ha was calculated as the weighted average of the partial 
specific volumes of the amino acids composing DR1-Ha.   
 
The hydrated volume VH of DR1-Ha was calculated using the equation: 
 
N
hydVMW
V waterproteinpsappH
))*(( ρ+=  
 
where MWapp is the apparent molecular weight of the protein, Vps is the partial specific volume 
(0.736 cm3/g), hydprotein is the estimated extent of hydration of the protein (0.35 g of water/g of 
protein), ρwater is the density of water at 20 °C (0.998 g/cm3), and N is Avogadro's number (6.02 
x 1023).  **NOTE: There is an error in this equation in the reference cited above (Zarutskie et. 
al., 1999).** 
 
The Stokes radius, Rs, was calculated using the hydrated volume, VH: 
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where f/fo is the frictional coefficient, a measure of how much the protein's shape deviates from a 
sphere.  From the DR1-Ha crystal structure, the monomer can be approximated as a prolate 
ellipsoid with a 76 Å major axis and a 38 Å minor axis, for an axial ratio of p ~2. The frictional 
efficient was calculated as follows: 
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Using the calculated frictional coefficient (1.044), the Stokes radius of the DR1-Ha monomer in 
the crystal structure was calculated to be 27.9 Å.  
 
For the crystallographic DR1-Ha dimer (assuming a spherical model), Jennifer Zarutskie 
calculated an axial rato if 1.04, a frictional coefficient of 1.00, and a Rs of 34.2 Å.    
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A.4.j FREEZING CELLS (PBMC’s, T cells, B cells) 
Procedure from T. Cameron and J. Ogrodnick-Cochran 
 
Prepare suspension media and freezing media as specified below and cool to 4°C. 
 
Spin cells down at 2000 RPM for 10 minutes and aspirate supernatant.   
 
Suspend cells to 1 x 10-7 cells/ml in cold suspension media.   
 
Aliquot into cryovials kept on ice (~0.5 ml/vial).   
 
Add an equal volume dropwise (~0.5 ml/vial) cold freezing media into each vial and mix.   
 
Place in Styrofoam and keep in –70°C freezer overnight.   
 
Move into liquid nitrogen cell dewar within 24 hours. 
 
Suspension Media:    Freezing Media: 
 20-50% Serum (human for PBMC’s)  20-50% Serum (human for PBMC’s) 
 in RPMI Media    14-20% Dimethyl Sulfoxide (DMSO) 
       in RPMI Media 
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A.4.k FREEZING BACTERIA (E. coli) 
Procedure from T. Kiziltepe 
 
Prepare freezing media as specified below. 
 
Grow cells in liquid culture as usual to OD600 ~0.7-1.0.   
 
Add 0.5 ml liquid culture to cryovials and mix with 0.5 ml freezing media.   
 
Keep in –70°C freezer.   
 
Freezing Media: 
 30% Glycerol  
 in 1x LB Media 
 AUTOCLAVE and cool completely before use 
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A.4.l MAKING UREA SOLUTIONS 
Protocol from Mia Rushe 
 
Procedure: 
 
1. Add concentrated buffer stock solution, any additives (such as EDTA or NaCl), and dry 
urea (FW = 60.06).  Add ddH2O to an appropriate volume to make 8 M Urea. 
2. Stir slowly—you can warm in a bucket of water, but do not warm too quickly or too 
much. 
3. After urea is dissolved, add Sigma mixed bed resin TMD-8, ½ teaspoon at a time until 
the beads stop turning yellow in the solution (i.e. there are a lot of blue beads). 
4. Stir slowly another 10 minutes, and then let the beads settle. 
5. Filter using a 0.2 µm membrane. 
6. Store at –20˚C if you are not going to use immediately. 
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A.4.m STOCK SOLUTIONS AND BUFFERS 
Keep a supply filtered to use in making other solutions  
Add ddH2O to 1 L for recipes unless otherwise indicated 
 
1 M Tris, pH 8.0   1 M Tris, pH 8.5   1 M Tris, pH 9.0 
40.46   g Tris Base   74.26 g Tris Base   101.03 g Tris Base 
104.95 g Tris-HCl   60.99 g Tris-HCl   18.28   g Tris-HCl 
 
10 x PBS    20 % NaN3    0.5 M EDTA 
80    g NaCl    200 g Sodium Azide   168.1 g EDTA 
2      g KCl         NaOH pellets (~ 20) 
11.5 g Na2HPO4          to pH 8.0-8.5 
2      g KH2PO4  
 
5 M NaCl    1 N NaOH    10 % SDS 
292.2 g NaCl    40 g NaOH pellets   100 g SDS 
       (very hygroscopic) 
 
4 M MgCl2    20 % glucose (sterile)   LB broth (sterile) 
381.2 g MgCl2   200 g glucose    10 g tryptone digest 
5   g yeast extract 
10 g NaCl 
 
Ethidium Bromide   NBT—freeze –20˚C   BCIP—freeze –20˚C 
1 g ethidium bromide   0.5 g nitro blue    0.5 g 5-bromo-4- 
** in 100 mL ddH2O      tetrazolium chloride      chloro-3-indolyl 
     ** in 10 mL 70% DMF     phosphate disodium 
          ** in 10 mL DMF 
 
5 mM DTT    8 M Urea—freeze, -20˚C 
0.77 g DTT    480.48 g urea 
(FW = 154.04)  
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Gene Construct HLA-DR1 AS (α chain, short) and AL (α chain, long) 
Plasmid Full length in pHN1 (T7 promoter) called pDRA10 
Short version in pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Mia Rushe in Larry Stern’s lab 
Sites used for 
cloning 
EcoRI and HindIII 
Insert size ~580bp AS, ~600bp AL 
For production in E. coli BL21 
Induce with IPTG 
Gene Sequence gaattcaggaggaatttaaaatgATCAAAGAAGAACATGTGATCATCCAGGCCGAGTTC 
TATCTGAATCCTGACCAATCAGGCGAGTTTATGTTTGACTTTGATGGTGATGAGATTTTC 
CATGTGGATATGGCAAAGAAGGAGACGGTCTGGCGGCTTGAAGAATTTGGACGATTTGCC 
AGCTTTGAGGCTCAAGGTGCATTGGCCAACATAGCTGTGGACAAAGCCAACTTGGAAATC 
ATGACAAAGCGCTCCAACTATACTCCGATCACCAATGTACCTCCAGAGGTAACTGTGCTC 
ACGAACAGCCCTGTGGAACTGAGAGAGCCCAACGTCCTCATCTGTTTCATCGACAAGTTC 
ACCCCACCAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAACCTGTCACCACAGGAGTG 
TCAGAGACAGTCTTCCTGCCCAGGGAAGACCACCTTTTCCGCAAGTTCCACTATCTCCCC 
TTCCTGCCCTCAACTGAGGACGTTTACGACTGCAGGGTGGAGCACTGGGGCTTGGATGAG
short: 
CCTCTTCTCAAGCACTGGGAGTTTGATGCTtaaaagctt 
long: 
CCTCTTCTCAAGCACTGGGAGTTTGATGCTCCAAGCCCTCTCCCAGAGACTACAGAGAAC 
taaaagctt 
Protein Sequence iqeefkMIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFAS 
FEAQGALANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFIDKFT 
PPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDE 
short: 
PLLKHWEFDAEND 
long: 
PLLKHWEFDAPSPLPETTENEND 
Protein MW AS: 21,264;  AL: 22,330 Da 
Protein pI AS: 4.75;  AL: 4.67 
Protein extinction 
coefficient 
28,000 at 280nm (unfolded) 
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Gene Construct HLA-DR1 ACS (α chain, short) and ACL (α chain, long) 
Uniquely reactive cysteine at C-terminus of protein chain 
Plasmid pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Jody Lubetsky in Larry Stern’s Lab 
Sites used for 
cloning 
EcoRI and HindIII 
Insert size ~580bp ACS, ~600bp ACL 
For production in E. coli BL21 
Induce with IPTG 
Gene Sequence xgaattcaggaggaatttaaaatgATCAAAGAAGAACATGTGATCATCCAGGCCGAGTTC 
TATCTGAATCCTGACCAATCAGGCGAGTTTATGTTTGACTTTGATGGTGATGAGATTTTC 
CATGTGGATATGGCAAAGAAGGAGACGGTCTGGCGGCTTGAAGAATTTGGACGATTTGCC 
AGCTTTGAGGCTCAAGGTGCATTGGCCAACATAGCTGTGGACAAAGCCAACTTGGAAATC 
ATGACAAAGCGCTCCAACTATACTCCGATCACCAATGTACCTCCAGAGGTAACTGTGCTC 
ACGAACAGCCCTGTGGAACTGAGAGAGCCCAACGTCCTCATCTGTTTCATCGACAAGTTC 
ACCCCACCAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAACCTGTCACCACAGGAGTG 
TCAGAGACAGTCTTCCTGCCCAGGGAAGACCACCTTTTCCGCAAGTTCCACTATCTCCCC 
TTCCTGCCCTCAACTGAGGACGTTTACGACTGCAGGGTGGAGCACTGGGGCTTGGATGAG 
short: 
CCTCTTCTCAAGCACTGGGAGTTTGATGCATGCTAAaagctt 
long: 
CCTCTTCTCAAGCACTGGGAGTTTGATGCTCCAAGCCCTCTCCCAGAGACTACAGAGAAC 
gcatgctaaaagctt 
Protein Sequence iqeefkMIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFAS 
FEAQGALANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFIDKFT 
PPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDE 
short: 
PLLKHWEFDACEND 
long: 
PLLKHWEFDAPSPLPETTENACEND 
Protein MW ACS: 21,367;  ACL: 22,504 Da 
Protein pI ACS: 4.75;  ACL: 4.67 
Protein extinction 
coefficient 
28,000 at 280nm (unfolded) 
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Gene Construct HLA-DR1 AL (α chain, long) 
Also called plasmid #196 
Plasmid pRMHA-3 (metallothionine promoter) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Made by Elizabeth Mellins at Stanford University 
Sites used for 
cloning 
BamHI symmetrically (new EcoRI site in sequence) 
Insert size ~670bp AL 
For production in S2 Drosophila cells 
Induce with CuSO4 
Gene Sequence GGATCCTATAAATATGGCCATAAGTGGAGTCCCTGTGCTAGGATTTTTCATCATAGCTGT
GCTGATGAGCGCTCAGGAATCATGGGCTATCAAAGAAGAACATGTGATCATCCAGGCCGA
GTTCTATCTGAATCCTGACCAATCAGGCGAGTTTATGTTTGACTTTGATGGTGATGAGAT
TTTCCATGTGGATATGGCAAAGAAGGAGACGGTCTGGCGGCTTGAAGAATTTGGACGATT
TGCCAGCTTTGAGGCTCAAGGTGCATTGGCCAACATAGCTGTGGACAAAGCCAACTTGGA
AATCATGACAAAGCGCTCCAACTATACTCCGATCACCAATGTACCTCCAGAGGTAACTGT
GCTCACGAACAGCCCTGTGGAACTGAGAGAGCCCAACGTCCTCATCTGTTTCATCGACAA
GTTCACCCCACCAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAACCTGTCACCACAGG
AGTGTCAGAGACAGTCTTCCTGCCCAGGGAAGACCACCTTTTCCGCAAGTTCCACTATCT
CCCCTTCCTGCCCTCAACTGAGGACGTTTACGACTGCAGGGTGGAGCACTGGGGCTTGGA
TGAGCCTCTTCTCAAGCAtTGGGAaTTcGATGCTCCAAGCCCTCTCCCAGAGACTACAGA
GAACtaaGGATCC 
Protein Sequence dpinMAISGVPVLGFFIIAVLMSAQESWAIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEI 
FHVDMAKKETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPITNVPPEVTV 
LTNSPVELREPNVLICFIDKFTPPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYL 
PFLPSTEDVYDCRVEHWGLDEPLLKHWEFDAPSPLPETTENENDgs 
Protein MW AL: 24,819 Da 
Protein pI AL: 4.63 
Protein extinction 
coefficient 
33,690 at 280nm (unfolded) 
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Gene Construct HLA-DR1 ACL (α chain, long) 
Also called X16-3 
Plasmid pRMHA-3 (metallothionine promoter) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Made by Tom Cameron in Larry Stern’s Lab 
Sites used for 
cloning 
EcoRI (? may be BamHI) to BamHI (new EcoRI site in sequence) 
Insert size ~680bp ACL 
For production in S2 Drosophila cells 
Induce with CuSO4 
Gene Sequence gaattctataaatATGGCCATAAGTGGAGTCCCTGTGCTAGGATTTTTCATCATAGCTGT
GCTGATGAGCGCTCAGGAATCATGGGCTATCAAAGAAGAACATGTGATCATCCAGGCCGA
GTTCTATCTGAATCCTGACCAATCAGGCGAGTTTATGTTTGACTTTGATGGTGATGAGAT
TTTCCATGTGGATATGGCAAAGAAGGAGACGGTCTGGCGGCTTGAAGAATTTGGACGATT
TGCCAGCTTTGAGGCTCAAGGTGCATTGGCCAACATAGCTGTGGACAAAGCCAACTTGGA
AATCATGACAAAGCGCTCCAACTATACTCCGATCACCAATGTACCTCCAGAGGTAACTGT
GCTCACGAACAGCCCTGTGGAACTGAGAGAGCCCAACGTCCTCATCTGTTTCATCGACAA
GTTCACCCCACCAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAACCTGTCACCACAGG
AGTGTCAGAGACAGTCTTCCTGCCCAGGGAAGACCACCTTTTCCGCAAGTTCCACTATCT
CCCCTTCCTGCCCTCAACTGAGGACGTTTACGACTGCAGGGTGGAGCACTGGGGCTTGGA
TGAGCCTCTTCTCAAGCAtTGGGAaTTcGATGCTCCAAGCCCTCTCCCAGAGACTACAGA
GAACCAACCTGCATGCtaaGGATCC 
(underlined sequence is uncertain) 
Protein Sequence dpinMAISGVPVLGFFIIAVLMSAQESWAIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEI 
FHVDMAKKETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPITNVPPEVTV 
LTNSPVELREPNVLICFIDKFTPPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYL 
PFLPSTEDVYDCRVEHWGLDEPLLKHWEFDAPSPLPETTENQPACENDgs 
Protein MW ACL: 25,218 Da 
Protein pI ACL: 4.63 
Protein extinction 
coefficient 
33,690 at 280nm (unfolded) 
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Gene 
Construct 
HLA-DR1 B1S (β chain, short) and B1L (β chain, long) 
Plasmid Full length in pHN1 (T7 promoter) called pDRB10 
Short version in pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Mia Rushe in Larry Stern’s Lab 
Sites used 
for cloning 
EcoRI and HindIII 
Insert size ~600bp B1S, ~620bp B1L 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
xgaattcaggaggaatttaaaatgGGGGACACCCGACCACGTTTCTTGTGGCAGCTTAAG 
TTTGAATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGCTGGAAAGATGCATCTAT 
AACCAAGAGGAGTCCGTGCGCTTCGACAGCGACGTGGGGGAGTACCGGGCGGTGACGGAG 
CTGGGGCGGCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCCTGGAGCAGAGGCGG 
GCCGCGGTGGACACCTACTGCAGACACAACTACGGGGTTGGTGAGAGCTTCACAGTGCAG 
CGGCGAGTTGAGCCTAAGGTGACTGTGTATCCTTCAAAGACCCAGCCCCTGCAGCACCAC 
AACCTCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAGGCAGCATTGAAGTCAGGTGGTTC 
CGGAACGGCCAGGAAGAGAAGGCTGGGGTGGTGTCCACAGGCCTGATCCAGAATGGAGAT 
TGGACCTTCCAGACCCTGGTGATGCTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACACC 
short: 
TGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGAGAGCAtaaaagctt
long: 
TGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGAGAGCACGGTCT 
GAATCTGCACAGAGCAAGtaaaagctt 
Protein 
Sequence 
iqeefkMGDTRPRFLWQLKFECHFFNGTERVRLLERCIYNQEESVRFDSDVGEYRAVTELGRP 
DAEYWNSQKDLLEQRRAAVDTYCRHNYGVGESFTVQRRVEPKVTVYPSKTQPLQHHNLLVCSV 
SGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTS 
short: 
PLTVEWRAEND 
long: 
PLTVEWRARSESAQSKEND 
Protein 
MW 
B1S: 22,185;  B1L: 23,059 Da 
Protein pI B1S: 5.98;  B1L: 6.23 
Protein 
extinction 
coefficient 
38,930 at 280nm (unfolded) 
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Gene 
Construct 
HLA-DR1 BCS (β chain, short) and BCL (β chain, long) 
Uniquely reactive cysteine at C-terminus of protein chain 
Plasmid Full length in pHN1 (T7 promoter) called pDRB10 
Short version in pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Jody Lubetsky in Larry Stern’s Lab 
Sites used 
for cloning 
EcoRI and HindIII 
Insert size ~600bp BCS, ~625bp BCL 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
xgaattcaggaggaatttaaaatgGGGGACACCCGACCACGTTTCTTGTGGCAGCTTAAG 
TTTGAATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGCTGGAAAGATGCATCTAT 
AACCAAGAGGAGTCCGTGCGCTTCGACAGCGACGTGGGGGAGTACCGGGCGGTGACGGAG 
CTGGGGCGGCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCCTGGAGCAGAGGCGG 
GCCGCGGTGGACACCTACTGCAGACACAACTACGGGGTTGGTGAGAGCTTCACAGTGCAG 
CGGCGAGTTGAGCCTAAGGTGACTGTGTATCCTTCAAAGACCCAGCCCCTGCAGCACCAC
AACCTCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAGGCAGCATTGAAGTCAGGTGGTTC 
CGGAACGGCCAGGAAGAGAAGGCTGGGGTGGTGTCCACAGGCCTGATCCAGAATGGAGAT 
TGGACCTTCCAGACCCTGGTGATGCTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACACC
short: 
TGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGAGAGCATGCTAA
aagctt  
long: 
TGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGAGAGCACGGTCT 
GAATCTGCACAGAGCAAGgcatgctaaaagctt 
Protein 
Sequence 
iqeefkMGDTRPRFLWQLKFECHFFNGTERVRLLERCIYNQEESVRFDSDVGEYRAVTEL 
GRPDAEYWNSQKDLLEQRRAAVDTYCRHNYGVGESFTVQRRVEPKVTVYPSKTQPLQHHN 
LLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTC 
short: 
QVEHPSVTSPLTVEWRACEND  
long: 
QVEHPSVTSPLTVEWRARSESAQSKACEND 
Protein 
MW 
BCS: 22,288;  BCL: 23,233 Da 
Protein pI BCS: 5.98;  BCL: 6.23  
Protein 
extinction 
coefficient 
39,050 at 280nm (unfolded) 
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Gene 
Construct 
HLA-DR1 Ha-B1S (Ha peptide: “KYVKQNTLKLAT” and linker at the 
N-terminus of the β chain, short)  
Plasmid pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by J. Stone based on Souheil Younes’ construct 
Sites used 
for cloning 
XbaI and HindIII 
(peptide cloned into MluI, SpeI site in the linker, MaeII site after linker, 
spliced from Souheil Younes’ construct into B1S at NsiI site) 
Insert size ~710bp Ha-B1S 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
tctagaaataattttgttgaattgctgagcaggaggaatttaaaATGGGGGACACGCGTG
TCAAGTATGTCAAACAGAATACCCTAAAACTGGCGACGCGTGGAGGTGGAGGCTCACTAG
TGGGAGGTGGCTCTGGTGGTGGTGGTTCGCGTCCACGTTTCTTGTGGCAGCTTAAGTTTG
AATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGCTGGAAAGATGCATCTATAACC
AAGAGGAGTCCGTGCGCTTCGACAGCGACGTGGGGGAGTACCGGGCGGTGACGGAGCTGG
GGCGGCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCCTGGAGCAGAGGCGGGCCG
CGGTGGACACCTACTGCAGACACAACTACGGGGTTGGTGAGAGCTTCACAGTGCAGCGGC
GAGTTGAGCCTAAGGTGACTGTGTATCCTTCAAAGACCCAGCCCCTGCAGCACCACAACC
TCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAGGCAGCATTGAAGTCAGGTGGTTCCGGA
ACGGCCAGGAAGAGAAGGCTGGGGTGGTGTCCACAGGCCTGATCCAGAATGGAGATTGGA
CCTTCCAGACCCTGGTGATGCTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACACCTGCC
AAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGAGAGCAtaaaagctt 
Protein 
Sequence 
k-fc-iaeqeefkMGDTRVKYVKQNTLKLATRGGGGSLVGGGSGGGGSRPRFLWQLKFEC 
HFFNGTERVRLLERCIYNQEESVRFDSDVGEYRAVTELGRPDAEYWNSQKDLLEQRRAAV 
DTYCRHNYGVGESFTVQRRVEPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNG 
QEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRAENDkl
Protein 
MW 
Ha-B1S: 25,086 Da 
Protein pI Ha-B1S: 8.26 ** very high—no refolding at normal DR1 conditions 
Protein 
extinction 
coefficient 
40,210 at 280nm (unfolded) 
Notes No refolding seen under normal refolding conditions for DR1-pep from 
E.coli.  Perhaps pH must be raised due to very high pI 
 
 247
 
Gene Construct HLA-DR1 B1L (β chain, long) 
Also called plasmid #197 
Plasmid pRMHA-3 (metallothionine promoter) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Made by Elizabeth Mellins at Stanford University 
Sites used for 
cloning 
BamHI symmetrically 
Insert size ~700bp BCL 
For production in S2 Drosophila cells 
Induce with CuSO4 
Gene Sequence GGATCCTATAAATATGGTGTGTCTGAAGCTCCCTGGAGGCTCCTGCATGACAGCGCTGAC
AGTGACACTGATGGTGCTGAGCTCCCCACTGGCTTTGGCTGGGGACACCCGACCACGTTT
CTTGTGGCAGCTTAAGTTTGAATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGCT
GGAAAGATGCATCTATAACCAAGAGGAGTCCGTGCGCTTCGACAGCGACGTGGGGGAGTA
CCGGGCGGTGACGGAGCTGGGGCGGCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCT
CCTGGAGCAGAGGCGGGCCGCGGTGGACACCTACTGCAGACACAACTACGGGGTTGGTGA
GAGCTTCACAGTGCAGCGGCGAGTTGAGCCTAAGGTGACTGTGTATCCTTCAAAGACCCA
GCCCCTGCAGCACCACAACCTCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAGGCAGCAT
TGAAGTCAGGTGGTTCCGGAACGGCCAGGAAGAGAAGGCTGGGGTGGTGTCCACAGGCCT
GATCCAGAATGGAGATTGGACCTTCCAGACCCTGGTGATGCTGGAAACAGTTCCTCGGAG
TGGAGAGGTTTACACCTGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGA
ATGGAGAGCACGGTCTGAATCTGCACAGAGCAAGtaaGGATCC 
Protein Sequence dpinMVCLKLPGGSCMTALTVTLMVLSSPLALAGDTRPRFLWQLKFECHFFNGTERVRLL 
ERCIYNQEESVRFDSDVGEYRAVTELGRPDAEYWNSQKDLLEQRRAAVDTYCRHNYGVGE 
SFTVQRRVEPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGL 
IQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKENDgs 
Protein MW B1L: 25,831 Da 
Protein pI B1L: 6.53 
Protein extinction 
coefficient 
39,050 at 280nm (unfolded) 
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Gene 
Construct 
HLA-DR1 HaB (Ha peptide: “KYVKQNTLKLAT” and linker at the N-
terminus of the β chain, long) 
Plasmid pRMHA-3 (metallothionine promoter) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Made by J. Stone 
Sites used 
for cloning 
Cloned from upstream HindIII in promoter from pCVDR1-Ha plasmid to 
NsiI (ATGCAT) site in plasmid #197 (β in pRMHA-3).  BamHI 
(GGATCC) downstream. SacI (GAGCTC) in signal sequence, MluI 
(ACGCGT) before and after peptide. 
For 
production 
in 
S2 Drosophila cells 
Induce with CuSO4 
Gene 
Sequence 
ggtcctgtcctgttctccagcATGGTGTGTtTGAAGCTCCtTGGAGGCTCCTGCAT 
GACAGCGCTGACAGTGACACtGATGGTGCTGAGCTCCCCACTGGCTTTGGCTGGGG 
ACACGCGTGTCAAGTATGTCAAACAGAATACCCTAAAACTGGCGACGCGTGGAGGT 
GGAGGCTCACTAGTGGGAGGTGGCTCTGGTGGTGGTGGTTCGCGTCCACGTTTCTT 
GTGGCAGCTTAAGTTTGAATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGC 
TGGAAAGATGCATCTATAACCAAGAGGAGTCCGTGCGCTTCGACAGCGACGTGGGG 
GAGTACCGGGCGGTGACGGAGCTGGGGCGGCCTGATGCCGAGTACTGGAACAGCCA 
GAAGGACCTCCTGGAGCAGAGGCGGGCCGCGGTGGACACCTACTGCAGACACAACT 
ACGGGGTTGGTGAGAGCTTCACAGTGCAGCGGCGAGTTGAGCCTAAGGTGACTGTG 
TATCCTTCAAAGACCCAGCCCCTGCAGCACCACAACCTCCTGGTCTGCTCTGTGAG 
TGGTTTCTATCCAGGCAGCATTGAAGTCAGGTGGTTCCGGAACGGCCAGGAAGAGA 
AGGCTGGGGTGGTGTCCACAGGCCTGATCCAGAATGGAGATTGGACCTTCCAGACC 
CTGGTGATGCTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACACCTGCCAAGTGGA 
GCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGAGAGCACGGTCTGAATCTG 
CACAGAGCAAGtaaGGATCC 
Protein 
Sequence 
signal sequence, cleaved: 
gpvlfssMVCLKLLGGSCMTALTVTLMVLSSPLALA 
final protein sequence: 
GDTRVKYVKQNTLKLATRGGGGSLVGGGSGGGGSRPRFLWQLKFECHFFNGTERV 
RLLERCIYNQEESVRFDSDVGEYRAVTELGRPDAEYWNSQKDLLEQRRAAVDTYCRHNYG
VGESFTVQRRVEPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVS
TGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKENDgs 
Protein 
MW 
Ha-B: 25,829 Da 
Protein pI Ha-B: 8.59 
Protein 
extinction 
coefficient 
40,210 at 280nm (unfolded) 
Notes Since this was cloned very far upstream, and multiple attempts at 
sequencing have yielded poor results, the upstream sequence (toward the 
promoter and HindIII site) is uncertain.  It looks to be different than the 
pRMHA-3 construct, but I’m not sure how far it is different—could just 
be the polyclonal site.  However, the resulting protein is able to bind to 
LB3.1 antibody and can activate DR1-Ha specific T cells and hybridomas. 
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Gene 
Construct 
HLA-DR1 HA3MB (HA3M peptide: “KYVKQATLALAA” and linker at 
the N-terminus of the β chain, long) 
Plasmid pRMHA-3 (metallothionine promoter) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Made by J. Stone 
Sites used 
for cloning 
Cloned from upstream HindIII in promoter from pCVDR1-HA3M plasmid 
to NsiI (ATGCAT) site in plasmid #197 (β in pRMHA-3).  BamHI 
(GGATCC) downstream. SacI (GAGCTC) in signal sequence, MluI 
(ACGCGT) before and after peptide. 
For 
production 
in 
S2 Drosophila cells 
Induce with CuSO4 
Gene 
Sequence 
ggtcctgtcctgttctccagcATGGTGTGTtTGAAGCTCCtTGGAGGCTCCTGCATGACA
GCGCTGACAGTGACACtGATGGTGCTGAGCTCCCCACTGGCTTTGGCTGGGGACACGCGT
GTCAAGTATGTCAAACAGGCAACCCTCGCACTGGCGGCGCGTGGAGGTGGAGGCTCACTA
GTGGGAGGTGGCTCTGGTGGTGGTGGTTCGCGTCCACGTTTCTTGTGGCAGCTTAAGTTT
GAATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGCTGGAAAGATGCATCTATAAC
CAAGAGGAGTCCGTGCGCTTCGACAGCGACGTGGGGGAGTACCGGGCGGTGACGGAGCTG
GGGCGGCCTGATGCCGAGTACTGGAACAGCCAGAAGGACCTCCTGGAGCAGAGGCGGGCC
GCGGTGGACACCTACTGCAGACACAACTACGGGGTTGGTGAGAGCTTCACAGTGCAGCGG
CGAGTTGAGCCTAAGGTGACTGTGTATCCTTCAAAGACCCAGCCCCTGCAGCACCACAAC
CTCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAGGCAGCATTGAAGTCAGGTGGTTCCGG
AACGGCCAGGAAGAGAAGGCTGGGGTGGTGTCCACAGGCCTGATCCAGAATGGAGATTGG
ACCTTCCAGACCCTGGTGATGCTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACACCTGC
CAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGAGAGCACGGTCTGAA 
TCTGCACAGAGCAAGtaaGGATCC 
Protein 
Sequence 
signal sequence, cleaved: 
gpvlfssMVCLKLLGGSCMTALTVTLMVLSSPLALA 
final protein sequence: 
GDTRVKYVKQATLALAARGGGGSLVGGGSGGGGSRPRFLWQLKFECHFFNGTERVRLLE 
RCIYNQEESVRFDSDVGEYRAVTELGRPDAEYWNSQKDLLEQRRAAVDTYCRHNYGVGES 
FTVQRRVEPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLI
QNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKENDgs 
Protein 
MW 
HA3M-B: 25,699 Da 
Protein pI HA3M-B: 8.30 
Protein 
extinction 
coefficient 
40,210 at 280nm (unfolded) 
Notes Since this was cloned very far upstream, and multiple attempts at 
sequencing have yielded poor results, the upstream sequence (toward the 
promoter and HindIII site) is uncertain.  It looks to be different than the 
pRMHA-3 construct, but I’m not sure how far it is different—could just 
be the polyclonal site.  However, the resulting protein is able to bind to 
LB3.1 antibody and does not activate DR1-Ha specific T cells and 
hybridomas, despite looking identical to the HaB protein from the similar 
S2 construct by SDS-PAGE and size exclusion chromatography. 
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Gene 
Construct 
HLA-DR1 αbsp and Ha-β chains (“bsp” biotinylation substrate peptide at 
the C-terminus of the α chain, and Ha peptide: “KYVKQNTLKLAT” and 
linker at the N-terminus of the β chain)  
Plasmid pCV (metallothionase promoters for each DR chain) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Constitutive GFP production (under COPIA promoter) 
Made by Souheil Younes 
Sites used 
for cloning 
MluI used for peptide upstream—unsure about downstream 
 
For 
production 
in 
S2 Drosophila 
Induce with CuSO4 
Gene 
Sequence 
Similar to DR1 AL in pRMHA-3 but with a bsp tag, and DR1 HaB 
in pRMHA-3  
Protein 
Sequence 
Similar to DR1 AL in pRMHA-3 but with a bsp tag, and DR1 HaB 
in pRMHA-3  
Notes Construct from Souheil Younes, not much information and difficult to 
obtain good sequencing data.  Lower protein production than pRMHA-3 
constructs. 
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Gene 
Construct 
HLA-DR1 αbsp and HA3Mβ chains (“bsp” biotinylation substrate peptide 
at the C-terminus of the α chain, and HA3M peptide: 
“KYVKQATLALAA” and linker at the N-terminus of the β chain)  
Plasmid pCV (metallothionase promoters for each DR chain) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Constitutive GFP production (under COPIA promoter) 
Made by Souheil Younes 
Sites used 
for cloning 
MluI used for peptide upstream—unsure about downstream 
 
For 
production 
in 
S2 Drosophila 
Induce with CuSO4 
Gene 
Sequence 
Similar to DR1 AL in pRMHA-3 but with a bsp tag, and DR1 
HA3MB in pRMHA-3  
Protein 
Sequence 
Similar to DR1 AL in pRMHA-3 but with a bsp tag, and DR1 
HA3MB in pRMHA-3  
Notes Construct from Souheil Younes, not much information and difficult to 
obtain good sequencing data.  Lower protein production than pRMHA-3 
constructs. 
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Gene 
Construct 
HLA-DR1 αbsp and p51-11β chains (“bsp” biotinylation substrate peptide 
at the C-terminus of the α chain, and p51-11 peptide and linker at the N-
terminus of the β chain—not sure of p51-11 sequence; unrelated to Ha)  
Plasmid pCV (metallothionase promoters for each DR chain) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Constitutive GFP production (under COPIA promoter) 
Made by Souheil Younes 
Sites used 
for cloning 
MluI used for peptide upstream—unsure about downstream 
 
For 
production 
in 
S2 Drosophila 
Induce with CuSO4 
Gene 
Sequence 
Similar to DR1 AL in pRMHA-3 but with a bsp tag, and DR1 
p51-11 in pRMHA-3  
Protein 
Sequence 
Similar to DR1 AL in pRMHA-3 but with a bsp tag, and DR1 
p51-11 in pRMHA-3  
Notes Construct from Souheil Younes, not much information and difficult to 
obtain good sequencing data.  Lower protein production than pRMHA-3 
constructs. 
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Gene 
Construct 
H2-Kbbsp (mouse heavy chain with bsp tag) 
Plasmid JA3 (T7 promoter) 
Kanamycin resistance gene for plasmid production in E. coli  
Made by NIH tetramer facility 
Sites used 
for cloning 
NdeI to HindIII 
Insert size ~900bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
CATATGGGACCACATTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGG 
CCTCGGGGAGCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCG 
TGCGCTTCGACAGCGACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGG 
ATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGGGAGACACAGAAAGCCAAGGG 
CAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGGCTACTACAACC 
AGAGCAAGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGGGG 
TCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGA 
TTACATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGG 
CGCTGATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGG 
GCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGAAGAACGG 
GAACGCGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACA 
GCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCT 
GCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACAT 
GGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCAT 
CTGTGGTGGTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCAT 
CAGGGGCTGCCTGAGCCCCTCACCCTGAGATGGGAGCCTCCTCCATCCGGATC 
CCTGCATCATATTCTGGATGCACAGAAAATGGTGTGGAATCATCGTTAAAAGC  
TT 
Protein 
Sequence 
hMGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWM 
EQEGPEYWERETQKAKGNEQSFRVDLRTLLGYYNQSKGGSHTIQVISGCEVGS 
DGRLLRGYQQYAYDGCDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRA 
YLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHHSRPEDKVTLRCWALGFYPA 
DITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLGKEQYYTCHVYHQ 
GLPEPLTLRWEPPPSGSLHHILDAQKMVWNHRENDkl 
Protein 
MW 
34,271.4 Da 
Protein pI 5.80 
Protein 
extinction 
coefficient 
78,900 at 280nm (unfolded) 
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Gene 
Construct 
H2-KbCS (short) and KbCL (long, with connecting peptide)  
Mouse heavy chain with uniquely reactive cysteine at the C-terminus 
Plasmid pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Mia Rushe in Larry Stern’s lab 
Sites used 
for cloning 
EcoRI to HindIII 
Insert size ~860bp (short) and 880bp (long) 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
gaattcAGGAGGAATTTAAAATGGGACCACATTCGCTGAGGTATTTCGTCACCG 
CCGTGTCCCGGCCCGGCCTCGGGGAGCCCCGGTACATGGAAGTCGGCTACGTGG 
ACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGAATCCGAGATATGAGC 
CGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGGGAGACAC 
AGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCG 
GCTACTACAACCAGAGCAAGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCT 
GTGAAGTGGGGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACG 
ACGGCcGtGATTACATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGG 
ACATGGCGGCGCTGATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGA 
GACTCAGGGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGA 
AGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCC 
ATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCT 
ACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGG 
ACATGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGG 
CATCTGTGGTGGTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACC  
short: 
ATCAGGGGCTGCCTGAGCCCCTCACCCTGAGATGGGAGCCTtgctaaaagctt  
long: 
ATCAGGGGCTGCCTGAGCCCCTCACCCTGAGATGGGAGCCTCCTCCATCCGGAT 
CCtgctaaaagctt 
Protein 
Sequence 
iqeefkMGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWME 
QEGPEYWERETQKAKGNEQSFRVDLRTLLGYYNQSKGGSHTIQVISGCEVGSDGRLLRGY 
QQYAYDGRDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLK 
NGNATLLRTDSPKAHVTHHSRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVET 
short: 
RPAGDGTFQKWASVVVPLGKEQYYTCHVYHQGLPEPLTLRWEPCENDkl  
long: 
RPAGDGTFQKWASVVVPLGKEQYYTCHVYHQGLPEPLTLRWEPPPSGSCENDkl 
Protein 
MW 
32,122 (short) and 32,547.4 (long) Da 
Protein pI 5.57 (short) and 5.57 (long) 
Protein 
extinction 
coefficient 
73,210 (short) and 73,210 (long) at 280nm (unfolded) 
 
 255
 
Gene 
Construct 
H2-Ldbsp (mouse heavy chain with bsp tag) 
Plasmid JA3 (T7 promoter) 
Kanamycin resistance gene for plasmid production in E. coli  
Made by NIH tetramer facility 
Sites used 
for cloning 
NdeI to HindIII 
Insert size ~900bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
CATATGGGCCCACACTCGATGCGGTATTTCGAGACCGCCGTGTCCCGGCCCGGC 
CTCGGGGAGCCCCGGTACATCTCTGTCGGCTATGTGGACAACAAGGAGTTCGTG 
CGCTTCGACAGCGACGCGGAGAATCCGAGATATGAGCCGCAGGCGCCGTGGATG 
GAGCAGGAGGGGCCGGAGTATTGGGAGCGGATCACGCAGATCGCCAAGGGCCAG 
GAGCAGTGGTTCCGAGTGAACCTGAGGACCCTGCTCGGCTACTACAACCAGAGC 
GCGGGCGGCACTCACACACTCCAGTGGATGTACGGCTGTGACGTGGGGTCGGAC 
GGGCGCCTCCTCCGCGGGTACGAGCAGTTCGCCTACGACGGCTGCGATTACATC 
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCAGATC 
ACCCGACGCAAGTGGGAGCAGGCTGGTGCTGCAGAGTATTACAGGGCCTACCTG 
GAGGGCGAGTGCGTGGAGTGGCTCCACAGATACCTGAAGAACGGGAACGCGACG 
CTGCTGCGCACAGATTCCCCAAAGGCACATGTGACCCATCACCCCAGATCTAAA 
GGTGAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCTGACATCACC 
CTGACCTGGCAGTTGAATGGGGAGGAGCTGACCCAGGACATGGAGCTTGTGGAG 
ACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTGGTGCCT 
CTTGGGAAGGAGCAGAATTACACATGCCGTGTGTACCATGAGGGGCTGCCTGAG 
CCCCTCACCCTGAGATGGGAGCCTCCTCCGTCCGGATCCCTGCATCATATTCTG 
GATGCACAGAAAATGGTGTGGAATCATCGTTAAAAGCTT 
Protein 
Sequence 
hMGPHSMRYFETAVSRPGLGEPRYISVGYVDNKEFVRFDSDAENPRYEPQAPWM 
EQEGPEYWERITQIAKGQEQWFRVNLRTLLGYYNQSAGGTHTLQWMYGCDVGSD 
GRLLRGYEQFAYDGCDYIALNEDLKTWTAADMAAQITRRKWEQAGAAEYYRAYL 
EGECVEWLHRYLKNGNATLLRTDSPKAHVTHHPRSKGEVTLRCWALGFYPADIT 
LTWQLNGEELTQDMELVETRPAGDGTFQKWASVVVPLGKEQNYTCRVYHEGLPE 
PLTLRWEPPPSGSLHHILDAQKMVWNHRENDkl 
Protein 
MW 
34,359.4 Da 
Protein pI 5.61 
Protein 
extinction 
coefficient 
91,560 at 280nm (unfolded) 
 
 256
 
Gene 
Construct 
H2-LdCS (short) and LdCL (long, with connecting peptide)  
Mouse heavy chain with uniquely reactive cysteine at the C-terminus 
Plasmid pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Mia Rushe in Larry Stern’s lab 
Sites used 
for cloning 
EcoRI to HindIII 
Insert size ~860bp (short) and 880bp (long) 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
gaattcaggaggaatttaaaATGGGCCCACACTCGATGCGGTATTTCGAGACCG 
CCGTGTCCCGGCCCGGCCTCGGGGAGCCCCGGTACATCTCTGTCGGCTATGTGG 
ACAACAAGGAGTTCGTGCGCTTCGACAGCGACGCGGAGAATCCGAGATATGAGC 
CGCAGGCGCCGTGGATGGAGCAGGAGGGGCCGGAGTATTGGGAGCGGATCACGC 
AGATCGCCAAGGGCCAGGAGCAGTGGTTCCGAGTGAACCTGAGGACCCTGCTCG 
GCTACTACAACCAGAGCGCGGGCGGCACTCACACACTCCAGTGGATGTACGGCT 
GTGACGTGGGGTCGGACGGGCGCCTCCTCCGCGGGTACGAGCAGTTCGCCTACG 
ACGGCcGtGATTACATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGG 
ACATGGCGGCGCAGATCACCCGACGCAAGTGGGAGCAGGCTGGTGCTGCAGAGT 
ATTACAGGGCCTACCTGGAGGGCGAGTGCGTGGAGTGGCTCCACAGATACCTGA 
AGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAGGCACATGTGACCC 
ATCACCCCAGATCTAAAGGTGAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCT 
ACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGACCCAGG 
ACATGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGG 
CATCTGTGGTGGTGCCTCTTGGGAAGGAGCAGAATTACACATGCCGTGTGTACC  
short: 
ATGAGGGGCTGCCTGAGCCCCTCACCCTGAGATGGGAGCCTtgctaaaagctt 
long: 
ATGAGGGGCTGCCTGAGCCCCTCACCCTGAGATGGGAGCCTCCTCCGTCCGGAT 
CCtgctaaaagctt 
Protein 
Sequence 
iqeefkMGPHSMRYFETAVSRPGLGEPRYISVGYVDNKEFVRFDSDAENPRYEP 
QAPWMEQEGPEYWERITQIAKGQEQWFRVNLRTLLGYYNQSAGGTHTLQWMYGC 
DVGSDGRLLRGYEQFAYDGRDYIALNEDLKTWTAADMAAQITRRKWEQAGAAEY 
YRAYLEGECVEWLHRYLKNGNATLLRTDSPKAHVTHHPRSKGEVTLRCWALGFY 
PADITLTWQLNGEELTQDMELVETRPAGDGTFQKWASVVVPLGKEQNYTCRVYH  
short: 
EGLPEPLTLRWEPCENDkl 
long: 
EGLPEPLTLRWEPPPSGSCENDkl 
Protein 
MW 
32,210 (short) and 32,635.4 (long) Da 
Protein pI 5.37 (short) and 5.37 (long) 
Protein 
extinction 
coefficient 
85,870 (short) and 85,870 (long) at 280nm (unfolded) 
 
 257
 
Gene 
Construct 
OVA-β2M-Kbbsp, Y84A (Single-chain class I MHC, Y84A to allow peptide 
to lay in groove more easily, position 121 is C, bsp peptide at C-terminus) 
Plasmid pET21a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Ted Hansen’s lab at Washington University Medical School 
Sites used 
for cloning 
NdeI and HindIII 
Insert size ~1326bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
GANTGTGAGCGGaTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TAcatatgAGTATCATTAATTTCGAAAAACTTGGAGGAGGTGCTAGCGGTGGTGGTGGTAGC
GGAGGTGGAGGCAGCATCCAGAAAACCCCTCAAATTCAAGTATACTCACGCCACCCACCGGA
GAATGGGAAGCCGAACATACTGAACTGCTACGTAACACAGTTCCACCCGCCTCACATTGAAA
TCCAAATGCTGAAGAACGGGAAAAAAATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGC
AAGGACTGGTCTTTCTATATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATA
CGCCTGCAGAGTTAAGCATGCCAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACA
TGGGCGGTGGTGGTTCCGGTGGAGGCGGTTCCGGAGGTGGTGGATCCGGTGGTGGAGGTAGT
GGCCCACACTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGAGCCCCG
GTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA
ATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGG
GAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGG
CGCCTACAACCAGAGCAaGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGG
GGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGATCACCAAACA
CAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACCTGGAGGGCACGTGCGTGG
AGTGGCTCCGCAGATACCTGAAGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAG
GCCCATGTGACCCATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACA
TGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCC
CCTCACCCTGAGATGGGAGCCTCCTCCATCCACTGGTGGCGGTCTGAACGACATCTTCGAGG
CTCAGAAAATCGAATGGCACGAATAAaagcttGCGGCCGCACTCGAGCACCACCACCACCAC
CACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTCC 
Protein 
Sequence 
xvsgstopqfpsrnnfv-l-egdihMSIINFEKLGGGASGGGGSGGGGSIQKTPQIQVYS 
RHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFT 
PTETDTYACRVKHASMAEPKTVYWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAV 
SRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQ 
SFRVDLRTLLGAYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGCDYIALNEDLKT 
WTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHH 
SRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLG 
KEQYYTCHVYHQGLPEPLTLRWEPPPSTGGGLNDIFEAQKIEWHEENDklaaalehhhhh 
hstopdpaankarkeaelaa 
Protein 
MW 
48,973 Da 
Protein pI 5.75 
Protein 
extinction 
coefficient 
95,520 at 280nm (unfolded) 
 
 258
 
Gene 
Construct 
SIY-β2M-Kbbsp, Y84A (Single-chain class I MHC, Y84A to allow peptide to 
lay in groove more easily, position 121 is C, bsp peptide at C-terminus) 
Plasmid pET21a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Vinay Mahajan in Jinazhu Chen’s lab at MIT 
Sites used 
for cloning 
NdeI and HindIII 
Insert size ~1326bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
GANTGTGAGCGGaTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TAcatatgAGTATCTACCGCTACTACGGCCTGGGAGGAGGTGCTAGCGGTGGTGGTGGTAGC
GGAGGTGGAGGCAGCATCCAGAAAACCCCTCAAATTCAAGTATACTCACGCCACCCACCGGA
GAATGGGAAGCCGAACATACTGAACTGCTACGTAACACAGTTCCACCCGCCTCACATTGAAA
TCCAAATGCTGAAGAACGGGAAAAAAATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGC
AAGGACTGGTCTTTCTATATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATA
CGCCTGCAGAGTTAAGCATGCCAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACA
TGGGCGGTGGTGGTTCCGGTGGAGGCGGTTCCGGAGGTGGTGGATCCGGTGGTGGAGGTAGT
GGCCCACACTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGAGCCCCG
GTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA
ATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGG
GAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGG
CGCCTACAACCAGAGCAaGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGG
GGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGATCACCAAACA
CAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACCTGGAGGGCACGTGCGTGG
AGTGGCTCCGCAGATACCTGAAGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAG
GCCCATGTGACCCATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACA
TGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCC
CCTCACCCTGAGATGGGAGCCTCCTCCATCCACTGGTGGCGGTCTGAACGACATCTTCGAGG
CTCAGAAAATCGAATGGCACGAATAAaagcttGCGGCCGCACTCGAGCACCACCACCACCAC
CACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTCC 
Protein 
Sequence 
xvsgstopqfpsrnnfv-l-egdihMSIINFEKLGGGASGGGGSGGGGSIQKTPQIQVYS 
RHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFT 
PTETDTYACRVKHASMAEPKTVYWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAV 
SRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQ 
SFRVDLRTLLGAYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGCDYIALNEDLKT 
WTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHH 
SRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLG 
KEQYYTCHVYHQGLPEPLTLRWEPPPSTGGGLNDIFEAQKIEWHEENDklaaalehhhhh 
hstopdpaankarkeaelaa 
Protein 
MW 
48,972 Da 
Protein pI 5.75 
Protein 
extinction 
coefficient 
95,570 at 280nm (unfolded) 
 
 259
 
Gene 
Construct 
OVA-β2M-KbCL, Y84A, C121R (Single-chain class I MHC, Y84A to allow 
peptide to lay in groove more easily, C121R to allow unique Cys at C-
terminus) 
Plasmid pET21a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by J. Stone 
Sites used 
for cloning 
NdeI and HindIII 
Insert size ~1281bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
GANTGTGAGCGGaTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TAcatatgAGTATCATTAATTTCGAAAAACTTGGAGGAGGTGCTAGCGGTGGTGGTGGTAGC
GGAGGTGGAGGCAGCATCCAGAAAACCCCTCAAATTCAAGTATACTCACGCCACCCACCGGA
GAATGGGAAGCCGAACATACTGAACTGCTACGTAACACAGTTCCACCCGCCTCACATTGAAA
TCCAAATGCTGAAGAACGGGAAAAAAATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGC
AAGGACTGGTCTTTCTATATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATA
CGCCTGCAGAGTTAAGCATGCCAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACA
TGGGCGGTGGTGGTTCCGGTGGAGGCGGTTCCGGAGGTGGTGGATCCGGTGGTGGAGGTAGT
GGCCCACACTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGAGCCCCG
GTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA
ATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGG
GAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGG
CGCCTACAACCAGAGCAaGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGG
GGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGATCACCAAACA
CAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACCTGGAGGGCACGTGCGTGG
AGTGGCTCCGCAGATACCTGAAGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAG
GCCCATGTGACCCATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACA
TGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCC
CCTCACCCTGAGATGGGAGCCTCCTCCATCCGGATCCTGCTAAaagcttGCGGCCGCACTCG
AGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTG
GCTGCTCC 
Protein 
Sequence 
xvsgstopqfpsrnnfv-l-egdihMSIINFEKLGGGASGGGGSGGGGSIQKTPQIQVYS 
RHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFT 
PTETDTYACRVKHASMAEPKTVYWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAV 
SRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQ 
SFRVDLRTLLGAYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGRDYIALNEDLKT 
WTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHH 
SRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLG 
KEQYYTCHVYHQGLPEPLTLRWEPPPSGSCENDklaaalehhhhhhstopdpaankarke 
aelaa 
Protein 
MW 
47,247 Da 
Protein pI 6.04 
Protein 
extinction 
coefficient 
89,830 at 280nm (unfolded) 
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Gene 
Construct 
SIY-β2M-KbCL, Y84A, C121R (Single-chain class I MHC, Y84A to allow 
peptide to lay in groove more easily, C121R to allow unique Cys at C-
terminus) 
Plasmid pET21a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Vinay Mahajan in Jianzhu Chen’s lab at MIT 
Sites used 
for cloning 
NdeI and HindIII 
Insert size ~1281bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
GANTGTGAGCGGaTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TAcatatgAGTATCTACCGCTACTACGGCCTGGGAGGAGGTGCTAGCGGTGGTGGTGGTAGC
GGAGGTGGAGGCAGCATCCAGAAAACCCCTCAAATTCAAGTATACTCACGCCACCCACCGGA
GAATGGGAAGCCGAACATACTGAACTGCTACGTAACACAGTTCCACCCGCCTCACATTGAAA
TCCAAATGCTGAAGAACGGGAAAAAAATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGC
AAGGACTGGTCTTTCTATATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATA
CGCCTGCAGAGTTAAGCATGCCAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACA
TGGGCGGTGGTGGTTCCGGTGGAGGCGGTTCCGGAGGTGGTGGATCCGGTGGTGGAGGTAGT
GGCCCACACTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGAGCCCCG
GTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA
ATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGG
GAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGG
CGCCTACAACCAGAGCAaGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGG
GGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGATCACCAAACA
CAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACCTGGAGGGCACGTGCGTGG
AGTGGCTCCGCAGATACCTGAAGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAG
GCCCATGTGACCCATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACA
TGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCC
CCTCACCCTGAGATGGGAGCCTCCTCCATCCGGATCCTGCTAAaagcttGCGGCCGCACTCG
AGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTG
GCTGCTCC 
Protein 
Sequence 
xvsgstopqfpsrnnfv-l-egdihMSIYRYYGLGGGASGGGGSGGGGSIQKTPQIQVYS 
RHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFT 
PTETDTYACRVKHASMAEPKTVYWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAV 
SRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQ 
SFRVDLRTLLGAYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGRDYIALNEDLKT 
WTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHH 
SRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLG 
KEQYYTCHVYHQGLPEPLTLRWEPPPSGSCENDklaaalehhhhhhstopdpaankarke 
aelaa 
Protein 
MW 
47,247 Da 
Protein pI 6.04 
Protein 
extinction 
coefficient 
89,830 at 280nm (unfolded) 
 
 261
 
Gene 
Construct 
p2Ca-β2M-KbCL, Y84A, C121R (Single-chain class I MHC, Y84A to allow 
peptide to lay in groove more easily, C121R to allow unique Cys at C-
terminus) 
Plasmid pET21a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Vinay Mahajan in Jianzhu Chen’s lab at MIT 
Sites used 
for cloning 
NdeI and HindIII 
Insert size ~1281bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
GANTGTGAGCGGaTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TAcatatgCTGAGCCCGTTCCCGTTCGACCTGGGAGGAGGTGCTAGCGGTGGTGGTGGTAGC
GGAGGTGGAGGCAGCATCCAGAAAACCCCTCAAATTCAAGTATACTCACGCCACCCACCGGA
GAATGGGAAGCCGAACATACTGAACTGCTACGTAACACAGTTCCACCCGCCTCACATTGAAA
TCCAAATGCTGAAGAACGGGAAAAAAATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGC
AAGGACTGGTCTTTCTATATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATA
CGCCTGCAGAGTTAAGCATGCCAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACA
TGGGCGGTGGTGGTTCCGGTGGAGGCGGTTCCGGAGGTGGTGGATCCGGTGGTGGAGGTAGT
GGCCCACACTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGAGCCCCG
GTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA
ATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGG
GAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGG
CGCCTACAACCAGAGCAaGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGG
GGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGATCACCAAACA
CAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACCTGGAGGGCACGTGCGTGG
AGTGGCTCCGCAGATACCTGAAGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAG
GCCCATGTGACCCATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACA
TGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCC
CCTCACCCTGAGATGGGAGCCTCCTCCATCCGGATCCTGCTAAaagcttGCGGCCGCACTCG
AGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTG
GCTGCTCC 
Protein 
Sequence 
xvsgstopqfpsrnnfv-l-egdihMLSPFPFDLGGGASGGGGSGGGGSIQKTPQIQVYS 
RHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFT 
PTETDTYACRVKHASMAEPKTVYWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAV 
SRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQ 
SFRVDLRTLLGAYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGRDYIALNEDLKT 
WTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHH 
SRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLG 
KEQYYTCHVYHQGLPEPLTLRWEPPPSGSCENDklaaalehhhhhhstopdpaankarke 
aelaa 
Protein 
MW 
47,219 Da 
Protein pI 5.94 
Protein 
extinction 
coefficient 
89,830 at 280nm (unfolded) 
 262
Gene 
Construct 
dEV8-β2M-KbCL, Y84A, C121R (Single-chain class I MHC, Y84A to allow 
peptide to lay in groove more easily, C121R to allow unique Cys at C-
terminus) 
Plasmid pET21a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Vinay Mahajan in Jianzhu Chen’s Lab at MIT 
Sites used 
for cloning 
NdeI and HindIII 
Insert size ~1281bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
GANTGTGAGCGGaTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TAcatatgGAACAATACAAATTCTACAGCGTGGGAGGAGGTGCTAGCGGTGGTGGTGGTAGC
GGAGGTGGAGGCAGCATCCAGAAAACCCCTCAAATTCAAGTATACTCACGCCACCCACCGGA
GAATGGGAAGCCGAACATACTGAACTGCTACGTAACACAGTTCCACCCGCCTCACATTGAAA
TCCAAATGCTGAAGAACGGGAAAAAAATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGC
AAGGACTGGTCTTTCTATATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATA
CGCCTGCAGAGTTAAGCATGCCAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACA
TGGGCGGTGGTGGTTCCGGTGGAGGCGGTTCCGGAGGTGGTGGATCCGGTGGTGGAGGTAGT
GGCCCACACTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGAGCCCCG
GTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA
ATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGG
GAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGG
CGCCTACAACCAGAGCAaGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGG
GGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGATCACCAAACA
CAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACCTGGAGGGCACGTGCGTGG
AGTGGCTCCGCAGATACCTGAAGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAG
GCCCATGTGACCCATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACA
TGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCC
CCTCACCCTGAGATGGGAGCCTCCTCCATCCGGATCCTGCTAAaagcttGCGGCCGCACTCG
AGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTG
GCTGCTCC 
Protein 
Sequence 
xvsgstopqfpsrnnfv-l-egdihMEQYKFYSVGGGASGGGGSGGGGSIQKTPQIQVYS 
RHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFT 
PTETDTYACRVKHASMAEPKTVYWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAV 
SRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQ 
SFRVDLRTLLGAYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGRDYIALNEDLKT 
WTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHH 
SRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLG 
KEQYYTCHVYHQGLPEPLTLRWEPPPSGSCENDklaaalehhhhhhstopdpaankarke 
aelaa 
Protein 
MW 
47,346 Da 
Protein pI 6.04 
Protein 
extinction 
coefficient 
92,390 at 280nm (unfolded) 
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Gene 
Construct 
E1-β2M-KbCL, Y84A, C121R (Single-chain class I MHC, Y84A to allow 
peptide to lay in groove more easily, C121R to allow unique Cys at C-
terminus) 
Plasmid pET21a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Vinay Mahajan in Jianzhu Chen’s lab at MIT 
Sites used 
for cloning 
NdeI and HindIII 
Insert size ~1281bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
GANTGTGAGCGGaTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TAcatatgGAAATCATTAATTTCGAAAAACTTGGAGGAGGTGCTAGCGGTGGTGGTGGTAGC
GGAGGTGGAGGCAGCATCCAGAAAACCCCTCAAATTCAAGTATACTCACGCCACCCACCGGA
GAATGGGAAGCCGAACATACTGAACTGCTACGTAACACAGTTCCACCCGCCTCACATTGAAA
TCCAAATGCTGAAGAACGGGAAAAAAATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGC
AAGGACTGGTCTTTCTATATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATA
CGCCTGCAGAGTTAAGCATGCCAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACA
TGGGCGGTGGTGGTTCCGGTGGAGGCGGTTCCGGAGGTGGTGGATCCGGTGGTGGAGGTAGT
GGCCCACACTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGAGCCCCG
GTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA
ATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGG
GAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGG
CGCCTACAACCAGAGCAaGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGG
GGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGATCACCAAACA
CAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACCTGGAGGGCACGTGCGTGG
AGTGGCTCCGCAGATACCTGAAGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAG
GCCCATGTGACCCATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACA
TGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCC
CCTCACCCTGAGATGGGAGCCTCCTCCATCCGGATCCTGCTAAaagcttGCGGCCGCACTCG
AGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTG
GCTGCTCC 
Protein 
Sequence 
xvsgstopqfpsrnnfv-l-egdihMEIINFEKLGGGASGGGGSGGGGSIQKTPQIQVYS 
RHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFT 
PTETDTYACRVKHASMAEPKTVYWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAV 
SRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQ 
SFRVDLRTLLGAYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGRDYIALNEDLKT 
WTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHH 
SRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLG 
KEQYYTCHVYHQGLPEPLTLRWEPPPSGSCENDklaaalehhhhhhstopdpaankarke 
aelaa 
Protein 
MW 
47,289 Da 
Protein pI 5.94 
Protein 
extinction 
coefficient 
89,830 at 280nm (unfolded) 
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Gene 
Construct 
GNY-β2M-KbCL, Y84A, C121R (Single-chain class I MHC, Y84A to allow 
peptide to lay in groove more easily, C121R to allow unique Cys at C-
terminus) 
Plasmid pET21a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Vinay Mahajan in Jinazhu Chen’s lab at MIT 
Sites used 
for cloning 
NdeI and HindIII 
Insert size ~1281bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
GANTGTGAGCGGaTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TAcatatgGGCAACTACAGCTTCTACGCCCTGGGAGGAGGTGCTAGCGGTGGTGGTGGTAGC
GGAGGTGGAGGCAGCATCCAGAAAACCCCTCAAATTCAAGTATACTCACGCCACCCACCGGA
GAATGGGAAGCCGAACATACTGAACTGCTACGTAACACAGTTCCACCCGCCTCACATTGAAA
TCCAAATGCTGAAGAACGGGAAAAAAATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGC
AAGGACTGGTCTTTCTATATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATA
CGCCTGCAGAGTTAAGCATGCCAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACA
TGGGCGGTGGTGGTTCCGGTGGAGGCGGTTCCGGAGGTGGTGGATCCGGTGGTGGAGGTAGT
GGCCCACACTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGAGCCCCG
GTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCGACGCGGAGA
ATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAGTATTGGGAGCGG
GAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGG
CGCCTACAACCAGAGCAaGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGG
GGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGATCACCAAACA
CAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACCTGGAGGGCACGTGCGTGG
AGTGGCTCCGCAGATACCTGAAGAACGGGAACGCGACGCTGCTGCGCACAGATTCCCCAAAG
GCCCATGTGACCCATCACAGCAGACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCTGACATCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACA
TGGAGCTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCC
CCTCACCCTGAGATGGGAGCCTCCTCCATCCGGATCCTGCTAAaagcttGCGGCCGCACTCG
AGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTG
GCTGCTCC 
Protein 
Sequence 
xvsgstopqfpsrnnfv-l-egdihMGNYSFYALGGGASGGGGSGGGGSIQKTPQIQVYS 
RHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFT 
PTETDTYACRVKHASMAEPKTVYWDRDMGGGGSGGGGSGGGGSGGGGSGPHSLRYFVTAV 
SRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNEQ 
SFRVDLRTLLGAYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYDGRDYIALNEDLKT 
WTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHH 
SRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLG 
KEQYYTCHVYHQGLPEPLTLRWEPPPSGSCENDklaaalehhhhhhstopdpaankarke 
aelaa 
Protein 
MW 
47,217 Da 
Protein pI 6.03 
Protein 
extinction 
coefficient 
92,390 at 280nm (unfolded) 
 265
Gene 
Construct 
HLA-A2bsp (heavy chain with C-terminal bsp sequence) 
Plasmid pHN1+ (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by from University of Massachusetts Medical School Tetramer Facility 
Sites used 
for cloning 
SacI and HindIII 
Insert size ~900bp (not certain) 
For 
production 
in 
E. coli BL21 or XA90 
Induce with IPTG 
Gene 
Sequence 
not checked 
HLA-A*020101 sequence from IMGT: 
ATGGCCGTCATGGCGCCCCGAACCCTCGTCCTGCTACTCTCGGGGGCTCTGGCCCTGA 
CCCAGACCTGGGCGGGCTCTCACTCCATGAGGTATTTCTTCACATCCGTGTCCCGGCC 
CGGCCGCGGGGAGCCCCGCTTCATCGCAGTGGGCTACGTGGACGACACGCAGTTCGTG 
CGGTTCGACAGCGACGCCGCGAGCCAGAGGATGGAGCCGCGGGCGCCGTGGATAGAGC 
AGGAGGGTCCGGAGTATTGGGACGGGGAGACACGGAAAGTGAAGGCCCACTCACAGAC 
TCACCGAGTGGACCTGGGGACCCTGCGCGGCTACTACAACCAGAGCGAGGCCGGTTCT 
CACACCGTCCAGAGGATGTATGGCTGCGACGTGGGGTCGGACTGGCGCTTCCTCCGCG 
GGTACCACCAGTACGCCTACGACGGCAAGGATTACATCGCCCTGAAAGAGGACCTGCG 
CTCTTGGACCGCGGCGGACATGGCAGCTCAGACCACCAAGCACAAGTGGGAGGCGGCC 
CATGTGGCGGAGCAGTTGAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCA 
GATACCTGGAGAACGGGAAGGAGACGCTGCAGCGCACGGACGCCCCCAAAACGCATAT 
GACTCACCACGCTGTCTCTGACCATGAAGCCACCCTGAGGTGCTGGGCCCTGAGCTTC 
TACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGGGAGGACCAGACCCAGGACA 
CGGAGCTCGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCGGCTGT 
GGTGGTGCCTTCTGGACAGGAGCAGAGATACACCTGCCATGTGCAGCATGAGGGTTTG 
CCCAAGCCCCTCACCCTGAGATGGGAGCCGTCTTCCCAGCCCACCATCCCCATCGTGG 
GCATCATTGCTGGCCTGGTTCTCTTTGGAGCTGTGATCACTGGAGCTGTGGTCGCTGC 
TGTGATGTGGAGGAGGAAGAGCTCAGATAGAAAAGGAGGGAGCTACTCTCAGGCTGCA 
AGCAGTGACAGTGCCCAGGGCTCTGATGTGTCTCTCACAGCTTGTAAAGTGTGA 
Protein 
Sequence 
not checked 
HLA-A*020101 sequence from IMGT: 
MAVMAPRTLVLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRF 
DSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQ 
RMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQL 
RAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLT 
WQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEP 
SSQPTIPIVGIIAGLVLFGAVITGAVVAAVMWRRKSSDRKGGSYSQAASSDSAQGSDVSL 
TACKVEND 
Protein 
MW 
~40,922 Da (full length from IMGT) 
Protein pI ~6.50 
Protein 
extinction 
coefficient 
~87,720 at 280nm (full length from IMGT, unfolded) 
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Gene 
Construct 
HLA-A2cys (heavy chain with C-terminal cysteine) 
Plasmid pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by J. Stone 
Sites used 
for cloning 
EcoRI and HindIII 
Insert size ~863bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
TTTTGTTgaattcAGGAGGAATTTAAAATGGGCTCTCACTCCATGAGGTATTTCTTCACATCC
GTGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCGCAGTGGGCTACGTGGACGACACGCAG
TTCGTGCGGTTCGACAGCGACGCCGCGAGCCAGAGGATGGAGCCGCGGGCGCCGTGGATAGAG
CAGGAGGGTCCGGAGTATTGGGACGGGGAGACACGGAAAGTGAAGGCCCACTCACAGACTCAC
CGAGTGGACCTGGGGACCCTGCGCGGCTACTACAACCAGAGCGAGGCCGGTTCTCACACCGTC
CAGAGGATGTATGGCTGCGACGTGGGGTCGGACTGGCGCTTCCTCCGCGGGTACCACCAGTAC
GCCTACGACGGCAAGGATTACATCGCCCTGAAAGAGGACCTGCGCTCTTGGACCGCGGCGGAC
ATGGCAGCTCAGACCACCAAGCACAAGTGGGAGGCGGCCCATGTGGCGGAGCAGTTGAGAGCC
TACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGGGAAGGAGACGCTG
CAGCGCACGGACGCCCCCAAAACGCATATGACTCACCACGCTGTCTCTGACCATGAAGCCACC
CTGAGGTGCTGGGCCCTGAGCTTCTACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGG
GAGGACCAGACCCAGGACACGGAGCTCGTGGAGACAAGGCCTGCAGGGGATGGAACCTTCCAG
AAGTGGGCGGCTGTGGTGGTGCCTTCTGGACAGGAGCAGAGATACACCTGCCATGTGCAGCAT
GAGGGTTTGCCCAAGCCCCTCACCCTGAGATGGGAGGCGTGCTAATAGTGAaagctt 
Protein 
Sequence 
fc-iqeefkMGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIE 
QEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQY 
AYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETL 
QRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQ 
KWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEACEND--kl 
Protein 
MW 
32,114 Da 
Protein pI 6.01 
Protein 
extinction 
coefficient 
75,060 at 280nm (unfolded) 
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Gene 
Construct 
HLA-B7bsp (heavy chain with C-terminal bsp sequence) 
Plasmid pET9a (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by from University of Massachusetts Medical School Tetramer Facility 
Sites used 
for cloning 
? 
Insert size ~900bp (not certain) 
For 
production 
in 
E. coli BL21 or XA90 
Induce with IPTG 
Gene 
Sequence 
not checked 
HLA-B*070201 sequence from IMGT: 
ATGCTGGTCATGGCGCCCCGAACCGTCCTCCTGCTGCTCTCGGCGGCCCTGGCCCTGACC
GAGACCTGGGCCGGCTCCCACTCCATGAGGTATTTCTACACCTCCGTGTCCCGGCCCGGC
CGCGGGGAGCCCCGCTTCATCTCAGTGGGCTACGTGGACGACACCCAGTTCGTGAGGTTC
GACAGCGACGCCGCGAGTCCGAGAGAGGAGCCGCGGGCGCCGTGGATAGAGCAGGAGGGG
CCGGAGTATTGGGACCGGAACACACAGATCTACAAGGCCCAGGCACAGACTGACCGAGAG
AGCCTGCGGAACCTGCGCGGCTACTACAACCAGAGCGAGGCCGGGTCTCACACCCTCCAG
AGCATGTACGGCTGCGACGTGGGGCCGGACGGGCGCCTCCTCCGCGGGCATGACCAGTAC
GCCTACGACGGCAAGGATTACATCGCCCTGAACGAGGACCTGCGCTCCTGGACCGCCGCG
GACACGGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGAGGCGGAGCAGCGG
AGAGCCTACCTGGAGGGCGAGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGGGAAG
GACAAGCTGGAGCGCGCTGACCCCCCAAAGACACACGTGACCCACCACCCCATCTCTGAC
CATGAGGCCACCCTGAGGTGCTGGGCCCTGGGTTTCTACCCTGCGGAGATCACACTGACC
TGGCAGCGGGATGGCGAGGACCAAACTCAGGACACTGAGCTTGTGGAGACCAGACCAGCA
GGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCAGAGA
TACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGAGCCG
TCTTCCCAGTCCACCGTCCCCATCGTGGGCATTGTTGCTGGCCTGGCTGTCCTAGCAGTT
GTGGTCATCGGAGCTGTGGTCGCTGCTGTGATGTGTAGGAGGAAGAGTTCAGGTGGAAAA
GGAGGGAGCTACTCTCAGGCTGCGTGCAGCGACAGTGCCCAGGGCTCTGATGTGTCTCTC
ACAGCTTGA 
Protein 
Sequence 
not checked 
HLA*020101 sequence from IMGT: 
MLVMAPRTVLLLLSAALALTETWAGSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRF 
DSDAASPREEPRAPWIEQEGPEYWDRNTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQ 
SMYGCDVGPDGRLLRGHDQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQR 
RAYLEGECVEWLRRYLENGKDKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITLT 
WQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEP 
SSQSTVPIVGIVAGLAVLAVVVIGAVVAAVMCRRKSSGGKGGSYSQAACSDSAQGSDVSL 
TAEND 
Protein 
MW 
~40,460 Da (full length from IMGT) 
Protein pI ~5.57 
Protein 
extinction 
coefficient 
~77,740 at 280nm (full length from IMGT, unfolded) 
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Gene 
Construct 
HLA-B7cys (heavy chain with C-terminal cysteine) 
Plasmid pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by J. Stone 
Sites used 
for cloning 
EcoRI and HindIII 
Insert size ~863bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
TTTTGTTgaattcAGGAGGAATTTAAAATGGGCTCCCACTCCATGAGGTATTTCTACACCTCC
GTGTCCCGACCCGGCCGCGGGGAGCCCCGCTTCATCTCAGTGGGCTACGTGGACGACACCCAG
TTCGTGAGGTTCGACAGCGACGCCGCGAGTCCGAGAGAGGAGCCGCGGGCGCCGTGGATAGAG
CAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCTACAAGGCCCAGGCACAGACTGAC
CGAGAGAGCCTGCGGAACCTGCGCGGCTACTACAACCAGAGCGAGGCCGGGTCTCACACCCTC
CAGAGCATGTACGGCTGCGACGTGGGGCCGGACGGGCGCCTCCTCCGCGGGCATGACCAGTAC
GCCTACGACGGCAAGGATTACATCGCCCTGAACGAGGACCTGCGCTCCTGGACCGCCGCGGAC
ACGGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGAGGCGGAGCAGCGGAGAGCC
TACCTGGAGGGCGAGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGGGAAGGACAAGCTG
GAGCGCGCTGACCCCCCAAAGACACACGTGACCCACCACCCCATCTCTGACCATGAGGCCACC
CTGAGGTGCTGGGCCCTGGGTTTCTACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGC
GAGGACCAAACTCAGGACACTGAGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAG
AAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCAT
GAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGAGGCGTGCTAATAGTGAaagctt 
Protein 
Sequence 
MGSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDR 
NTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDGKDYIA 
LNEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLERADPPKTH 
VTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPS 
GEEQRYTCHVQHEGLPKPLTLRWEACEND 
Protein 
MW 
32,223.4 Da 
Protein pI 5.36 
Protein 
extinction 
coefficient 
70,650 at 280nm (unfolded) 
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Gene 
Construct 
Β2M (human light chain, beta-2 microglobulin) 
Plasmid (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by NIH tetramer facility 
Sites used 
for cloning 
 
Insert size ~300bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
not checked 
Protein 
Sequence 
not checked  
sequence from Reid et.al., J Exp Med v. 184 (2279) 1996: 
IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSK 
DWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM 
Protein 
MW 
11,731 Da 
Protein pI 6.07 
Protein 
extinction 
coefficient 
19,180 at 280nm (unfolded) 
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Gene 
Construct 
Biotin Ligase enzyme (BirA) containing his-tag for purification 
Plasmid pET22b 
Amp resistance gene for plasmid production in E. coli  
Made by Kai Wucherpfennig  
Sites used 
for cloning 
NdeI to XhoI 
Insert size ~967bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
**protein is soluble—not in inclusion bodies** 
Gene 
Sequence 
CATATGAAGGATAACACCGTGCCACTGAAATTGATTGCCCTGTTAGCGAACGGTGAATTT 
CACTCTGGCGAGCAGTTGGGTGAAACGCTGGGAATGAGCCGGGCGGCTATTAATAAACAC 
ATTCAGACACTGCGTGACTGGGGCGTTGATGTCTTTACCGTTCCGGGTAAAGGATACAGC 
CTGCCTGAGCCTATCCAGTTACTTAATGCTAAACAGATATTGGGTCAGCTGGATGGCGGT 
AGTGTAGCCGTGCTGCCAGTGATTGACTCCACGAATCAGTACCTTCTTGATCGTATCGGA 
GAGCTTAAATCGGGCGATGCTTGCATTGCAGAATACCAGCAGGCTGGCCGTGGTCGCCGG 
GGTCGGAAATGGTTTTCGCCTTTTGGCGCAAACTTATATTTGTCGATGTTCTGGCGTCTG 
GAACAAGGCCCGGCGGCGGCGATTGGTTTAAGTCTGGTTATCGGTATCGTGATGGCGGAA 
GTATTACGCAAGCTGGGTGCAGATAAAGTTCGTGTTAAATGGCCTAATGACCTCTATCTG 
CAGGATCGCAAGCTGGCAGGCATTCTGGTGGAGCTGACTGGCAAAACTGGCGATGCGGCG 
CAAATAGTCATTGGAGCCGGGATCAACATGGCAATGCGCCGTGTTGAAGAGAGTGTCGTT 
AATCAGGGGTGGATCACGCTGCAGGAAGCGGGGATCAATCTCGATCGTAATACGTTGGCG 
GCCATGCTAATACGTGAATTACGTGCTGCGTTGGAACTCTTCGAACAAGAAGGATTGGCA 
CCTTATCTGTCGCGCTGGGAAAAGCTGGATAATTTTATTAATCGCCCAGTGAAACTTATC 
ATTGGTGATAAAGAAATATTTGGCATTTCACGCGGAATAGACAAACAGGGGGCTTTATTA 
CTTGAGCAGGATGGAATAATAAAACCCTGGATGGGCGGTGAAATATCCCTGCGTAGTGCA 
GAAAAACTCGAGCACCACCACCACCACCACTGA 
Protein 
Sequence 
hMKDNTVPLKLIALLANGEFHSGEQLGETLGMSRAAINKHIQTLRDWGVDVFTVPGKGYS 
LPEPIQLLNAKQILGQLDGGSVAVLPVIDSTNQYLLDRIGELKSGDACIAEYQQAGRGRR 
GRKWFSPFGANLYLSMFWRLEQGPAAAIGLSLVIGIVMAEVLRKLGADKVRVKWPNDLYL 
QDRKLAGILVELTGKTGDAAQIVIGAGINMAMRRVEESVVNQGWITLQEAGINLDRNTLA 
AMLIRELRAALELFEQEGLAPYLSRWEKLDNFINRPVKLIIGDKEIFGISRGIDKQGALL 
LEQDGIIKPWMGGEISLRSAEKLEHHHHHHEND 
Protein 
MW 
36,450 Da 
Protein pI 6.73 
Protein 
extinction 
coefficient 
47,510 at 280nm (unfolded) 
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Plasmid pLM1 (T7 promoter) 
Amp resistance gene for E. coli  
Size 3467 bp 
For 
production 
in 
E. coli—Induce with IPTG 
Contains Ampicillin resistance gene 
Multicloning 
site 
EcoRI (850) to HindIII (901) including Ecl135II (858, blunt), 
SacI (860), Acc65I (862), AvaI, KpnI, and XmaI (866), SmaI 
(868, blunt), BamHI (871), SalI (883), AccI (884, 2bp 
overhang), HincII (885, blunt), PstI (893), SbfI (893), BspMI 
(896), and SphI (899). Number indicates bp before the cut. 
Gene 
Sequence 
ACTTTGTCTTCCCCCTTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGC 
AGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCG 
TCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCA 
GAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAA 
GGAGAAAATACCGCATCAGGCGAAATTGTAAACGTTAATATTTTGTTAAAATTCGCGT 
TAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCC 
TTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAG 
AGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGG 
GCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCG 
TAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAG 
CCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGC 
TGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCC 
GCTACAGGGCGCGTCGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGA 
TCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGCGAAATTAATACGACTCACTATAGG 
GAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTGAATTCGAGCTCGGTACCCGG 
GGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCTGTTTTGGCGGATGAGAGA 
AGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAA 
TTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTG 
AAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCC 
AGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTT 
GTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGT 
TGCGAAGCAACGGCCCGGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCAT 
CAAATTAAGCAGAAGGCCATCCTGACGGATGGCCTTTTTGCGTTTCTACAAACTCTTT 
TGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGAT 
AAATGCTTCAATAATCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGC 
GTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCT 
GCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGG 
GATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAA 
AGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAA 
TCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT 
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACC 
TGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTA 
TCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTT 
CAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGAC 
ACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGT 
AGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACA 
GTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCT 
CTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCA 
GATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCT 
GACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAA 
GGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTAT 
ATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCA 
GCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTA 
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CGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACG 
CTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGA 
AGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTA 
GAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCAT 
CGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCA 
AGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTC 
CGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACT 
GCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTAC 
TCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGT 
CAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAA 
ACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATG 
TAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTG 
GGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAA 
ATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTAT 
TGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTC 
CGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGAC 
ATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCCCCT 
 
http://
wishart.biology.ualberta.ca/PlasMapper.
 273
 
Notes Enzyme   #Cuts    Site position (Fragment length) 
AatII    1         3393  (3467) 
Acc65I   1          861  (3467) 
AccI     1          882  (3467) 
AflIII   1         1582  (3467) 
AhdI     1         2470  (3467) 
AlwNI    1         1993  (3467) 
AvaI     1          865  (3467) 
BamHI    1          870  (3467) 
BpmI     1         2544  (3467) 
BsaAI    1          476  (3467) 
BsmBI    1           61  (3467) 
BspMI    1          886  (3467) 
BstAPI   1          194  (3467) 
DraIII   1          473  (3467) 
Ecl136II 1          855  (3467) 
EcoO109I 1         3450  (3467) 
EcoRI    1          849  (3467) 
HincII   1          882  (3467) 
HindIII  1          900  (3467) 
KpnI     1          861  (3467) 
NaeI     1          579  (3467) 
NdeI     1          198  (3467) 
NgoMIV   1          579  (3467) 
PciI     1         1582  (3467) 
PsiI     1          348  (3467) 
PstI     1          888  (3467) 
PvuII    1          781  (3467) 
SacI     1          855  (3467) 
SalI     1          882  (3467) 
SapI     1         1459  (3467) 
SbfI     1          887  (3467) 
ScaI     1         2953  (3467) 
SmaI     1          865  (3467) 
SphI     1          894  (3467) 
XmaI     1          865  (3467) 
 
BanII    2          549   (306)     855  (3161) 
BcgI     2         2979    (12)    2991  (3455) 
BglI     2          720  (1869)    2589  (1598) 
BmrI     2         1136  (1384)    2520  (2083) 
BsmFI    2          997  (2449)    3446  (1018) 
BsrDI    2         2529   (180)    2709  (3287) 
BsrFI    2          579  (1976)    2555  (1491) 
BtsI     2         2868    (26)    2894  (3441) 
EaeI     2         1421  (1442)    2863  (2025) 
Eco57I   2         2109  (1032)    3141  (2435) 
FspI     2          731  (1964)    2695  (1503) 
PvuI     2          751  (2091)    2842  (1376) 
SspI     2          268  (3009)    3277   (458) 
TatI     2          182  (2771)    2953   (696) 
TfiI     2         1417   (140)    1557  (3327) 
XbaI     2          831    (45)     876  (3422) 
XmnI     2          926  (2144)    3070  (1323) 
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No Sites found for the following Restriction Endonucleases 
AfeI          AflII         AgeI          ApaI          AscI 
AvrII         BaeI          BbeI          BbsI          BbvCI 
BclI          BglII         BlpI          BplI          Bpu10I 
BsaBI         BseRI         BsgI          BsiWI         BsmI 
BspEI         BsrGI         BssHII        BstBI         BstDSI 
BstEII        BstXI         BstZ17I       Bsu36I        BtgI 
BtrI          ClaI          EagI          EcoNI         EcoRV 
FseI          HpaI          KasI          MfeI          MluI 
MscI          NarI          NcoI          NheI          NotI 
NruI          NsiI          PacI          PflMI         PmeI 
PmlI          Ppu10I        PpuMI         PshAI         PspOMI 
RsrII         SacII         SanDI         SexAI         SfiI 
SfoI          SgfI          SgrAI         SnaBI         SpeI 
SrfI          StuI          StyI          SwaI          TliI 
Tth111I       XcmI          XhoI           
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Plasmid pRMHA-3 (metallothionine promoter) 
Amp resistance gene for plasmid production in E. coli  
no resistance for S2; co-transfect with pNeo (G418 resistance) 
Size 3849 bp 
From Chris Garcia at Stanford. Reference: Bunch et. al., Nucleic Acids 
Research, Feb. 1988, 16(3):1043. 
Promoter Metallothionine promoter—sequence starts at position 2: 
GTTGCAGGACAGGATGTGGTGCCCGATGTGACTAGCTCTTTGCTGCA... 
For 
production 
in 
S2 Drosophila cells 
Induce with CuSO4 
Gene 
Sequence 
**ONLY HAVE HARD COPY OF THIS SEQUENCE** 
 
Polclonal site reads: 
GAATCATCTCAGTGCAACTAAAGGGGGGAATTCGAGCTCGGTACCCGGGGATCCTCTAG 
AGTCGACCTGCAGGCATGCAATTCGATGCACACTCACATTCTTCTCCTAATACGATAAT 
AAAACTTTCCATGAAAAATATGGAAAAATAT 
 
Which includes EcoRI (GAATTC), SacI (GAGCTC), KpnI (GGTACC), 
AvaI (CCCGGG), SmaI (CCCGGG, blunt), Xma I (CCCGGG), BamHI 
(GGATCC), SalI (GTCGAC) unique sites. XbaI (TCTAGA) is also 
present, but NOT unique (there is another at pos 1210). 
 
Absent sites from vector include: AflII, AgeI, AscI, AvrII, 
BglII, BspeI, ClaI, DsaI, EcoRV, MluI, NcoI, NheI, NotI, 
SacII, SnaBI, SplI, XhoI. 
Notes Contains an Ampicillin resistance gene for production in E. coli. 
 
stopATG 
  signal sequence                gene 
(e.g. for secretion) 
EcoRI BanII or SacI
Model Cloning Scheme:
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C.1 PEPTIDE SEQUENCES 
 
Name Sequence 
Starting peptides for making peptide-based crosslinkers 
pep2 fluorescein-βA-E-K-S-G-S-K-G-NH2 
pep3 fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-K-G-NH2 
pep4 fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-K-S-S-E-G-K-G-NH2 
het2 fluorescein-βA-E-K-S-G-S-C-G-NH2 
het3a fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-C-G-NH2 
het3b fluorescein-βA-E-K-S-G-S-G-C-S-G-E-S-K-G-NH2 
het4a fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-K-S-S-E-G-C-G-NH2 
het4b fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-C-S-S-E-G-K-G-NH2 
het4c fluorescein-βA-E-K-S-G-S-G-K-S-G-E-S-C-S-S-E-G-C-G-NH2 
het4d fluorescein-βA-E-K-S-G-S-G-C-S-G-E-S-K-S-S-E-G-C-G-NH2 
Binds to DR1, from influenza haemagglutinin 
Ha P-K-Y-V-K-Q-N-T-L-K-L-A-T-NH2 
Binds to DR1, from human class I MHC HLA-A2 
A2 V-G-S-D-W-R-F-L-R-G-Y-H-Q-Y-A-NH2 
Bind to DR1, from HIV-1 
gags (PG13, p24(34))  P-E-V-I-P-M-F-S-A-L-S-E-G-NH2 
gagL (PP16) P-E-V-I-P-M-F-S-A-L-S-E-G-A-T-P-NH2 
Binds to DR1, from BZLF-1 protein of Epstein Barr Virus 
EBV Q-H-Y-R-E-V-A-A-A-K-S-S-E 
Binds to DR1, from Nuclear Protein 
NP [206-217] N-F-W-R-G-E-N-G-R-K-T-R-N 
Binds to DR1, from Transferrin Receptor 
Tfr R-V-E-Y-H-F-L-S-P-Y-V-S-P-K-E-S-P 
Binds to DR1, from Tetanus Toxin 
TT Q-Y-I-K-A-N-S-K-F-I-G-I-T-E 
Binds to DR1, from another strain of influenza (Flu strain B) 
FluB P-Y-Y-T-G-E-H-A-K-A-I-G-N 
Binds to DR1, from influenza matrix protein 
MA S-G-P-L-K-A-E-I-A-Q-R-L-E-D 
Binds to Ld--stimulatory to 2C T cells 
QL9 Q-L-S-P-F-P-F-D-L 
Binds to Ld and Kb weakly—weak agonist for 2C in complex with both 
p2Ca L-S-P-F-P-F-D-L 
Binds to Ld—does not stimulate 2C 
MCMV Y-P-H-F-M-P-T-N-L 
Binds to Kb—stimulates 2C T cells 
SYRGL S-I-Y-R-Y-Y-G-L 
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C.1 PEPTIDE SEQUENCES 
Name Sequence 
Binds to Kb—stimulates OT-1 T cells 
OVA S-I-I-N-F-E-K-L 
Binds to Kb—does not stimulate 2C T cells 
SEV F-A-P-G-N-Y-P-A-L 
Binds to Kb—2C weak agonist 
dEV8 E-Q-Y-K-F-Y-S-V 
Binds to Kb—2C antagonist 
GNY G-N-Y-S-F-Y-A-L 
Binds to Kb—OT-1 antagonist 
E1 E-I-I-N-F-E-K-L 
Bind to A2, from Modified Vaccinia Ankara 
MVA-165 K-V-D-D-T-F-Y-Y-V 
MVA-74A C-L-T-E-Y-I-L-W-V 
Binds to B7, from EBNA protein of Epstein Barr Virus 
B7 EBNA 3A R-P-P-I-F-I-R-R-L 
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C.2 EBV BZLF-1 OVERLAPPING PEPTIDES 
 
Overlapping peptides from Melissa Precopio from BZLF-1.  This protein is an immediate early 
gene product of the Epstein Barr Virus which functions as a transcription factor.  These peptides 
are 25-mers that overlap by 10 amino acids. 
 
# Peptide Sequence MW 
1 MMDPNSTSEDVKFTPDPYQVPFVQA 2844.16 
2 DPYQVPFVQAFDQATRVYQDLGGPS 2799.05 
3 RVYQDLGGPSQAPLPCVLWPVLPEP 2762.19 
4 CVLWPVLPEPLPQGQLTAYHVSTAP 2717.18 
5 LTAYHVSTAPTGSWFSAPQPAPENA 2600.83 
6 SAPQPAPENAYQAYAAPQLFPVSDI 2645.91 
7 APQLFPVSDITQNQQTNQAGGEAPQ 2639.82 
8 TNQAGGEAPQPGDNSTVQTAAAVVF 2430.57 
9 TVQTAAAVVFACPGANQGQQLADIG 2430.72 
10 NQGQQLADIGVPQPAPVAAPARRTR 2611.95 
11 PVAAPARRTRKPQQPESLEECDSEL 2808.12 
12 ESLEECDSELEIKRYKNRVASRKCR 3042.44 
13 KNRVASRKCRAKFKQLLQHYREVAA 3001.55 
14 LLQHYREVAAAKSSENDRLRLLLKQ 2952.41 
15 NDRLRLLLKQMCPSLDVDSIIPRTP 2894.44 
16 MCPSLDVDSIIPRTPDVLHEDLLNF 2840.26 
min QHYREVAAAKSSE 1475.58 
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C.3 HIV-1 GAG OVERLAPPING PEPTIDES 
 
Overlapping peptides from Phillip Norris from gag p24, which is a major core protein of the 
human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals 
mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis 
for determining HIV infection by ELISA and Western blot assays. The protein is also being 
investigated as a potential HIV immunogen in vaccines.  These peptides are 22-mers overlapping 
by 12 residues. 
 
# Peptide Sequence MW 
p24-109 PIVQNIQGQMVHQAISPRTLNA 2415.80 
p24-110 VHQAISPRTLNAWVKVVEEKAF 2522.93 
p24-111 NAWVKVVEEKAFSPEVIPMFSA 2478.89 
p24-112 AFSPEVIPMFSALSEGATPQDL 2307.60 
p24-113 SALSEGATPQDLNTMLNTVGGH 2213.40 
p24-114 DLNTMLNTVGGHQAAMQMLKET 2403.77 
p24-115 GHQAAMQMLKETINEEAAEQDR 2500.74 
p24-116 ETINEEAAEWDRVHPVHAGPIA 2441.64 
p24-117 DRVHPVHAGPIAPGQMREPRGS 2364.67 
p24-118 IAPGQMREPRGSDIAGTTSTLQ 2286.54 
p24-119 GSDIAGTTSTLQEQIGWMTNNP 2321.50 
p24-120 LQEQIGWMTNNPPIPVGEIYKR 2583.99 
p24-121 NPPIPVGEIYKRWIILGLNK 2320.81 
p24-122 KRWIILGLNKIVRMYSPTSILD 2617.19 
p24-123 IVRMYSPTSILDIRQGPKEPFR 2604.07 
p24-124 LDIRQGPKEPFRDYVDRFYKTL 2757.14 
p24-125 FRDYVDRFYKTLRAEQASQEVK 2750.07 
p24-126 TLRAEQASQEVKNWMTETLLVQ 2575.92 
p24-127 VKNWMTETLLVQNANPDCKTIL 2531.97 
p24-128 CQNANPDCKTILKALGPAATLE 2271.63 
p24-129 ILKALGPAATLEEMMTACQGVG 2204.64 
p24-130 LEEMMTACQGVGGPGHKARVL 2184.97 
p24-131 VGGPGHKARVLAEAMSQVTNTATIM 2539.95 
min-“gagL” PEVIPMFSALSEGATP 1645.89 
antag-“gagS” PEVIPMFSALSEG 1376.59 
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C.4 SOME MODIFIED VACCINIA ANKARA PEPTIDES 
 
Peptides from John Cruz in Alan Rothman’s lab which gave some response in an ELISPOT 
test or proliferation assay.  These peptides are derived from Modified Vaccinia Ankara, and 
they were tested for binding to HLA-A2. 
    
Peptide Name protein Amino Acid number Amino Acid Sequence 
MVA074A B22R  079-087 CLTEYILWV 
MVA165 C7L  074-082 KVDDTFYYV 
MVA103A A44L  292-300 ILFRKPSLL 
MVA115 I5L  007-015 VLTAIGITV 
MVA119 J4R  141-149 KMLETEIVV 
MVA123 A36R  016-024 ILVCYILYI 
MVA126 F12L  050-058 VMAMMNITI 
MVA129 F12R  196-204 VLPFDIKYI 
MVA 138 F12R  552-560 KMIYDLNAV 
MVA150 A17L  070-078 VLALYSPPL 
MVA155 AAB96557  020-028 YLYNYTIAV 
MVA158 H3L  292-304 GLIVILFIMFMLI 
MVA163 A7L  152-160 NIIKFETML 
MVA167 D12L  251-259 RVYEALYYV 
MVA176 L2R  078-086 TLTIFYYFI 
MVA179 A41L  011-019 CIPFSFQTV 
MVA183 F14L  039-047 ELLNILTEL 
MVA189 I8R  197-205 KLLLWFNYL 
MVA198 I4L  094-106 FSEVMEDLFNYVN 
MVA103B A44L  281-289 KMYACKNDM 
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